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Tremendous progress against AIDS over the last 15 years have inspired a global 
commitment to end the epidemic by 2030. The United Nations General Assembly 
agreed in June 2016 that ending AIDS by 2030 requires a Fast–Track response to 
reach three milestones by 2020:
 ■ Reduce new HIV infections to fewer than 500 000 globally by 2020.
 ■ Reduce AIDS-related deaths to fewer than 500 000 globally by 2020.
 ■ Eliminate HIV-related stigma and discrimination by 2020.
Remarkable scale up of antiretroviral therapy has put the world on track to reach 
the target on AIDS-related deaths. Intensive efforts to eliminate mother-to-child 
transmission of HIV have achieved steep declines in the annual number of new 
HIV infections among children, from 290 000 [250 000–350 000] in 2010 to 150 
000 [110 000–190 000] in 2015.
However, problems remain with HIV prevention. Declines in new HIV infections 
among adults have slowed, threatening further progress towards the end of the 
AIDS epidemic. Since 2010, the annual number of new infections among adults 
(15+) has remained static at an estimated 1.9 million [2015 range of 1.7 million–2.2 
million].
Efforts to reach fewer than 500 000 new HIV infections by 2020 are off track. This 
simple conclusion sits atop a complex and diverse global tapestry. Data from 146 
countries show that some have achieved declines in new HIV infections among 
adults of 50% or more over the last 10 years, while many others have not made 
measurable progress, and yet others have experienced worrying increases in new 
HIV infections.
INTRODUCTION
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Percent change in new HIV infections among adults (aged 15 years and older), from 2005 to 2015
Sources: UNAIDS 2016 estimates; European Centre for Disease Prevention and Control (Austria, Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Ger-
many, Hungary, Iceland, Ireland, Lithuania, Luxembourg, Malta, Netherlands, Norway, Poland, Portugal, Romania, Slovakia, Slovenia, Sweden, United Kingdom, Albania, Andorra, Bosnia and 
Herzegovina, Macedonia, Israel, Montenegro, San Marino, Serbia, Switzerland and Turkey); Centers for Disease Control and Prevention. HIV Surveillance Report, 2014; vol. 26. http://www.cdc.
gov/hiv/library/reports/surveillance/. Published November 2015. Accessed [10 July 2016]. Russian Federation 2016 Global AIDS Response Progress Reporting submission. China 2016 Global 
AIDS Response Progress Reporting submission.
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Gaps in coverage of key prevention services
Programmatic progress is also varied. The scale up of services to prevent 
mother-to-child transmission of HIV has not been matched in other key prevention 
areas, leaving sizable gaps in services. Progress in the provision and use of 
condoms has largely stalled; the gap in sub-Saharan Africa alone is about 3 billion 
male condoms a year, or 50% of the estimated need. Voluntary medical male 
circumcision has been rapidly expanded—reaching almost 11.7 million men in 14 
priority countries in just a few years—but the annual numbers of circumcisions 
performed within eight of these countries declined in 2015 compared to 2014. Key 
harm reduction services are unavailable in most of the countries where injecting 
drug use has been documented. The promise of one of the newest tools in the 
HIV prevention arsenal—pre-exposure prophylaxis (PrEP)—is only just beginning 
to be seen as a handful of countries move forward from successful demonstration 
projects to full regulatory approval and programme rollout.
Meanwhile, the preventative effect of antiretroviral therapy has been limited 
because 43% [38–47%] of people living with HIV do not know their HIV status and 
62% [59–65%] of people living with HIV are not virally suppressed—well shy of 
the 90–90–90 target. Reaching the third 90—which translates to 73% of people 
living with HIV virally suppressed—can only achieve up to 50% of the incidence 
reduction required to end the AIDS epidemic by 2030 (1). In the past, present and 
far into the future, primary prevention is an essential component of the response.
PREVENTION GAPS
Only 38% of people living with HIV are virally suppressed. 
Condoms available in sub-Saharan Africa cover just 50% of the need.
Two-thirds of young people do not have correct and comprehensive 
knowledge of HIV.
Condom use is much too low across all population groups at higher risk of 
infection.
43% of countries with documented injecting drug use do not have  
needle-syringe programmes in place.
The annual number of voluntary medical male circumcisions must nearly 
double to reach the 2020 target.
PrEP coverage is less than 5% of the 2020 target.
1 900 000  
new HIV infections 
among adults 2015
Fewer than 
500 000
new HIV infections 
among adults in 2020
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Populations and locations in greatest need
The heterogeneity of the HIV epidemic underscores the importance of a location–
population approach to efficient planning and programming of HIV prevention 
services. 
Many populations continue to be left behind. Young women aged 15–24 years 
are at particularly high risk of HIV infection, accounting for 20% of new HIV 
infections among adults globally in 2015, despite accounting for just 11% of the 
adult population. In sub-Saharan Africa, young women accounted for 25% of new 
HIV infections among adults and women accounted for 56% of new HIV infections 
among adults. Gender inequalities, including gender-based violence, exacerbate 
women’s and girls’ physiological vulnerability to HIV and block their access to HIV 
services. Young people are denied the information and the freedom to make free 
and informed decisions about their sexual health, with most lacking the knowledge 
required to protect themselves from HIV. The impact of these barriers is strongest 
in high-prevalence settings, predominantly in eastern and southern Africa.
Key populations—including sex workers, people who inject drugs, transgender 
people, prisoners and gay men and other men who have sex with men—remain at 
much higher risk of HIV infection. Recent studies suggest that people who inject 
drugs are 24 times more likely to acquire HIV than adults in the general population, 
sex workers are 10 times more likely to acquire HIV and gay men and other men 
who have sex with men are 24 times more likely to acquire HIV. In addition, 
transgender people are 49 times more likely to be living with HIV and prisoners are 
five times more likely to be living with HIV than adults in the general population (2).
Gay men and  
other men who have sex 
with men 
=  
24 TIMES
Sex workers  
=  
10 TIMES
People who  
inject drugs  
=  
24 TIMES
The risk of HIV acquisition compared to adults  
(aged 15 years and older) in the general population
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Globally, new infections among key populations and their sexual partners 
accounted for 36% of all new HIV infections in 2015. Criminalization and 
stigmatization of same-sex relationships, cross-dressing, sex work and drug 
possession and use block access to HIV prevention services and increases risky 
behaviours. Homophobia drives gay men and other men who have sex with men 
away from HIV testing and HIV prevention activities and is associated with lower 
adherence to treatment. Women in key populations face specific challenges and 
barriers, including violence and violations of their human rights. 
The people in greatest need vary by location. Key populations tend to migrate to 
cities in search of safer and more secure communities (3). The incidence of HIV 
among adolescent girls and young women in eastern and southern Africa is highest 
in parts of South Africa and southern Mozambique, plus the whole of Swaziland 
and Lesotho.
Sex workers 
4%
People who inject drugs 
7%
Clients of sex workers 
and other sexual partners 
of key populations
16%
Gay men and other men who 
have sex with men
8%
Transgender people*
0.4%
Rest of population 
65%
Source: UNAIDS special analysis, 2016; for more details, see annex on methodology.
* Reflects only Asia and Pacific and Latin America regions.
Distribution of new HIV infections by population, global, 2014
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Subnational HIV incidence (%) among young women (aged 15–24 years), by age group, 
eastern and southern Africa, 2014–2015
YOUNG WOMEN 15–19 YEARS OLD YOUNG WOMEN 20–24 YEARS OLD
Sub-national HIV incidence (%)
Source: UNAIDS estimates, 2014–2016 plus additional source. See annex on methods for details. 
The location–population approach also means that local stakeholders—
including local government, local civil society organizations and local 
communities—are at the centre of their own local responses. Analysis of 
local data on the level and trends in the epidemic, on the coverage of local 
programmes, and on bottlenecks created by local policies and practices, is 
critical to efficient and effective service delivery. 
Combination HIV prevention
Continued HIV testing and treatment scale up must be accompanied by a much 
stronger primary prevention response. Individual countries have shown that 
barriers to services can be removed and that prevention programmes can be 
brought to scale within a few years. South Africa built the world’s largest condom 
programme in just a few years and doubled the amount of condoms distributed 
per male, per year in at least seven of nine provinces (4). Mozambique has 
1.00–1.49%> 2.80% 0.00–0.49%1.50–1.99% 0.50–0.99%2.00–2.80%
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increased the number of voluntary medical male circumcision performed from 
just 100 in 2009 to almost 200 000 in 2015, and India has showed the world how 
location–population approaches that engage beneficiaries in their design and 
implementation can result in a marked decrease in new infections when brought 
to scale (5).
However, few countries have consistently applied a combination HIV prevention 
approach, which provides packages of services—including behavioural, 
biomedical and structural components—tailored to priority population 
groups within their specific local contexts. For example, young people in 
high prevalence countries need more than condoms and behaviour change 
communications. They also require comprehensive sexuality education and 
access to effective HIV and sexual and reproductive health services without 
economic barriers, such as prohibitive costs, or structural barriers, such as 
parental consent laws. A combination package for gay men and other men who 
have sex with men should include easy access to condoms, lubricant and PrEP, 
as well as efforts to address homophobia; a package for people who inject 
drugs should feature comprehensive harm reduction services, including needle-
syringe programmes and opioid substitution therapy (6).
All programmes require a strong community empowerment element and 
specific efforts to address legal and policy barriers, as well as the strengthening 
of health systems, social protection systems and actions to address gender 
inequality and stigma and discrimination. 
Five pillars for achieving less than 500 000 new 
infections by 2020
Getting back on track to reducing new infections to 500 000 by 2020 requires 
continued progress towards the 90–90–90 target and intensive focus on five 
prevention pillars delivered through a people-centred, combination approach:
1. Combination prevention, including comprehensive sexuality education, 
economic empowerment and access to sexual and reproductive health 
services for young women and adolescent girls and their male partners 
in high-prevalence locations.
2. Evidence-informed and human rights-based prevention programmes for 
key populations, including dedicated services and community mobilization 
and empowerment.
3. Strengthened national condom programmes, including procurement, 
distribution, social marketing, private-sector sales and demand creation.
4. Voluntary medical male circumcision in priority countries that have high 
levels of HIV prevalence and low levels of male circumcision, as part of 
wider sexual and reproductive health service provision for boys and men.
5. Pre-exposure prophylaxis for population groups at higher risk of HIV 
infection.
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These pillars are reflected in the bold prevention targets for 2020 set by the 
United Nations General Assembly within the 2016 Political Declaration on HIV and 
AIDS to ensure that 90% of people at risk of HIV infection access comprehensive 
prevention services, including harm reduction; to reduce below 100 000 per 
year the number of adolescent girls and young women aged 15–24 years newly 
infected with HIV globally; to make 20 billion condoms available annually in low- 
and middle-income countries; to reach 25 million additional young men in high 
HIV incidence areas with voluntarily medical male circumcision and to provide 
three million people at higher risk of HIV infection with PrEP.
FIVE PREVENTION PILLARS
United Nations General Assembly prevention targets
Young women  
and adolescent 
girls and their 
male partners
Key  
populations
Condoms
Voluntary  
medical male  
circumcision
Pre-exposure  
prophylaxis
1 2 3 4 5
Ensure that 90% 
of people at risk of 
HIV infection access 
comprehensive 
prevention services, 
including harm 
reduction, by 2020. 
Reduce below 
100 000 per year 
the number of 
adolescent girls and 
young women aged 
15–24 years old newly 
infected with HIV 
globally by 2020.
Ensure that 90% 
of people at risk of 
HIV infection access 
comprehensive 
prevention services, 
including harm 
reduction, by 2020.
Make 20 billion 
condoms annually 
available in low- and 
middle-income 
countries by 2020.
Reach 3 million 
people at higher 
risk of HIV infection 
with pre-exposure 
prophylaxis by 2020.
Reach 25 million 
additional young men 
in high HIV incidence 
areas with voluntarily 
medical male 
circumcision by 2020.
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Investment in effective prevention
Strengthened global political commitment to HIV prevention must be followed 
by strengthened financial commitment. The successes of the global AIDS 
response to date have been fuelled by extraordinary investment. The total 
amount of financial resources for AIDS responses in low- and middle-income 
countries1 reached an estimated US$ 19 billion in 2015, double the amount 
of resources available in 2006. However, international funding for in-country 
services in 2015 declined for the second year in a row to US$ 8.2 billion—a 
7% reduction from the US$ 8.7 billion in 20142. Public and private domestic 
investment increased by US$ 0.4 billion over the same period, resulting in 
approximately similar total resource availability in 2014 and 2015.
1 Excluding the following countries that recently transitioned into high-income brackets and remaining classified as high income at the 
time of this report: Argentina, Equatorial Guinea, Chile, Hungary, Latvia, Lithuania, Russian Federation, St. Kitts and Nevis, Seychelles, 
Uruguay and Venezuela, The domestic and international investments in the AIDS responses of these countries have been included in 
previous UNAIDS estimates and global targets. Updates are expected pending the annual revisions by the World Bank on the income 
level classification of countries.
2 The decline in international funds is partially driven by the appreciation of the US dollar. However, when assessed in the currencies 
of origin, most donors decreased their funding. On the other hand, the Global Fund for AIDS, Tuberculosis and Malaria (Global Fund) 
partially recovered from a 2014 decrease attributable to the roll out of its new funding model. PEPFAR has noted that a portion of US 
funds that were initially expected to be available in 2015 were rescheduled during annual planning and are expected to be used in 
2016 partially to fund the DREAMS project and other initiatives such as the recent commitment of US$ 100 million for services for key 
populations.
3 The percentage required for prevention varies by country. It might be lower than 25% in high-prevalence countries with large num-
bers of people needing antiretroviral therapy, and higher than 25% in countries with epidemics highly concentrated among key popu-
lations and low treatment needs. (Stover J, Bollinger L, Izazola JA, Loures L, DeLay P, Ghys PD, et al. (2016) What Is Required to End 
the AIDS Epidemic as a Public Health Threat by 2030? The Cost and Impact of the Fast-Track Approach. PLoS ONE 11(5):e0154893).
Resources available for HIV by source of funding, 2000–2015
2000
$10
$12
$8
$6
$4
$2
$0
2015
Source: UNAIDS estimates, June 2016; UNAIDS-Kaiser Family Foundation reports on Financing the Response to AIDS in Low- and Middle-Income Countries till 2015, OECD CRS last accessed 
June 2016.
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Available data show that investments in HIV prevention have slightly increased over 
time in a number of countries. However, more rapid increases in expenditures for 
HIV treatment translate to a declining trend in the percentage of total resources 
dedicated for a wide range of prevention services, including the prevention of 
mother-to-child transmission, reaching about 20% in recent years—short of the 
commitment made within the 2016 Political Declaration on HIV and AIDS to ensure 
that financial resources for HIV prevention are adequate and constitute no less than 
a quarter of AIDS spending globally.3
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4 Effective prevention programmes were defined as those with proven efficacy and are included within five pillars programmes for key 
populations (sex workers and their clients, gay men and other men who have sex with men, transgender people, prisoners and people 
who inject drugs, including harm reduction); condom promotion and provision; voluntary medical male circumcision; pre-exposure 
prophylaxis; and comprehensive HIV prevention programmes focused on young women and adolescent girls, including cash transfers.
For example, HIV prevention services accounted for 20–23% of the total resources 
provided by the United States President’s Emergency Plan for AIDS Relief (PEPFAR) 
from 2012 to 2014 (7). If expenditures for the prevention of mother-to-child transmission 
and voluntary HIV testing and counselling are excluded, the prevention share was 13–
16% of the total, including 4% for services focused on key populations (8). Additional 
central funding for voluntary medical male circumcision or prevention among young 
women and girls through the DREAMS partnership is not fully accounted for in this 
analysis. PEPFAR remains the largest international donor of effective prevention. 
While a detailed expenditure analysis by the Global Fund to Fight AIDS, Tuberculosis 
and Malaria was not available, a preliminary analysis conducted by the Global Fund 
Secretariat for this report indicates that about 14% of Global Fund expenditure in 
2014 was on primary prevention. 
As well as increased, investments must be rebalanced to address the limited amount 
number of resources currently available for the five pillars of effective and proven 
primary prevention. For example, HIV prevention for key populations in low- and 
middle-income countries accounted for less than 2% of total HIV resources in 2015, 
or around 9% of the resources for prevention. The majority of resources for services 
focused on key populations come from international donors, barring exceptions such 
as Brazil, Mexico and a few countries in Asia and the Pacific. In June 2016, PEPFAR 
announced a special key populations investment fund of US$ 100 million that will 
help fill the funding gap, but not address the need for sustainable, country-owned 
financing sources. 
An analysis of four countries from different regions, and with different epidemic 
patterns, found that funding of effective and focused primary prevention was 
insufficient—6% in Brazil, 4% in Cameroon, 15% in Myanmar and 10% in South Africa.
Source: Global AIDS Response Progress Reporting, 2010-2014.  
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Spending on programmes specifically for key populations as a percentage of total preven-
tion spending by source, 2010–2014
Domestic public
International
0.0
0.5
1.0
1.5
2.0
2.5
3.0
3.5
4.0
Gay men and other men who 
have sex with men
Sex workers People who inject drugs
2.4%
3.1%
1.8%
0.2%
0.7%
0.8%
2.1%
3.8%
3.3%
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Percentage of investments for effective prevention and other prevention categories, four 
countries, 2013–2014
MYANMAR
Effective prevention 
15%
Other prevention 
3%
Other AIDS  
expenditure 
82%
CAMEROON
Effective prevention 
4%
Other prevention 
15%
Other AIDS  
expenditure 
81%
SOUTH AFRICA
Effective prevention 
10%
Other prevention 
5%
Other AIDS  
expenditure 
85%
BRAZIL
Effective prevention 
6%
Other prevention 
2%
Other AIDS  
expenditure 
92%
Closing the prevention gap
Building on the momentum established at the 2016 United Nations General 
Assembly High-Level Meeting on Ending AIDS requires translating the 
commitments within the Political Declaration into action. Global targets and 
milestones need to be translated into national and sub-national targets, as well 
as implementation plans to reach these targets that focus on the populations and 
locations in greatest need, and also address the legal, social and economic barriers 
to prevention service access and uptake. At the local level, stakeholders need to 
analyse and understand their local prevention needs and mount an appropriate 
combination prevention response. 
Source: Global AIDS Response Progress Reporting.
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STRUCTURAL  
CHANGE
Within the response to AIDS, leaving no one behind is both a moral and human rights 
imperative and a public health necessity. HIV-related vulnerabilities are fuelled by 
inequalities and prejudices entrenched within the legal, social and economic structures 
of society. Harmful cultural and social gender norms, criminalization of same-sex 
relationships, cross-dressing, sex work, and drug use, and laws that require third-party 
authorization for sexual and reproductive health services block HIV prevention and 
increase risky behaviour. Homophobia drives gay men and other men who have sex 
with men away from HIV testing and HIV prevention activities, and is associated with 
lower adherence to treatment.
Empowering women and girls, young people and key populations with the agency to 
claim their rights, receive a quality education, enjoy health lives and take measures 
to protect themselves from HIV is a requisite component of combination HIV 
prevention—structural change that reflects the interconnected nature of the Sustainable 
Development Goals. 
PREVENTION GAPS
 ■ Gender inequalities, including gender-based violence, exacerbate women and 
girls’ vulnerability to HIV and block their access to HIV services. 
 ■ Third-party authorization requirements remain an important barrier to uptake 
of HIV and sexual and reproductive health services among adolescents and 
young people.
 ■ Key populations face specific challenges and barriers, including violence and 
violations of their human rights, with women in key populations particularly 
affected.
 ■ Homophobia is a barrier to HIV services for gay men and other men who have 
sex with men.
 ■ Criminalization and stigmatization of same-sex relationships, cross-dressing, 
sex work and drug use blocks HIV prevention services and increases risky 
behaviours.
 ■ Stigma and discrimination related to HIV and towards key populations in 
health-care settings undermine access to HIV prevention and other health 
services. 
WAY FORWARD
 ■ Strengthen legislation, law enforcement and programmes to end intimate 
partner violence.
 ■ Increase girls’ access to secondary education.
17 
 ■ Use cash transfers to empower women economically, to keep them in school and to enable 
them to make healthy partner choices.
 ■ Remove third-party authorization requirements and other barriers to women and young 
people’s access to HIV and sexual and reproductive health services.
 ■ Decriminalize same-sex relationships, cross-dressing, sex work and drug possession and 
use for personal consumption.
 ■ Bring to scale community empowerment and other programmes that have been proven to 
reduce stigma, discrimination and marginalization, including in health-care settings.  
THE HOMOPHOBIC CLIMATE INDEX, 2016
Source: Lamontagne et al, 2016.
0.68 - 0.800.00 - 0.29 0.84 - 1.000.48 - 0.68 No data0.80 - 0.840.29 - 0.48
Homophobic Climate Index (HCI)
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Prevalence of recent intimate partner violence among ever-married or partnered women, 
aged 15–19 years, compared to those aged 15–49 years, 32 countries, 2010–2014 
Reported by adolescent girls (aged 15–19 years)
Reported by women (aged 15–49 years)
Colombia
Peru
Nicaragua
Honduras
Haiti
34
20
12
16
2233
37
13
8
11
1615
Mali
31
30
30
52
Democratic Republic 
of the Congo
36 37
29
27
27
20
Zambia
Namibia
Gabon
40 32
Gambia
5 7
Cameroon
Dominican Republic
Sierra Leone
Togo
13 13
Côte d’Ivoire
19 22
Burkina Faso
5 9
9 11
Nigeria
19 
Source: Population-based surveys, 2010–2014.
Cameroon
Kyrgyzstan
Egypt
Nepal
Cambodia
Philippines
Jordan
36
3
17
16
7
12
18
34
23
22
8
23
8
4
37
26
31
31
17
14
14
11
7
14
35
26
 18
15
28
5
5
27
22
33
United Republic of 
Tanzania
Kenya
Pakistan
Tajikistan
Mozambique
South Africa
Comoros
Zimbabwe
Malawi
Uganda
34 21
Rwanda
Burkina Faso
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Violence increases HIV risk for women
The fear of intimate partner violence has been shown to be an important barrier 
to the uptake of HIV testing and counselling, to the disclosure of HIV-positive 
status, and to treatment uptake and adherence, including among pregnant 
women living with HIV who are receiving antiretroviral therapy as part of 
services to prevent mother-to-child transmission (1). Experiences of physical and 
emotional intimate partner violence in settings with male controlling behaviour 
and HIV prevalence above 5% have been strongly associated with HIV infection in 
women (2). In some regions, women who experienced physical or sexual intimate 
partner violence were 1.5 times more likely to acquire HIV than women who had 
experienced violence (3). 
Such violence can also disrupt HIV prevention services. For example, a study 
among African serodiscordant couples enrolled in a trial of oral daily PrEP 
suggests that recent intimate partner violence (physical, verbal and economic) 
reduces the seronegative partner’s adherence to medication. Such recent 
intimate partner violence (within the previous three months) was associated with 
a 50% higher likelihood of low PrEP adherence, after adjusting for age, years of 
education, study site, any additional sex partners and time on study (4).  
The 2016 Political Declaration on HIV and AIDS acknowledges the link between 
violence and HIV, and it calls for an end to all forms of violence and discrimination 
against women and girls. Globally, prevalence of recent intimate partner violence 
among ever-married or partnered women aged 15 to 49 years decreased between 
2000 and 2014 in 12 of 17 countries that had data for more than one year. Despite 
these declines, however, global prevalence of recent intimate partner violence 
remained high, particularly in sub-Saharan Africa: the median prevalence of recent 
intimate partner violence among ever-married or partnered women aged 15 to 49 
years in 21 sub-Saharan African countries was 26.1%. 
Adolescent girls are more vulnerable to intimate partner violence. In 22 of the 32 
countries with available data, young women reported experiencing more recent 
intimate partner violence than women in older age groups (5). Some of the intimate 
partner violence experienced by young women occurs within the context of child 
marriage. A violation of fundamental human rights, child marriage can severely 
compromise a girl’s development, result in early pregnancy and social isolation, 
interrupt her schooling, and limit her opportunities for a career and vocational 
advancement (6).
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Percent of ever-married or partnered women (aged 15–49 years) reporting experiences of 
physical and/or sexual violence by a former or current male intimate partner in the past 12 
months, most recent data, 2010–2014 
20 – 40% 10 – 19% 0 – 9% 
Cameroon Cambodia Burkina Faso
Colombia Dominican Republic Comoros
Côte d’Ivoire Egypt Gambia
Democratic Republic of the Congo Haiti Nicaragua 
Gabon Honduras Philippines
Kenya Jordan South Africa 
Malawi Kyrgyzstan
Mali Nepal
Mozambique Nigeria
Namibia Pakistan
Rwanda Peru
Sierra Leone Tajikistan
United Republic of Tanzania Togo
Uganda
Zambia
Zimbabwe
Source: Population–based surveys, 2010-2014.
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Child marriage legislation, by country, 2015
Bangladesh, Democratic Republic of the Congo, Egypt, Eritrea, the Gambia, 
Ghana, India, Kenya, Lao People’s Democratic Republic, Mongolia, Nigeria, 
Pakistan, Sierra Leone, Sweden, Switzerland, Vietnam
Bhutan, Fiji, South Sudan, China, Nepal
Malaysia, Mali, Qatar, Syrian Arab Republic, Uzbekistan 
Bahrain, Afghanistan
Kuwait, West Bank and Gaza, Yemen
Iran
Timor-Leste
Sudan
Burundi, Canada, Comoros, Czech Republic, Denmark, Finland, Grenada, Iceland, 
Madagascar, Malawi, Maldives, Mauritania, Micronesia, Morocco, Namibia, New Zealand, 
Oman, Palau, Panama, Solomon Islands, Togo, Trinidad and Tobago, United Arab Emirates, 
Samoa, Burkina Faso, Botswana, Swaziland, Uganda, Vanuatu
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Albania, Angola, Antigua and Barbuda, Argentina, Armenia, Australia, Austria, Azerbaijan, the Bahamas, Barbados, Belarus, Belgium, Belize, Benin, 
Bolivia, Bosnia and Herzegovina, Brazil, Brunei Darussalam, Bulgaria, Cabo Verde, Cambodia, Central African Republic, Chile, Colombia, Republic 
of Congo, Costa Rica, Croatia, Cyprus, Djibouti, Dominica, Dominican Republic, Ecuador, El Salvador, Estonia, Ethiopia, France, Georgia, Germany, 
Greece, Guatemala, Guinea-Bissau, Guyana, Haiti, Hungary, Iraq, Ireland, Israel, Italy, Jamaica, Jordan, Kazakhstan, Kosovo, Kyrgyz Republic, Latvia, 
Lesotho, Liberia, Lithuania, Luxembourg, Macedonia, Malta, Marshall Islands, Mauritius, Mexico, Moldova, Montenegro, Mozambique, Netherlands, 
Nicaragua, Norway, Peru, Poland, Portugal, Romania, Russian Federation, San Marino, Sao Tome and Principe, Senegal, Serbia, Seychelles, Slovakia 
Republic, Slovenia, South Africa, Spain, Sri Lanka, St. Kitts and Nevis, St. Lucia, St. Vincent and the Grenadines,  Taiwan, Tajikistan, Tonga, Tunisia, 
Turkey, Ukraine, United Kingdom, United Republic of Tanzania, United States, Uruguay, Venezuela, Zimbawe, Algeria, Republic of Korea, China, Japan, 
Libya, Myanmar, Paraguay, Thailand, Cameroon, Chad, Côte d’Ivoire, Gabon, Guinea, Honduras, Hong Kong, Indonesia, Kiribati, Niger, Papua New 
Guinea, Puerto Rico, Rwanda, Singapore, Suriname, Zambia, Equatorial Guinea, Philippines 
124
Source: Women, business and the law 2016: getting to equal. Washington, DC: World Bank; 2016.
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Girls, education and HIV
Studies have shown that increasing educational achievement among women and 
girls is linked to better sexual and reproductive health outcomes, including lower 
rates of HIV infection, delayed childbearing, safer births and safer abortions, and 
other development outcomes (7, 8). The education and empowerment of women 
and girls also are fundamental to preventing gender-based violence (9). An analysis 
of data from 44 countries found that completing secondary education significantly 
reduces a woman’s personal risk of partner violence (sexual or physical violence in 
the past 12 months), and that a girl’s education is more strongly associated with 
reduced risk of partner violence in countries where spousal abuse is more common 
(10). Girls with at least six years of school education are more likely to be able to 
protect themselves from HIV and other diseases (11).
Cash transfers have been found to help girls remain in school, which in turn leads 
to reduced HIV prevalence and incidence. In several randomized control trials, 
school attendance and safer sexual health were directly incentivized through a 
cash transfer, and there was a positive effect on HIV outcomes (12).
A study in South Africa found that financial support augmented with social 
support  from parents or teachers increased HIV-prevention benefits over cash 
alone, with reductions in incidence of multiple and concurrent partners and 
other HIV-risk behaviours for both boys and girls (13). A follow-up study found 
that combining cash transfers with free education and psychosocial support 
interventions led to cumulative reductions in HIV risk behaviours among 
adolescents (13).  
Ensuring a coherent policy and legal framework for 
young people and women
In many settings, parental and other third-party consent requirements for access to 
HIV and sexual and reproductive health services remain an important barrier to their 
uptake. Adolescents often are reluctant to seek services that require the consent of a 
parent or guardian. Similarly, laws that restrict people’s access to health services—for 
example, by requiring third-party authorization for accessing sexual and reproductive 
health services or by criminalizing certain consensual sexual behaviours—exclude 
people from the health information and services they need (14). 
Laws that foster the wide dissemination of objective comprehensive sexuality 
information improve knowledge not only of what protects or damages sexual health, 
but also where and how to seek further information, counselling and treatment. 
Further efforts are needed to ensure that the legal framework is responsive and 
sensitive to the challenges that young people face when attempting to access 
HIV and sexual and reproductive health services. This includes striking down 
requirements for parental or spousal consent, which poses additional challenges, 
particularly for adolescent girls and young women. Young key populations also must 
be ensured a protective legal environment where their identities and the behaviour 
pertaining to their populations are not criminalized, and where their rights are 
respected, protected and promoted.
24 
Parental consent for sexual and reproductive health and HIV testing services for young 
people, 2016
Among 90 countries with available data:
require young people to receive 
the consent of parents or legal 
guardians in order to access one 
or more sexual and reproductive 
health service.
require young people to receive 
the consent of parents or legal 
guardians in order to  
access HIV testing.
72 58COUNTRIES
COUNTRIES
Source: Sexual Rights Initiative. Sexual rights database (http://sexualrightsdatabase.org/map/25/Age%20of%20sexual%20consent%20-%20different%20sex, Accessed 23 June 2016).
Criminalization, discrimination and marginalization 
of key populations
Punitive laws, policies and practices affecting key populations can block their 
access to HIV-related services. This is particularly true for the criminalization 
of drug use, sex work, same-sex sexual activity, cross-dressing or activities 
considered to be imitating the opposite sex. For example, when possession of 
injecting equipment or condoms is used by criminal justice systems as evidence 
of drug use or sex work, people at high risk of HIV infection are less likely to use 
these proven prevention tools (15–19).
As of June 2016, same-sex sexual acts were illegal in 73 countries and five 
entities. This is a decrease from 92 in 2006. The death penalty could be applied 
for same-sex sexual acts in 13 countries (or parts of countries), an increase from 
nine countries in 2006 (20)1.  Such criminalization can deter men who have sex 
1The 2006 figures are taken from the video found at http://ilga.org/what-we-do/state-sponsored-homophobia-report/
previous-editions/.
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with men from seeking out HIV prevention, testing and other services when they 
need them. 
Across the world, many countries continued to criminalize some aspect of sex 
work in 2015 (21). The criminalization of drug use and people who use drugs 
also impedes access to HIV services (see the chapter on Harm reduction for 
more information). Transgender people are among the most marginalized 
people across the world, with many denied recognition of their gender and, by 
extension, the identity documents they need to access education, employment 
and appropriate health care. Cross-dressing or activities considered to be 
imitating the opposite sex also can be penalized. According to the activist 
organization Transrespect, 55 countries and territories (of 112 with available 
data) criminalized and/or prosecuted transgender people in 2015. A further 
seven countries and territories (of 110 with available data) criminalized cross-
dressing, and 12 countries and territories (of 111 with available data) prosecuted 
cross-dressing (22). In some countries, laws that criminalize transgender people 
exist but are not currently enforced. In others, prosecution occurs without the 
existence of a criminalizing law through the application of other laws, or it occurs 
without a legal basis (22). 
Overly broad criminalization of HIV non-disclosure, exposure or transmission 
deters people from seeking to know their own status or from accessing 
HIV services, including prevention services and commodities. Overly broad 
criminalization of HIV non-disclosure, exposure or transmission refers to the 
application of criminal law in relation to HIV that (i) is not guided by the best 
available scientific and medical evidence relating to HIV, (ii) fails to uphold the 
principles of legal and judicial fairness2,  and (iii) infringes upon the human rights 
of those involved in criminal law cases. Such application of the criminal law 
can be based on HIV-specific criminal statutes, or it can rely on the application 
of general criminal law provisions (23). By 2015, 72 countries had laws that 
specifically allowed for HIV criminalization, an increase from 61 in 2014 (23)3.  
Prosecutions for HIV non-disclosure, potential or perceived exposure and/or 
unintentional transmission had been reported in 61 countries, an increase from at 
least 49 in 2014 (23).
The Global Commission on HIV and the Law has shaped global actions to 
improve the links between legal environments and HIV responses since 2012 
(24).  Despite this, punitive laws, policies and practices continue to deny people 
access to effective services. HIV Justice Worldwide is a new initiative made up 
of global, regional and national civil society organizations—most of them led by 
people living with HIV—that is working to build a worldwide movement to end 
HIV criminalization. The initiative seeks to end HIV criminalization by empowering 
people living with HIV and those who advocate on their behalf to convince 
policy-makers, criminal justice actors and other relevant stakeholders to abolish 
existing laws and to oppose the passage of proposed laws designed to regulate, 
control and punish people living with HIV on the basis of their HIV status (25).
2This includes key criminal law principles of legality, foreseeability, intent, causality, proportionality and proof.
3In 2014, UNAIDS reported 61 countries with laws allowing for HIV criminalization. Although this increase is partly due to 
methodological improvements, it is also due to new laws enacted in Botswana, Côte d’Ivoire, Nigeria and Uganda. 
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The human and economic cost of homophobia  
Despite recent progress in the acceptance of gay men and other men who 
have sex with men in society in many countries, homophobia and stigma and 
discrimination based on sexual orientation are still prevalent globally. This 
discrimination is a barrier to HIV services, lowers adherence to antiretroviral 
therapy and has a human and economic cost (26, 27).
A Homophobic Climate Index (HCI)—considering institutional, social and 
behavioural homophobia, and reflecting the laws and legislation and the level of 
acceptance in society—shows where efforts are needed to address homophobia 
and protect the rights of sexual minorities (see world map at the start of the 
chapter). The closer the HCI is to 1.0, the higher the homophobia, stigma and 
discrimination. 
Stigma related to sexual orientation is also associated with lower economic output 
at country level (26, 28, 29). A recent country-by-country analysis found that the 
region with the highest cost of homophobia as a share of gross domestic product 
(GDP) in 2015 was the Middle East and North Africa, reaching 0.59% of GDP, and 
the lowest cost as a share of GDP was in western and central Europe and North 
America, at 0.13% of GDP. The highest total cost of homophobia was in Asia and 
the Pacific, at US$88.3 billion annually.
Cost of homophobia as a share of GDP and in value, per region, per year
0.4
Middle East and North Africa  
US$ 16.9 billion
Asia and the Pacific 
US$ 88.3 billion
Western and central Europe and 
North America 
US$ 49.7 billion
Eastern Europe and central Asia 
US$ 10.9 billion
Sub-Saharan Africa 
US$ 4.9 billion
Latin America and the Caribbean  
US$ 8.0 billion
0.5
0.6
0.7
0.3
0.2
0.1
0
The size of the bubble  represents the total cost of  homophobia,  per year, in  billions of US dollars,  per region.
Population of gay men and other men who have sex with men = 3% of males (aged 15–64 years). Elasticity  of homophobia = 1.19 ; Regression  fit curve R2 = 0.82.
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Higher levels of homophobia within a country resulted in more than proportionate 
higher costs as a share of national GDP (30). The economic cost of homophobia 
among the 10 countries with the highest HCI reached 0.2–0.6% of GDP, which 
is more than 10 times the share in the 10 countries with the lowest HCI. The 
study also found that a higher HCI was associated with higher levels of human 
rights violations, gender inequality and negatively associated with the overall life 
satisfaction index of its citizens. This quantification of the human and economic 
costs of homophobia reinforces the importance of inclusive laws and policies for 
sexual minorities within efforts to improve economic and social development.
Women in key populations: violence and access  
to services
Women in key populations face specific challenges and barriers, including 
violence and violations of their human rights in health care settings and from 
uniformed personnel. 
Violence is especially prevalent in the lives of sex workers, who (irrespective of 
gender) are frequently subject to sexual and physical violence, and who are likely 
to be working and living in environments that deprived them of basic rights and 
protections (31, 32). The criminalization of sex work facilitates these rights violations 
(33). A modelling study estimated that eliminating sexual violence against sex 
workers could avert 17% of HIV infections in Kenya and 20% in Canada (32). 
Women who inject drugs faced higher levels of stigma, discrimination and vulnerability 
to harm than their male counterparts (34). Those who had experienced sexual violence 
were more likely to be living with HIV than other women who inject drugs (35). Despite 
such evidence, services for women who have experienced violence and for people who 
use drugs are often disconnected, leading to a protection gap for women who inject 
drugs and experience intimate partner violence (36). 
Bringing proven approaches to scale 
In the past 15 years, global progress against HIV and AIDS has been significant, 
thanks to scientific advancements, treatment access, human rights activism, global 
solidarity and the mobilization and activism of civil society. These gains, however, 
have been uneven. Throughout the world, stigma, discrimination and exclusion—as 
well as power imbalances and unequal gender relations—continue to make women 
and girls, young people and key populations vulnerable to HIV, hindering access 
to HIV prevention, treatment and care services. As HIV cannot be addressed only 
through bio-medical approaches, the response requires simultaneous advancements 
in terms of sexual and reproductive health and rights, access to education and 
employment, social justice and gender equality. Moving forward, isolated successes 
require replication, and small-scale programmes that have been proven to work need 
to be scaled up with sustainable funding and political commitment. 
For example, strategic litigation is effective in upholding rights and changing the 
course of the response. In March 2015, a legal provision that criminalized any act 
that exposes another person to HIV and obliged people living with HIV in Kenya to 
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disclose their HIV status was declared unconstitutional by the High Court of Kenya 
(37). It was the first time anywhere in the world that such a legal provision was held 
unconstitutional.
Social support, protective social norms and social capital (including participation 
and inclusion) can enable key populations to protect themselves from the effects 
of HIV and address it (38). Community empowerment-based approaches to 
addressing HIV among sex workers also have been associated with increases in 
consistent condom use and reductions in HIV infections (39). Rights- and law-
oriented education can contribute to all of these benefits. HIV and harm reduction 
training for police officers can improve rates of referral to harm reduction services, 
and it can reduce the intent to extrajudicially confiscate syringes (40).
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CONDOMS
Condoms are at the centre of a combination HIV prevention approach; they 
are also cost-effective tools for preventing other sexually transmitted infections 
and unintended pregnancies. An estimated 45 million HIV infections have been 
averted through condom use globally since 1990 (1). Achieving the global condom 
target for 2020 would avert 3.4 million new infections (1). The cost per infection 
averted would be approximately $450, well below the lifetime cost of providing 
antiretroviral treatment (1).
PREVENTION GAPS
 ■ Stagnation of international and domestic funds for condom procurement and 
programming.
 ■ An annual gap of more than 3 billion male condoms in sub-Saharan Africa. 
 ■ Inconsistent condom use within many populations and locations in greatest 
need, including challenges for women to negotiate condom use.
 ■ Insufficient availability of lubricants and female condoms.
WAY FORWARD
 ■ Increase resources for condom procurement, distribution and promotion.
 ■ Provide male and female condoms in combination prevention packages.
 ■ Diversify condom products, including provision of female condoms alongside 
male condoms and lubricants.
 ■ Develop new approaches to increase condom use and to enhance the positive 
perception of condoms among the various populations in need.
 ■ Engage communities in condom provision and use innovative service provision 
mechanisms. 
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NUMBER OF HIV INFECTIONS AVERTED THROUGH CONDOM USE, GLOBAL,1990–2015
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Source: John Stover, Avenir Health, 2016. The Contribution of Condoms to HIV Prevention. Data for Fast-Tracking Condom Programmes. Presented at of the Global Condom Steering Group 
21-23 March 2016, Geneva.
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In 2015, an estimated 1.9 million [1.7 million–2.2 million] adults (15+) were newly 
infected with HIV—the vast majority through sexual transmission—and an estimated 
357 million people acquired chlamydia, gonorrhoea, syphilis or trichomoniasis (2). 
Every year, more than 200 million women have unmet needs for contraception, leading 
to approximately 80 million unintended pregnancies. Condoms effectively prevent all 
of these conditions.  
Optimal condom programming is a key part of the ambitious global targets to provide 
access to comprehensive prevention services to 90% of people at risk of HIV infection 
and to reduce new HIV infections to fewer than 500 000 globally. In recognition of 
this, countries agreed in the 2016 Political Declaration on ending AIDS to increase the 
annual availability of condoms to 20 billion by 2020. This includes approximately eight 
billion condoms for sub-Saharan Africa annually and 30–50 condoms per male, per 
year in high-prevalence countries.
Condom availability
In 2015, international donor investment in condom programmes was between US$ 75–
100 million globally—a level of investment that has remained stagnant since 2011 (3). 
In some countries, donor investment in condoms declined. As a result, the total volume 
of condoms distributed by Population Services International, a leading condom social 
marketing organization, decreased from 1.3 billion in 2011 to 1.1 billion in 2015 (4).
In 2015, in sub-Saharan Africa (5), an average of 10 male condoms was available for 
every man aged 15–64 years and just one female condom per eight women aged 
15–64 years (6). The number of female condoms distributed was only 1.6% of the total 
condom distribution. Condom availability varied between as many as 40 condoms 
per man aged 15–64 years in Namibia and South Africa to fewer than five condoms 
per man aged 15–64 years in Angola and South Sudan. Condom distribution was 
particularly low in some countries in western and central Africa, such as Burundi, Chad, 
Guinea and Mali (7).
The estimated condom need in 47 countries in sub-Saharan Africa in 2015 was 6 billion 
male condoms, with a range of needs from 55.4 condoms per man aged 15–64 years 
per year in Botswana to 13.2 condoms per man per year in Ethiopia and fewer than five 
per man per year in Liberia1. 
The needs of sex workers and their clients accounted for 37.8% of the total need; those 
of non-regular partners for 20.3%; and other users of condoms for family planning for 
14.6%; those of HIV-affected couples for 13.7%; and those of men who have sex with 
men for 7.6% (8).  
However, an estimated 3 billion condoms were distributed in sub-Saharan Africa 
in 2015, indicating that approximately half of the condom need was not met. In 
individual countries, the gaps ranged from more than 75% in 17 countries to a 6.3% 
surplus in South Africa. An estimated US$ 97.6 million per year is needed to close the 
procurement gap—US$ 22 million in Nigeria alone (8).
1 Based on a spreadsheet tool developed to generate national condom needs estimates by aggregating specific needs estimates for 
preventing HIV, sexually transmitted infections and unintended pregnancy for major sub-populations with exposure to infections, including sex 
workers, gay men and other men who have sex with men, people with non-regular partners, young people, people living with HIV and family 
planning clients who use condoms. For each sub-population, need is calculated using published data on population size, HIV prevalence, 
sexual behaviour and condom use targets (80–95%). Overlap between estimates for sub-populations are corrected and assumptions for 
wastage are included. The national condom gap is calculated using data on total annual male and female condom distribution.
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Condom use
In three countries with more than a 30% decline in new HIV infections since 2005, 
nationally representative population-based survey data show steady increases in 
condom use among men with multiple sexual partners. 
However, in sub-Saharan Africa, overall levels of condom use remain low. In 23 
of 25 countries in sub-Saharan Africa with available data, condom use at last 
sex among men with multiple sexual partners was lower than 50% (9). In 13 of 
the 25 countries with available data, women with multiple partners in the 12 
months preceding the survey were more likely to use condoms than their male 
counterparts.
Among young people in sub-Saharan Africa condom use remained low. In 15 of 
23 countries less than 60% of young men aged 15–24 with multiple partners used 
a condom during their last sexual intercourse. In 19 of 23 countries, less than 60% 
of young women with multiple partners reported condom use. In some countries, 
it is challenging for women, especially young women, to negotiate condom use 
with their male partners. Evidence from Asia suggests that women with greater 
autonomy in decision-making are more likely to negotiate safer sex, have higher 
HIV-related knowledge and to use condoms (10).
Trends in the percent of men who report using a condom at last sexual intercourse among 
men with multiple partners, select countries, 2000–2015
Source; Demographic and Health Surveys, 2000-2015.
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Source: Demographic and Health Surveys, 2010–2015.
Percent of men and women (aged 15–49 years) who report using a condom at last sexual 
intercourse among those with multiple partners in the 12 months prior to the survey, 
sub-Saharan Africa, most recent data, 2010–2015
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Source: Demographic and Health Surveys, 2010-2015.
Percent of young women and men (aged 15–24 years) reporting use of a condom at last 
sex among those with multiple partners in the 12 months prior to the survey, sub-Saharan 
Africa, 2010–2015
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Condom use among key populations
Condom use among sex workers and their clients and other sexual partners 
must be 100% or combined with pre-exposure prophylaxis (PrEP) to prevent 
HIV transmission. PrEP availability is currently extremely limited, with recent 
modelling suggesting that typical antiretroviral therapy coverage will not be 
sufficient to slow HIV incidence among sex workers, and that antiretroviral 
therapy coverage at approximately 80% must be accompanied by increased 
condom use (11). These data reinforce the importance of combination HIV 
prevention strategies, including the integration of condoms throughout the 
continuum of HIV services and increased linkages between HIV and sexual and 
reproductive health services and the use of combination prevention strategies.
Of the 89 countries reporting on condom use with the last client by sex workers, 
32 reported greater than 90% coverage. Condom use reported by sex workers 
in Asia Pacific is 90% or greater in five countries, including the two largest, China 
and India. Elsewhere, countries with important epidemics among sex workers, 
such as the Philippines, Indonesia and Pakistan, condom use with last commercial 
partner was suboptimal and dangerously low in Pakistan. Most other regions 
show a similar pattern, with a few countries doing reasonably well, but many 
others falling short—and some far short. Lesotho, where HIV prevalence among 
female sex workers was 72%, condom use with the last client was only 65%. 
Countries in the Middle East and North Africa generally have inadequate condom 
use to prevent HIV transmission to and from sex workers.
Gay men and other men who have sex with men, and who have multiple sexual 
partners also require consistent condom use. However, condom use in many 
countries is not occurring at sufficient levels to reduce HIV transmission rates. 
Overall, many countries report levels of condom use which are insufficient to 
curtail HIV transmission among men who have sex with men. Only three of 104 
countries with available data reported greater than 90% condom use at last 
sexual intercourse. Data on other sexually transmitted infections among gay men 
and other men who have sex with men are further evidence of the insufficient use 
of condoms (12). Low condom use in high-income countries—where antiretroviral 
therapy coverage and condom availability are high—is consistent with evidence 
of complacency or condom fatigue (13).
Condom use with the most recent sex partner among people who inject drugs is 
almost universally low. No countries were above 90% and only five of 60 countries 
reported between 70% and 89% coverage. In areas with high prevalence of 
injection drug use and HIV, such as Manipur, India, non-injecting female partners 
exhibit very high HIV prevalence, in large part due to low condom use (14,15). A 
study in Viet Nam, where HIV prevalence is extremely high among people who 
inject drugs—as high as 46% in some cities—shows that there are high rates of 
serodiscordance in couples with one partner who injects drugs. More than 40% 
of women in two cities where the study was conducted did not know that their 
male sexual partner who injected drugs was also living with HIV. 
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Data on condom use among transgender people are lacking, but there is 
evidence that condom use in this population is low. A study in Cambodia found 
that consistent condom use by transgender people was higher (40%) with female 
partners than with male partners (20–40%), with the lowest rates of consistent 
condom use with male partners when buying sex (16).
>90% 70-89% <70%
Antigua and Barbuda Algeria Bangladesh
Armenia Angola Belize
Benin Belarus Burundi
Botswana Bosnia and Herzegovina Comoros
Bulgaria Burkina Faso Democratic Republic of the Congo
Central African Republic Cambodia Djibouti
Chile Cameroon Egypt
China Cape Verde Indonesia
Colombia Congo Iran
Ecuador Costa Rica Lesotho
Eritrea Côte d'Ivoire Mauritius
Fiji Cuba Micronesia (Federated States of)
Finland Czech Republic Pakistan
Georgia Guyana Seychelles
Guinea Jamaica Sierra Leone
India Malawi Somalia
Kazakhstan Malaysia Sudan
Kenya Mexico Switzerland
Kyrgyzstan Mongolia Tunisia
Lao People's Democratic Republic Montenegro Uganda
Lebanon Myanmar Uzbekistan
Mali Nicaragua Vanuatu
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Percent of sex workers reporting condom use with last client, most recent data, 2013–2015
Source: 2016 Global AIDS Response Progress Reporting.
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>90% 70-89% <70%
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Percent of gay men and other men who have sex with men reporting condom use with last 
male partner, most recent data, 2013–2015
Source: 2016 Global AIDS Response Progress Reporting.
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>90% 70-89% <70%
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Source: 2016 Global AIDS Response Progress Reporting.
In most countries laws, regulations or policies are obstacles for the distribution of 
condoms to people in prisons and other closed settings. In countries where they 
are available, condoms are often not easily accessible, lubricant is rarely provided 
and distribution is limited to a fraction of the prisons. Also, in many countries, 
access to condoms in prisons is limited to conjugal visiting rooms and not for use 
between prisoners. Access to female condoms is even lower.
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Female condoms in combination prevention
Female condoms are currently the only widely available method giving women 
and adolescent girls greater control over protecting themselves from HIV, other 
sexually transmitted infections and unintended pregnancy (17). A growing body 
of evidence shows that effective female condom promotion to both women and 
men can increase the proportion of protected sex acts. Studies conducted in 
a variety of contexts show that the female condom is widely acceptable and a 
realistic alternative to the male condom. Increasing method choice can increase 
uptake and use of contraceptives, including condoms, with one study showing 
that providing a choice of condoms successfully increased acceptability (18). 
The promotion of female condoms can be paired with biomedical technologies, 
such as PrEP and other forms of microbicides, to reduce HIV, other sexually 
transmitted infections and unwanted pregnancies. Integrating male and female 
condom promotion into other services, such as family planning, HIV counselling, 
testing and treatment, voluntary medical male circumcision and prevention 
of mother-to-child transmission, can also help to increase the demand for this 
method. Female condoms should be promoted as an additional option for both 
men and women, rather than as a replacement for the male condom (18).
A new generation of comprehensive condom 
programmes
The challenge ahead is to invest in, and scale up, a new generation of data-
driven and people-centred comprehensive condom programmes, including 
demand creation, community mobilization, supply chain management, planning, 
programme management and monitoring and evaluation. Comprehensive condom 
programmes should use a total market approach that includes the public and 
private sectors and social marketing.
Condom programming needs to be predicated on sexual and reproductive health 
and rights and gender equality. It must integrate—and be integrated into—
comprehensive sexuality education and efforts to promote respect for the right 
to the enjoyment of sex and to the expression of sexual identity. In order to be 
responsive to individual and context-specific needs, young people, people living 
with HIV, sex workers, men who have sex with men and people who inject drugs—
alongside other vulnerable populations—will need to be involved in the planning 
and implementation of condom programming. These populations should also 
contribute to efforts to improve data and increase innovation through programme 
science, market research, needs estimates, costing and monitoring and evaluation. 
National and community leadership will be essential to increasing domestic 
funding and ownership of national condom strategies and to moving away from 
programmes that are primarily funded and managed by international donors.
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VOLUNTARY MEDICAL  
MALE CIRCUMCISION
Voluntary medical male circumcision is a cost-effective, one-time intervention 
that provides lifelong partial protection against female-to-male HIV transmission. 
Modelling studies have suggested that achieving 80% circumcision prevalence among 
men aged 15 to 49 years by 2015—and then sustaining it—would avert 3.4 million HIV 
infections by 2025 (1). 
Since 2007, tremendous efforts have been made to scale up voluntary medical male 
circumcision in 14 priority countries in eastern and southern Africa that have high 
levels of HIV prevalence and low levels of male circumcision. By the end of 2015, 
nearly 11.6 million men in these countries had been medically circumcised.
PREVENTION GAPS
 ■ Following years of rapid increase, annual numbers of circumcisions performed 
within eight of the 14 priority countries declined in 2015. 
 ■ The annual number of circumcisions performed in the 14 priority countries1 
must more than double to reach the 2020 target of 25 million additional young 
men in high-prevalence settings being circumcised.
WAY FORWARD
 ■ Integrate vertical programmes within national health systems.
 ■ Promote voluntary medical male circumcision as part of a core package of health 
services for men and boys, using approaches that are tailored for various age 
groups and locations.
 ■ Increase domestic funding to ensure sustainability.
 ■ Widen the use of new non-surgical circumcision devices.
 ■ Develop new approaches for adolescent and early infant circumcision.
 ■ Break down myths and misconceptions about circumcision.
1The 14 priority countries include Botswana, Ethiopia, Kenya, Lesotho, Malawi, Mozambique, Namibia, Rwanda, South Africa , Swaziland, 
United Republic of Tanzania, Uganda, Zambia, Zimbabwe. The 2020 target also includes South Sudan. 
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CUMULATIVE NUMBER OF VOLUNTARY MEDICAL MALE CIRCUMCISIONS, 14 PRIORITY 
COUNTRIES, 2009–2015
ANNUAL NUMBER OF VOLUNTARY MEDICAL MALE CIRCUMCISIONS, 14 PRIORITY 
COUNTRIES, 2009–2015
Sources: 2016 Global AIDS Response Progress Reporting.
0
5
10
15
20
25
30
35
40
37
2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020
Sources: 2016 Global AIDS Response Progress Reporting.
N
um
b
er
 (m
ill
io
n)
0
0.5
1
1.5
2
2.5
3
3.5
2009 2010 2011 20132012 2014 2015
Ethiopia
Swaziland
Botswana
Namibia
Lesotho
Malawi
Rwanda
Zimbabwe
Mozambique
Kenya
Zambia
United Republic of Tanzania
South Africa
Uganda
N
um
b
er
 (M
ill
io
n)
42 
Progress among priority countries varied widely between 2009 and 2015. Ethiopia, 
Kenya and the United Republic of Tanzania had surpassed their national coverage 
targets, and Mozambique, South Africa, Uganda and Zambia had achieved between 
50% and 70% of their coverage targets by the end of 2015. In Botswana and 
Swaziland, however, coverage was around 45%, and in Lesotho, Malawi, Namibia, 
Rwanda and Zimbabwe, coverage was under 35% in 2015.
The United Nations General Assembly set an ambitious target in the 2016 Political 
Declaration on HIV and AIDS to provide voluntary medical male circumcision to an 
additional 25 million young men in high HIV incidence areas between 2016 and 2020.
The drop in annual numbers of circumcisions is a 
cause for concern
A steady increase in the annual number of men voluntarily circumcised between 
2008 and 2014 was followed in 2015 by a worrying decline in annual circumcisions 
within eight of the 14 priority countries. The cumulative number of circumcisions 
among all 14 priority countries dropped to 2.6 million in 2015 (compared to 3.2 
million in 2014). In Ethiopia, South Africa and Swaziland, however, the number of 
circumcisions remained stable in 2015; in Kenya, Malawi and Namibia, the annual 
number of circumcisions increased.  
Programme managers in the priority countries are examining the causes of this 
decline. Potential reasons may include reporting challenges, temporary disruptions 
caused by changes in procedures, reductions in funding and a natural decline after 
early adopters had been reached (2). 
Among the nine priority countries with age-disaggregated data (Botswana, Ethiopia, 
Kenya, Lesotho, Mozambique, Rwanda, Swaziland, Zambia, Zimbabwe), uptake of 
voluntary medical male circumcision was highest among those aged 10–14 years, 
followed by those aged 15–19 years and 20–24 years. The analysis of disaggregated 
data by age or age bands allows for more precise monitoring of progress in each age 
band, and for taking action as needed to improve services.
Getting circumcision back on track
Achieving the 2020 target will require continued increases in the scale of 
programmes in the priority countries. Instead of less than 3 million male 
circumcisions annually, more than 5 million will need to be performed. In some 
countries, this will require the integration of vertical programmes within national 
health systems and the strengthening of the capacity of public health systems 
to manage these programmes at both the national and local levels. In addition, 
voluntary medical male circumcision should be part of a core package of health 
services for men and boys, using approaches that are tailored for various age groups 
and locations. Similarly, increases in domestic funding will be required to ensure the 
sustainability of programmes in countries that currently rely on international funding 
for the majority of their programme budgets. 
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Measures are already being taken to improve programme coverage and efficiency. 
In all 15 of the priority countries (including South Sudan), more nurses are being 
trained to provide voluntary medical male circumcision services. The introduction 
of male circumcision devices also is providing an alternative to conventional surgical 
circumcision methods that require greater surgical skill and clinical infrastructure, 
both of which are limited in resource-poor settings.
There also is a continuing need to break down myths and misconceptions about 
circumcision—and to navigate cultural sensitivities—through intensification of 
demand creation strategies. Innovation in service packages and provision also 
can address the concerns of potential clients. For example, male circumcision 
devices have been reported to increase the acceptability of voluntary medical male 
circumcision. As of the end of 2015, two such devices had been pre-qualified by the 
WHO for use. 
Meanwhile, studies are underway to inform new approaches—including participatory 
ones—to provide comprehensive and sustainable services for adolescents, and to 
increase feasibility of early infant circumcision. 
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HARM  
REDUCTION1
People who inject drugs are among the key populations most at risk to acquire or 
transmit HIV. Yet they are also among those with the least access to HIV prevention, care 
and treatment services because their drug use is often stigmatized and criminalized.
The tools and strategies required to improve the health and lives of people who use drugs 
are well known and readily available. Needle–syringe programmes reduce the spread 
of HIV, hepatitis C and other bloodborne viruses. Opioid substitution therapy and 
other evidence-informed forms of drug dependence treatment curb drug use, reduce 
vulnerability to infectious diseases, and improve uptake of health and social services.
The overwhelming body of evidence on the effectiveness of harm reduction, including 
in prisons and other closed settings,  is the basis for a comprehensive package of 
interventions recommended by the World Health Organization (WHO), the United 
Nations Office on Drugs and Crime (UNODC) and the Joint United Nations Programme 
on HIV/AIDS (UNAIDS) for preventing the spread of HIV and reducing other harms 
associated with drug use. Few countries have achieved sufficient coverage of harm 
reduction services, however.
PREVENTION GAPS
 ■ Needle–syringe programmes are available in only 90 of the 158 countries where 
injecting drug use has been documented. Only 8 countries have at least one 
programme in prisons.
 ■ Only 12 countries provide the recommended threshold of 200 clean needles per 
person who injects per year.
 ■ Less than 80% of people who inject drugs reported injecting with a clean needle the 
last time they injected in 22 of the 59 countries with available data.
 ■ At least one opioid substitution therapy site is available in only 80 of the 158 
countries where injecting drug use has been documented. Only 43 countries have 
programmes in prisons.
 ■ HIV prevalence among women who inject drugs is often greater than their male 
peers, highlighting a need for gender-sensitive harm reduction interventions.  In 
24 of 35 countries reporting to the 2016 Global AIDS Response Progress Report, 
median HIV prevalence among women was 50% higher, with a range of 2% to 530%.
 ■ Criminalization of drug possession and use perpetuates risky forms of drug use, 
increases HIV risk, discourages people who use drugs from seeking health care, and 
reinforces the marginalization of people who use drugs. Presently, 11 countries have 
compulsory detention and 15 have death penalties for people who used drugs.
1 This chapter contains excerpts from the UNAIDS report “Do no harm”, published in April 2016 (1). Some estimates, programme data 
and country examples have been updated to reflect the latest round of Global AIDS Response Progress Reporting (2).
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AVAILABILITY OF NEEDLE–SYRINGE EXCHANGE PROGRAMMES AND OPIOID 
SUBSTITUTION THERAPY, 2014
Opioid substitution therapy only
Needle–syringe programmes only
Neither available
Not known
Both needle–syringe programmes  
and opioid substitution therapy available
Source: The global state of harm reduction 2014. London: Harm Reduction International; 2014 (http://www.ihra.net/files/2015/02/16/GSHR2014.pdf).
WAY FORWARD
 ■ Ensure that all people who inject drugs, including people in prisons and other 
closed settings, have access to harm-reduction services to prevent HIV infection.
 ■ Ensure that all people who inject drugs and are living with HIV and/or hepatitis C 
have access to lifesaving treatment.
 ■ Ensure all people who use drugs have access to non-coercive and evidence-
informed drug dependence treatment, including opioid substitution therapy, 
consistent with international human rights standards.
 ■ Adapt and reform laws to ensure people who use drugs do not face punitive 
sanctions for the use of drugs or possession of drugs for personal consumption.
 ■ Ensure widespread, community-based availability of naloxone as a lifesaving 
public health measure.
 ■ Support and empower community and civil society organizations, including 
organizations and networks of people who use drugs, in the design and delivery 
of HIV prevention services.
 ■ Combine treatment with other combination prevention approaches, e.g. pre-
exposure prophylaxis and condom promotion for serodiscordant couples.  
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Insufficient harm reduction coverage
Efforts to criminalize and aggressively police and sanction the use of narcotic 
drugs and psychotropic substances have had little or no impact on the number 
of people using drugs. Country data collected by UNODC show that the 
percentage of people who use illicit drugs has remained stable, fluctuating 
between 4.6% and 5.2% of adults, since at least 2006 (3). The rights-based public 
health alternative is harm reduction: services, programmes and policies that 
seek to reduce the health, social and economic harms of drug use to individuals, 
communities and societies.
In too many countries with large populations of people who inject drugs, 
however, harm reduction has not expanded beyond small-scale pilot schemes 
funded by external donors. In 2014 needle–syringe programmes were available in 
only 90 of the 158 countries where injecting drug use has been documented, and 
opioid substitution therapy was available in only 80 of these countries (4).
Needle–syringe programmes
Decades of experience within dozens of countries supports the effectiveness 
of needle–syringe programmes (4-6). Across eight countries in eastern Europe 
and central Asia, a tripling of needle–syringe programme coverage between 
2005 and 2010 reduced injecting risk behaviour related to HIV and hepatitis C 
and reduced new infections (7). Many individual programmes have achieved 
outstanding results. Ten years of needle–syringe programming in Australia 
reduced the number of cases of HIV by up to 70% and reduced the number of 
cases of hepatitis C by up to 43% (8). In New York a sharp decrease in new HIV 
infections among people who inject drugs between 1992 and 2012 has been 
attributed to the implementation and expansion of syringe exchange since 1992 
(9).
Costing US$ 23–71 per person per year, needle–syringe programmes are 
relatively inexpensive to implement and are much more affordable than the 
lifetime health-care costs required to treat a person living with HIV (10). 
Conversely, the absence of needle–syringe programmes is a common feature in 
explosive increases in HIV incidence in communities that use drugs, for example 
in India, Philippines, and Indiana in the United States of America (11-13).
Of 60 countries that provided data on needle–syringe programming in 2015, 
however, only 13 reported more than the recommended threshold of 200 clean 
needles provided per person who injects per year (2).
In Asia and the Pacific, where distribution per country was the highest in the 
world, a regional median of 84% of people who inject drugs reported the use of 
sterile injecting equipment at last injection, and over 80% reported safe injecting 
practices in 9 of the 15 countries that reported (2).
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Source: 2016 Global AIDS Response Progress Reporting.
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Opioid substitution therapy
Drug dependence is a chronic health condition. As with other chronic conditions, 
long-term and continued treatment is often required, and affected people 
remain vulnerable to relapse throughout their lifetime (3). Despite these 
challenges, systematic reviews of opioid substitution therapy (mostly methadone 
or buprenorphine maintenance therapy) have demonstrated its effectiveness 
in the reduction or complete cessation of the use of heroin and other opioids 
(14,15). This in turn yields individual and public health dividends. Methadone 
maintenance therapy has been associated with a 54% reduction in the risk of 
HIV infection within populations of people who inject drugs (16). It has been 
calculated that providing sufficient access to this critical component of harm 
reduction could prevent 130 000 new HIV infections outside sub-Saharan Africa 
every year (17).
Substitution therapy has also been shown to decrease the risk of hepatitis C 
infection (18), to increase adherence to antiretroviral therapy for HIV (19), to lower 
out-of-pocket health expenditures (20), and to reduce opioid overdose risk by 
almost 90% (21). The scale-up of methadone maintenance therapy in diverse 
country contexts, including Portugal (20), Viet Nam (22) and New Zealand (23), 
has also been associated with a decrease in crimes committed by people who 
use drugs.
Median percent of people with opioid dependence use receiving opioid substitution 
therapy, 2015
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Global coverage of opioid substitution therapy, however, remained inadequate 
to reduce injection and thereby reduce HIV transmission: among the 72 countries 
reporting opioid treatment data, median coverage was 17% of people who 
use drugs. In eastern Europe and central Asia, opioid substitution therapy 
was available in all countries except the Russian Federation, Turkmenistan and 
Uzbekistan but capacity to provide such therapy remained low in many settings.
Available data from Asia and the Pacific also indicated low coverage in 2015, with 
an estimated 120 000 people who used drugs enrolled in opioid substitution 
therapy and coverage in the 12 countries that reported data ranging from 0.5% of 
people who inject drugs in Afghanistan to 24% among people who inject drugs in 
Malaysia (2). In China a free voluntary methadone programme served more than 
184 000 people (nearly 10% of the country’s people who inject drugs) in 2015 
(24). Combined with the national needle–syringe programme, this service has 
resulted in dramatic reductions in the proportion of new HIV diagnoses among 
people who inject drugs (25).
In the Middle East and North Africa, opioid substitution therapy was well-
established in the Islamic Republic of Iran, Lebanon and Morocco. Over 24 000 
of an estimated 200 000 people who inject drugs in the Islamic Republic of 
Iran received opioid substitution therapy in communities and prisons in 2015, 
and the number of newly reported cases of HIV among these people dropped 
significantly. In Morocco 820 people who inject drugs received treatment at new 
drug dependence treatment centres, including in one prison. In Lebanon more 
than 1500 people were receiving community treatment in 2015.
Overdose treatment
Opioid overdose claims the lives of an estimated 70 000–100 000 people each 
year (21). Naloxone is an extremely effective treatment for opioid drug overdose 
(26). Naloxone is relatively inexpensive, and using it may result in a life saved. In 
most countries, however, naloxone is accessible only by prescription or through 
hospitals and ambulance crews, who may not reach a person in need until it is 
too late. WHO recommends that people likely to witness an opioid overdose 
including people who use opioids, and their family and friends, especially 
for people just released from prison, should have access to naloxone and be 
instructed in its use for emergency management of suspected opioid overdose.
Barriers to harm reduction
The exclusion and marginalization of people who use drugs has been 
acknowledged as one of several unfortunate consequences of the international 
drug control system (27). Civil society organizations of people who use drugs 
describe pejorative terms such as “junkie” and “addict” commonly used in news 
media as hate speech that dehumanizes and stereotypes them as unpredictable, 
violent, and unable to exercise agency and self-determination (28). Such beliefs 
weaken human rights safeguards and create barriers to employment, health care 
and social services. These barriers are even larger when people who use drugs 
internalize societal stigma. Judgemental feelings among health-care providers 
have been linked to lower-quality health care and lower health outcomes (29,30).
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In many countries, laws, policies, pratices and other structural barriers facilitate 
discrimination of people with a history of drug use and create barriers to HIV 
prevention services. Criminal justice systems that use possession of drug 
paraphernalia or drug residue within injecting equipment as evidence of illegal 
drug possession or use are particularly disruptive to needle–syringe programmes 
(31). Syringe confiscation has been associated with increases in HIV infection 
among female sex workers who inject drugs (32). In parts of eastern Europe and 
central Asia, nongovernmental organizations report that police may consider 
needle–syringe distribution as promotion of illegal drug use, which leads to a 
high rate of turnover among outreach workers who fear they may be arrested for 
carrying injecting equipment (32). Police crackdowns on drug use, random urine 
drug screens, and police surveillance of health-care and harm-reduction service 
providers discourage people who use drugs from accessing these services (31).
Laws and policies that make drug use a criterion for loss of child custody, 
forced or coerced sterilization or abortion, and denial of welfare benefits have 
a disproportionate impact on women who use drugs (33,34). In some countries, 
such as the Russian Federation, opioid substitution therapy is unavailable or 
illegal, and in other countries, even though it may be available, police reportedly 
target people accessing treatment for drug arrests (35).
The threat of being sent to a compulsory detention centre is a powerful deterrent to 
accessing harm reduction services in at least 17 countries in Asia and Latin America 
(36,37). The United Nations High Commissioner for Human Rights, the United 
Nations Special Rapporteur on Torture and the United Nations Special Rapporteur 
on the Right to Health have raised serious concerns regarding the decision-making 
process for sending people to compulsory drug detention facilities, the conditions 
within the centres, and the forms of treatment provided (38-40).
Legislation that criminalizes possession and use of drugs for personal consumption 
is one of the most formidable barriers to the provision of harm-reduction services. 
Criminalization has been shown to perpetuate risky forms of drug use, to increase 
the risk of illness (including from HIV infection) among people who use drugs, to 
discourage people who use drugs from seeking health care, and to reinforce the 
marginalization by society of people who use drugs (38).
Decriminalization and depenalization
A large body of evidence shows that alternatives to incarceration such as 
community-based drug dependence treatment are more cost effective at 
reducing health, social and economic harms of drug use (41). Several countries 
are moving away from criminalization of drug use. Armenia, Belgium, Chile, the 
Czech Republic, Estonia, Mexico and Portugal are among the countries that have 
adopted some form of decriminalization policy since 2000 (41).
The Czech Republic’s decriminalization of the use and possession of small 
quantities of drugs combined with relatively high coverage of needle–syringe 
programmes and opioid substitution therapy have been credited with the 
country’s remarkably low rates of HIV among people who inject drugs, especially 
when compared with other countries in central and eastern Europe (42). HIV 
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prevalence among people who inject drugs in 2012 was estimated to be 0.1% in 
the Czech Republic (43).
Among the best-documented policy changes is Portugal’s. In 2000 Portugal 
passed a new drug law that downgraded purchase, possession and consumption 
of small amounts of narcotic drugs from criminal to administrative offences. 
Under the law an individual can possess a 10-day supply of drugs before facing 
criminal charges as a drug dealer. The law also put in place a wide range of drug 
use prevention measures focused on high-risk groups and areas and systematic 
application of harm-reduction measures, including needle–syringe distribution 
and drug dependence treatment (44).
The 10 years after Portugal’s law was enacted saw a decline in the rate of crimes 
related to drug consumption, especially petty thefts (45). There is evidence of 
reductions in problematic drug use, drug-related harms and criminal justice 
overcrowding, and the number of people entering drug dependence treatment 
programmes in Portugal increased from just over 5000 in 2008 to 40 000 in 2010 
(45). Since 2000 there has been a steady decrease in the number of people who 
inject drugs being newly infected with HIV in Portugal, and a huge decrease in 
the percentage of people who inject drugs representing new HIV infections (45). 
In 2013 a total of 78 new HIV cases were related to drug use, compared with 1430 
in 2010 (46). A similar downward trend has been observed for hepatitis C and 
hepatitis B among people attending drug treatment centres, despite an increase 
in the number of people seeking treatment (46).
Number of people newly diagnosed with HIV in Portugal since the decriminalization of drug 
use, 2000–2013
Source: Domoslawski A. Drug Policy in Portugal: the benefits of decriminalization drug use. Warsaw: Open Society Foundations; 2011.
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The combination approach
Individual harm reduction approaches are successful in reducing the harms related 
to drug use, but they are even more effective when delivered as a package, not only 
together but combined with other prevention services such as condom programmes 
and treatment (10). Condom provision within harm-reduction programmes can 
help to reduce the transmission of HIV from people who inject drugs to their sexual 
partners (47). Ensuring HIV tests are offered routinely to people who access needle–
syringe services and opioid substitution therapy helps to identify people living with 
HIV as soon as possible after infection and the immediate initiation of antiretroviral 
therapy (1). People living with HIV who inject drugs are more likely to remain on 
antiretroviral therapy if they are also accessing opioid substitution therapy; in 
addition, early initiation of treatment contributes to the suppression of viral load and 
maximizes the prevention benefits of such treatment (16, 48). Increasing the provision 
of such combined approaches—including those that incorporate pre-exposure 
prophylaxis for people who inject drugs at particularly high risk, and for their sexual 
partners—will enhance the benefits of harm reduction.
Community engagement
Peer- and community-driven provision of harm-reduction services has been 
proven to increase uptake of services. These approaches provide a vital way 
to ensure that people who inject drugs can access programmes, and the 
approaches should be scaled up and expanded.
In one district in Viet Nam where 75% of the people living with HIV were 
people who inject drugs, programming moved from a traditional approach 
(using behaviour change communication, commodities provision and voluntary 
counselling and testing referral) to a peer-driven intervention approach with web-
based outreach. Two outreach workers (one from an HIV outpatient clinic and 
one from a methadone maintenance therapy clinic) recruited people who inject 
drugs, providing them with “coupons” and other incentives and referrals for HIV 
testing services (and, where necessary, care and treatment). These initial recruits 
(or “seeds”) pass coupons to other people in their own networks, including other 
people who inject drugs and their sexual partners. The programme resulted in 
improvements in tracking people through the cascade of services, and increases 
in testing and diagnosis—from 94 people tested (3.2% of whom tested positive) 
in 2013 to 483 people (6.8% of whom tested positive) in 2015. In 2016, of 
the 10.9% of people tested who were living with HIV, 41.6% were enrolled in 
treatment (49).
In Ukraine community outreach workers increased the uptake of methadone 
maintenance therapy and antiretroviral therapy among people who inject drugs 
by 36% (almost 200 and 1000 people, respectively) in 10 months (50). The 
Government of Belarus plans to directly contract nongovernmental organizations 
to provide HIV services (51). In the Islamic Republic of Iran nongovernmental 
organizations provide comprehensive harm-reduction services—including needle 
exchange, methadone maintenance, general medical care, voluntary counselling 
and testing for HIV, and the provision of food, clothes and other basic needs—
through drop-in centres and referrals to public health care facilities (52).
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VIRAL  
SUPPRESSION
Strong adherence to antiretroviral therapy suppresses viral load to undetectable levels 
within people living with HIV, greatly reducing the risk of transmitting the virus to others 
(1–3). When large proportions of people living with HIV within a community are on 
treatment, it has been shown to have a preventive effect within that community (4, 5). 
This preventive effect of treatment has been heralded as a game-changer within the global 
response to HIV. Achievement of the 90–90–90 target by 2020 alongside high coverage of 
other HIV prevention interventions can make the end of the AIDS epidemic a reality by 
2030 (6).
PREVENTION GAPS
 ■ An estimated 38% [35–41%] of people living with HIV worldwide are not virally 
suppressed.
 ■ More than 15.6 of the 36.7 million people living with HIV do not know their 
HIV status.
 ■ Access to treatment and viral suppression levels are lower among key 
populations compared to the general population in many countries, and lower 
among men compared to women.
 ■ Gaps in access to HIV testing and treatment are largest in western and central 
Africa and the Middle East and North Africa.
 ■ Stigma, discrimination and other human rights violations deter people 
from seeking testing and treatment and compromise sustained adherence to 
antiretroviral treatment.
 ■ The preventative benefits of treatment are not being realized fully due to failure to 
reach people soon after infection, when viral load levels are high. 
 ■ Disruptions of viral suppression of those on treatment, due to lack of adherence 
or viral resistance, limit the potential gains of treatment.
WAY FORWARD
 ■ Expand innovative HIV testing strategies, such as self-testing and partner-
supported testing services.
 ■ Use cash transfers to increase HIV testing uptake and treatment adherence.
 ■ Increase community engagement in HIV testing and treatment programmes.
 ■ Implement human rights programmes to remove structural barriers to testing 
and treatment.
 ■ Adopt the 2015 WHO guidelines that call for the immediate offer of 
antiretroviral therapy following diagnosis.
 ■ Reduce cost and increase coverage of viral load testing.
 ■ Combine treatment with other combination prevention approaches, including 
pre-exposure prophylaxis  and condom promotion for serodiscordant couples.  
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RECOMMENDED ANTIRETROVIRAL TREATMENT INITITATION THRESHOLD AMONG 
PEOPLE LIVING WITH HIV PER MINISTRY OF HEALTH GUIDELINES, MID-2016
PROGRESS TOWARDS 90–90–90 TARGET, GLOBAL, 2015
Percentage of people living with  
HIV who know their HIV status1
57% 
(53–62%)
90%
46% 
(43–50%)
81%
38% 
(35–41%)
73%
Percentage of people living with 
HIV who are on antiretrovial
Percentage of people living with 
HIV who are virally suppressed2
Source: UNAIDS special analysis, 2016; for more details, see annex on methods.
1 2015 measure derived from data reported by 87 countries, which accounted for 73% of people living with HIV worldwide.    
2 2015 measure derived from data reported by 86 countries. Worldwide, 22% of all people on antiretroviral therapy were reported to have received a viral load test during the reporting period. 
       
Source: World Health Organization, 2016.
CD4 count of 350 cells/mm3 or less
CD4 count of 500 cells/mm3 or less
Recommending treat all later in 2016
Treat all
Policy not available
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The scale-up of treatment is among the greatest successes of the global AIDS response 
to date. In the past two years the number of people living with HIV on antiretroviral 
therapy has increased by about a third, reaching 17.0 million people. These gains are 
largely responsible for a 26% decline in AIDS-related deaths globally since 2010, from an 
estimated 1.5 million [1.3 million–1.7 million] in 2010 to 1.1 million [940 000–1.3 million] 
in 2015. In the world’s most affected region, eastern and southern Africa, the number 
of people on treatment has more than doubled since 2010, reaching nearly 10.3 million 
people, and AIDS-related deaths have decreased by 36% since 2010.
Analysis of the available data validated by UNAIDS in partnership with UNICEF and 
WHO,1 however, suggests that much greater progress in the areas of testing and 
treatment is required to reach the 2020 target of fewer than 500 000 new HIV infections 
in 2020. In 2015, of the 36.7 million [34.0 million–39.8 million] people living with HIV 
globally, an estimated 57% [53–62%] knew their HIV status, 46% [43–50%] were on 
antiretroviral therapy, and 38% [35–41%] had achieved viral suppression.
The global gap to achieving the 90–90–90 target in 2015 was around 11.9 million people 
living with HIV who did not know their status, 12.7 million people in need of antiretroviral 
therapy, and 13.0 million people living with HIV who were not virally suppressed.
1 A full description of the methods for deriving the 90–90–90 measures  are provided in the annex to this report.
90–90–90 target cascade, global, 2015
Source: UNAIDS special analysis, 2016; for more details, see annex on methods.
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Access to treatment among key populations 
remains a challenge
Studies indicate that access to antiretroviral therapy coverage among key 
populations compared to the general population continues to be lower in many 
countries, with uptake hampered by punitive legal environments, the stigma 
surrounding HIV testing and fear that a diagnosis of HIV may be disclosed to 
others without consent.  Among gay men and other men who have sex with men, 
in 7 of 10 countries with available data, treatment coverage was considerably 
lower than coverage among all men living with HIV. Treatment coverage levels 
among people who inject drugs were more similar to coverage among men 
generally, but differences were still observed in 4 of 8 countries. Female sex 
workers were also less likely to access treatment than the general adult female 
population, with just 3 of 12 countries having similar levels of coverage. In 
Cambodia, transgender people had higher treatment coverage than female sex 
workers but lower than the general adult female population. 
Antiretroviral therapy coverage among select key population groups and the general adult 
male population (aged 15 years and older), matched by survey year, 2013–2015
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Source: UNAIDS, the Global Fund to Fight AIDS, Tuberculosis and Malaria, and the World Health Organization. Key Population Atlas. In press. 2016.
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Antiretroviral therapy coverage among select key population groups and the general adult 
female population (aged 15 years and older), matched by survey year, 2013–2015
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Source: UNAIDS, the Global Fund to Fight AIDS, Tuberculosis and Malaria, and the World Health Organization. Key Population Atlas. In press. 2016.
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Regional cascades reveal variations in progress
Western and central Europe and North America were the closest to achieving the first 
90, with 86% [78–95%] of people living with HIV knowing their status, followed by Latin 
America and the Caribbean at 75% [64–87%]. Coverage of antiretroviral therapy in 
western and central Europe and North America was similarly highest at 59% [54–66%] of 
all people living with HIV, closely followed by Latin America at 55% [47–64%] and eastern 
and southern Africa at 55% [50–58%]. These regions also made measurable progress 
toward achieving high viral load suppression coverage in the population. Nearly half, 
or 47% [43–52%] of people living with HIV in western and central Europe and North 
America were virally suppressed. Coverage was 45% [42–49%] in eastern and southern 
Africa and 41% [35–47%] in Latin America and the Caribbean.
Considerable work remains in the other regions to reach the 90–90–90 target by 
2020. In the Middle East and North Africa and western and central Africa regions, 
just over a third of people living with HIV are aware of their status, and nearly 9 in 
10 people living with HIV have not achieved viral suppression. Viral suppression 
levels in Eastern Europe are also very low at 19% [17–20%], explained in part by the 
fact that only 1 in 5 people living with HIV are on antiretroviral treatment.
Of note, the availability of reported data on viral load testing and suppression in 2015 
was extremely limited in many regions, especially in western and central Africa and 
in eastern and southern Africa, with test results available for around 2% and 14%, 
respectively, of the population on antiretroviral therapy. As a result, it is difficult to 
generalize results to the overall population in these regions in particular.
59 
Progress toward the 90–90–90 target, by region, 2015
Improving knowledge of HIV status
Rapid increases in the proportion of people living with HIV who have been 
diagnosed requires expansion of innovative testing strategies. Self-testing kits 
are both discreet and convenient for people who may be reluctant to take a test 
at a health facility or who live in places where health facilities are inaccessible. 
Self-testing may be particularly valuable for members of key populations, who 
may fear HIV-related or behaviour-related stigma and discrimination in health 
care settings, and other vulnerable groups, such as adolescents and young 
people who may require parental permission to access sexual and reproductive 
health services (7, 8).
Self-tests are a screening tool, however, and results need to be confirmed by a 
health worker (7). The accuracy and sensitivity of some self-test kits is high (over 
90% for saliva-based tests), but because they are used by untrained people the 
level of user error can also be high (0.37–5.4%) (7).
Self-testing services are increasingly being used by countries throughout the 
world, including Australia, Brazil, France, Moldova, the United Kingdom of Great 
Britain and Northern Ireland and the United States of America. In 2015 Kenya 
announced plans to introduce self-test kits and began evaluating distributors. 
A two-year project to scale up self-testing in Malawi, Zambia and Zimbabwe 
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was launched by UNITAID and PSI in 2015, focused on places and people where 
access to testing is restricted (in rural and peri-urban areas and among female 
sex workers and gay men and other who have sex with men) (9).
There is evidence that incentivizing people, including with monetary incentives, 
for HIV and sexually transmitted infection testing can lead to higher rates of 
uptake of HIV counselling and testing (10). In rural districts in Malawi the retrieval 
of test results was on average 43% points higher among participants in a study 
who were offered door-to-door HIV testing and who received a voucher for up 
to US$ 3 when they went to a clinic to collect their results. For every additional 
dollar of incentive provided, there was an increase of 9% (11). At an urban clinic 
in the United States, monetary incentives of US$ 5 and US$ 10 increased test 
acceptance rates by 12% and nearly 13%, respectively, although lower incentives 
(US$ 1) had no impact. Incentives were particularly successful among people 
reporting HIV risk factors, with increased acceptance rates from 62% to 66% 
(12). In South Africa a food voucher worth US$ 5 for households increased the 
probability of HIV testing consent during home visits by 29% (13).
Assisting people diagnosed with HIV to inform their sexual partners of the result 
may also increase the uptake and yield of HIV testing services. “Assisted partner 
services” used within a randomized control trial in Kenya led to a four-fold 
increase in the rates of testing of the sexual partners of people living with HIV, 
and a similar increase in the number of people testing positive and enrolling into 
HIV care (14). A partner-referral study in the United Republic of Tanzania enrolled 
390 index clients who were diagnosed with HIV through self-initiated and 
provider-initiated voluntary testing services. Of the 438 sexual partners identified 
by the index clients, 238 were tested for HIV following referral from either the 
index client or a health-care provider, and 147 tested positive for HIV (15).
Community-led services
In 2015, the LINKAGES project, funded by the United States Agency for 
International Development, introduced a number of innovative approaches to 
their traditional, group-based “hot-spot” outreach model in order to improve HIV 
testing, care and treatment services for gay men, other men who have sex with 
men and transgender women in four high-prevalence provinces of Thailand. 
Using an enhanced outreach model, community-based supporters conduct 
structured outreach focused on individual risk assessments. Clients are 
registered, offered monetary incentives to act as peer mobilizers and asked 
to recruit and refer their friends and sexual partners for rapid HIV testing at 
community-led drop-in HIV service delivery centres. People who test positive are 
provided with point-of-care CD4 testing and referred for immediate treatment 
initiation, with ongoing support and follow-up by community-based supporters 
and case managers. People who test negative but are at high risk of infection can 
access free pre-exposure prophylaxis, and they are contacted regularly for repeat 
HIV testing.
The enhanced model also includes a mobile data-collection platform, eCascade, 
which links outreach activities to community-based HIV testing to clinic-based 
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antiretroviral therapy via a smartphone application and a cloud-based database. 
This platform enables implementing partners to track referrals across services 
in real time, respond to client drop-out, adapt outreach approaches to target 
efforts where they are needed, and follow-up with clients via SMS messaging.
Programme data from the first nine months of implementation in the city of Chiang 
Mai–between July 2015 and March 2016–indicated that the enhanced model 
can lead to significantly higher rates of HIV testing uptake (77%) compared with 
traditional group-based outreach (31%), although overall numbers of people 
reached was lower. 
The data also showed that a relatively small number of motivated peer mobilizers 
can contribute significantly to project reach and improved health outcomes: 115 
peer motivators successfully recruited 608 new clients. Clients reached via this 
method were more likely to receive an HIV test (94%) than those reached with 
traditional “hot-spot” recruitment (54%). In addition, among clients who tested 
positive for HIV, those reached via social network recruitment were more likely to 
initiate antiretroviral therapy (77% compared with 38%).
Source: LINKAGES Thailand, 2016.
Comparison of models to reach gay men and other men who have sex with men and  
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Adoption of World Health Organization treatment 
guidelines
Earlier initiation of treatment could be made through wider adoption of World 
Health Organization (WHO) treatment guidelines that call for the immediate offer 
of antiretroviral therapy following diagnosis. Of the 148 countries with information 
about national treatment policies or plans, approximately one-quarter have already 
adopted a “treatment for all” approach and 44 countries plan to do so by the end 
of 2016. Of the remaining countries, 11 continue to limit treatment to people living 
with HIV who have a CD4 count of 350 cells/mm3 or lower.
Increased access to and use of routine viral load 
testing
The goal of antiretroviral therapy is viral suppression—a viral load that is so low 
that it cannot be detected by viral load tests. A person living with HIV who is virally 
suppressed is not only less prone to HIV-related illness but also much less likely to 
transmit the virus.
Periodic viral load tests are the most accurate way of determining whether 
antiretroviral therapy is working to suppress replication of the virus. A low viral 
load in a person on treatment indicates that treatment is effective; a high viral 
load indicates either that the medication is not being taken properly or that the 
virus is becoming resistant to the medication. Regular viral load testing helps 
health-care workers to identify these challenges early and to intervene to provide 
adherence support in the first instance, potentially delaying the need to switch 
people to more costly second- and third-line medicines. Continued high viral 
loads despite this support may indicate the need to change medication.
HIV testing and treatment initiation by outreach model type, all sites, Thailand,  
July 2015–March 2016  
Source: LINKAGES Thailand, 2016.
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Viral load testing is far more sensitive than CD4 tests and therefore more likely to 
detect treatment failure early. As a result, people living with HIV on antiretroviral 
therapy with routine viral load monitoring have better health outcomes than 
people monitored with CD4 testing alone, including lower rates of loss to 
follow-up and death and may be more motivated to stay in care and adhere 
to treatment. In 2013 WHO recommended viral load testing as the preferred 
monitoring tool for diagnosing and confirming antiretroviral therapy failure, and 
early infant diagnosis with a viral load test four to six weeks after birth for infants 
born to mothers living with HIV.
Unfortunately, the cost and complexity of currently available technologies limit 
the availability of viral load testing in resource-poor settings. In 2015 the national 
guidelines of 47 out of 54 low- and middle-income countries recommended 
routine viral load monitoring for people on treatment. In reality, however, viral 
load testing was available only in Cameroon, Kenya, Malawi, Namibia, South 
Africa, Swaziland, Thailand and Uganda (16). South Africa discontinued routine 
CD4 monitoring for people living with HIV who are virally suppressed in 2013, 
with anticipated savings of US$ 68 million by 2017 (17).
Viral load testing systems are rapidly becoming cheaper, more robust and simpler to 
use. The UNAIDS Diagnostic Initiative has an agreement with Roche Pharmaceuticals 
to establish a price ceiling for viral load tests in 83 low- and middle-income countries 
(18), while in 2015 the Global Fund announced framework agreements with seven 
manufacturers that were expected to lower all-inclusive prices for viral load tests (19). 
Point-of-care viral load testing technologies and increases in volume are expected to 
lower costs further (20). The widespread implementation of routine viral load testing 
may result in overall cost savings for HIV programmes because people may be able to 
stay on first-line therapy longer (21).
Greater political will and funding are needed to scale up capacity in low- and middle-
income countries, and civil society has a major role to play in advocacy—for the scale-
up of viral load testing, affordable testing systems, and research and development.
Enabling prevention through human rights 
programmes
Stigmatizing attitudes and behaviours on the part of health workers have been widely 
documented and found to constitute an important barrier to seeking, using and 
adhering to HIV prevention services and treatment, as well as disclosure of HIV status 
(22). A programme designed specifically to address prejudice among health workers 
toward gay men and other men who have sex with men in Kenya has shown that a 
number of participants felt the training helped them to normalize their interactions 
with gay men and other men who have sex with men or “compartmentalize” their 
fears and prejudices to provide good care to this population; they also felt that other 
health workers needed similar training to overcome denial and prejudice (23). An 
additional assessment undertaken two years later showed that some participants felt 
the training helped them greatly in their work, and they said that similar training should 
be provided to all health workers, police, religious leaders and others in the community 
(24). 
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PRE-EXPOSURE  
PROPHYLAXIS
Pre-exposure prophylaxis (PrEP) is the latest addition to efforts to expand 
combination prevention options for people at high risk of HIV infection. The 
number and scope of PrEP activities is increasing globally, while the scale and 
coverage outside the United States of America remain limited. In June 2016 an 
estimated 60 000 people were enrolled on PrEP, the majority of whom were in the 
United States. A significant but unquantifiable number of people are accessing 
PrEP through less regulated means, for example via the internet. The rapid 
establishment of government-regulated programmes will improve the monitoring 
and evaluation of PrEP’s use and its impact on the epidemic. Considerable 
additional effort will be needed to attain the new global target of reaching three 
million people at substantial risk of HIV infection with PrEP by 2020.
PREVENTION GAPS
 ■ PrEP is just getting off the ground: progress towards the 2020 PrEP target stands at 2%.
 ■ Availability and awareness is limited.
 ■ Regulatory approval is limited to seven countries.
 ■ PrEP provision should be sensitive to the context of the populations at risk 
including stigmatization, criminalization and intimate partner violence.
WAY FORWARD
 ■ Regulatory approval in all countries with optimal use of TRIPS flexibilities and 
price negotiation to improve access.
 ■ National guidelines and roll-out of national programmes.
 ■ Awareness-raising among populations at higher risk of HIV 
 ■ Advocacy for PrEP in collaboration with the priority populations and sensitive 
to their legislative environment and health seeking options. 
 ■ Integration of PrEP provision to strengthen combination prevention 
programmes.
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COUNTRIES THAT HAVE DEMONSTRATION PROJECTS OR HAVE APPROVED 
TENOFOVIR DISOPROXYL FUMARATE/EMTRICITABINE FOR PRE-EXPOSURE 
PROPHYLAXIS, AS OF JUNE 2016
Sources: AVAC, Ongoing and Planned PrEP Open Label, Demonstration and Implementation Projects, as of June 2016 (http://www.avac.org/sites/default/files/resource-files/PrEP_Trials_Dem-
onstration_Projects_June_2016.pdf); http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm312210.htm; Registrar of Medicines, Medicines Control Council, Department of 
Health, Republic of South Africa. Press release: Medicines Control Council approves fixed-dose combination of tenofovir disoproxyl fumarate and emtricitabine for pre-exposure prophylaxis of 
HIV. 3 December 2015; http://ansm.sante.fr/S-informer/Points-d-information-Points-d-information/L-ANSM-etablit-la-RTU-de-Truvada-dans-la-prophylaxie-pre-exposition-au-VIH-Point-d-infor-
mation;  http://www.mccza.com/documents/2e4b3a5310.11_Media_release_ARV_FDC_PrEP_Nov15_v1.pdf; http://www.hc-sc.gc.ca/dhp-mps/prodpharma/rds-sdr/drug-med/rds-sdr-truvada-
187173-eng.php; https://www.avert.org/news/peru-latest-country-approve-prep; AVAC. South Africa and Kenya Approval of Oral PrEP Should Spur Rollout. 17 December 2015 (http://www.
avac.org/blog/south-africa-and-kenya-approval-oral-prep); Australian Government Therapeutics Goods Administration, Prescription medicines: new or extended uses, or new combinations of 
registered medicines, 7 July 2016(   https://www.tga.gov.au/prescription-medicines-new-or-extended-uses-registered-medicines) 
*These countries also have completed, ongoing and/or planned demonstration projects.  
** These projects investigate different aspects of PrEP provision and impact including acceptability, safety, adherence, effect, appropriate service delivery, integration in combination preven-
tion services, costing and associated behavioural aspects. Their aim is to increase access to PrEP for those people who could benefit most from it, especially in situations of stigma, marginal-
ization and criminalization.  
Ongoing and planned demonstration projects** 
Completed demonstration projects   
Regulatory approval of PrEP*  
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PrEP empowers individuals with limited personal prevention options to discreetly 
take control of their own HIV risk. Randomized control trials have confirmed the 
efficacy of daily oral PrEP. Demonstration projects, offering PrEP as a choice 
through user-friendly services, have shown its potential value in diverse settings, as 
well as strong demand and adherence among people at high risk of HIV infection, 
including HIV-negative partners within serodiscordant couples, gay men and other 
men who have sex with men, and some young women and female sex workers.
Based on the evidence, the World Health Organization (WHO) recommends 
effering the use of daily oral PrEP containing tenofovir disoproxil fumarate as 
an additional prevention choice for all population groups at substantial risk 
of HIV infection as part of a combination HIV prevention programme. Priority 
populations for PrEP rollout should be people at substantial risk of HIV infection, 
broadly identified as populations with an HIV incidence of about 3 per 100 
person-years or higher (1).
The United States approved the use of PrEP in 2012 and clinical guidelines were 
issued in 2014 (2). France began offering PrEP within its national health-care 
system in January 2016, following the issue of a temporary recommendation for 
use in November 2015 (3). By mid-2016, 60 clinics were offering the service in 
France and 437 people had started taking PrEP through the public health system 
(4). In December 2015 South Africa became the first country in sub-Saharan 
Africa to issue full regulatory approval of PrEP (5) and to include PrEP in the 
national HIV programme followed swiftly by Kenya (6). Regulatory authorities in 
Australia, Canada and Peru have also approved PrEP. At least 26 countries have 
planned or ongoing demonstration projects for PrEP (7), and in some countries 
Cumulative number of completed, ongoing and planned PrEP open-label, demonstration 
and implementation projects, 2011–2016
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Source: AVAC, Ongoing and Planned PrEP Open Label, Demonstration and Implementation Projects, as of June 2016 (http://www.avac.org/sites/default/files/resource-files/PrEP_Trials_
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“off-label use”1 is facilitated by the health system or individual health-care 
providers.
Key evidence on PrEP
 ■ Randomized controlled trials of the effectiveness of oral PrEP have been 
conducted among serodiscordant couples, heterosexual men, women, gay 
men and other men who have sex with men, people who inject drugs and 
transgender women (1).
 ■ PrEP works—when taken. The level of protection was strongly correlated with 
adherence (1).
 ■ PrEP has a very good safety profile. Rates of any adverse events did not differ 
between PrEP and a placebo (1).
 ■ Risk of drug resistance is low when given to people not infected with HIV, 
occurring in approximately 1 in 1000 people using PrEP in clinical trials (1).
 ■ No evidence for risk compensation in sexual practices, such as decreased 
condom use or more sexual partners, has emerged in any PrEP studies or 
programmes (1).
 ■ PrEP can be used with hormonal contraception. Recommended PrEP regimens 
do not appear to alter the effectiveness of hormonal contraception (1).
 ■ PrEP can be used during pregnancy. No increase occurred in adverse 
pregnancy-related events among women taking PrEP in early pregnancy (1).
 ■ PrEP is acceptable when provided as a choice that is sensitive to the context 
of the population at risk of HIV. Various populations report that they find 
PrEP acceptable, and individuals have shown substantial interest in PrEP as 
an additional choice for HIV prevention (1).
 ■ Adherence can be maintained. Demonstration projects and experience in 
everyday settings are proving that people can adhere to daily oral PrEP (1).
 ■ Early efforts to monitor the scale-up of PrEP have been through tracking 
new prescriptions that have been filled and patient numbers reported by 
demonstration projects. Drug manufacturers have registered a total of  
50 000 new PrEP starts in the United States from 2012 to the end of 2015 (11). 
Along with the demonstration projects being conducted around the world, 
the total global number of people registered on PrEP is estimated at 60 000, 
with the majority in the United States. Additional private off-label prescribing 
and other less regulated means, such as internet purchasing, obscure a 
significant but unquantifiable proportion of PrEP use. The establishment of 
additional government-regulated programmes will improve the monitoring 
and evaluation of the use of PrEP and its impact on the epidemic.
PrEP delivery is best integrated within combination HIV prevention services, 
including a comprehensive and non-stigmatising assessment of the risk of HIV 
acquisition, regular and quality-assured HIV testing, and tailored HIV prevention 
choices. Ensuring the full participation of communities is critical to developing 
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and implementing services, including the monitoring of adherence. Advocacy 
and awareness-raising for PrEP must be in collaboration with priority populations 
and must be sensitive to structural barriers and stigma and discrimination within 
their environment.
Different population groups require different types of PrEP service provision and 
adherence support. Several innovations in PrEP are being explored, including 
intermittent use—taking PrEP before and after sexual activity (8) and the use 
of a vaginal ring that slowly releases the antiretroviral dapivirine (9). Other PrEP 
formulations including long-acting injections and topical gels are under active 
research. (10).
The cost of PrEP is an important concern, even in high-income countries. A survey 
of 31 western and eastern European countries conducted by the European Centre 
for Disease Prevention and Control found that 21 countries considered the cost of 
PrEP drugs a highly important limiting factor; the second most important limiting 
factor was the cost of service delivery (4). Currently, 112 low- and middle-income 
countries can access generic TDF/FTC through voluntary licensing agreements 
that allow the marketing and purchase of the generic product. Approval of 
the use of antiretroviral medication as prevention is required at country level, 
possibly through sharing of approval data from stringent regulatory authorities. In 
the short term an off-label clinical approval could also be considered. The use of 
other PrEP regimens containing generic TDF, including the more widely available 
TDF/3TC and TDF alone, is currently under consideration. PrEP is expected to be 
cost-effective where the incidence of HIV is greater than 3 per 100 person-years 
and perhaps also at lower incidences (1). Ultimately the cost-effectiveness of 
PrEP will be determined by the cost of PrEP medication, how efficiently it can be 
delivered to the people in greatest need, and its impact.
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SOCIAL AND BEHAVIOUR CHANGE 
COMMUNICATION AND DEMAND GENERATION
Behaviour change communication and demand generation form a basic component 
of combination prevention. They are an inclusive way of addressing the cultural 
contexts within which risk behaviours occur, and of stimulating uptake of HIV 
prevention services. These programmes entail a range of activities, from individual 
counselling to community awareness-raising to communications through mass 
media. They also feature intensive approaches involving a combination of activities 
to address multiple outcomes, including knowledge, risk perception, norms, skills, 
sexual behaviours and HIV service demand. 
Multi-media, school-based and broader community mobilization activities 
complement the delivery of HIV services such as condom distribution, voluntary 
medical male circumcision, HIV testing and PrEP. As new biomedical tools are rolled 
out, effective social-behavioural and structural programmes help maximize their 
efficacy, for example by mitigating the potential emergence of risk compensation.  
PREVENTION GAPS
 ■ Most young people lack the knowledge required to protect themselves from HIV. 
 ■ There has been little progress on partner reduction in sub-Saharan Africa.
 ■ Investments in programmes that promote abstinence and faithfulness are not 
cost effective.
 ■ Systematic implementation of behaviour and social change communication and 
demand generation has not taken place. 
WAY FORWARD
 ■ Ensure that the design and implementation of behaviour change programmes 
are based on solid evidence of what works.
 ■ Widely disseminate objective, comprehensive information on sexuality, 
including through comprehensive sexuality education. 
 ■ Leverage the global revolution in information and communications technology 
to improve behaviour change communications and link people at risk of HIV 
infection to services. 
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CORRECT AND COMPREHENSIVE KNOWLEDGE ABOUT HIV AMONG YOUNG PEOPLE 
(AGED 15–24 YEARS), SUB-SAHARAN AFRICA, 2000–2008 COMPARED TO 2009–2015
2000–2008 2009–2015
Source: Population-based surveys, 2000–2015.
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Struggles to improve knowledge, risk perception 
and partner reduction 
The latest available data show that most young people lack the knowledge 
required to protect themselves from HIV. In sub-Saharan Africa, survey data 
from 35 countries show that only 36% of young men and 30% of young women 
correctly identified ways of preventing the sexual transmission of HIV and 
rejected major misconceptions about HIV transmission (1). In 23 countries outside 
of sub-Saharan Africa, just 13.8% of young men and 13.6% of young women had 
correct and comprehensive knowledge about HIV (1). 
Analysis of comparable surveys conducted in sub-Saharan Africa from 2000 
to 2008 and from 2009 to 2015 show that rates of correct and comprehensive 
knowledge increased by 6.8 percentage points among young men and by 4.4 
percentage points among young women. Knowledge of new interventions such 
as PrEP and voluntary medical male circumcision is not included in the above 
analysis, and may be lower (1). 
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There are also considerable gaps in comprehensive basic knowledge among 
adolescent girls and young women (2).  Knowledge on specific risk factors such 
as transmission in sexual networks, risk of age-disparate sex and anal sex, newer 
biomedical prevention methods such PrEP or links between HIV and gender-
based violence is also likely to be low. Furthermore, there are gaps in personal 
risk perception. In one survey, a significant proportion of young adults living with 
HIV who did not yet know their HIV status, said they did not perceive themselves 
at high risk of HIV (3). Similarly, young women at high risk of HIV participating 
in a clinical trial for PrEP did not take the medication regularly due to low risk 
perception (4). Conversely, perception of HIV risk has been shown to be associated 
with higher use of PrEP among young women at high risk of HIV (4), as well as two 
to five times higher use of condoms among adolescents aged 12–19 (5).
There has been no significant change in the number of sexual partners reported at the 
aggregate level in sub-Saharan Africa, suggesting that behaviour change communication 
programmes aiming at this particular outcome have largely failed.  Population-based 
surveys show that the proportion of adults (aged 15–49 years) with multiple sexual 
partners in the 12 months prior to the survey has declined slightly among women 
and increased slightly among men. As with other aspects of combination prevention, 
aggregate data on partner reduction may not do full justice however, and a more 
granular analysis informing local responses may be required. Some countries, including 
prominently South Africa, have retained social and behaviour change communication 
within their national strategies to promote such changes. 
Programmes that promote abstinence and faithfulness have not achieved 
population-level reductions in numbers of sexual partners reported in the last 
year, age at sexual debut and teen-age pregnancy (6). The results suggest that 
alternative funding priorities for HIV prevention—including the promotion of 
condom use, voluntary medical male circumcision and treatment, combined with 
structural approaches—may yield greater health benefits.
Reinvigorating behaviour and social change 
communication
Although behaviour change communication programmes are difficult to evaluate, 
a range of evidence suggests that they can make a significant contribution to 
other prevention approaches if they are designed and implemented well. Early 
declines in HIV incidence in sub-Saharan Africa were associated with changes 
in behaviour. In Uganda in the early 1990s and in Zimbabwe in the late 1990s, 
incidence decline occurred before the emergence of effective biomedical 
prevention tools, at times when people started to intensively speak about HIV in 
their social networks and large increases in interpersonal communication about 
HIV were recorded (7, 8). A meta analysis demonstrated the effectiveness of 
social and behaviour change programmes in increasing condom use and other 
HIV-related outcomes (9). Large-scale multi-channel programmes that achieved 
high coverage and measurable effects on attitudes, condom use and uptake of 
HIV testing services included the LoveLife multi-media campaign in South Africa 
(10), Zimbabwe’s national behaviour change programme  and the multi-country 
One Love campaign in southern Africa (11, 12). 
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Intensive inter-personal communication approaches have also been shown to 
be effective. The SHARE1 project in Rakai, Uganda, achieved reductions in HIV 
incidence and intimate partner violence and increases in disclosure of HIV status 
through the addition of a community-level mobilization intervention to change 
attitudes, social norms and behaviours related to intimate partner violence, 
and a screening and brief intervention to promote safe HIV disclosure and risk 
reduction in women seeking HIV counselling and testing services (13). The SASA! 
programme in Kampala, Uganda, combined community mobilization on HIV and 
intimate partner violence prevention, which reduced sexual concurrency reported 
by men by over 40% and changed norms around intimate partner violence (14). 
It has also been shown that school-based sex education is an effective strategy 
for reducing HIV-related risk. Students who received school-based sex education 
interventions had significantly greater HIV knowledge and condom use, fewer 
sexual partners and delayed sexual debut (15).
Despite the evidence, systematic implementation of behaviour and social change 
communication and demand generation has not taken place.  On the contrary, 
there has been a worrying pattern of deprioritization and discontinuation of these 
programmes in recent years. However, the evidence from initiatives like SHARE, 
SASA! and Stepping Stones has rekindled interest in these programmes, with 
critical elements being incorporated into new, large-scale programmes, such as 
DREAMS2, which provides HIV services to young women and girls and addresses 
structural drivers that increase their HIV risk, including poverty, gender inequality, 
sexual violence and a lack of education, in 10 countries of eastern and southern 
Africa3.
Comprehensive sexuality education
The objective of comprehensive sexuality education is to ensure that young people 
receive comprehensive, life skills-based sexuality education, and that they gain 
the knowledge and skills to make conscious, healthy and respectful choices about 
relationships and sexuality. Comprehensive sexuality education can therefore 
be considered a specific form of social and behaviour change communication 
programme involving young people in the school setting. It is firmly grounded in 
human rights, including the rights of the child and the empowerment of children 
and young people (16). There is clear evidence that comprehensive sexuality 
education can facilitate the adoption of safer sexual behaviours, such as delayed 
sexual debut and increased condom use, and thereby contribute to reducing 
sexually transmitted infections, HIV transmission and unintended pregnancy (15, 
17–19). In addition, comprehensive sexuality education programmes that have an 
explicit focus on gender rights and gender power dynamics have been shown to 
be more effective than those that do not (20). 
When governments do not provide comprehensive sexuality education, they 
limit the chances that young people have to acquire quality information and skills 
that could help them make informed decisions about their health and sexuality. 
1Safe Homes and Respect for Everyone
2Determined, Resilient, Empowered, AIDS-free, Mentored and Safe women
3Kenya, Lesotho, Malawi, Mozambique, South Africa, Swaziland, Uganda, United Republic of Tanzania, Zambia and Zimbabwe. 
74 
Some political and religious groups continue to oppose comprehensive sexuality 
education, and it has historically faced resistance from some governments in 
global decision-making forums. By 2015, however, many countries had embraced 
the concept of comprehensive sexuality education and were engaged in 
strengthening its implementation at the national level (16, 21). In 2015, UNAIDS 
and the African Union included comprehensive, age-appropriate sexuality 
education as one of five key recommendations to Fast-Track the HIV response 
and end the AIDS epidemic among young women and girls across Africa (22). 
Meanwhile, many countries in Asia and the Pacific, West Africa and Europe 
were revising their policies and approaches to scale up sexuality education (16). 
Despite this, a major gap remains between global and regional policies and the 
actual implementation of comprehensive sexuality education on the ground.  
Comprehensive sexuality education is also only effective if it allows increased 
knowledge, self-esteem and skills of sexually active young people to translate 
into access to HIV and sexual and reproductive health services.
New media
The global revolution in information and communications technology, which has 
dramatically altered the ways in which people network, interact, communicate 
and share information, offers new opportunities to expand and reinvigorate 
social-behavioural and prevention demand creation programming. While stand-
alone media approaches are unlikely to yield the desired results, the leveraging 
of new information tools, such as the integration of mobile telecommunications 
within health programmes, has been shown to improve service delivery.
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ELIMINATING NEW HIV INFECTIONS  
AMONG CHILDREN
The steady scale up and improvement of services to prevent mother-to-child 
transmission of HIV has reduced the annual number of new infections among children 
globally by 56% since 2010 and by 70% since 2000. Since 1995, an estimated 1.6 
million new HIV infections among children have been averted due to the provision of 
antiretroviral medicines to women living with HIV during pregnancy or breastfeeding. 
The vast majority of these infections (1.3 million) were averted between 2010 and 2015. 
PREVENTION GAPS
 ■ The number of new infections among women of reproductive age (aged 15 to 49 
years) has not declined over the past five years.  
 ■ A widespread unmet need for family planning exists in many countries. 
 ■ Over 300 000 women did not receive antiretroviral medicines to prevent mother-
to-child transmission in 2015.
 ■ Treatment drop-out rates among women who are pregnant and breastfeeding 
remain high, leading to increased risk of transmission to their children.  
WAY FORWARD
 ■ Focus combination HIV prevention initiatives on women and girls in high-
prevalence settings, including primary prevention among young women and 
identification and treatment for serodiscordant couples. 
 ■ Help women living with HIV avoid unintended pregnancies by ensuring they 
have access to sexual and reproductive health services, including contraception.
 ■ Scale up programmes and initiatives that support and advocate for male and 
intimate partner engagement in the prevention of mother-to-child transmission.
 ■ Strengthen community engagement, community service-delivery models and 
community support as well as rights-based approaches to prevention of mother 
to child transmission.
 ■ Scale up the provision of early diagnosis, treatment and care for infants and 
children. 
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NATIONALLY RECOMMENDED ANTIRETROVIRAL REGIMEN FOR PREVENTING 
MOTHER-TO-CHILD TRANSMISSION OF HIV, MID-2016
New HIV infections among children (aged 0–14 years) with and without the provision of antiretroviral medicines to 
prevent mother-to-child transmission, global, 1995–2015
Source: World Health Organization, 2016.
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The world has committed to establishing an AIDS-free generation. This commitment 
follows unprecedented achievements driven by the Global Plan towards the 
elimination of new HIV infections among children by 2015 and keeping their mothers 
alive (the Global Plan)1. The dramatic declines in new child infections and AIDS-related 
deaths over the past five years were primarily due to the wide-spread expansion 
of antiretroviral medicines for mothers living with HIV, both during and after their 
pregnancies. The provision of these services has averted 1.6 million HIV infections 
among children since 2000. As of June 2016, four countries have been certified by the 
World Health Organization to have eliminated mother to child transmission: Armenia, 
Belarus, Cuba, and Thailand.
Less progress, however, was made in other areas. There has been little change in 
the rate of new HIV infections among women, and there is still a widespread unmet 
need for family planning in many countries (1). Globally, new infections among young 
women aged 15 to 24 years decreased by 6% between 2010 and 2015, and by 2% 
among women of reproductive ages (15 to 49 years). There were an additional 5.2 
million women of reproductive age newly infected between 2010 and 2015, including 
1.2 million in South Africa. The burgeoning cohort of adolescents about to commence 
their reproductive careers means that these numbers are likely to continue growing 
unless intensive primary prevention efforts succeed. As a result, the substantial need 
for services for preventing mother-to-child transmission among women of reproductive 
age will continue for the foreseeable future.
1 For more information, see the final progress report of the Global Plan—On the Fast-Track to an AIDS-free generation—on the 
UNAIDS website (www.unaids.org). 
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Rapid increase in services to prevent  
mother-to-child transmission
The use of antiretroviral medicines during pregnancy and breastfeeding prevents 
onward transmission of HIV. In eastern and southern Africa, seven countries had greater 
than 90% coverage of services to prevent mother-to-child transmission, including South 
Africa, which is home to 25% of the region’s pregnant women living with HIV.  
Considerable gaps in coverage remained across the world, however, especially in 
western and central Africa, Asia and the Pacific, and the Middle East and North Africa. 
An estimated 45% of new HIV infections among children in 2015 occurred in western 
and central Africa: the 31% reduction in new child HIV infections in western and central 
Africa between 2010 and 2015 was considerably lower than the 66% reduction in 
eastern and southern Africa. 
The situation was particularly challenging in Nigeria, which in 2015 had the second 
largest HIV epidemic in the world. Nigeria had the greatest number of new HIV 
infections among children in the world—an estimated 41 000 [28 000–57 000] — 
roughly equivalent to the next eight countries combined. There has only been a 21% 
decline in new paediatric HIV infections in Nigeria since 2009, compared to the 60% 
average among the other Global Plan priority countries (1).
Distribution of new HIV infections among children (aged 0–14 years) by country, 2015
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Mother-to-child trasmission rate by region, 2010 and 2015
Threefold decrease in mother-to-child transmission 
rate 
As a result of increased coverage and improved regimens, rates of HIV 
transmission from mothers to infants during pregnancy and breastfeeding have 
decreased around the world. The largest decline was in eastern and southern 
Africa, where it fell from 18% of infants born to mothers living with HIV in 2010 
to 6% in 2015—a threefold decrease. The region that showed the least amount 
of progress was the Middle East and North Africa, where nearly one third of 
women living with HIV pass the virus on to their children. The mother-to-child 
transmission rates in Asia and the Pacific and western and central Africa also were 
well above the global average of 10%. 
30
35
25
20
15
10
5
0
Eastern and 
southern 
Africa
Latin America 
and the  
Caribbean
Global Western 
and central 
Africa
Asia and the 
Pacific
Middle East 
and North 
Africa
2010
2015
Source: UNAIDS 2016 estimates.
Pe
rc
en
t (
%
)
81 
Antiretroviral medicine regimen used in preventing mother-to-child transmission, global, 
2010–2015
Transition to immediate and lifelong treatment
One reason for the impressive declines in HIV transmission rates was the 
improvement in prophylaxis regimens over the past five years. In 2010, the 
majority of pregnant women were provided with antiretroviral medicines that had 
limited effectiveness and were used solely to prevent onward transmission to 
the child. Scientific advancements and operational experience have shown that 
immediate and lifelong antiretroviral therapy for pregnant women diagnosed 
with HIV is more effective than on-again, off-again approaches. In 2015, the 
WHO recommended that all pregnant women be provided with Option B+, 
which involves immediate offer of lifelong antiretroviral therapy—going beyond 
pregnancy, delivery and breastfeeding—regardless of CD4 count. In 2015, the 
global roll-out of Option B+ improved suppression of viral loads during both 
the breastfeeding period and afterwards, making future pregnancies safer. By 
2015, 91% of the 1.1 million women receiving antiretroviral medicines to prevent 
mother-to-child transmission were on lifelong antiretroviral therapy. 
2015
Source: 2016 Global AIDS Response Progress Reporting and UNAIDS 2016 estimates.
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Family planning
Some gains also were made in the efforts to prevent unintended pregnancies in 
countries with large numbers of paediatric HIV infections. Between the periods 
of 2000–2004 and 2010–2014, unmet needs for family planning among married 
women declined by more than 10 percentage points in Ethiopia, Kenya, Lesotho, 
Malawi and Rwanda. Among the countries with available data in sub-Saharan 
Africa, Zimbabwe had the lowest unmet need for family planning among married 
women (10%) (2). There is, however, still a lack of information about the use of 
contraception among many women in sub-Saharan Africa, specifically at the 
national level for women living with HIV. Some earlier studies have suggested 
that women living with HIV may be more motivated to use contraception and 
therefore have different unmet needs than other women, but there is still a 
knowledge gap in this area (3).  
Trends in unmet need for family planning among married women, select countries, 2000–2015
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Community engagement and support
A major contributor to the successful increase in treatment coverage for pregnant 
women living with HIV was the involvement of communities. Entry and retention 
in care were improved through community engagement and support, and 
through community service-delivery models. Networks and support groups of 
women living with HIV were particularly valuable in boosting outreach activities 
and service delivery, providing counselling, supporting treatment adherence, 
educating women about their reproductive rights, encouraging them to seek care 
and HIV testing, and providing psychosocial support to women coming to terms 
with a new diagnosis of HIV. 
In many countries, community health workers were trained and enlisted in 
providing basic services, strengthening referral systems and supporting mothers 
and their families. At the end of 2015, more than half the countries in sub-Saharan 
Africa used community health workers to provide and support key HIV services, 
including antiretroviral therapy provision and the prevention of mother-to-child 
transmission (1). New methods of community engagement were implemented 
to bring services to remote communities, mobilize opinion leaders and deliver 
decentralized health care. 
Community organizations were most effective when they received adequate 
support from the formal health system and when their capabilities and expertise 
were recognized. It will be important to ensure continued support for them going 
forward. 
Involving men
Engaging male partners and fathers as parents who also desire healthy children 
and healthy families is vital to continued success. Successfully engaging men in 
testing and treatment to prevent HIV transmission reduces the number of new 
infections in women, and the greater engagement of men would improve results 
at every step of the cascade for elimination.
Men need to be involved in family planning, with reproductive health positioned 
as the domain of both sexes, and more emphasis should be placed on promoting 
and facilitating couples testing. When men test positive for HIV, partner testing 
also is needed to identify HIV-negative women in serodiscordant relationships, 
and to diagnose women living with HIV and initiate treatment as soon as possible. 
Start Free, Stay Free, AIDS Free 
The Start Free, Stay Free, AIDS Free initiative, which was launched in 2016 and 
is led by UNAIDS and PEPFAR, aims to build on the progress achieved under 
the Global Plan through a super Fast-Track approach to the scale up of HIV 
prevention, treatment, care and support services for children, adolescents 
and young women (4). The initiative aims to elevate and amplify efforts that 
are already accelerating progress, including the DREAMS Partnership, the 
Accelerating Children’s HIV/AIDS Treatment (ACT) Initiative and ALL-IN.
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The initiative has three parts. 
 ■ Start Free aims to complete the job started by the Global Plan by reaching 
and sustaining 95% of pregnant women living with HIV with lifelong HIV 
treatment by 2018, and by reducing the number of newly infected children to 
fewer than 40 000 by 2018 and 20 000 by 2020.  
 ■ Stay Free has the objective of ensuring that children with an HIV-free start 
stay HIV-free throughout their childhood. It will do this by intensifying the 
focus on reaching and empowering adolescent girls and young women and 
engaging men and boys. Stay Free includes the targets of the 2016 Political 
Declaration on HIV and AIDS to reduce the number of new HIV infections 
among adolescents and young women to fewer than 100 000 by 2020. It also 
seeks to provide voluntary medical male circumcision for HIV prevention to 
25 million additional men globally by 2020, including 11 million men in the 
geographic areas of highest HIV burden (with a focus on young men aged 15 
to 29 years). 
 ■ Finally, AIDS Free targets the children and adolescents living with HIV who 
often are left behind by HIV responses. The initiative aims to provide 1.6 
million children (aged 0 to 14 years) and 1.2 million adolescents (aged 15 to 
19 years) living with HIV with antiretroviral therapy by 2018.
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EASTERN AND  
SOUTHERN AFRICA
Eastern and southern Africa has only 6.2% of the world’s population but is home 
to half of the world’s people living with HIV. The region made progress in reducing 
new HIV infections between 2010 and 2015, particularly among children, but new 
HIV infections among adults are not declining fast enough. Women accounted for 
59% of all adults living with HIV, and more than 20% of new infections in 2014 were 
among key populations and their sexual partners. The rate of new HIV infections 
remained high among young women in particular. In some countries there were high 
levels of transactional sex and age-disparate sexual relationships. Programmes and 
initiatives to address societal and structural barriers faced by young people, especially 
for young girls and women, gained momentum in 2015. Programming for key 
populations was insufficient, however. Other challenges include the marginalization 
of key populations due to legal barriers to accessing services or because of stigma and 
discrimination, and heavy reliance on international resources to fund responses to 
HIV.
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TRENDS AND TARGETS
Progress towards the 90–90–90 target, eastern and southern Africa, end-2015
Percentage of people living with HIV 
who know their HIV status1
Percentage of people living with HIV 
who are on antiretroviral treatment
Percentage of people living with HIV 
who are virally suppressed2
56% 
(52-60%)
90%
54% 
(50-58%)
81%
45% 
(42-48%)
73%
Source: UNAIDS special analysis, 2016; for more details, see annex on methods.
1 2015 measure derived from data reported by 12 countries, which accounted for 85% of people living with HIV in the region.
2 2015 measure derived from data reported by 8 countries. Regionally, 14% of all people on antiretroviral therapy were reported to have received a viral load test during the reporting period.
Source: UNAIDS 2016 estimates. Source: UNAIDS 2016 estimates.
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Source: UNAIDS special analysis, 2016; for more details, see annex on methods.
HIV epidemic in eastern and southern Africa
Although eastern and southern Africa has only 6.2% of the world’s population, 
it is home to half of the world’s people living with HIV. The region continued 
to be the hardest hit by the HIV epidemic, with 46% of the world’s new HIV 
infections in 2015. Nearly 40% of new HIV infections in the region in 2015 were 
in South Africa, and another 50% occurred in eight countries: Ethiopia, Kenya, 
Malawi, Mozambique, Uganda, the United Republic of Tanzania, Zambia and 
Zimbabwe.
New HIV infections decreased marginally in eastern and southern Africa 
between 2010 and 2015. New HIV infections among adults declined by 4% to 
an estimated 910 000 [790 000–1 100 000]. New paediatric infections declined 
by 66% between 2010 and 2015 to an estimated 56 000 [40 000–76 000]. 
This impressive decline in paediatric infections is due to the rapid increase in 
coverage of services for prevention of mother-to-child transmission from 61% 
[55–67%] in 2010 to 90% [82–>95%] in 2015. With committed efforts paediatric 
infections could reach the region’s 2020 target, but adult infections are not 
declining fast enough.
Distribution of new HIV infections among population groups, eastern and southern Africa, 
2014
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Progress varied among countries. Between 2010 and 2015 annual numbers 
of new HIV infections among adults declined by more than 20% in Botswana, 
Malawi, Mozambique, Uganda and the United Republic of Tanzania, but the 
annual number of new HIV infections among adults increased by more than 20% 
in Eritrea and Madagascar.
Women accounted for 59% of all adults aged 15 years and older living with HIV 
in the region, and the rate of new HIV infections remained high among young 
women aged 15–24 years. There were approximately 4500 new HIV infections 
weekly among young women in the region, which is double the number seen in 
young men.
More than 20% of new infections in 2014 were among gay men and other men 
who have sex with men, sex workers, people who inject drugs and the sexual 
partners of key populations (1).
HIV prevalence among these populations is often extremely high. For example, 
in South Africa, surveillance data published in 2015 estimated HIV prevalence 
among sex workers was 72% in Johannesburg, 40% in Cape Town and 54% in 
Durban (2). Prevalence among gay men and other men who have sex with men 
ranged from 9.9% to 32.9% in country surveys conducted between 2013 and 2015 
(3). Age-specific data from Kenya, Mauritius, Seychelles and the United Republic 
of Tanzania in 2013 showed that many people who inject drugs acquire HIV 
before they reach the age of 25 years (3).
HIV prevalence among sex workers, eastern and southern Africa, most recent data, 2013–2015
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HIV prevalence among gay men and other men who have sex with men, eastern and southern 
Africa, most recent data, 2013–2015
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HIV prevalence among people who inject drugs, eastern and southern Africa, 2015, most 
recent data, 2013–2015
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Progress and gaps in prevention
Young women and girls and their male partners
Correct and comprehensive knowledge regarding HIV prevention among young 
people aged 15–24 years in the region improved between the 2000–2008 period 
and the 2009–2015 period, especially among young women. Still less than half, 
however, had comprehensive knowledge—37% and 41% among young women and 
young men, respectively, in surveys conducted in recent years (4). The proportion 
of young people who reported having their first sexual experience before age 15 
years decreased by 20% over the same time period to 11% of young men and 12% 
of young women surveyed (4).
Rapid assessments conducted in Botswana, Swaziland and Zimbabwe for the 
ALL IN initiative to end AIDS among adolescents found high levels of reported 
occurrences of transactional sex in Botswana and age-disparate sexual 
relationships in Swaziland (5). Data on sexual and reproductive adolescent health 
revealed high rates of sexually transmitted infections and teenage pregnancy (5).
Programmes and initiatives launched to scale up HIV prevention services for young 
people, especially for young girls and women, gathered pace in 2015. These included 
DREAMS for young girls and women (supported by the United States President’s 
Emergency Plan for AIDS Relief, the Bill and Melinda Gates Foundation and the Nike 
Foundation), ALL IN for adolescents (supported by United Nations agencies and 
partners), and various programmes supported by the Global Fund to Fight AIDS, 
Source: Demographic and Health Surveys, 2000-2015
Comprehensive knowledge of HIV prevention among young people (aged 15–24 years), 
2000–2015
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Percent change in young people (aged 15–24 years) reporting sexual debut before the age of 
15, select countries in eastern and southern Africa, 2000-2008 compared to 2009-2015
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Source: 2016 Global AIDS Response Progress Reporting. 
Tuberculosis and Malaria (Global Fund). The implementation of gender-transformative 
HIV programming to address the structural and knowledge barriers was also gaining 
momentum. These interventions include keeping girls in school and providing 
comprehensive sexuality education, a commitment made by ministers of health and 
education from 20 countries in eastern and southern Africa in 2013 (6), and providing 
girl-friendly sexual and reproductive health services, eliminating gender-based violence, 
eliminating female genital mutilation, scaling up male involvement in the HIV response, 
empowering women economically, ensuring the involvement of women in leadership 
structures and processes, and promulgating and implementing protective laws.
Several priority countries in eastern and southern Africa, including Ethiopia, Malawi, 
Swaziland and Zimbabwe, have held dedicated national prevention consultations in 
recent months  to explore how prevention responses can be revitalized. Government 
representatives  of Kenya, Zimbabwe and South Africa have met to plan the 
development of a regional roadmap to accelerate scale up of combination HIV 
prevention services at local levels and increased investments for combination HIV 
prevention.
Percent (%)
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Key populations
In 2015 UNAIDS and the World Bank synthesized available quantitative and 
qualitative data on four key populations (sex workers, gay men and other men who 
have sex with men, people who inject drugs and transgender people) from 18 
countries in eastern and southern Africa. Key findings from this regional synthesis 
include the following:
 ■ All 18 countries identify female sex workers in national AIDS plans or strategies 
as being essential to reach with effective programme implementation.
 ■ Seventeen of the 18 countries identified men who have sex with men as a key 
population in their national AIDS plans or strategies.
 ■ In many countries the prioritization of key populations within national AIDS 
plans and strategies has not resulted in sufficient financial allocation and 
programme implementation to address their needs.
 ■ Dedicated programmes for female sex workers, including service delivery 
and community mobilization, are more common than for the other three key 
populations.
 ■ Programmes for men who have sex with men are particularly constrained by 
widespread homophobia.
 ■ Female sex workers had more accurate knowledge of HIV than people 
who inject drugs and men who have sex with men, although the extent of 
comprehensive knowledge throughout the region remains insufficient among 
all four populations.
 ■ Consistent condom use varied widely, and nowhere was it above 80% across 
all partner types for any of the four populations, indicating inadequate 
protection from HIV and other sexually transmitted infections.
 ■ Data and information on transgender people in the 18 countries are extremely 
limited.
 ■ None of the 18 countries had extensive community mobilization for the four 
key populations, but community networks are emerging. Regional networks 
are in place for female sex workers and men who have sex with men.
 ■ The overall legal and social environment for all four key populations is 
challenging, with some aspect of sex work criminalized in 17 countries and 
same-sex relationships criminalized in 15 countries.
Kenya, Madagascar, Mauritius, Mozambique, South Africa and the United Republic 
of Tanzania are all home to significant populations of people who inject drugs. 
Although limited in scope, surveys among people who inject drugs in sub-Saharan 
Africa suggest high HIV prevalence. In Kenya, where HIV prevalence among people 
who inject drugs in 2011 was 18% versus 5.6% in the general population, low 
condom use and unsafe injecting practices exacerbate transmission (7). Needle 
and syringe programmes and opioid substitution therapy is being scaled up in the 
United Republic of Tanzania and in Kenya.
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Risky sexual behaviours and condom use
Nationally representative population-based surveys conducted in the region 
suggest that sexual risk behaviours among men and women are still common. 
On average 13% of men in the most recent surveys reported multiple sexual 
partnerships during the 12 months before the survey (8). The proportion of 
adult women reporting multiple sexual partnerships was much lower, at 2%, and 
declined between the 2000–2008 time period and the 2009–2015 time period 
(4). Trends varied between countries. Ethiopia, Malawi, Rwanda and Zimbabwe 
saw increases in multiple partnerships among both men and women, while the 
proportion of men and women with multiple partners in Zambia and Madagascar 
declined.
Source: Demographic and Health Surveys, 2000–2015.
Trends in proportion of adults (aged 15–49 years) reporting multiple sexual partnerships in 
the previous 12 months, select countries in eastern and southern Africa, 2000–2008 compared 
to 2009–2015
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Condom availability for men aged 15–64 years varied widely by country, with only 5 
of the region’s 15 countries meeting the United Nations Population Fund  (UNFPA) 
regional benchmark of 30 male condoms distributed per man per year (2011–2014) (9). 
Namibia had the highest level of availability of male condoms, with 54 available per 
man per year, followed by Swaziland (51), Botswana (50), Zimbabwe (33) and Lesotho 
(31); in Angola and South Sudan only 5 and 0.4 condoms per man per year were 
available, respectively (9). Women in the region were even more underserved: female 
condoms accounted for a small fraction of the condoms procured in 2015 (10).
This lack of condom availability contributed to levels of condom use that were not 
high enough to significantly curtail rates of HIV, sexually transmitted infections or 
unintended pregnancies. Population-based surveys conducted between 2009 and 
2015 indicate that condom use at last sex among adults aged 15–49 years who had 
sexual intercourse with more than one partner within the past 12 months was only 
23% among men and 33% among women. There was substantial variation among 
countries, ranging from as low as 7% among men in Madagascar to 69% among 
women in Namibia and 83% among men in Swaziland. Demographic and Health 
Surveys conducted between 2008 and 2015 found that condom use among men 
who paid for sexual intercourse in the preceding 12 months was higher, at about 
60% on average (11).
Source: Population-based surveys 2009–2015. 
Condom use at last sexual intercourse among people with multiple partners, select countries 
in eastern and southern Africa, most recent data, 2009–2015
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In response to the insufficient levels of condom use, a regional “condom push” 
initiative in 2015 resulted in seven countries developing action plans. Production of 
female condoms in the region was discussed with manufacturers, with South Africa 
championing local production. These initiatives aim to contribute to the UNFPA goal 
of ensuring that 10% of condoms procured in each country are female condoms (10).
Voluntary male medical circumcision
There was tremendous progress in the uptake of voluntary male medical circumcision 
between 2008 and 2014. Following several years of nearly exponential increase, 
however, the number of men circumcised in 2015 was lower in 8 out of 14 priority 
countries (Botswana, Ethiopia, Lesotho, Rwanda, Uganda, United Republic of 
Tanzania, Zambia and Zimbabwe). An estimated 2.6 million males were circumcised 
in 2015, compared with 3.1 million males in 2014 (although challenges remain in 
compiling data on male circumcisions).
Progress varied across countries. Countries such as Kenya, Ethiopia and the 
United Republic of Tanzania have achieved or exceeded targets to reach 80% of 
the estimated number of eligible men. Mozambique, South Africa, Uganda and 
Zambia reached 50–79% of eligible men. In Lesotho, Malawi, Namibia, Rwanda and 
Zimbabwe, however, less than 35% of eligible men have been circumcised.
Pre-exposure prophylaxis
In December 2015 South Africa became the first country in sub-Saharan Africa to 
issue full regulatory approval of pre-exposure prophylaxis (PrEP), followed swiftly 
by Kenya (see Pre-exposure prophylaxis chapter). Pre-exposure prophylaxis is also 
included within the Kenya HIV Prevention Revolution Road Map and the South 
Africa National Sex Worker Plan 2016–2019. Kenya, South Africa and Zimbabwe have 
ongoing demonstration or research projects that are investigating the uptake and 
impact of PrEP specifically with young women and girls in high-incidence areas. Their 
focus includes service delivery, adherence, gender-based violence and preferred 
choice of PrEP formulation.
Viral suppression
A key determinant to viral suppression among people living with HIV is knowledge 
of status. An estimated 56% [52–60%] of people living with HIV in eastern and 
southern Africa in 2015 knew their HIV status, and about 54% [50–58%] were on 
antiretroviral therapy. Considerable gaps in the treatment cascade remained in many 
countries. Achieving the 90–90–90 target required diagnosing more than 6.4 million 
people living with HIV who did not know their HIV status, starting an additional 5.2 
million people on antiretroviral therapy, and ensuring an additional 5.3 million people 
living with HIV achieved viral suppression. As a result of these gaps, only 45% [42–49%] 
of all people living with HIV in eastern and southern Africa had achieved the viral 
suppression necessary to prevent HIV transmission. However, viral suppression data in 
the region are extremely limited. Only 14% of the total population of people living with 
HIV on antiretroviral therapy had a viral load testing result. 
Low rates of HIV testing weaken the links between prevention, treatment and care 
services in the region (12). To address this challenge, Kenya, Malawi, South Africa and 
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Uganda have adopted innovative approaches to HIV testing in recent years, including 
provider-initiated testing, moonlight testing, targeted community-based HIV testing and 
door-to-door testing campaigns. Many countries, including Namibia, Malawi, Rwanda, 
Botswana, South Africa and Swaziland, are piloting HIV self-testing. In Namibia, for 
example, pharmacies sell over-the-counter rapid test kits for HIV self-testing.
Countries in eastern and southern Africa have made remarkable progress in the scale-
up of antiretroviral therapy reaching 54% [50-58%] of people living with HIV. Paediatric 
treatment in particular had improved since 2010, with regional coverage reaching 
63% [56–71%] and Botswana and Namibia achieving coverage of over 95% of children 
living with HIV. However, gaps still remain in the provision of treatment to populations 
who are affected by humanitarian emergencies, who face disruptions in HIV treatment, 
heightened exposure to HIV vulnerability and risks and limited access to quality health 
care and nutritious food.
By the end of 2015 all countries in the region were at least implementing the 2013 
World Health Organization (WHO) treatment guidelines, expanding eligibility for 
antiretroviral therapy and ensuring that antiretroviral drugs were used within a broad 
continuum of care (13). Yet the population effect of antiretroviral treatment on reduced 
transmission depends on high coverage of antiretroviral treatment among all people 
living with HIV. Many countries, including Kenya, Malawi, Namibia and Uganda, had 
begun adopting the 2015 WHO recommendation to immediately offer treatment 
to people diagnosed with HIV. Lesotho officially adopted and began the roll-out of 
“test and treat” guidelines in April 2016, Botswana launched a “treat all” strategy in 
June 2016, and South Africa plans to start offering treatment immediately following 
diagnosis before the end of 2016. Weak health and community systems, however, 
continue to undermine scale-up of testing and treatment.
Although viral load testing in the region was unavailable to the majority of people on 
antiretroviral therapy, many countries, including Botswana, Namibia, Malawi, Kenya, 
South Africa, Swaziland and Uganda, had ongoing pilot and research projects on 
viral load testing. Key challenges include inadequate viral load testing equipment, 
transportation of samples, and human capacity within laboratory systems to undertake 
the considerable volume of testing required. An estimated 45% [42-48%] of people 
living with HIV in eastern and southern Africa had suppressed viral loads in 2015.
Challenges
Girls and young women have to be placed at the centre of the response if the region 
is to end AIDS by 2030. In 2015 two-thirds of new HIV infections among young people 
aged 15–24 years occurred among adolescent girls and young women. These high 
levels of infection are driven largely by high prevalence in the community, gender 
inequality and inequity, traditions, and limited educational opportunities.
Extremely high levels of sexual abuse and violence against female children, including 
underage, child and forced marriage, undermine regional development goals and the 
HIV response. The region had seven million child brides in 2015 (14). A positive change 
in Malawi was the passage in April 2015 of a new Marriage Act that increased the age of 
marriage to 18 years.
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Despite 15 of 19 countries in the region having domestic violence and sexual 
offences laws, more than 30% of ever married or partnered women aged 15–24 
years experienced physical or sexual violence from a male intimate partner in 
the previous 12 months in Uganda, the United Republic of Tanzania, Zambia and 
Zimbabwe; this figure was 50% among girls aged 15–19 years in Namibia (3).
Key populations are often marginalized due to legal barriers to accessing services or 
because of stigma and discrimination and had not received adequate attention from 
national programmes (15). Serious challenges remain, including the criminalization 
of same-sex sexual relations, drug use and sex work; insufficient implementation of 
harm-reduction programmes; and insufficient protection of men and women from 
discrimination, harassment, and sexual and physical violence and abuse arising from 
their perceived or actual sexual orientation or gender identities (15).
Strategic information is lacking for a number of countries in the region. Weak 
national systems for case-based surveillance hinder the ability to report routine, 
localized data and for monitoring of prevention and treatment cascades. Most 
countries do not have systems for unique identification of individuals, which 
makes tracking them across prevention and treatment services difficult, leading 
to inaccuracies in the reported data. There is a lack of technical capacity, human 
resource availability or coordination in some countries for collecting or reporting 
standardized, sex- and age-disaggregated programmatic data at the subnational 
level. With the increasing focus on prioritizing locations and populations most in 
need, this makes granular data collection difficult.
Countries in eastern and southern Africa remained heavily reliant on international 
resources to fund their responses to HIV. The exception is South Africa, where 
approximately 80% of the national response is financed through domestic 
resources. Insufficient financial resources, combined with the lack of strategic 
information, led to many high-impact HIV prevention programmes not being 
implemented to the necessary standard or scale.
Opportunities
Investments and sustainable financing
By December 2015 Botswana, Ethiopia, Kenya, Mauritius, South Africa, Swaziland, 
Uganda and Zimbabwe had produced national HIV investment cases that promote 
effective, efficient and sustainable investments in their HIV responses by targeting 
specific locations and populations. Malawi, Mozambique and Zambia used the 
investment approach to develop national strategic plans and inform their concept 
notes for Global Fund grants.
As a result of South Africa’s high-level epidemic and the Government’s commitment 
to fund lifelong treatment for existing patients, the total cost of the HIV programme 
will increase in coming years. According to South Africa’s investment case, if the 
appropriate investments and programme scale-up are made to reach the 90–90–90 
treatment targets, annual resource needs will begin to decline in 15–20 years. 
By comparison, more gradual scale-up will result in larger future budgets and an 
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increase in overall long-term spending (16). The analysis helped to convince the 
South African Treasury to increase budget allocations for HIV (17). 
The recent drought due to El Niño has caused additional challenges for people 
living with HIV in southern Africa. Food insecurity requires coping strategies that 
might increase risky behaviour. In addition food insecurity might reduce adherence 
to antiretroviral therapy leading to drug resistance and increases in transmission.
Regional dialogue has underscored the need to determine how much low- and 
middle-income countries can contribute to their HIV programmes, given the rapid 
economic growth across the region, and how international assistance can best 
contribute to efforts to end AIDS as a public health threat by 2030 (18). To advance 
the African Union Roadmap for Shared Responsibility and Global Solidarity and 
promote sustainability of responses, the regional economic communities (East 
African Community and South African Development Community) undertook 
financing analyses to explore the fiscal space for health and HIV and innovative 
options for financing AIDS responses. As a result, both communities have endorsed 
action frameworks on sustainable financing that commit countries to increase 
domestic spending, address inefficiencies in health services, and explore innovative 
financing mechanisms in the next five years.
Using evidence to inform programming
In the context of declining international resources for AIDS, it is increasingly 
important to gather and use strategic information to guide the efficient delivery 
of services to the locations and populations in greatest need. All of the region’s 
countries routinely update estimates of HIV infections and treatment coverage, 
and report on global indicators. With international support, most have further 
generated subnational HIV estimates of people living with HIV and new infections 
and AIDS-related deaths, linking them to data on treatment and other service 
provision within maps to identify geographical gaps in service coverage. Kenya 
also launched a “Situation Room” that uses a tablet-based application to provide 
policy-makers and programme-planners with real-time monitoring of the latest 
strategic information and evidence to inform their decision-making.
Engaging communities
Civil society and communities are vital to the region’s achievement of the targets 
in the 2016 Political Declaration on ending AIDS. In Botswana, Communities Acting 
Together to Control HIV (CATCH) facilitated community-driven activities through 
household consultations, joint planning and community-led implementation and 
monitoring. During a two-month period 1656 households were reached in five 
villages by a team of trained CATCH facilitators. This has resulted in invitations for 
engagement from other villages and schools (19).
The Community Health Alliance Uganda conducted a two-month pilot programme 
to help address challenges faced by pregnant and breastfeeding women living 
with HIV, including by providing funds for transport to clinics, and by recruiting and 
training volunteers through the local association of people living with HIV to conduct 
counselling, run awareness campaigns and mobilize local community leaders. The 
number of monthly clinic visits by pregnant and breastfeeding women increased 
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during the project period (20). Models such as these that leverage civil society to 
bring HIV services closer to communities need to be expanded and sustained.
National and regional support for such efforts grew in 2015, with increasing interest 
from several governments in understanding the unique contributions of community 
groups, cost their efforts and define how useful approaches could be scaled up. 
Malawi undertook a mapping of community-based service delivery models to 
inform its national dialogue on scaling up the antiretroviral therapy programme. 
Zimbabwe defined a national operational plan for scaling up community treatment 
action groups linked to health facilities.
Integrating sexual and reproductive health and HIV services
A multilaterally funded pilot project to support linkages between sexual and 
reproductive health and HIV services had been in place in Botswana, Lesotho, 
Malawi, Namibia, Swaziland, Zambia and Zimbabwe since 2011. By the end of 2015 
a total of 52 health facilities across these 7 countries had provided integrated 
sexual and reproductive health and HIV services and increased both access and 
uptake. In Botswana and Zimbabwe client satisfaction had risen, with 57% and 
60% of service users, respectively, citing a reduced number of visits as a benefit 
of integrated services, and 41% and 34%, respectively, reporting that integrated 
services provided a good opportunity to access additional services (21,22). 
Challenges remained, however, with competing interests, changes in leadership, 
multiple and parallel initiatives, and a shortage of health-care workers impeding 
the integration of services. 
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WESTERN AND  
CENTRAL AFRICA
Knowledge about HIV among young people in western and central Africa was 
alarmingly low, with a significant gap in sexual and reproductive health services for 
adolescents and young people, including HIV prevention services. New infections 
among key populations and their sexual partners accounted for more than a quarter 
of all new infections in 2014, and HIV prevalence among key populations was 
significantly higher than that among the general population. Condom use at last 
sexual intercourse varied, with indications that use was high among sex workers. 
There were condom use increases among women but not among men in the past 15 
years. Uptake of HIV testing services in the general population was low, but there 
was relatively high testing coverage among female sex workers. Despite an increase 
in the availability of antiretroviral therapy in the region between 2010 and 2015, 
coverage remained well below the global average, contributing to low levels of viral 
suppression. Challenges include high levels of stigma and discrimination (including 
the denial of health services), high rates of gender-based violence (including in 
conflict and emergency situations) and gender inequities.
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Source: UNAIDS 2016 estimates. Source: UNAIDS 2016 estimates.
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Source: UNAIDS special analysis, 2016; for more details ,see annex on methods.
Progress towards the 90–90–90 target, western and central Africa, 2015
1 2015 measure derived from data reported by 12 countries, which accounted for 73% of people living with HIV in the region.
2 2015 measure derived from data reported by 7 countries. Regionally, 2% of all people on antiretroviral therapy were reported to have received a viral load test during the reporting period.
Percentage of people living with HIV 
who know their HIV status1
Percentage of people living with HIV 
who are on antiretroviral treatment
Percentage of people living with HIV 
who are virally suppressed2
36% 
(30-44%)
90%
28% 
(23-34%)
81%
12% 
(10-15%)
73%
New HIV infections among adults (aged 15 years and 
older), western and central Africa, 2010–2015
New HIV infections among children (aged 0–14 years), 
western and central Africa, 2010–2015
New HIV infections Target New HIV infections Target
114 
Source: UNAIDS 2016 estimates.
   Rest of the 
region
Ghana
   Democratic Republic of 
the Congo
     Côte d’Ivoire
    Cameroon
Nigeria
Percent change in new HIV infections among adults (aged 15 years and older), western and 
central Africa, from 2010 to 2015
0-50-100 50
Equatorial Guinea
Burundi
Ghana
Gabon
Sierra Leone
Democratic Republic of the Congo
Mauritania
Chad
Gambia
Guinea
Western and central Africa
Nigeria
Central African Republic
Cote d’Ivoire
Benin
Cameroon
Burkina Faso
Mali
Liberia
Cape Verde
Togo
Senegal
Niger
Percent (%)
Source: UNAIDS 2016 estimates.
Distribution of new HIV infections by country, western and central Africa, 2015
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other sexual partners of key 
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15%
People who 
inject drugs
0,4%
Sex workers
10%
Source: UNAIDS special analysis, 2016; for more details, see annex on methods.
HIV epidemic in western and central Africa
Western and central Africa’s 25 countries had a combined population of 
approximately 425 million people in 2015. The average HIV prevalence among 
adults was 2.2% [1.8–2.7%]. An estimated 6.5 million people were living with 
HIV in the region in 2015, of whom 500 000 [400 000–630 000] were children. 
Women accounted for 54% of adults aged 15 years and older living with HIV. 
There was wide variation both between and within countries, with national adult 
prevalence ranging from 0.5% [0.4–0.6%] in Niger and Senegal to 4.9% [4.4–5.3%] 
in Equatorial Guinea.
There were an estimated 410 000 [310 000–530 000] new infections, of which  
66 000 [47000–87 000] were among children and 200 000 [150 000–260 000] were 
among women. New infections among children decreased by 31% since 2010, 
reflecting the scale-up of coverage of prevention of mother-to-child transmission 
services from 23% [19–28%] to 48% [40–58%]. Among adults there was no decline 
in new infections since 2010, with the number remaining static at 350 000  
[270 000–450 000] per year.
Distribution of new HIV infections among population groups, western and central Africa, 2014
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An estimated 60% of new HIV infections in the region in 2015 occurred in Nigeria, 
and another 30% occurred in seven countries: Cameroon, Chad, Côte d’Ivoire, 
Democratic Republic of the Congo, Ghana, Guinea and Mali.
There were 650 000 [500 000–850 000] young people aged 15–24 years living 
with HIV in the region in 2015. The number of new infections among young people 
aged 15–24 years decreased between 2010 and 2015, from 120 000 [92 000– 
150 000] to 110 000 [88 000–150 000], including a reduction from 37 000  
[30 000–47 000] to 36 000 [30 000–47 000] among adolescents aged 15–19 years.
Sixty-four per cent of new infections among young people in western and central 
Africa were among young women. Gender inequalities and gender-based violence 
in the region made girls and young women more vulnerable than boys and young 
men to HIV infection. Girls and women faced high levels of gender-based violence 
and in conflict situations sexual violence against women and girls is commonly used 
as a strategy of war. In emergencies, women and girls are particularly vulnerable 
and have specific needs that are often ignored, including services for safe 
pregnancy and childbirth and protection from gender-based violence. Additionally, 
emergencies often cause a disruption to HIV treatment and services, increased 
food insecurity and destruction of livelihoods as well as heightened exposure to 
HIV vulnerability and risks (1).
New infections among key populations and their sexual partners accounted for 
more than a quarter of all new infections in the region in 2014 (2). HIV prevalence 
among sex workers, people who inject drugs and men who have sex with men was 
significantly higher than the prevalence in the general population. 
HIV prevalence among gay men and other men who have sex with men, western and central 
Africa, most recent data, 2013–2015
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117 
In 2015 HIV prevalence was 17% among men who have sex with men, 16.5% among 
sex workers and 6.5% among people who inject drugs (3). HIV prevalence among 
women who inject drugs is much higher than among men who inject drugs. For 
example in Nigeria HIV prevalence among female and male injecting drug users was 
14% and 3% respectively. Similarly, in Senegal HIV prevalence among female and 
male injecting drug users was 28% and 7%, respectively.
HIV prevalence among these key populations also varied by country. In the 12 
countries that reported data in 2015, HIV prevalence among gay men and other men 
who have sex with men ranged from 3.6% in Burundi to 37.2% in Cameroon. In the 
15 countries that reported data in 2015, HIV prevalence among female sex workers 
ranged from 4% in Mauritania to 24% in Mali.
Progress and gaps in prevention
Young women and girls and their male partners
Knowledge about HIV among young people in the region continued to be alarmingly 
low: data from recent household surveys suggest that only 24% of young women 
aged 15–24 years and 31% of young men of the same age had comprehensive and 
correct knowledge of how to prevent HIV.
HIV prevalence among sex workers in western and central Africa, most recent data, 2011–2015
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Western and central Africa also had poor educational outcomes more generally, 
especially for adolescent girls. School completion rates continued to be very low. 
The United Nations Children’s Fund estimates that 18.8 million children in the region 
were not in school (4). Girls were particularly disadvantaged: just over half (54%) of 
young women aged 15–24 years in the region are literate (4).
Although there is a lack of reliable age- and sex-disaggregated data on adolescents’ 
and young people’s sexual and reproductive health in the region, available evidence 
indicates a significant gap in service availability. The lack of targeted, youth-friendly 
HIV prevention services for young people and adolescents was due to systemic 
factors, including insufficiently trained health workers; legal factors, including 
restrictive laws and regulations, such as on the age of consent; and social factors, 
including a cultural perception of adolescents and young people as sexually inactive 
children, all of which creates a barrier to their involvement in decision-making around 
their sexual health. Population growth among young people and adolescents 
in western and central Africa was also the highest in the world (5), creating an 
additional burden on health and education services. Urgent attention must be paid 
to prevention-related solutions that can be scaled up easily.
Source: Population based surveys 2000–2014.
Trends in comprehensive, correct knowledge of HIV among young men and women  
(ages 15–24 years), western and central Africa, 2000–2008 to 2009–2014
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Additional efforts are needed to reach men in this region with HIV prevention 
messages and behaviour change initiatives that promote gender equality. 
Key populations
Key populations were prioritized in HIV responses across the region, with almost 
all countries carrying out size estimations, programmatic mapping and integrated 
biological behavioural surveys to improve and tailor programmes.
There were also a number of regional programmes providing multi-country 
combination prevention solutions. The Abidjan-Lagos Corridor Organization 
provided sex workers, men who have sex with men, people who inject drugs and 
truck drivers in Côte d’Ivoire, Ghana, Togo, Benin and Nigeria with behavioural 
change communication, condoms and lubricants, testing, management of 
sexually transmitted infections, and referral to treatment. The Projet Frontières et 
Vulnérabilités au VIH en Afrique de l’Ouest (Project on Borders and Vulnerability to 
HIV in West Africa) provided men who have sex with men and sex workers in Burkina 
Faso, Cabo Verde, Gambia, Guinea, Guinea-Bissau, Mali, Niger and Senegal with 
capacity-building initiatives, awareness-raising, testing and treatment. The Regional 
HIV/AIDS Prevention Project in Western and Central Africa (PACTE – VIH) provided 
female sex workers and their clients and men who have sex with men in Burkina Faso 
and Togo with comprehensive prevention and support, an enabling environment 
and technical assistance. The Health Policy Project provided sex workers and men 
who have sex with men in Benin, Burkina Faso, Cameroon, Côte d’Ivoire, Guinea, 
Mali, Mauritania, Niger and Togo with an enabling environment for evidence-based 
programming. Needle and syringe programmes and opioid substitution therapy are 
only nationally available in Senegal.
Condom programmes
Condom programmes were a priority prevention intervention across the region. 
Social marketing, including through civil society organizations and in health 
facilities, was the main strategy for distribution. Few countries had comprehensive 
condom programming plans, however, and often where they did exist they were not 
implemented.
Available data for 2010–2014 from 18 countries indicated that condom use at last 
sex with a non-marital, non-cohabiting partner was higher among men than among 
women (6). Most countries in the region reported having more than 80% condom 
use at last sex among sex workers in 2013–2015.
The most recently available survey data suggested that condom use among female 
sex workers remained high within most countries in the region, while among men 
who have sex with men it varied between 32% in Sierra Leone and 85% in Benin.
Viral suppression
Viral suppression in the region is very low due to low testing uptake and low 
antiretroviral coverage. An estimated 36% [30–44%] of people living with HIV in 
western and central Africa in 2015 knew their HIV status, and about 28% [23–34%] 
were on antiretroviral therapy. Achieving the 90–90–90 target in 2015 required 
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Percent of women and men (aged 15–49 years) using a condom at last sexual intercourse with 
a non-marital partner in the year before the survey, most recent data, 2010–2014
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Condom use at last sexual intercourse among gay men and other men who have sex with 
men, western and central Africa, most recent data, 2012–2015
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diagnosing more than 3.5 million people living with HIV who did not know their 
HIV status, starting an additional 3.4 million people on antiretroviral therapy, and 
ensuring an additional 3.9 million people living with HIV achieved viral suppression. 
As a result of these gaps, only 12% [10–15%] of all people living with HIV in western 
and central Africa had achieved the viral suppression necessary to prevent HIV 
transmission. However, viral suppression data in the region are extremely limited. 
Only 2% of the total population of people living with HIV on antiretroviral therapy 
had a viral load testing result.
Most countries in the region implemented provider-initiated testing and counselling 
in health facilities targeting the general population. The most recently available 
survey data suggest that uptake of HIV testing services in the general population 
is low, and that more women than men, and more adults aged 25 years and older 
than young people, know their status. By contrast, the involvement of civil society 
organizations and the use of peer-led community approaches led to relatively high 
testing coverage among female sex workers, with the majority of countries having 
coverage of 60% or above.
Challenges
Human rights
Data from 16 People Living with HIV Stigma Index surveys conducted in the region 
between 2011 and 2015  showed that stigma and discrimination against people living 
with HIV remained high. People living with HIV reported verbal violence in the form 
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HIV testing coverage among female sex workers, western and central Africa in 2013 and 2015
Source: 2016 Global AIDS Response Progress Reporting.
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of insults, harassment and threats, with the proportion who had suffered ranging 
from 15% in Sierra Leone to 70% in Cameroon. 
Many people also reported being forced to change their place of residence or 
being unable to rent accommodation (53% of those interviewed in the Democratic 
Republic of the Congo, 12% in Ghana, 10% in Mali). People had been denied access 
to health services and reproductive health services because of their HIV status, with 
the proportion of interviewees reporting such discrimination ranging from 1% in 
Benin to 21% in Nigeria. The proportion of people living with HIV who reported self-
stigmatizing ranged from 16% in Chad to 67% in Liberia.
Using the Stigma Index data to inform national action plans to reduce stigma 
and discrimination at national and regional levels was also a challenge. Although 
Burkina Faso, Côte d’Ivoire, Guinea-Bissau and Niger had begun to implement the 
recommendations of their national Stigma Index surveys, funding was limited.
Women and girls
Gender assessments of national epidemics and responses were conducted in 
Burundi, Burkina Faso, Cameroon, Chad, Democratic Republic of the Congo, Gabon, 
2015
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Nigeria and Senegal. These reinforced that women and girls in the region are more 
vulnerable to HIV—in part due to laws and policies that maintain traditional gender 
roles—and that women in key populations had limited access to services.
Rates of gender-based violence were high: 9.3% of ever-married or partnered 
women in Burkina Faso (and over 40% of female sex workers), 31.4% in Cameroon 
and 31.5% in Gabon had experienced physical and/or sexual violence from an 
intimate partner in the previous 12 months.
The responsiveness of HIV programmes and strategies to women’s needs was 
uneven. HIV-related data were often not disaggregated by sex, age, sexual orientation 
or gender identity. Although Nigeria had several strategies on gender equality 
and HIV, budget allocations for these interventions were less than 1% of the total 
expenditure on HIV. Innovative HIV testing strategies are needed, including self-testing 
options, community-based testing, provider-initiated testing and counselling for 
priority groups. These strategies should be informed by epidemiological data, should 
include case-finding via family-centred approaches and a special focus on men.
Opportunities
Fast-Track Cities initiative
Nine of the 15 cities identified in the region as priorities for the Fast-Track Cities 
initiative (Abidjan, Abuja, Accra, Cotonou, Douala, Lagos, Libreville, Lomé, Yaoundé) 
were implementing city action plans on HIV. Abidjan, Bamenda, Douala and Yaounde 
conducted mapping exercises to identify hotspots for sex work and access of sex 
workers to treatment and prevention of mother-to-child transmission services. In 
Benin and Togo, other cities were also involved in the initiative. Over 200 mayors in 
the region had signed the Paris Declaration on HIV and committed to ending the 
AIDS epidemic as a public health threat in cities by 2030.
As part of these efforts, tripartite memoranda of understanding were signed in 
2015 between Microsoft, the Global Alliance of Mayors and Leaders of Africa and 
of African Descent and the Accra Metropolitan Assembly and Senegalese Mayors’ 
Association. Microsoft’s CityNext programme aims to assist cities in building “centres 
of excellence” and in the remote provision of clinical services, and to support 
e-learning, e-citizen and e-health initiatives. The programme will also enable cities to 
reduce costs without reducing services and provide real-time information to improve 
services and involve citizens (7). The overall goal of the initiative is to contribute to 
more sustainable, secure, smart and healthy cities in which every individual and every 
company will do better.
Improving the efficiency and sustainability of HIV programmes
Western and central African countries, with their diverse epidemics and responses, 
and in the context of declining international resources, worked with international 
partners to improve HIV programmes efficiency, effectiveness and sustainability.
Pilots of innovative financing mechanisms, such as taxes on imports, tobacco, 
transport, hotels and tourism and levies on telephone calls, were undertaken. Studies 
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were established in Burundi, Cameroon, Côte d’Ivoire, Democratic Republic of the 
Congo, Ghana, Nigeria and Togo using the United States President’s Emergency 
Plan for AIDS Relief (PEPFAR) Sustainability Index and Dashboard and the UNAIDS 
investment approach to establish a baseline from which to measure national progress 
towards sustainable HIV responses.
Côte d’Ivoire, Senegal and Togo conducted modelling exercises of their epidemics 
and responses, which informed realignments of their national strategic plans and 
oriented resources to achieve the 90–90–90 treatment target. Nigeria began 
developing investment cases for its six most affected states to mobilize domestic 
resources and make state-level responses more effective. Other actions to improve 
the use of funds in the region included prioritizing interventions in locations and for 
populations where they would have the most impact.
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ASIA AND  
THE PACIFIC 
Asia and the Pacific has the second highest number of people living with HIV in 
the world. The region’s HIV epidemic is concentrated among key populations and 
their intimate partners. Progress in reducing new HIV infections has slowed in 
recent years, and there are rising epidemics in some countries. Insufficient coverage 
of harm reduction services threatens further progress. Condom use was low among 
gay men and other men who have sex with men in several countries, and across 
the region among people who inject drugs. Prevention programmes often struggle 
to reach young key populations. Other challenges include the criminalization and 
incarceration of key populations, stigma and discrimination (particularly in health-
care settings), lack of innovation in service delivery models, slow pace of introducing 
new technologies, and strong dependence on international financing for effective 
prevention measures.
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Percentage of people living with  
HIV who know their HIV status1
64% 
(55–74%)
90%
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Source: UNAIDS special analysis, 2016; for more details, see annex on methods.
1 2015 measure derived from data reported by 16 countries, which accounted for 93% of people living with HIV in the region.    
2 2015 measure derived from data reported by 15 countries. Regionally, 29% of all people on antiretroviral therapy were reported to have received a viral load test during the reporting period 
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Progress towards the 90–90–90 target, Asia and the Pacific, 2015
New HIV infections among adults (aged 15 years  
and older), Asia and the Pacific, 2010–2015
New HIV infections among children (aged  
0–14 years), Asia and the Pacific, 2010–2015
Source: UNAIDS 2016 estimates. Source: UNAIDS 2016 estimates.
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Source: UNAIDS 2016 estimates.
Distribution of new HIV infections by country, Asia and the Pacific, 2015
Percent change in new HIV infections among adults (aged 15 years and older), Asia and the 
Pacific, from 2010 to 2015
Source: UNAIDS 2016 estimates.
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The HIV epidemic in Asia and the Pacific
Asia and the Pacific is the region with the second highest number of people living 
with HIV in the world, with an estimated 5.1 million [4.4–5.9 million] people in 2015. 
Within the region, women accounted for 36% of all adults living with HIV.
There were an estimated 300 000 [240 000–380 000] new HIV infections in the 
region in 2015, with young people aged 15 to 24 years accounting for 37% of all 
new HIV infections. 
Asia and the Pacific has made progress in reducing new infections, with a 5% 
decline between 2010 and 2015. An encouraging decline in new HIV infections 
among children also was registered: 30% between 2009 and 2015. Reductions in 
new infections are occurring more slowly than they did over the previous 10 years, 
however, and this is concerning. 
While the decline in new infections was significant in many countries that have 
mature epidemics (such as Cambodia, India and Thailand), these gains were 
offset by rising epidemics in other countries, such as Indonesia, Pakistan and the 
Philippines. Ten countries—China, India, Indonesia, Malaysia, Myanmar, Pakistan, 
Papua New Guinea, the Philippines, Thailand and Viet Nam—accounted for 96% of 
the region’s new HIV infections in 2015.
The HIV epidemic in Asia and the Pacific is concentrated among key populations 
(gay men and other men who have sex with men, sex workers, people who inject 
drugs and transgender people) and their intimate partners, and low national 
prevalence masks much higher prevalence in specific places, particularly urban 
areas. This underscores the need for a location and population approach that 
maximizes the impact of scarce resources. 
Transmission patterns vary, both from country to country and within individual 
countries over time. In Malaysia and Thailand, for example, the percentage of new 
infections through injecting drug use steadily decreased between 1995 and 2015; 
in the Philippines and Thailand, the percentage of new infections through male-to-
male sex dramatically increased over the same period (1).
HIV prevalence among female sex workers was over 5% in three of the 21 countries 
that provided data (Indonesia, Malaysia and Myanmar). In urban areas, HIV 
prevalence was much higher: in Ha Noi, Viet Nam, it was 18% (almost seven times 
the national average), and in Yangon, Myanmar, it was 25% (almost twice the 
national average). National HIV prevalence among male sex workers was higher 
than 5% in three of the eight countries that provided data between 2012 and 2015 
(Indonesia, Nepal and Thailand). 
HIV prevalence among gay men and other men who have sex with men in 2015 was 
higher than 5% in nine of the 19 countries that reported data. HIV prevalence was 
particularly high in many cities and urban areas: it was 28.6% in Bangkok (Thailand), 
26.6% in Yangon (Myanmar) and 20.3% in Yogyakarta (Indonesia).  
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Percent (%)
Source: HIV sentinel surveillance reports and integrated biological and behavioural surveillance reports and 2016 Global AIDS Response  
Progress Reporting.
HIV prevalence among key populations, select geographical locations in Asia and the Pacific, 
most recent data, 2013-2015
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HIV prevalence among young gay men and other men who have sex with men 
(aged 15 to 24 years) was higher than 5% in six of the 13 countries that provided 
data. High incidence of HIV among young gay men and other men who have 
sex with men in urban areas also is a concern. Findings from an HIV incidence 
cohort study in China indicate that the incidence of HIV among young men who 
have sex with men (aged 18 to 25 years) was as high as 18.9, 10.6 and 5.6 per 100 
person years in Guiyang, Beijing and Shanghai, respectively (2). Similarly, a study 
in Bangkok showed an overall high HIV incidence among younger cohorts of men 
who have sex with men compared to their older peers: HIV incidence was 8.8 per 
100 person years among those aged 18 to 21 years and 3.7 per 100 person years 
among men over 30 years of age (3). 
Asia and the Pacific is home to one third of the world’s population of people who 
inject drugs, and 14% of all people who are living with HIV (4). In 2015, national 
HIV prevalence among people who inject drugs was higher than 5% in 11 of the 
15 countries that provided data; among young people who inject drugs (those 
aged 15 to 24 years), national HIV prevalence was over 5% in four of the ten 
countries that provided age-disaggregated data. The incarceration rate of people 
who inject drugs is very high and they represent an important part of the prison 
population. For example, in Indonesia, with HIV prevalence among prisoners 
reported at 3%, a survey among prisoners incarcerated for drug-related crimes, 
showed that more than one-third had injected heroin. (5)
There were geographical areas with extremely high HIV prevalence among 
people who inject drugs in the region: Kota Pontianak, Indonesia (60.7%); 
Faisalabad, Pakistan (47.4%); Kelantan, Malaysia (44.7%); Muse, Myanmar (43%); 
and Cebu City, Philippines (42.8%). In Afghanistan, Myanmar, Pakistan and Viet 
Nam, people who inject drugs accounted for 20–65% of all new HIV infections 
among adults aged 15 to 49 in 2015 (6).  
Data on national HIV prevalence among transgender people remain limited, but 
available subnational data indicate high HIV prevalence in certain locations, for 
example, 30.8% in Jakarta, Indonesia and 19.3% in Kuala Lumpur, Malaysia. 
Progress and gaps in prevention
Key populations
There are multiple challenges to reaching sex workers with HIV prevention 
services, including migration and mobility, a shift towards online and freelance 
sex work, drug use (including injecting drug use), and punitive laws, policies and 
law-enforcement approaches. These factors increase vulnerability to violence 
and HIV among sex workers. Despite these challenges, behavioural surveys show 
that condom use at last commercial sex by female sex workers reached a median 
of 81% in Asia and the Pacific, with five countries surpassing 90%. High condom 
use correlates with reports of declining HIV infections among sex workers in the 
region.
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Scaled up combination prevention can increase consistent condom use and reduce HIV 
infections among female sex workers
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HIV testing among key populations, Asia and the Pacific, most recent data, 2010–2015
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Behavioural surveys in the region indicate that around half of the surveyed gay 
men and other men who have sex with men were under 25 years of age. Compared 
to their older counterparts, fewer young men who have sex with men were being 
reached by HIV prevention programmes, fewer had access to HIV testing services 
and fewer were using condoms. Overall, 62% of men used a condom at last anal 
sex with a man (regional median). No country reported condom use at 90% or 
higher, although five countries—Cambodia, China, India, Nepal and Thailand—
reported condom use over 80%. In Afghanistan, only 17% of men reported using a 
condom at last anal sex with a man. 
Overall, 85% of people who inject drugs (regional median) reported use of sterile 
injecting equipment at last injection; over 80% reported safe injecting practices in 
nine of the 15 responding countries. In several countries where HIV prevalence is 
high among people who inject drugs, the coverage of needle–syringe programmes 
was still low, with fewer than 100 clean needles and syringes provided per person 
in need per year.
Sterile injecting equipment distributed by harm reduction programmes, Asia and the Pacific, 
most recent data, 2014–2015
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Available data on opioid substitution therapy programmes indicate low coverage in 
2015. In the eight countries that reported data (Afghanistan, Bangladesh, Cambodia, 
India, Indonesia, Malaysia, Myanmar and Viet Nam), an estimated 120 000 people 
who used drugs were enrolled in opioid substitution therapy, with coverage ranging 
from 0.5% of people who inject drugs in Afghanistan to 24% in Malaysia.
Opioid substitution therapy is available in prisons in Indonesia and Malaysia and one 
Indian prison. Needle and syringe programs are not available in any prison in the region.
For the region as a whole, only 55% of people who inject drugs reported using a 
condom the last time they had sex.
Viral suppression 
An estimated 64% [55–74%] of people living with HIV in Asia and the Pacific in 2015 
knew their HIV status, and about 41% [35–47%] of those who knew their status were 
on antiretroviral therapy. Considerable gaps in the treatment cascade remained in 
many countries. Achieving the 90–90–90 target by 2020 requires diagnosing 1.3 million 
people living with HIV who do not know their HIV status, starting an additional 2 million 
people on antiretroviral therapy and ensuring that an additional 1.9 million people 
living with HIV achieve viral suppression in the next 5 years. The gaps in diagnosis and 
treatment led to just 34% [29-39%] of all people living with HIV in Asia and the Pacific 
achieving the viral suppression necessary to prevent HIV transmission.
HIV testing data from across the region show that 1.9 million people living with 
HIV did not know their HIV status in 2015. Importantly, HIV testing rates remained 
suboptimal among key populations in many countries. Fewer than one in three 
people [8–73% in 15 countries] who inject drugs had tested for HIV in the past 12 
months and knew the results, while about half of female sex workers [5–91% in 18 
countries], male sex workers [5–68% in six countries] and men who have sex with 
men [14–87% in 20 countries] surveyed in the region knew their HIV status. 
Out of the 39 countries in the region, just 15 reported data on viral load testing in 
2015. The percentage of people among those tested who were virally suppressed 
ranged from 58% in Pakistan and 63% in Viet Nam, to more than 90% in Cambodia, 
China, Mongolia, Nepal, the Philippines and Thailand.
Challenges 
To enable Asia and the Pacific to reach its Fast-Track targets, countries must 
address chronic bottlenecks that continue to hamper the scale-up of effective 
programmes that include community members, especially those among key 
populations. Challenges that need to be overcome include the criminalization of 
key populations, stigma and discrimination (particularly in health care settings), a 
lack of innovation in service delivery models, and the slow pace of introducing and 
adapting new technologies at a scale that will make a difference. 
A common response to drug use in the region is the confinement of people who inject 
drugs in compulsory treatment and rehabilitation centres. In total, 455 814 people who 
use drugs were incarcerated in 948 centres in seven countries in 2014. The number of 
people confined in these centres has decreased by only 4% since 2012 (7). 
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A significant proportion of key populations use social media and mobile 
applications to network, and national programmes are failing to implement new 
approaches to reaching them with effective HIV services. For example, in the 
Philippines in 2011, 21% of surveyed gay men and other men who have sex with men 
were members of social networking sites; by 2015, this had increased to 80%, and 
nearly 40% [16-92%] found at least one sex partner through these sites (8, 9). 
In 2014, an estimated US$ 2.4 billion was spent on HIV responses in Asia and the 
Pacific. The region’s upper-middle-income countries were almost fully funding their 
responses: China (99% domestically funded), Malaysia (94% domestically funded) 
and Thailand (89% domestically funded). Despite this, the strong dependence on 
international financing for prevention—and the limited fiscal space and political 
will of countries to invest in effective combination prevention programmes for key 
populations—remains a major impediment to the response.
Opportunities
A Fast-Track response in Asia and the Pacific will require countries to seize key 
opportunities. This includes introducing and scaling up new approaches and 
Percent distribution of prevention spending by financing source, Asia and the Pacific, most 
recent data, 2009–2014
Source: 2016 Global AIDS Response Progress Reporting.
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technologies like task-shifting, active case finding and management, reanimating 
combination prevention including pre-exposure prophylaxis (PrEP) and community-
based treatment alternatives and services for people who use drugs, and the smart use 
of social media for HIV prevention.
PrEP is an additional prevention option that should be used widely in the region in 
conjunction with other appropriate combination prevention interventions, including 
sexual and reproductive health services. PrEP for gay men and other men who 
have sex with men is currently being piloted in five sites in Thailand, and there is an 
ongoing study on its use among female sex workers in India (10). The Philippines and 
Viet Nam also are in the process of designing pilot studies on PrEP for gay men and 
other men who have sex with men in Manila and Ho Chi Minh City, respectively. 
In the Philippines, the community-based organization LoveYourself has 
implemented an innovative Platinum service that provides confidential HIV 
counselling and testing for young gay professional men in discreet but accessible 
locations, delivering the results on the same day (11).
Achieving the 90-90-90 target will require innovation and a mix of strategies to 
expand HIV testing for key populations and their intimate partners (including 
Source: Information based on communications with national HIV programmes and UNAIDS country offices.
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community-based and community-led HIV testing), early treatment initiation and 
retention, and application of routine viral load testing. It also will require peer support 
across the continuum of prevention, treatment and care. Efforts to support countries 
to protect and use Trade-Related Aspects of Intellectual Property Rights (TRIPS) 
flexibilities to ensure sustained access to affordable medicines, diagnostics and 
commodities—including second- and third-line antiretroviral therapy regimens, and 
tuberculosis and hepatitis C medications—must be intensified.
It is important to promote an investment approach that supports countries in the 
implementation of evidence-based programming, including the development of 
transitional financing plans and the use of universal health coverage schemes to 
ensure the sustainability of the AIDS response.  
The Asia–Pacific Regional Framework for Action to End AIDS by 2030—the regional 
framework adopted by 53 Member States of the United Nations Economic and Social 
Commission for Asia and the Pacific—continues to guide national efforts towards 
accelerating action and investment in the HIV response to end the AIDS epidemic as a 
public health threat by 2030.
141 
142 
LATIN AMERICA  
AND THE CARIBBEAN 
New HIV infections among children across Latin America and the Caribbean 
declined as a result of strong programmes to prevent mother-to-child transmission. 
Among adults, however, rates of new HIV infections slowly but steadily rose by 3% 
between 2010 and 2015. This rise was in contrast to a sharp 20% decline during 
the previous decade. The HIV epidemic is concentrated among key populations, 
particularly gay men and other men who have sex with men. Young people in the 
Caribbean are also disproportionately vulnerable to HIV. Prevention is inadequately 
funded across the region, although some countries were beginning to implement 
combination prevention, including pre-exposure prophylaxis (PrEP). Other 
challenges include; insuring the rights of key populations, especially lesbian, gay, 
bisexual, transgender and intersex (LGBTI) people, are recognized; eliminating 
widespread discrimination in the provision of health and other social services and 
discriminatory and punitive laws and policies against people living with HIV; and 
removing barriers that prevent adolescents and young people from accessing sexual 
and reproductive health and HIV services and commodities. 
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Source: UNAIDS special analysis, 2016; for more details, see annex on methods.
Progress towards the 90–90–90 target, Latin America and the Caribbean, 2015
1 2015 measure derived from data reported by 15 countries, which accounted for 76% of people living with HIV in the region.
2 2015 measure derived from data reported by 21 countries. Regionally, 77% of all people on antiretroviral therapy were reported to have received a viral load test during the reporting period.
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Source: UNAIDS 2016 estimates.
Distribution of new HIV infections by country, Latin America and the Caribbean, 2015
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Source: UNAIDS 2016 estimates.
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Source: UNAIDS special analysis, 2016.
The HIV epidemic in Latin America  
and the Caribbean
In Latin America and the Caribbean, the rate of new HIV infections remained stable 
between 2010 and 2015 at about 100 000 [86 000–120 000] annually. This overall 
trend, however, masked differences between Latin America and the Caribbean, and 
between adults and children and in contrast to the previous decade. 
Among adults in Latin America, the annual number of new HIV infections has 
slowly risen since 2000, reaching about 91 000 [76 000–109 000] in 2015. Increases 
were greatest, above 20%, between 2010 and 2015 in select countries in Central 
America, including Belize, Nicaragua, and Guatemala. Steady albeit smaller 
increases were observed for the same time period in Mexico and Panama (8%), 
Chile (6%), Colombia (5%) and Brazil (4%). Among adults in the Caribbean, years 
of steady declines in new HIV infections between 2000 and 2012—primarily due to 
early  prevention efforts in Haiti—have slowed and then reversed in recent years. 
The annual number of new HIV infections in the Caribbean was estimated at 9000 
[7500–11 000] in 2015. While the rates of new infections among adults in the two 
subregions in 2015 were similar, there were 10 times as many new HIV infections in 
Latin America as in the Caribbean in 2015, reflecting the much larger population size 
of Latin America.
Distribution of new HIV infections among population groups, Latin America and the 
Caribbean, 2014
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New HIV infections among children declined across Latin American and the 
Caribbean by more than 50%, down from an estimated 4700 [3500–6400] in 2010 
to 2100 [1600–2900] in 2015. Progress was greatest in the Caribbean, where new 
infections among children plummeted from an estimated 2300 [1600–3000] in 
2010 to 400 [200–700] in 2015. The Caribbean’s share of new infections among 
children in the region declined from 48% to 19%.  
Brazil alone accounted for more than 40% of all new HIV infections in the region, 
and an additional 41% of total new infections occurred in seven countries: 
Argentina, the Bolivarian Republic of Venezuela, Colombia, Cuba, Guatemala, 
Mexico and Peru. 
Source: 2016 Global AIDS Response Progress Reporting.
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The HIV epidemic remained predominately concentrated among key populations. 
Gay men and other men who have sex with men accounted for nearly one third 
of new HIV infections in 2014, while all key populations and their sexual partners 
accounted for nearly two thirds of new infections (1).   
HIV prevalence among gay men and other men who have sex with men was 
particularly high in urban areas. For example, a sero-behavioural surveillance 
survey conducted in São Paulo in 2012 found an HIV prevalence of 15.4% among 
gay men and other men who have sex with men who were over the age of 18 years 
(30). Among those aged 18 to 24 years, HIV prevalence was already 6.4%.
Transgender women have some of the highest HIV prevalence rates in countries 
where data are collected on this key population. Data reported to UNAIDS by 
countries based on special surveys among key populations between 2011 and 2015 
also show much higher HIV prevalence among transgender women sex workers 
than among male and female sex workers.
Two million [1.7 million–2.3 million] people were living with HIV in the region, of 
whom 670 000 [570 000–800 000] were adult women and 32 000 [27 000–38 000] 
were children under the age of 15.   
Progress and gaps in prevention
Across Latin America and the Caribbean, prevention is inadequately funded and 
does not reach sufficient percentages of key populations (32). Although all 17 
Latin American countries provided free male condoms through the public health 
service, only six provided free female condoms (Brazil, Ecuador, Mexico, Peru, the 
Plurinational State of Bolivia and Uruguay) (2, 3). 
Condom use among key populations in the region varied. Among gay men and other 
men who have sex with men, condom use during last anal sex ranged from 40% to 
88%, with five countries reaching 80% or higher. An additional 13 countries reached 
at least 60%.
Among sex workers, condom use during their last transactional sex ranged from 
57% in Belize to greater than 95% in Panama and Antigua and Barbuda. In the 16 
countries that reported data to UNAIDS, condom use among transgender people 
ranged from 63% to greater than 95%. 
Although reported condom use among key populations appeared relatively high, 
improved linkages across HIV prevention, testing and treatment services and greater 
access to PrEP are needed to further reduce new HIV infections. Data from Mexico 
illustrate the challenge: continuum of care cascades for general and key populations 
show that the percentage of people living with HIV who have been diagnosed 
is lower among people who inject drugs and men who have sex with men. As a 
result, fewer people from key populations living with HIV are receiving treatment to 
suppress the virus (4). Mexico is exploring through a demonstration project how to 
increase use of PrEP.
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Condom use at last sexual intercourse among gay men and other men who have sex with men,  
Latin America and the Caribbean, most recent data, 2013–2015
Source: 2016 Global AIDS Response Progress Reporting.
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Pre-exposure prophylaxis
As part of its efforts to implement combination prevention, Brazil conducted a 
study of PrEP among men who have sex with men and transgender women. The 
study showed a 51% uptake of PrEP among all those who were potentially eligible 
to receive it, including 67% uptake among potentially eligible transgender women 
and 78% uptake among potentially eligible people who had self-referred. Rates of 
uptake were increased when those eligible had a steady partner (58%), assessed 
themselves as being at high risk of acquiring HIV (61%) and had an HIV test in the 
previous year (58%). 
These data suggest that the higher an individual’s perceived risk of HIV, the more 
likely they were to seek and use PrEP (5). Other research showed that Brazil’s 
universal health care system and the range of prevention and care services 
that are already available to transgender women, people living with HIV and 
gay men and other men who have sex with men would be major facilitators in 
the implementation of PrEP, but that increasing awareness of the availability 
of PrEP, improving the frequency of testing and creating greater awareness of 
risk perception among these key populations—especially among transgender 
women—is required (6). 
Young people
Young people, and especially among key populations, in Latin America and the 
Caribbean are disproportionately at risk of HIV infection, and they face greater 
barriers to accessing prevention services. Specific to young women, survey data from 
Barbados, Belize, Costa Rica, Cuba, the Dominican Republic, El Salvador, Guyana, 
Panama and Uruguay show that between 5–16% of young women aged 15 to 24 years 
report they became sexually active before the age of 15. Despite this, girls in these 
countries need parental consent or accompaniment to access sexual and reproductive 
health care services. 
In the Caribbean, young women who are in sexual relationships with older men may 
be at higher risk of HIV infection. Survey data from the Caribbean show that 9–24% 
of women aged 15 to 24 years reported having sex with a man at least 10 years 
older than themselves within the last 12 months. Other risk factors—such as multiple 
sexual partners and inconsistent condom use—compound the risk of age mixing in 
these countries. 
Viral suppression 
An estimated 77% [65–91%] of people living with HIV in Latin America in 2015 knew 
their HIV status, and 55% [47–64%] of people living with HIV were on antiretroviral 
therapy and around 43% [36–51%] of all people living with HIV in Latin America 
had achieved viral suppression. Achieving the 90–90–90 target in 2015 would 
have required diagnosing nearly 220 000 people living with HIV who did not know 
their HIV status, starting an additional 430 000 people on antiretroviral therapy 
and ensuring that an additional 510 000 people living with HIV achieved viral 
suppression. 
In the Caribbean, an estimated 62% [53–74%] of people living with HIV in 2015 had 
been diagnosed, meaning an additional 78 000 people needed to be diagnosed to 
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HIV testing in key populations, Latin America and the Caribbean, most recent data, 
2013–2015
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have achieved the first 90 in 2015. Among all people living with HIV, 50% [43–59%] 
were on treatment. 
Estimates of viral suppression were much lower in the Caribbean than they were in 
Latin America, at 27% [24–44%] of all people living with HIV. Starting an additional 86 
000 people living with HIV on treatment and achieving viral suppression in over 120 
000 people living with HIV was required to achieve the 90–90–90 target in 2015.
Survey data indicate that periodic HIV testing and knowledge of HIV status were 
particularly low among key populations. HIV testing in the last 12 months among gay 
men and other men who have sex with other men ranged from 5% to 70%, showing 
large differences in access to testing services between countries in the region. Testing 
coverage among sex workers was higher among female sex workers (ranging from 39% 
to 98%) than among male sex workers (ranging from 17% to 70%). Among countries 
that reported on transgender sex workers, HIV testing was between 28% and 85%.   
Smaller-scale studies on HIV testing produced similar results. In Buenos Aires, 
Argentina, a 2014 survey found that 52% of gay men and other men who have sex 
with men had never been tested for HIV, and 20% had only been tested once. Among 
the 17% of study participants who were found to be living with HIV, almost half were 
HIV testing among sex workers, Latin America and the Caribbean, most recent data, 
2013–2015
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unaware of their status (7). In another study in Brazil, almost half of gay men and other 
men who have sex with men surveyed in 2009 had never been tested for HIV (8). 
Progress in scaling up treatment services was uneven across the region. In the 
Caribbean, antiretroviral therapy coverage increased from 20% [16–25%] in 2010 to 
50% [43–59%] in 2015. Progress was slower in Latin America, although the overall 
coverage in 2015 was higher: it rose from 34% [29–40%] in 2010 to 56% [47–66%] in 
2015. Brazil, Barbados and Chile were able to achieve very high levels of viral load 
suppression among people on treatment of 90%, 88% and 84%, respectively, while 
also reaching relatively high levels of antiretroviral therapy coverage (55%, 43% and 
87%, respectively). In 2013, approximately 71% of patients receiving antiretroviral 
therapy were on a first-line regimen, indicating that an estimated 29% of patients had 
already experienced a treatment failure (10).
Treatment in Latin America was largely funded by domestic sources, but in the 
Caribbean, 11 out of 16 countries were highly (75–100%) dependent on external 
sources (9). The sustainability of the scale-up and achievement of sustained viral 
suppression was threatened by the relatively high cost of antiretroviral medicines. 
Middle-income countries in Latin America (such as Argentina and Brazil) paid higher 
prices for a number of second- and third-line treatments (11).
Challenges
Rights of key populations
Some countries in the region have made significant progress in recognizing the rights 
of LGBTI people. Argentina, Brazil, Chile, Colombia, Costa Rica, Ecuador, Mexico and 
Uruguay allow marriage or civil unions between people of the same sex (2, 3).
Despite this progress, there were still high rates of violence against LGBTI people 
across the region (12). According to the Inter-American Commission on Human 
Rights Registry of Violence against LGBTI people—which documented violence 
against LGBTI persons in member states of the Organization of American States1  
during a 15-month period in 2013 and 2014 (13)—gay men and other men who 
have sex with men and transgender women represented the majority of the victims 
of killings and acts of police abuse, and lesbian women and bisexual persons were 
particularly affected by intrafamily and sexual violence (12).
Between 2008 and the end of 2015, more than 2000 murders of transgender and 
gender-diverse people were reported in 65 countries worldwide. Of these, more 
than 1500 were reported in Central and South America. Brazil and Mexico had the 
highest absolute numbers of such murders in the world (802 and 229, respectively), 
while the numbers in Colombia (105), the Bolivarian Republic of Venezuela (98) 
and Honduras (79) also were higher than anywhere else in the world apart from the 
United States (132) (14). 
1 Argentina, Barbados, Belize, the Bolivarian Republic of Venezuela, Brazil, Canada, Chile, Colombia, Cuba, the Dominican 
Republic, Ecuador, El Salvador, Guatemala, Guyana, Haiti, Honduras, Jamaica, Mexico, Nicaragua, Panama, Paraguay, Peru, the 
Plurinational State of Bolivia, the United States of America and Uruguay. 
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The vast majority of killings and acts of violence against LGBTI people went 
unpunished. Obstacles to access to justice included fear of filing complaints, inaction 
or abuse by government authorities, and flawed investigations (12). In fact, a 2012 
government survey in Argentina found that 83% of transgender women surveyed 
had been victims of grave acts of violence and discrimination perpetrated by police 
(15). A 2014 study from the Dominican Republic found that 36% of transgender sex 
workers had been forced to perform “sexual favours” for police officers to avoid 
being arrested (15). 
Eleven Caribbean countries have discriminatory laws against same-sex sexual 
acts. The penalty in most of these countries is imprisonment for 10 years. In Belize, 
Dominica, Jamaica, Saint Kitts and Nevis, and Saint Vincent and the Grenadines, the 
penalty for same-sex sexual acts is imprisonment for up to 14 years (16). Although 
these laws tend not to be enforced, their existence is used to hassle, persecute, 
harass and threaten persons with different sexual orientations or gender identity or 
expressions, and they contribute to a context that condones discrimination, stigma 
and violence against LGBTI people (12, 16).
Stigma and discrimination
Discrimination in health and other social services was widespread, and discriminatory 
and punitive laws and policies further limited access to services. Key populations 
and women living with HIV were subject to practices such as forced sterilization and 
denial of health services (17–19).
Nicaragua and Paraguay had restrictions on the permanent stay of people living 
with HIV who had been in the country longer than three months. In both countries, 
resident permits were withdrawn in the case of a positive HIV test. In Paraguay, an 
exception was made if individuals could prove they had sufficient resources to pay 
for their own treatment. 
In the Caribbean, small island states face challenges in ensuring the confidentiality of 
people living with HIV, and people living with HIV and members of sexual minorities 
can be easily identified for harassment and violence (20).
Young people 
Across the region, there were a number of barriers preventing adolescents and 
young people, especially among key populations, from accessing sexual and 
reproductive health and HIV services and commodities (2, 3). The provision of 
comprehensive sexual education also varies widely across the region, and in some 
countries, it continued to be provided at the discretion of educational centres and 
teachers (21). 
For most countries in Latin America, the average age of consent for heterosexual 
intercourse was 14. In the Caribbean, it was 16 (22). In many countries, young people 
who had reached the age of consent but had not attained the age of majority (i.e. 
they were not legally considered to be adults) required parental or guardian consent 
to access HIV and sexual and reproductive health services (2, 3). This meant that 
sexually active young people were being denied services, leaving them vulnerable to 
unwanted pregnancy and sexually transmitted infections (2, 3). 
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Similar barriers existed for HIV testing. In nine of 17 countries, minors required parental 
or guardian consent to take an HIV test and find out the results. A few countries in 
the Caribbean have developed policies allowing minors to access HIV testing without 
parental consent, either allowing it at any age (such as in Guyana) or above the age 
of 14 (as in Trinidad and Tobago) (23, 24). In Mexico and Panama, adolescents had to 
be accompanied by a parent, a legal guardian or other state-recognized individuals 
responsible for the well-being of adolescents in order to receive their test results. 
In Paraguay, health staff could request authorization to conduct an HIV test in the 
absence of parents or guardians. 
Opportunities
Self-testing
In 2015, Brazil began providing self-testing kits to the general population. These kits 
were made available free of charge from pharmacies, medication distribution centres, 
health services and government health programmes, as well as through the mail. The 
oral self-testing kits featured clear instructions and a telephone helpline (25). 
From January 2015 to March 2016, more than 4000 HIV tests were performed by four 
testing units in Curitiba, Brazil. More than 72 000 people accessed the online platform 
“A Hora e Agora” and around 2900 self-testing HIV kits were distributed (26). 
Regional support for a Fast-Track approach
The Second Latin American and Caribbean Forum on the Continuum of HIV Care 
issued a call to action—including regional Fast-Track prevention targets for 2020 and 
2030—with an emphasis on combination prevention packages for gay men and other 
men who have sex with men, transgender women, sex workers, people who use drugs 
and young people (27). These targets are consistent with the 2016 Political Declaration 
on HIV and AIDS, which calls for a reduction of the annual number of people newly 
infected with HIV in the region to 40 000 adults and fewer than 500 children by 2020. 
The Central American Regional Coordination Mechanism—the HIV advisory body of 
the Central American Health Ministers Commission—is strongly committed to the  
90–90–90 target and the Fast-Track initiative, and was implementing a regional 
sustainability strategy. The objective of the strategy was to accelerate progress 
towards meeting the commitment to universal access, the Sustainable Development 
Goals and the Rio Call to Action in prevention, care, treatment and support for HIV. 
This was to be accomplished by orienting efforts and increased resources to the most 
effective interventions in Central America, including strengthening primary health care 
systems (31).
The region also has strong inter-institutional and civil society networks. These include 
the Horizontal Technical Cooperation Group (HTCG), REDLACTRANS (a regional 
network of transgender people), REDTRASEX (a regional network of sex workers), ICW 
Latina (the International Community of Women living with HIV) and REDCA+ (a Central 
American network of people living with HIV) in Latin America. In the Caribbean, CVC 
COIN (a coalition of community leaders and nongovernmental organizations working 
with vulnerable populations), Caribbean Sex Workers Coalition, CARIFLAGS (a forum for 
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Liberation and Acceptance of Genders and Sexualities) and CRN+ (a regional network 
of HIV-positive people) are among the lead civil society organizations that work in close 
collaboration with the Pan Caribbean Partnership against HIV & AIDS (PANCAP).
Ensuring respect for the rights of people living with HIV, women at risk and key 
populations
The second Latin American and Caribbean Forum on the Continuum of HIV 
resulted in the Rio Call to Action, which set targets for combination prevention and 
zero discrimination, along with a number of priorities for achieving these targets. 
Those priorities include the following:
 ■ Basing all commitments and subsequent actions on respect for—and 
promotion and assurance of—human rights with a gender perspective. 
 ■ Increasing actions aimed at reducing prejudice, violence, stigma and 
discrimination associated with HIV or against persons living with HIV and key 
populations (gay men and other men who have sex with men, female and male 
sex workers, transgender persons, drug users, persons in prisons, and women 
and girls) and other populations left behind by the response. This was to be 
done through actions such as eliminating legal and political barriers, reducing 
discrimination in health care settings, addressing the specific needs of women 
and girls, reducing violence and guaranteeing access to justice. 
 ■ Strengthening national strategic information systems to ensure appropriate 
monitoring of progress (27).
PANCAP is working closely with UNDP and UNAIDS to document and address 
gaps in human rights throughout the region. This work is bringing together 
stakeholders and the leadership in the Caribbean Community (CARICOM) to 
advocate for attaining the Fast-Track targets by 2020.
The Organization of American States and its human rights body, the Inter-American 
Commission of Human Rights (the Commission), is providing legal protection for 
people living with and affected by HIV according to its 2013 resolution on HIV and 
the promotion and protection of human rights in the HIV response. For example, 
as part of a 2015 case in Mexico that involved the discriminatory treatment and 
forced retirement of soldiers living with HIV, the Commission recommended that 
the country provide the victims with any comprehensive health services needed, 
make complete reparations to the victim (including financial and moral reparations, 
and an agreement to reinstate the petitioners in the army), and implement training 
in the armed services on nondiscrimination against people living with HIV. Mexico 
complied with all of the recommendations (28). 
The Commission also continued to monitor violence against LGBTI people, 
including by publishing a report on such violence and publicly denouncing it (29). 
It also monitored gender equality, women’s rights, women’s access to information, 
violence against women and the administration of justice.2
2 For examples of reports on these subjects, please visit http://www.oas.org/en/iachr/reports/thematic.asp. 
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MIDDLE EAST AND  
NORTH AFRICA
Although the Middle East and North Africa was the region with the lowest HIV 
prevalence, at 0.1% [<0.1–0.2] among adults aged 15–49 years, new infections in 
the region increased by 4% between 2010 and 2015. More than 95% of new HIV 
infections in the Middle East and North Africa occurred among key populations 
and their sexual partners. Harm reduction services were established practice in 
four countries, two of which have high HIV prevalence among people who inject 
drugs. Prevention services were available for gay men and other men who have sex 
with men, sex workers and migrants in some countries, while many countries have 
included prisoners in their HIV programming. Across the region, however, there 
were major gaps in HIV prevention programming. Access to and uptake of HIV 
testing services were limited, with only 37% [26–54%] of people living with HIV in 
the region aware of their status in 2015. Coverage of antiretroviral therapy was 17% 
[12–24%] in 2015, far below the global average, contributing to low viral suppression 
of only 11% [8–16%] of all people living with HIV. Challenges in the region include 
the criminalization of drug use, sex work and same-sex sexual behaviour, with 
penalties including imprisonment and death. Prevention programmes for gay men 
and other men who have sex with men and sex workers rarely receive support 
from domestic resources or through public services. Conflicts and humanitarian 
emergencies have disrupted health and social services and responses to HIV.
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TRENDS AND TARGETS
Percentage of people living with  
HIV who know their HIV status1
37% 
(26–54%)
90%
17% 
(12–24%)
81%
11% 
(8–16%)
73%
Percentage of people living with HIV 
who are on antiretroviral treatment
Percentage of people living with 
HIV who are virally suppressed2
Source: UNAIDS special analysis, 2016; for more details, see annex on methods.
1 2015 measure derived from data reported by 7 countries, which accounted for 77% of people living with HIV in the region.    
2 2015 measure derived from data reported by 8 countries. Regionally, 41%  of all people on antiretroviral therapy were reported to have received a viral load test during the reporting period. 
       
Progress towards the 90–90–90 target, Middle East and North Africa, 2015
Source: UNAIDS 2016 estimates. Source: UNAIDS 2016 estimates.
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Distribution of new HIV infections by country, Middle East and North Africa, 2015
Percent change in new HIV infections among adults (aged 15 years and older) by country, 
Middle East and North Africa, from 2010 to 2015
Source: UNAIDS 2016 estimates.
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HIV epidemic in the Middle East and North Africa
In 2015 the Middle East and North Africa was home to about 445 million people, of 
whom 233 million were aged 15 years and older. Although there are sociocultural 
similarities across the countries in the region, there are also vast differences in 
terms of economic and development status affecting both national HIV epidemics 
and responses.
There were an estimated 230 000 [160 000–330 000] adults and children living with 
HIV in the Middle East and North Africa, making it the region with the world’s lowest 
HIV prevalence —0.1% [<0.1–0.2%] among adults aged 15–49 years. Six countries 
were home to more than 90% of the estimated people living with HIV in the region, 
with almost 75% living in the Islamic Republic of Iran, Sudan and Somalia, and a further 
20% living in Morocco, Egypt and Djibouti. Between 2010 and 2015 new infections in 
the Middle East and North Africa increased by 4%, with an estimated 21 000  
[12 000–37 000] new infections in 2015 compared with 20 000 [15 000–29 000] in 
2010. This increase occurred among both men and women but was greater among 
men.
Distribution of new HIV infections among population groups, Middle East and North Africa, 
2014
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About 95% of the new HIV infections in 2015 occurred in only five countries: the 
Islamic Republic of Iran, Sudan, Somalia, Egypt, Morocco and Yemen. Since 2010 
new infections among adults have increased by more than 40% in Egypt and by 
more than 30% in Lebanon and Yemen. Algeria and Morocco experienced declines 
in new HIV infections of 46% and 31%, respectively.
HIV prevalence among gay men and other men who have sex with men, Middle East and 
North Africa, most recent data, 2013–2015
Source: 2016 Global AIDS Response Progress Reporting.
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HIV prevalence among people who inject drugs, Middle East and North Africa, most 
recent data, 2013–2015
8
6
4
2
0
Is
la
m
ic
 R
ep
ub
lic
 
o
f I
ra
n
M
o
ro
cc
o
Tu
ni
si
a
A
lg
er
ia
E
g
yp
t
Sa
ud
i A
ra
b
ia
O
m
an
Le
b
an
o
n
10
Pe
rc
en
t (
%
)
Sy
ria
n 
A
ra
b
 
R
ep
ub
lic
161 
HIV prevalence among sex workers, Middle East and North Africa, most recent data, 
2013–2015
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More than 95% of new HIV infections occurred among key populations 
(predominantly people who inject drugs, gay men and other men who have sex 
with men and female sex workers) and their sexual partners. HIV prevalence was 
considerably higher among these key populations compared with the general 
population, although there was much variation among countries. Approximately 6 
out of 10 of the region’s people living with HIV were men and boys, reflecting the 
predominantly male profile of two of the region’s three key populations.
Progress and gaps in prevention
Effective prevention of HIV in the region depends on reaching and engaging with 
key populations and tailoring prevention packages to meet national and local needs.
In 2014 Egypt conducted a first comprehensive review of size estimates for 
gay men and other men who have sex with men, sex workers and people who 
inject drugs in 5 of its 27 administrative districts. The size estimation exercise 
was followed by scaling up services in these districts and a focus on “hotspots”, 
resulting in a significant increase in coverage of prevention services. As an 
example, the number of sex workers who received an HIV test through the outreach 
services and linkage increased from 72 in 2014 to 295 in 2015. Provision of these 
services was led by a consortium of civil society organizations, which offered a 
comprehensive programme of activities, including condom promotion, needle and 
syringe distribution, targeted education, and voluntary counselling and testing for 
all individuals reached by the programme. About 3 000 people who inject drugs 
had been reached in 2015.
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Sudan continued to make considerable progress in supporting the scale-up 
of comprehensive HIV prevention activities for key populations, conducting 
integrated biological and behavioural surveillance of these populations in 2015. 
The surveys provide detailed state-by-state figures on condom use, testing and 
HIV prevalence among sex workers and gay men and other men who have sex with 
men. Condom use among sex workers and gay men and other men who have sex 
with men increased to 35% and 27% in 2015, compared with 23% and 20% in 2013, 
respectively; HIV testing coverage figures were 29% and 17% in 2015, showing an 
increase from the 2013 figures of 9% and 5%, respectively.
In Morocco subregional and city-level programmes were also expanding. In Agadir, 
Casablanca, Marrakech and Tangier, gay men and other men who have sex with 
men have been reached with HIV prevention services, resulting in condom use 
figures above 50% in all but Marrakech (46%) and HIV testing coverage of above 
50% in all but Marrakech (43%). Migrant populations (identified as a vulnerable 
population in the country) benefited from a comprehensive and targeted HIV 
programme. By the end of 2015, from an estimated number of 30 000 migrants, 
more than 10 000 had been tested for HIV and reached with combined prevention 
programmes delivered by nongovernmental organizations; approximately 300 
migrants were receiving free antiretroviral therapy.
People who inject drugs
There is moderate HIV prevalence among people who inject drugs in the region 
but much higher prevalence in the Islamic Republic of Iran and Morocco. In these 
countries, opioid substitution therapy was established practice (albeit on a far 
smaller scale in Morocco). In 2015 in the Islamic Republic of Iran, from an estimated 
number of 200 000 people who inject drugs, more than 24 000 were receiving 
opioid substitution therapy in communities and in prisons.
In Morocco new opioid substitution  treatment centres were opened, including 
in one prison, and the number of people who inject drugs receiving treatment 
reached 820 in 2015. Two rehabilitation centres providing harm-reduction services 
for people who inject drugs were also opened. Needle and syringe programmes 
were key to increasing safe injection practices in both the Islamic Republic of Iran 
and Morocco, with needles and syringes distributed or available for purchase from 
pharmacies. Together these programmes resulted in rates of safe injection of 82% 
and 80% in the Islamic Republic of Iran (2014) and Morocco (2015), respectively. 
In Lebanon, which has a much lower HIV prevalence among people who inject drugs, 
opioid substitution therapy programmes have been established. In 2015 more than 
1500 people were receiving this service in communities. Safe injection practices have 
been reported by more than 90% of people who inject drugs in Beirut.
In Tunisia, although opioid substitution therapy programmes have not yet started, 
needle and syringe programmes have resulted in safe injection in more than 88% 
of people who inject drugs.
In Tripoli, Libya, where the HIV prevalence among people who inject drugs was 
reported to be above 80%, the current conflict situation has made it difficult to 
establish any programme for this population.
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Gay men and other men who have sex with men
A UNAIDS-supported project to address the vulnerabilities of gay men and other men 
who have sex with men in Egypt helped to achieve significant growth in reach and 
geographical coverage of related services from 2013. Innovations included outreach 
to men in slum areas through community-based organizations and awareness outreach 
and prevention services for the female sexual partners of gay men and other men 
who have sex with men. A third approach, online outreach, was particularly effective, 
as police action against this population had intensified, making street outreach more 
challenging. Following online outreach, meetings are arranged with beneficiaries to 
deliver condoms and lubricants; the project also facilitates access to good-quality, 
stigma-free health services and psychosocial and legal support. In the period 2014–
2015 in Alexandria, the project reached around 1000 beneficiaries, distributed more 
than 3100 condoms and lubricants packages and facilitated 300 visits to project 
services. In Gharbya governorate, to which the project was expanded in 2015, nearly 
300 beneficiaries were reached and over 500 preventive packages were distributed.
In Lebanon a programme for men who have sex with men reached impact-level 
coverage in Beirut, where a study in 2014 showed testing coverage and condom use 
above 75%.
Sex workers
In Sudan a 2015 evaluation of interventions focused on key populations  showed that 
peer education efforts had been effective: of the more than 1000 men who have sex 
with men and female sex workers who had received peer education, 92% had been 
tested for HIV at least once and about 70% reported using condoms both in the past 
six months and during last sexual intercourse.
Prisoners
Many countries in the region have developed HIV programmes to offer prevention 
services to prisoners, mostly for those who inject drugs. Among the countries that 
have reported HIV prevalence among the prisoner population, the Islamic Republic 
of Iran has the highest prevalence of 1.4%; Morocco, Oman and Saudi Arabia 
reported prevalence ranging from 0.3–0.8%. and Tunisia reported a prevalence of 
0.1%.
Transgender people
For most of the countries in the region, transgender people have not been 
acknowledged as a separate key population. Accordingly, there are very limited data 
available on this key population. The Islamic Republic of Iran has identified male-
to-female transgender people as a high-risk population and in 2014 conducted a 
study establishing a 2% HIV prevalence among this group. Large-scale programmes, 
however, are yet to be established.
Lebanon’s national AIDS programme has acknowledged transgender people as a 
high-risk population, although no data have been published on this group. 
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Summary of behavioural data among key populations, most recent data, 2013–2015
<50% 50% - 75% >75% 
CONDOM USE
Sex workers
Egypt Djibouti Algeria 
Somalia Morocco Lebanon
Sudan Tunisia
Gay men and other men who have sex with men
Egypt Tunisia Lebanon
Sudan Morocco
People who inject drugs
Algeria Iran (Islamic Republic of)
Egypt
Lebanon 
Morocco 
Tunisia 
HIV TESTING
Sex workers
Egypt Lebanon Algeria
Morocco Djibouti
Somalia 
Sudan 
Tunisia 
Gay men and other men who have sex with men
Egypt Morocco Algeria
Sudan Lebanon
Tunisia
People who inject drugs
Egypt Algeria 
Iran (Islamic Republic of) Lebanon
Morocco
Oman
Syrian Arab Republic
Tunisia
SAFE INJECTION PRACTICE 
People who inject drugs
Algeria Iran (Islamic Republic of)
Egypt Lebanon
Morocco
Tunisia
Source: 2016 Global AIDS Response Progress Reporting.
165 
Viral suppression
An estimated 37% [26–54%] of people living with HIV in the Middle East and North Africa 
in 2015 knew their HIV status, about 17% [12–24%] were on antiretroviral therapy and only 
11% [8–16%] had achieved viral suppression. Considerable gaps to reach the 90–90–90 
target remained for this region in particular cascade remained. To achieve  the 90–90–90 
target in 2015 required diagnosing nearly 122 000 people living with HIV who did not 
know their HIV status, starting an additional 148 000 people on antiretroviral therapy, and 
ensuring an additional 142 000 people living with HIV achieved viral suppression.
With only a little over a third of people aware of their HIV status in 2015, the most 
important barrier to achieving the 90–90–90 target in the Middle East and North Africa 
was limited access to and uptake of HIV testing services. Although the primary approach 
to service provision in the region is health facility-based voluntary counselling and testing, 
in some countries testing programmes are focused on premarital screening and pre-
employment screening of migrants. In some cases this screening is conducted without 
informed and unforced consent, for example as a prerequisite for renewing a work permit 
or for issuing a marriage certificate. These practices are a  violation of human rights and 
contrary to World Health Organization (WHO) and UNAIDS recommendations to ensure 
that all HIV tests are done confidentially and with informed consent (1).
Efforts have been made to increase testing coverage within a human rights framework. 
For example, several countries have expanded community support for testing and 
treatment programmes among key populations and in key locations. Algeria, Djibouti, 
Egypt, the Islamic Republic of Iran, Morocco and Sudan conducted community testing 
campaigns. In Morocco, where less than 40% of people living with HIV were aware of their 
status, HIV testing targets were revised to increase the focus on vulnerable populations 
and regions with higher HIV burden. In 2014, community testing, with HIV counselling 
and testing provided by non-clinical peer educators, was introduced by the Association 
de Lutte contre le Sida in Agadir, Casablanca, Marrakech and Rabat as part of a pilot 
prevention programme for key populations. External evaluation of the initiative was under 
way in preparation for potential scale-up. At the same time, efforts were made to integrate 
HIV testing services into basic health-care facilities. As a result, by 2015, nearly half of 
people living with HIV were aware of their status.
In Algeria more than 770 000 HIV tests were conducted in more than 2000 testing sites, 
resulting in an increase in estimated coverage of people living with HIV who know their 
HIV status from around 77% to more than 90%. In Djibouti more than  
21 000 HIV tests were provided in 2015, pushing the proportion of people living with 
HIV who know their status to 70%. In Egypt, the Islamic Republic of Iran and Sudan 
the figures are still below 50%. These latter three countries and other countries of the 
region gathered together in December 2015 in a regional meeting and developed 
roadmaps for Fast-Tracking HIV testing and linkage to services to reach the 90–90–90 
target. The meeting resulted in the Algiers Declaration on Fast-Tracking HIV Testing 
in the Middle East and North Africa. In the Declaration countries called for investment 
in strategic information to guide actions to increase HIV testing and set annual testing 
targets; implement strategic approaches for innovative, rights-based and participatory 
community-based testing; scale up services for key populations; increase resources for 
HIV testing; and reinforce partnerships between governments, civil society, the private 
sector and academia to Fast-Track testing.
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Coverage of antiretroviral therapy in the Middle East and North Africa was 17% 
[12–24%] in 2015, far below the global average, in major part due to low levels of 
HIV testing and diagnosis. Like rates of testing, however, coverage had increased—
by 37% between 2013 and 2015 in the region as a whole, and by more than 50% 
in Algeria and Egypt. If other countries replicate the pace of Algeria and Egypt, 
then the region will be able to reach its target of 81% treatment coverage among 
people living with HIV by 2020.
In Morocco national guidelines on antiretroviral therapy were reviewed in 2015 
to ensure a “treat all” approach could be delivered across treatment facilities. A 
review of service delivery and care for people living with HIV was also conducted 
in this year. Combined with increased decentralization of the care system and 
increased testing, and attempts to address the challenges identified in a 2014 
cascade analysis at main treatment sites, these efforts meant that the coverage 
of antiretroviral therapy among adults rose from 13% [11–15%] in 2013 to 35% 
[30–41%] in 2015.
In Egypt a similar approach of expanding testing sites and community testing 
resulted in a 46% increase in treatment coverage from 2013 to 2014 and another 
25% increase from 2014 to 2015, although the treatment coverage is still lower than 
20%. There is an urgent need to increase the pace.
In the Islamic Republic of Iran and Sudan the national strategic plans explicitly 
incorporated the 90–90–90 target.
Although only an estimated 11% [8–16%] of people living with HIV in the region 
have suppressed viral loads, it appears that the vast majority of people who know 
their status and initiate antiretroviral therapy remain on treatment. More than 80% 
of people on antiretroviral therapy in the region were retained in treatment after 12 
months according to available data, but fewer countries have passed 90% retention 
on the first year. For the few countries with viral load suppression data from more 
than 75% of people on treatment, the figures vary widely: 90% in Jordan and Saudi 
Arabia, 80% in Lebanon, 75% in Oman and 53% in Algeria.
Egypt revised its clinical care guidelines in May 2014 and undertook a cascade 
analysis, which highlighted key gaps, including in retention on treatment. It then 
introduced innovative approaches to improve adherence during the first year 
of treatment (during which the highest dropout rates were identified). These 
approaches included enlisting civil society support, scaling up psychosocial 
counselling, implementing a “buddy system” of social workers for people living 
with HIV, and reviewing all case records to identify people whose access to 
treatment had been interrupted and to identify potential barriers to access and 
adherence. In addition, remote treatment centres were authorized to prescribe 
medication and provide follow-up to patients to improve adherence in remote 
locations. A referral protocol was established between the national AIDS programme 
and Cairo University hospitals  to facilitate the exchange of information and strengthen 
the links between people newly diagnosed with HIV and the continuum of care. The 
outcome of these changes can be seen over the past 2 years, when the 12-month 
retention on treatment has increased from 73% in 2013 to 80% in 2015.
In Yemen until 2015, despite civil and political instability and intermittent power, 
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treatment sites continued to deliver services and to collect data.1 International 
assistance was provided for peer support and patient transport. As a result, adherence 
improved and the number of patients lost to follow-up decreased. In 2014, 68% 
of people who had previously interrupted treatment restarted. New software was 
instrumental in improving follow-up, particularly of people who missed appointments.
Challenges
Legal and policy environment
In all of the countries in the Middle East and North African, members of at least one 
of the key populations can face criminal charges because of their sexual orientation, 
gender, identity, occupation or behaviours. Drug use is criminalized in all countries, 
and in some countries carrying even a small amount of drugs can lead to long-term 
imprisonment. Many countries have specific laws against sex work and sex outside 
marriage, with penalties that include capital punishment. Gay men and other men who 
have sex with men can face severe legal sanctions, with penalties that include death 
in many countries. Meanwhile, mandatory HIV testing of refugees and asylum seekers 
without pre- and post-test counselling and without guarantee for privacy is also a 
reality in a number of countries.
Investment in HIV prevention among key populations
Prevention programmes for gay men and other men who have sex with men and sex 
workers rarely received support from domestic resources or through public services. 
Even though these populations have been included in many national strategic plans, 
public funding is rarely used for specific programmes for them, and it is usually grants 
from the Global Fund to Fight AIDS, Tuberculosis and Malaria or smaller-scale grants 
from other donors that provide the necessary resources for the relevant programmes. 
HIV testing and some other services that are provided through public health services 
do receive funding from public resources.
HIV in humanitarian settings
Several of the countries in the region were challenged by conflict or humanitarian 
emergencies, with rapidly changing environments, violence, displacement of 
people within and across borders, resource constraints, and disruption of already 
stretched health and social services. These situations also disrupt responses to HIV. 
The protection of people who are affected by humanitarian emergencies, including 
refugees, asylum seekers and internally displaced people, and their human rights 
should be prioritised.
Opportunities
Leadership, commitment and partnerships
The political leadership of the League of Arab States and UNAIDS resulted in the 
development and endorsement of the Arab AIDS Strategy in March 2014 and the 
1 With the exception of active conflict areas in Aden and Taiz.
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Council of Arab Health Ministers following up the implementation of the Strategy in 
all Member States in February 2015. This leadership is also clearly reflected in the 
Algiers Call for Action on Advancing Gender Equality and the HIV Response that 
followed the High-Level Meeting of Women Leaders in the region, held jointly by 
the League of Arab State, UNAIDS, UN Women and the Government of Algeria in 
November 2014.
In October 2015 Djibouti was the first Arab country to ratify the Arab Convention 
on Preventing HIV and Protecting the Rights of People Living with HIV, which 
was adopted in 2012 by the Arab Parliament and provides a legal framework for 
countries to apply human rights principles in their responses to HIV (2). Djibouti’s 
First Lady also took the lead in promoting the elimination of mother-to-child 
transmission and female genital mutilation. The First Lady of Sudan, meanwhile, 
worked to engage multi-stakeholder commitment to the elimination of mother-
to-child transmission, the acceleration of prevention, testing and treatment, and 
challenging stigma and discrimination against people living with HIV. The First Lady 
of Sudan is also pushing for law reform to raise the legal age of marriage for girls in 
Sudan to 18 years.
In an unprecedented step for civil society in the region, the Regional Arab Network 
Against AIDS signed a Memorandum of Agreement in December 2014 with the 
League of Arab States on the role of civil society in the implementation of the Arab 
AIDS Strategy. This represents the first partnership within the region between civil 
society and such a significant intergovernmental body.
People living with HIV and civil society organizations, including MENARosa (the first 
regional network dedicated to supporting women living with HIV), played key roles 
in supporting access to and retention in treatment through therapeutic education 
programmes, psychosocial support and income-generating activities. 
In Lebanon, a circular by Lebanese Internal Security Forces (ISF) requesting 
emergency rooms to report any drug-related emergency to the police has been 
recently reversed by the Ministry of Public Health. Skoun, the Lebanese Addiction 
Centre, along with its key partners played a catalytic role in advocating for the 
policy change. Prior to the revocation, fear of arrest and prosecution deterred 
people who use drugs from accessing emergency services.
Domestic financing, shared responsibility and regional solidarity
Limited amounts of international funding are available for AIDS responses in the 
region. Among the middle-income countries in the region, Algeria and the Islamic 
Republic of Iran financed more than 80% of their national HIV programmes. Jordan 
and Lebanon also financed more than 80% of their national HIV programmes, 
although their programmes were much smaller. Morocco has developed an 
ambitious plan to reach 70% national financing by 2018. Djibouti has developed a 
national strategy to implement the African Union Shared Responsibility and Global 
Solidarity roadmap to mobilize domestic resources for sustainable funding for the 
national response. In 2015 Somalia, Sudan and the Islamic Republic of Iran had 
their concept notes to the Global Fund to Fight AIDS, Tuberculosis and Malaria 
approved.
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In 2015 the Organization of the Petroleum Exporting Countries (OPEC) Fund 
for International Development contributed US$ 1.2 million for strengthening 
innovative approaches to testing, treatment and the prevention of mother-to-child 
transmission in the region. The Fund covers six non-OPEC countries (Djibouti, 
Morocco, Somalia, Sudan, Tunisia and Yemen) and region-wide activities.
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EASTERN EUROPE  
AND CENTRAL ASIA
Eastern Europe and central Asia is the only region in the world where the HIV 
epidemic continued to rise rapidly. The epidemic is concentrated predominantly 
among key populations, and in particular people who inject drugs, and there is low 
coverage of harm-reduction and other HIV prevention programmes in key countries 
within the region. Although sexual partners of key populations are at elevated risk 
of HIV infection, condom use is inconsistent among key populations across the 
region. There were big gaps in the HIV testing and treatment cascade, and coverage 
of antiretroviral therapy in the region remained significantly lower than the global 
average, resulting in low levels of viral suppression. Stigma and discrimination 
towards people living with HIV and key populations remain high. New conservative 
legislation is placing additional restrictions on same-sex relationships, sex work and 
drug use and , which could entrench barriers to HIV services for key populations. 
Prevention programmes are under threat as international support for HIV responses 
decreases and domestic funding for HIV prevention fails to keep pace.
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Source: UNAIDS special analysis, 2016; for more details, see annex on methods.
Progress towards the 90–90–90 target, eastern Europe and central Asia, 2015
1 2015 measure derived from data reported by 11 countries, which accounted for 98% of people living with HIV in the region.    
2 2015 measure derived from data reported by 11 countries. Regionally, 77% of all people on antiretroviral therapy were reported to have received a viral load test during the reporting period.
New HIV infections among adults (aged 15 years and older), eastern Europe and central Asia, 2010–2015
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Distribution of new HIV infections by country, eastern Europe and central Asia, 2015
Percent (%)
Source: UNAIDS 2016 estimates.
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Source: UNAIDS special analysis, 2016; for more details, see annex on methods.
HIV epidemic in eastern Europe and central Asia
Eastern Europe and central Asia is the only region in the world where the HIV 
epidemic continued to rise rapidly. There was a 57% increase in annual new HIV 
infections between 2010 and 2015.
More than 80% of the region’s new HIV infections in 2015 were in the Russian 
Federation, and an additional 15% occurred in Belarus, Kazakhstan, the Republic of 
Moldova, Tajikistan and Ukraine.
The epidemic is concentrated predominantly among key populations and their 
sexual partners, in particular people who inject drugs, who accounted for more 
than half of new HIV infections in 2015.
Low coverage of prevention programmes, in particular harm-reduction 
interventions among people who inject drugs, is largely to blame for this continued 
rise.
The vast majority of people living with HIV in the region resided in capitals or 
large cities where HIV prevalence among key populations is often extremely high. 
For example, a survey of people who inject drugs conducted in five Russian cities 
(Abakan, Barnaul, Volgograd, Naberezhnye Chelny, Perm) in 2015 found that one 
People who 
inject drugs 
51%
Clients of sex workers and 
other sexual partners of 
key populations 
33%
Rest of population 
4%
Gay men and other men 
who have sex with men
6%
Sex workers 
6%
Distribution of new HIV infections among population groups, eastern Europe and Central 
Asia, 2014
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in three people who inject drugs were living with HIV. HIV prevalence among 
people who inject drugs was also high, exceeding 20% in some cities in Belarus 
(Svetlogorsk, Minsk, Pinsk) and 15 of 33 cities in Ukraine, but was under 10% in 
other countries in the region.
Prevention of mother-to-child transmission coverage in the region was more 
than 95%, and the transmission rate was less than 4% in seven of the region’s 15 
countries. In Belarus and Armenia the transmission rate was less than 2%, and all 
criteria have been met, allowing for validation of elimination of mother-to-child 
transmission.
Progress and gaps in prevention
The scale of prevention programmes for key populations was insufficient to curb 
the region’s surging epidemics. This was particularly true in the Russian Federation, 
home to the region’s largest HIV epidemic and largest population of people who 
inject drugs (1.5 million) (1).
Harm reduction
Opioid substitution therapy was available in all countries except the Russian 
Federation, Turkmenistan and Uzbekistan. Capacity to provide such therapy 
remained low; coverage was 5.3% in Belarus, 4.9% in Kyrgyzstan, 3.5% in Ukraine 
and 0.2% in Kazakhstan. Similarly, the sterile injecting equipment distributed 
through needle–syringe programmes was insufficient across the region, except in 
Kyrgyzstan, where 241 needles were provided per client per year (target is 200).
Prevalence of HIV among people who inject drugs in five cities of the Russian Federation, 
2015
Source: Esvero. Report on results of bio-behavioural study among people who inject drugs in Abakan, Barnaul, Volgograd, Naberezhnye Chelny and Perm, 2015.
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In most countries, people who use drugs reported high levels of use of clean 
needles at last injection. When the supply of clean syringes and needles via 
outreach workers and needle exchange points declines, however, there is a 
corresponding decline in the use of sterile injection equipment—for example, in 
Kazakhstan after a Global Fund to Fight AIDS, Tuberculosis and Malaria (Global 
Fund) grant ended. This trend must be urgently counteracted by all national AIDS 
programmes that transition from Global Fund support (2).
A needle-syringe programme in prisons is only available in Kyrgyzstan, Moldova 
and one prison in Tajikistan. Access to opioid substitution therapy for maintenance 
treatment in prisons is much lower than in the community, where accessible, in 
Moldova, Kyrgyzstan, and some police detention centres in Ukraine. (3)
Expanded coverage with a comprehensive harm reduction package of 
interventions will be required to have any noticeable effect on reducing the harms 
associated with injecting drug use.
Sexual transmission of HIV
Unprotected sex is a cause of an ever growing number of new HIV infections. 
Sexual partners of key populations are at elevated risk of HIV infection. In certain 
countries key populations report high levels of condom use. For instance, self-
reported condom use among gay men and other men who have sex with men 
ranged from 49% in the Republic of Moldova to 82% in Kyrgyzstan, among 
sex workers from 52% in Uzbekistan to 95% in Kazakhstan, and among people 
who inject drugs from 36% in Georgia to 60% in Belarus (4). Condom use is 
inconsistent, however, and levels of condom use vary between types of sexual 
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encounter. For instance, in Kazakhstan 95% of sex workers use condoms with 
clients but only 35% do so with stable partners; 84% of gay men and other men who 
have sex with men use condoms with occasional male partners but only 52% do so 
with regular male partners; and 77% of people who inject drugs use condoms with 
occasional sexual partners but only 35% do so with regular partners (2).
Drastically scaling up the number of people living with HIV on antiretroviral therapy 
to suppress viral load in combination with consistent condom use can help reduce 
the number of sexually transmitted HIV infections.
Viral suppression
An estimated 67% [62–72%] of people living with HIV in eastern Europe and central 
Asia in 2015 knew their HIV status, and about 21% [20–23%] were on antiretroviral 
therapy. The gap to achieving the 90–90–90 target in 2015 was more than 354 500 
people living with HIV who did not know their HIV status, 917 000 people in need 
of antiretroviral therapy, and 832 400 people living with HIV who were not virally 
suppressed. As a result of these gaps, only 19% [17-20%] of all people living 
with HIV in eastern Europe and central Asia had achieved the viral suppression 
necessary to prevent HIV transmission.
Country and regional HIV testing and treatment data presented in cascades 
emphasize that the biggest gaps are the number of people living with HIV who 
remain undiagnosed, and the number of people living with HIV who know their HIV 
status but have not started treatment.
Large proportions of key population groups remain undiagnosed in the region, 
presenting a major obstacle to achieving 90–90–90. Status awareness among sex 
Source: Ganina LY, et al. Review of HIV epidemic in Kazakhstan in 2013–2015. Almaty: 2016.
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Treatment cascade of services for people living with HIV in Ukraine, 2015
People living with HIV who 
know their status
People living with HIV  
linked to care
People living with HIV who are 
on antiretroviral treatment
People living with HIV who  
are virally suppressed
58%
126 604 45%
98 325 28%
60 753
21%
47 205
220 000
198 000
178 200
160 380
90%
90%
90%
Source: CDC Ukraine, 2016.
People living with HIV
workers ranges from 22% in the Republic of Moldova and 35% in Uzbekistan to 
80% in Kazakhstan. Testing coverage was generally higher among gay men and 
other men who have sex with men and lower among people who inject drugs. 
In Ukraine available survey data suggest that less than 60% of gay men and 
other men who have sex with men reported taking an HIV test and receiving the 
results within the previous 12 months. Among female sex workers in Ukraine and 
Kyrgyzstan, 59% had an HIV test and received the results. The highest recorded 
rate of HIV testing among people who inject drugs was 58%, in Kazakhstan. The 
proportion is lower in other countries in the region. HIV testing is offered in some 
prison systems, however, several countries in the region have mandatory HIV 
testing in prisons, which the UN does not condone. A major barrier to expanded 
ART coverage is the lack of continuity between treatment in the community and 
prison system (5). 
Coverage of antiretroviral therapy in the region remained significantly lower than 
the global average. Kazakhstan, Kyrgyzstan and Tajikistan reported less than 
20% of sex workers living with HIV receiving antiretroviral therapy. Coverage 
among gay men and other men who have sex with men was lower. Kazakhstan 
and Ukraine reported 27% and 26% antiretroviral therapy coverage, respectively, 
among people who inject drugs, while coverage in Kyrgyzstan and Tajikistan was 
below 20%. Almost all countries in the region had not revised their AIDS treatment 
guidelines to reflect the latest World Health Organization recommendations to 
offer antiretroviral therapy immediately after diagnosis.
The price of antiretroviral medications and the unit costs for treatment-related 
services also remained high in several countries with large numbers of people living 
with HIV, impeding scale-up.
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On average, 82% of people on antiretroviral therapy have a suppressed viral load. 
The highest rate was in the Russian Federation (85.2% of people on antiretroviral 
therapy), followed by Ukraine (77.7% of people on antiretroviral therapy); the 
lowest rate was in Tajikistan (32%). Given that only 21% of people living with HIV 
were on treatment, however, the prevention effect of the suppressed viral load 
would have only a marginal effect on reduction in HIV incidence.
Challenges
Lack of national commitment to combination prevention
Even the limited coverage by prevention programmes was under threat. The Global 
Fund has been the region’s largest donor for HIV prevention among key populations 
since 2004. As of July 2013, however, the Russian Federation was classified by the 
World Bank as a high-income country; 7 of the other 14 countries are classified as 
lower-middle-income countries. As a result, international support to HIV programmes 
in the region is decreasing, and new domestic funding for HIV prevention is not 
keeping pace as the priority of HIV programmes in many countries is to increase 
coverage of antiretroviral treatment.
In the Russian Federation, 30 projects serving some 27 000 people who inject 
drugs were left without financial support after the Global Fund grant ended in 
2014. Although remaining projects in 16 cities continued to provide essential HIV 
services to people who inject drugs in 2015, their scale is not sufficient to change the 
trajectory of the HIV epidemic in the Russian Federation.
Source: Median prices from the 2014 MSH/WHO International Drug Price Indicator Guide, 2014 edition. Geneva: World Health Organization; 2015 (http://apps.who.int/medicinedocs/
en/m/abstract/Js21983en/).
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Legislative barriers to access for key populations
A new wave of conservative legislation in the region places additional restrictions on 
same-sex relationships, sex work and drug use and risks entrenching the barriers to HIV 
services for key populations.
On several occasions in 2014 and 2015 the Parliament of Kyrgyzstan tried to pass a 
homophobic bill that would make creating a positive attitude to non-traditional sexual 
relations a criminal offence. In October 2015 the Parliament of Tajikistan doubled 
the fine for sex work; a sex worker can also be given up to 15 days of home arrest. 
In Belarus, in 2015, fines were introduced for non-medical drug use; second-time 
offenders within one year may be sentenced to a two-year prison term. In the Russian 
Federation a so-called “law on foreign agents” interrupted the work of community-
based organizations that receive international funding to provide HIV prevention 
services to key populations in the absence of domestic funding for these purposes.
Stigma and discrimination towards people living with HIV and key populations also 
remained high. Over 50% of men and women aged 15–49 years in eight countries 
with available data reported they would not buy fresh vegetables from a shopkeeper 
living with HIV, a question used to measure discriminatory attitudes towards people 
living with HIV (6). People living with HIV surveyed as part of the People Living with 
HIV Stigma Index in 2015 reported experiencing stigma and discrimination in many 
aspects of their lives, including denial of health or dental services in the previous 12 
months (17.6% in Kazakhstan, 8.0% in Kyrgyzstan, 17.0% in Tajikistan) and refusal of 
employment (5.8% in Kazakhstan, 9.3% in Kyrgyzstan, 14.8% in Tajikistan) (7).
Urban centres: high prevalence, large numbers of key populations
Moscow (Russian Federation), Kyiv (Ukraine), Almaty (Kazakhstan), Tashkent 
(Uzbekistan), Minsk (Belarus) and Chisinau (Republic of Moldova) are large urban 
centres and home to a considerable proportion of the region’s key populations and 
people living with HIV. The city of Kyiv has signed the 2014 Paris Declaration on 
Fast-Track Cities, which committed cities to focusing on vulnerable and marginalized 
people, including key populations, in order to reduce vulnerability and foster tolerance 
and achieve the 90–90–90 treatment targets by 2020.
Services for vulnerable and marginalized women and children
Despite the overall progress in this area, access to prevention of mother-to-child 
transmission and other HIV services was still insufficient for the most vulnerable and 
socially marginalized groups of women, including irregular migrants and pregnant 
women who use drugs. This resulted in an increased risk of HIV transmission for these 
women and their infants. For instance, in Kyrgyzstan there is an increasing trend of 
denial of prevention of mother-to-child transmission services and antiretroviral 
therapy by women for religious reasons; such women choose not to be examined by 
a doctor or to discover their HIV status, and even if they do know their status refuse 
prevention of mother-to-child transmission services. They also refuse to have their 
children examined and treated for HIV. According to the 2015 mid-term evaluation 
of the state programme on HIV (8), 89 children were born to women living with HIV 
in 2012; only 59 children were tested for HIV (66.3%), and the status of the remaining 
30 children was unclear.
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In addition, children in the region who are living with HIV continue to need support 
as they become adolescents to attend school and ensure a smooth transition from 
paediatric to adult care.
Opportunities
Potential efficiency gains
Political commitment to Fast-Track the AIDS response by 2020 in the region 
remains uncertain, especially against the backdrop of limited government 
budgets and diminishing donor funding. Significant gains could still be made, 
however, through more efficient use of existing resources. An analysis of the 
allocation of existing resource in nine countries found that optimization of the 
use of these resources by focusing on the most effective HIV services among the 
populations and locations in greatest need could reduce new HIV infections by 
6–36% (9–15).
Some countries in the region are already addressing this issue. In Belarus, one 
of the region’s upper-middle-income countries, HIV prevalence among the 
estimated 67 000 people who inject drugs is 25%. The Government of Belarus 
has pledged to increase national funding for HIV services from 35% in 2016 
to 62% in 2018, and to 100% following the cessation of Global Fund funding. 
Resourcing plans include using new social contracting mechanisms and local 
budgets to directly contract nongovernmental organizations to provide HIV 
services. Targets include expanding HIV prevention services to 60% of people, 
including needle–syringe distribution to 45 000 people who inject drugs and 
opioid substitution therapy to 4900 people, by the end of 2018 (16).
Innovative HIV testing strategies
Increasing the number of people living with HIV who know their HIV status 
will require innovative strategies that focus on key populations who may feel 
uncomfortable or even afraid to access services at public health clinics. In the 
Republic of Moldova nongovernmental organizations are conducting saliva-
based HIV test for key populations and serodiscordant couples alongside harm-
reduction and other HIV prevention services. Special regulation and bylaws 
have been approved by the Moldovan Ministry of Health to ensure the quality 
and legitimacy of these screening tests and referral to the health system for 
confirmatory diagnosis (17). Since May 2016 HIV self-testing kits have been 
available in Moldovan pharmacies for US$ 25. A leaflet accompanies the test 
kit to explain the steps to be taken depending on the screening test result. A 
communication campaign on testing was simultaneously organized with the 
launch of the self-test to encourage uptake. Early evidence suggests that the self-
test is well accepted and empowering for people who may otherwise not seek to 
learn their HIV status.
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WESTERN AND CENTRAL EUROPE  
AND NORTH AMERICA
In 2015 there were an estimated 91 000 [89 000-97 000] new HIV infections in 
western and central Europe and North America, including fewer than 1000 new 
infections among children. The annual number of new adult HIV infections 
remained stable between 2010 and 2015, but there were considerable variations 
among key populations and modes of transmission in different countries. Nine out 
of 10 new HIV infections in 2014 were among key populations and their sexual 
partners. In western and central Europe long-term high coverage of harm reduction 
programmes has reduced the number of new infections among people who inject 
drugs, but there are indications that levels of condom use have not improved among 
gay men and other men who have sex with men. Pre-exposure prophylaxis (PrEP) 
was available in Canada, France and the United States of America, and 17 European 
countries had pre-exposure prophylaxis demonstration projects in process or 
planned. The number of HIV tests performed in western and central Europe and the 
United States has increased steadily. Testing levels were highest among gay men and 
other men who have sex with men, however, and there is evidence that diagnoses 
are often made several years after infection. A major challenge is the continued 
disproportionate effect of HIV on gay men and other men who have sex with 
men, people who inject drugs, African American men and women, and migrants 
originating from high-endemic areas.
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New HIV infections among adults (aged 15 years and older), western and central Europe and North America, 
2010–2015
TRENDS AND TARGETS
Source: UNAIDS special analysis, 2016; for more details, see annex on methods.
Progress towards the 90–90–90 target, western and central Europe and North America, 2015
1 2015 measure derived from data reported by 14 countries, which accounted for 83% of people living with HIV in the region.
2 2015 measure derived from data reported by 16 countries. Regionally, 44% of all people on antiretroviral therapy were reported to have received a viral load test during the reporting period.
Percentage of people living with HIV 
who know their HIV status1
Percentage of people living with HIV 
who are on antiretroviral treatment
Percentage of people living with HIV 
who are virally suppressed2
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(54–66%)
81%
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Source: UNAIDS 2016 estimates.
2010
120
100
80
60
40
20
0
2015 2020
N
um
b
er
s 
(t
ho
us
an
d
)
New HIV infections Target
184 
Rest of the region
United States of America
Spain
United Kingdom
Turkey
Germany
Italy
France
Source: UNAIDS 2016 estimates.
Distribution of new HIV infections by country, western and central Europe and North 
America, 2015
Percent change in new HIV diagnoses by mode of transmission, western and central Europe 
and North America, from 2010 to 2014
Source: UNAIDS analysis using data from: European Centre for Disease Prevention, WHO Regional Office for Europe. HIV/AIDS surveillance in Europe 2014; United States Centers for Disease Control 
and Prevention. HIV Surveillance Report, 2014; vol. 26; Public Health Agency of Canada. HIV and AIDS in Canada: Surveillance Report to December 31, 2014.
Countries not included in the analysis: Estonia, Poland, Italy, Spain, Turkey, Israel and Switzerland.         
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Source: UNAIDS special analysis, 2016; for more details, see annex on methods.
HIV epidemic in western and central Europe and 
North America
There were an estimated 91 000 [89 000–97 000] new HIV infections in western 
and central Europe and North America in 2015, including fewer than 1000 new 
infections among children. More than half of all new HIV infections occurred in 
the United States of America, and more than a quarter occurred in six countries: 
France, Germany, Italy, Spain, Turkey and the United Kingdom of Great Britain and 
Northern Ireland (1).
The annual number of new HIV infections among adults in western and central 
Europe and North America remained stable between 2010 and 2015, raising 
concerns regarding the region’s progress towards its 2020 target of 23 000 new 
HIV infections. Stability in the overall trend of new infections hides changes among 
key populations that accounted for the vast majority of new HIV infections. New 
diagnoses among gay men and other men who have sex with men increased by 
17% in western and central Europe and by 8% in North America between 2010 and 
2014 (2,3). Over the same period, the annual number of new diagnoses among 
people who inject drugs in North America decreased by 26%. In western and 
central Europe several outbreaks of HIV among people who inject drugs caused 
new diagnoses within this population to increase in 2011 and 2012, following 
Distribution of new HIV infections among population groups, western and central Europe 
and North America, 2014
Rest of population 
7%
Sex workers 
1%
Gay men and other men  
who have sex with men
49%
People who inject drugs
15%
Clients of sex workers 
and other sexual 
partners of key 
populations
28%
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several years of decline. Outbreaks related to injecting drug use in areas of Greece 
and Romania led to approximately a 20-fold increase in HIV diagnoses among 
people who inject drugs in these two countries between 2010 and 2012 and still 
had an effect on the number of new diagnoses in 2015 (4,5). The annual number of 
new diagnoses attributed to heterosexual transmission in North America declined 
by 16%, reflecting reductions in new HIV infections among women of African 
descent (3,5,22). However, in 2014 African American women accounted for 4654 
new HIV diagnoses in the United States (2). In 2010 the rate of new HIV infections 
among African American women was estimated to be 20 times that of Caucasian 
women and nearly five times that of Hispanic women (22).
In western and central Europe the number of heterosexually acquired HIV 
diagnoses also decreased. This trend is mostly due to reduced number of 
diagnoses among migrants from high-endemic areas (1). Nonetheless, HIV 
diagnoses among migrants remain high accounting for 32% of all new HIV 
diagnoses in Europe in 2014. There is evidence that a considerable proportion of 
the infections were acquired post-migration (23).
A UNAIDS analysis of available data across western and central Europe and North 
America suggests that 9 out of 10 new HIV infections in 2014 were among key 
populations and their sexual partners, with gay men and other men who have sex 
with men accounting for nearly half of all infections. HIV testing data from 2014 
show that gay men and other men who have sex with men accounted for more than 
two-thirds of HIV diagnoses in North America and more than half of HIV diagnoses 
in western Europe. In central Europe a larger proportion of new diagnoses were 
attributed to injecting drug use, including nearly a third of diagnoses in 2014 in the 
Baltic countries of Estonia, Latvia and Lithuania (2).
Source: UNAIDS analysis using data from: European Centre for Disease Prevention, WHO Regional Office for Europe. HIV/AIDS surveillance in Europe 2014; Centers for Disease Control and 
Prevention. HIV Surveillance Report, 2014; vol. 26; Public Health Agency of Canada. HIV and AIDS in Canada: Surveillance Report to December 31, 2014.
Distribution of new HIV diagnoses by mode of transmission, western and central Europe and 
North America, 2014
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Source: European Centre for Disease Prevention and Control, WHO Regional Office for Europe. HIV/AIDS surveillance in Europe 2014.
Hungary
Croatia
Slovenia
Czech Republic
Cyprus
Slovakia
Malta
Netherlands
Germany
Poland
Spain
Greece
United Kingdom
Ireland
Denmark
EU/EEA
Austria
Italy
Belgium
Norway
France
Bulgaria
Finland
Sweden
Portugal
Luxembourg
Romania
Latvia
Lithuania
Estonia
0 20 40 60 10080
Gay men and other men who 
have sex with men
People who inject drugs
Heterosexual men and women
Other
Percent of new HIV diagnoses,by mode of transmission and country, EU/EEA, 2014
There was considerable variation among countries in the proportion of new diagnoses 
by mode of transmission. In western and central Europe the percentage of new HIV 
diagnoses in 2014 among gay men and other men who have sex with men ranged from 
less than 10% in Latvia, Lithuania and Estonia to more than 80% in Hungary, Croatia 
and Slovenia.
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Source: 2016 Global AIDS Response Progress Reporting. 
HIV prevalence among people who inject drugs, western and central Europe and North 
America, most recent data, 2011–2015
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HIV prevalence among gay men and other men who have sex with men, western and central 
Europe and North America, most recent data, 2013–2015
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Source: 2016 Global AIDS Response Progress Reporting.
HIV prevalence remained considerably higher among key populations, again with large 
variations among countries. The highest prevalence of HIV infection among people 
who inject drugs in the region in 2015 was in Estonia (48%), followed by Latvia (27%) 
and Romania (21%). In the Czech Republic, where drug use is decriminalised and 
coverage of harm-reduction services is relatively high, HIV prevalence among people 
who inject drugs was 0.2% in 2013.In 2010 the rate of new HIV infections among 
African American women was estimated to be 20 times that of white women and 
nearly five times that of Hispanic women (22).
In 2014, 32% of all HIV diagnoses in Europe were among migrants. There is 
evidence that a considerable proportion of the infections were acquired after 
migration (23).
Progress and gaps in prevention
Key populations
In western and central Europe high coverage of harm-reduction programmes for 
more than a decade has reduced the number of people who inject drugs newly 
diagnosed with HIV from 2161 in 2005 to 1126 in 2014 (2). In the United States 
heroin use increased among men and women in most age groups and across all 
income levels, with a total increase of 63% between 2002 and 2013. This trend 
coincided with an increase in hepatitis C virus infections and new outbreaks of HIV 
associated with injecting drug use (10).
Increases in the annual number of cases of sexually transmitted infections such as 
gonorrhea, syphilis and HIV diagnoses in the European Union and the United States 
(9) suggest that levels of condom use among gay men and other men who have sex 
with men have not improved.
HIV prevalence among male and female sex workers in Europe, select countries, most recent 
data, 2011–2015
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Pre-exposure prophylaxis
In the United States PrEP has been recommended since 2012 for people at ongoing 
substantial risk of HIV infection, including HIV-negative people in a sexual relationship 
with a person living with HIV, people who inject drugs, and gay men and other men 
who have sex with men who do not consistently use condoms. Of the 1.2 million 
people who were eligible for PrEP, however, only an estimated 30 000 were prescribed 
it in 2015 (11). Increasing PrEP coverage in the United States could prevent around 
48 000 new infections within five years and up to 185 000 new infections in the same 
period if increased coverage were combined with expanded testing and treatment 
(12). Canada approved the use of PrEP among adults at high risk of HIV infection in 
February 2016 (13).
In France, following the issuing of temporary regulatory approval in November 2015, 
60 clinics were offering PrEP by mid-2016, and 437 people were enrolled during the 
first three months of the programme, which represents around 2–4% of the  
10 000–20 000 people at high risk of acquiring HIV (14). A survey conducted by the 
European Centre for Disease Prevention and Control found that 17 European countries 
had PrEP demonstration projects in process or planned. The survey found that national 
health systems view the relatively high cost of PrEP as the biggest barrier to full 
adoption of this HIV prevention option (15).
Viral suppression
An estimated 86% [78–95%] of people living with HIV in western and central Europe 
and North America in 2015 knew their HIV status, and about 59% [54–66%] were on 
antiretroviral therapy. In 2015 approximately 90% of the people who had initiated 
antiretroviral therapy remained on treatment after 12 months (6). Nearly half of all 
people living with HIV in western and central Europe and North America had achieved 
the viral suppression necessary to prevent HIV transmission (47% [43-52]). Achieving 
the 90–90–90 target required diagnosing around 102 000 people living with HIV who 
did not know their HIV status, starting an additional 521 800 people on antiretroviral 
therapy, and ensuring an additional 613 900 people living with HIV achieved viral 
suppression.
Median CD4 cell count per mm3 at HIV diagnosis, by mode of transmission, EU/EEA, 
2005–2014
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HIV testing among key populations populations, western and central Europe and North 
America, most recent data, 2011–2015
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Evidence suggests that diagnoses of HIV infection are often made several years 
after infection. Nearly half of all people diagnosed with HIV in western and central 
Europe in 2014 had a CD4 count below 350 cells/mm3, and 27% had advanced 
HIV infection (CD4 count below 200 cells/mm3). CD4 counts below 350 cells/mm3 
at diagnosis were more common among people who inject drugs (61%) and less 
common among gay men and other men who have sex with men (37%). 
The median CD4 count at diagnosis in western and central Europe has improved 
over time among gay men and other men who have sex with men and among 
people who acquired HIV through heterosexual contact, but the average CD4 
count at diagnosis among people who inject drugs has fluctuated (2).
In the United States the median CD4 count at presentation for care for the years 
2010–2012 was 341 cells/mm3, while in Canada it was 285 cells/mm3 (16). There are 
indications that CD4 counts at initiation of treatment are increasing in the United 
States: in New York state the median initial CD4 count at diagnosis rose from 315 
cells/mm3 in 2006 to 378 cells/mm3 in 2013 (17).
Of the 24 countries in the western and central Europe and North American region 
with available data, the percentage of gay men and other men who have sex with 
men who reported taking an HIV test and receiving the results between 2011 
and 2015 was more than half in only 9 countries. In the United States a survey of 
gay men and other men who have sex with men found that 75% of respondents 
living with HIV were aware of their HIV status, compared with 71% of HIV-negative 
respondents (18). Across the region, levels of testing were lowest among gay men 
and other men who have sex with men, at 41% in 2015.
Opportunities
HIV Care Continuum Initiative and Affordable Care Act in the United States
In the United States the HIV Care Continuum Initiative was launched in 2013 to 
accelerate improvements in HIV prevention and care by enhancing capacity in all 
states of the United States to systematically identify and re-engage people living 
with HIV. Key priorities for improving outcomes along the care continuum include 
expanding the workforce by engaging and training non-traditional providers 
and expanding proven models of team-based, patient-centred approaches that 
facilitate ongoing engagement in care. The initiative was later incorporated into 
the National HIV/AIDS Strategy for the United States. 
At the same time, thousands of additional people living with HIV in the United 
States have been enrolled in comprehensive health insurance through the 
implementation of the Affordable Care Act (20). Early studies of the Affordable 
Care Act’s effect on the health care of people living with HIV in the United States 
suggest that many people have used the systems established under the Act to 
find more affordable and comprehensive health insurance coverage (21).
Harm reduction in western and central Europe
Decriminalization and de-penalization of drugs for personal consumption, similar 
to Portugal and Czech Republic, would reduce the pressures on people who 
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inject drugs to avoid engaging with HIV prevention and treatment services. 
This would also create opportunities to expand needle-syringe programmes, 
which should occur regardless of the legal status of drug consumption. Similarly, 
decriminalization of sex work could empower women and men engaged in 
commercial sex work to seek and utilize HIV prevention and treatment services.
Innovative engagement strategies
The widespread use of mobile dating apps among gay men and other men who 
have sex with men offers opportunities for collaboration to engage with men, to 
inform users of the locations of HIV testing or prevention services.
Reduction of legislative barriers
Increasing levels of official recognition of same sex marriages and other steps 
toward improved integration of the lesbian, gay, bisexual, transgender and 
intersex people community needs can reduce stigma and discrimination of 
community members, aiding access to needed HIV services.
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Progress on preventing HIV infections among adults has stalled in recent years. 
The rates of new HIV infections among young women and girls and their male 
sexual partners in high-prevalence settings in Africa remains unacceptably high, 
and among key populations globally they have hardly changed since 2010. 
Antiretroviral therapy roll-out has led to a massive reduction in AIDS-related 
deaths, but viral suppression rates are still too low to realize the prevention 
dividend of treatment. 
The United Nations General Assembly has agreed on an ambitious impact target: 
reducing new HIV infections to fewer than 500 000 globally by 2020. Enhanced 
treatment roll-out and greater progress on viral suppression will contribute to 
reaching this target. Fully closing the prevention gap will require intensive focus 
on five pillars delivered through a people-centred, combination approach:
1. Combination prevention including comprehensive sexuality education, 
economic empowerment, and access to sexual and reproductive health 
services for young women and adolescent girls and their male partners in 
high-prevalence locations.
2. Evidence-informed and human rights-based prevention programmes for key 
populations, including dedicated services and community mobilization and 
empowerment.
3. Strengthened national condom programmes, including procurement, 
distribution, social marketing, private-sector sales and demand creation.
4. Voluntary medical male circumcision in priority countries that have high 
levels of HIV prevalence and low levels of male circumcision, as part of wider 
sexual and reproductive health service provision for boys and men.
5. Pre-exposure prophylaxis for population groups at higher risk of HIV 
infection.
Evidence from a diversity of countries shows that a combination approach to 
prevention—comprehensive packages of behavioural, biomedical and structural 
components, tailored to priority population groups within their specific local 
contexts—produces the strongest results. Research in South Africa has shown 
that combining cash transfers with free education and psychosocial support 
interventions boosted reductions HIV risk behaviours among adolescents (1). In 
three countries of Central America, the combination of integrated prevention 
campaigns with biomedical and structural components improved condom use 
by sex workers with regular partners, in part by allowing sex workers to address 
deeper factors that influence their behaviours (2).
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Strategies for success
Translating evidence into policies and programmes and bringing HIV prevention 
programmes to scale requires strengthening prevention management capacity to 
oversee decentralized planning, and to ensure the procurement and supply of critical 
prevention commodities. The quality and effectiveness of prevention can be improved 
by using prevention demand-and-supply cascades to highlight bottlenecks. While 
prevention cascades are inherently more difficult to define and use than the HIV testing 
and treatment cascades, interest has grown, with several methods and country-specific 
cascades now under development, aiming to improve prevention management.
A location–population approach, with local-level actions based on local-level data, 
will be critical to addressing the heterogeneity of the epidemic, and to ensuring local 
ownership of the response. Further progress on prevention also requires re-thinking 
community outreach and service delivery models for key populations. More than ever 
an integrated approach is needed in which key populations are reached by a range of 
programmes that provide basic prevention services, such as access to condoms, injecting 
equipment, testing, PrEP and treatment, as well as a range of non-HIV specific services 
including social and legal support. But as long as most key population programmes are 
funded by external donors, and reluctance remains among many governments to invest 
in services to these marginalized members of society, it will be difficult to further expand 
and systematize existing community-based outreach approaches and also provide 
community-based testing, PrEP and immediate access to treatment.  
Reductions 
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among 
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Effective and  
consistent utilization  
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Empowerment to make 
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Of critical importance for the future of the prevention response will be the 
relationship between government and community actors. Renewed prevention 
activism and a new compact between government and civil society organizations are 
needed. This partnership must go beyond grass-roots advocacy for risk awareness 
and “staying HIV free”. Country compacts should include strengthened and clearly 
defined civil society roles in prevention programme planning, implementation 
and joint monitoring of progress against ambitious targets. Experience from 
Australia, India, South Africa and several countries in western and central Europe 
and North America shows that while government commitment and funding 
provide the foundation of successful prevention responses, prevention programme 
implementation, especially with regards to key populations, should be carried out 
in collaboration with civil society and peer organizations that have the trust and ear 
of the populations at greatest need of services. Formal contractual arrangements 
between government and civil society organizations, including supervision and 
mentoring, and capacity building, should be put in place across countries.
Greater ambition can only be realized with greater investment. In late 2015, UNAIDS, 
launched a campaign to stimulate progress on prevention investments, the Quarter 
for prevention campaign, which calls on all countries to examine their investment 
portfolios, and for at least 25% of global HIV resources to be invested in effective 
primary prevention programmes. This call was taken up the United Nations General 
Assembly at the High Level Meeting on Ending AIDS. However, investments in 
effective HIV prevention in low- and middle-income countries remain inadequate and 
are too often dependent on international donors who themselves face constraints 
in their allocation of financial resources for prevention. Larger and more balanced 
investments in AIDS responses are needed, in line with commitments made within 
the 2016 Political Declaration on HIV and AIDS.
Pulling together for prevention: translating global 
commitments into country action
The targets and commitments in the 2016 Political Declaration on HIV and AIDS 
establish the basis for action. Global targets need to be translated into national and 
sub-national implementation plans that focus on the populations and locations in 
greatest need, and address the legal, social and economic barriers to prevention 
service access and uptake at national and local levels.   
Key partners must pull together for prevention and ensure that sufficient technical 
capacity and financial resources are made available. A key catalyst for country action 
will be global guidance on how to define service reach, access or coverage within 
each of the five pillars. With countries and communities at the centre, a re-doubling 
of effort on combination prevention will put the world on track to achieving fewer 
than 500 000 new infections by 2020, and to ending the AIDS epidemic by 2020.
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For more information: aidsinfo.unaids.org
The data provided in this document are just a sample of the data available from
UNAIDS. 
Additional data are available at aidsinfo.unaids.org, including:
 ■ Additional Global AIDS Response Progress Reporting Indicators on 
prevention, mother-to-child transmission, 90–90–90 targets, stigma and 
discrimination
 ■ A Key Population Atlas of maps on key populations, including the latest 
available data on key populations at increased risk of HIV infection.
 ■ Estimates of new HIV infections, people living with HIV and AIDS-related 
deaths by different age groups, children (age 0–14 years), adolescents (age 
10–19 years), young people (age 15–24 years), adults (age 15–49) older 
people (age 50 years and over), and by sex
 ■ Subnational data for selected countries
 ■ Data in different formats: spreadsheet, maps, graphics
 ■ Comparable data over multiple years, and across countries, which can also 
be extracted to spreadsheets for further analysis.
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Part 1. HIV estimates in annex tables and in report
Introduction
UNAIDS annually provides revised global, regional and country-specific modelled 
estimates to track the HIV epidemic, using the best available epidemiological and 
programmatic data. Modelled estimates are required because it is impossible to 
count the exact number of people living with HIV, people who are newly infected 
with HIV or people who have died from AIDS-related causes in any country. 
Knowing this for certain requires testing every person for HIV regularly and 
investigating all deaths, which is logistically impossible and ethically problematic. 
Modelled estimates and the lower and upper bounds around these estimates 
provide a scientifically appropriate way to describe HIV epidemic levels and 
trends.
Partnerships in developing methods for UNAIDS estimates
Country teams use UNAIDS-supported software to develop estimates annually. 
The country teams comprise primarily epidemiologists, demographers, 
monitoring and evaluation specialists and technical partners.
The software used to produce the estimates is Spectrum—developed by Avenir 
Health (www.avenirhealth.org)—and the Estimates and Projections Package, 
which is developed by the East-West Center (www.eastwestcenter.org). The 
UNAIDS Reference Group on Estimates, Modelling and Projections provides 
technical guidance on the development of the HIV component of the software 
(www.epidem.org). 
Brief description of methods used by UNAIDS to create estimates
For countries where HIV transmission is high enough to sustain an epidemic in 
the general population, available epidemiological data typically consist of HIV 
prevalence results from surveillance among pregnant women attending antenatal 
care clinics and from nationally representative population-based surveys. 
Because antenatal clinic surveillance is performed regularly, these data can be 
used to inform national prevalence trends, whereas data from population-based 
surveys—which are conducted less frequently but have broader geographical 
coverage and also include men—are more useful for informing national HIV 
prevalence levels. For a few countries in sub-Saharan Africa that have not 
conducted population-based surveys, HIV prevalence levels are adjusted based 
on comparisons of antenatal clinic surveillance and population-based survey 
data from other countries in the region. The HIV prevalence curves and numbers 
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of people on antiretroviral therapy are then used to derive an estimate of HIV 
incidence trends.
Historically, countries with high HIV transmission have produced separate 
HIV prevalence and incidence trends for rural and urban areas when there are 
well established geographical differences in prevalence. To better describe 
and account for further geographical heterogeneity, an increasing number of 
countries have produced subnational estimates (such as at the province or state 
level) that, in some cases, also account for rural and urban differences. These 
subnational or rural-urban estimates and trends are then aggregated to obtain 
national estimates using Spectrum.
In countries with low-level HIV epidemics where HIV transmission occurs largely 
among key populations at higher risk of HIV infection (such as people who inject 
drugs, sex workers or gay men and other men who have sex with men), the data 
from repeated HIV prevalence studies—usually focused on key populations—
are most often used to inform national estimates and trends. Estimates of the 
size of key populations are increasingly derived empirically in each country or, 
when studies are not available, based on regional values and consensus among 
experts. Other data sources—including population-based surveys, surveillance 
among pregnant women and HIV case reporting data—are used to estimate the 
HIV prevalence in the general, low-risk population. The HIV prevalence curves 
and numbers of people on antiretroviral therapy are then used to derive national 
HIV incidence trends. 
For many countries in western and central Europe and North America and in 
Latin America and the Caribbean that have insufficient HIV surveillance or survey 
data—but have strong vital registration and disease reporting systems—HIV 
case reporting and AIDS-related mortality data are used to directly inform trends 
and levels in national HIV prevalence and incidence. These methods also allow 
countries to take into account evidence of underreporting or reporting delays in 
HIV case report data, as well as the misclassification of deaths from AIDS-related 
causes.
In all countries where UNAIDS supports the development of estimates, 
assumptions about the effectiveness of HIV programme scale-up and patterns 
of HIV transmission and disease progression are used to obtain age- and sex-
specific estimates of the number of people living with HIV, the number of people 
newly infected with HIV and the number of people dying from AIDs-related 
causes as well as other important indicators (including programme coverage 
statistics). These assumptions are based on systematic literature reviews and 
analyses of raw study data by scientific experts. Demographic population data, 
including fertility estimates, are derived from the latest revision of the United 
Nations Population Division’s World Population Prospects.
Selected inputs into the model—including the number of people on antiretroviral 
therapy and the number of women accessing services for preventing the mother-
to-child transmission of HIV by type of regimen—are reviewed and validated 
in partnership with the World Health Organization (WHO), the United Nations 
Children’s Fund (UNICEF) and other partners. 
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Final country-submitted files containing the modelled outputs are reviewed at 
UNAIDS to ensure that the results are comparable across regions and countries 
and over time.
Uncertainty bounds around UNAIDS estimates
The software calculates uncertainty bounds around each estimate that define the 
range within which the true value (if it could be measured) lies. Narrow bounds 
indicate that an estimate is precise, and wide bounds indicate greater uncertainty 
regarding the estimate. 
In countries using HIV surveillance data, the quantity and source of the data 
available partly determine the precision of the estimates; countries with more HIV 
surveillance data have smaller ranges than countries with less surveillance data or 
smaller sample sizes. Countries in which a national population-based survey has 
been conducted generally have smaller ranges around estimates than countries 
where such surveys have not been conducted. In countries using HIV case 
reporting and AIDS-related mortality data, the number of years of data and the 
magnitude of the cases reported or AIDS-related deaths observed will contribute 
to determining the precision of the estimate. 
The number of assumptions required to arrive at the estimate also contributes to 
the extent of the ranges around the estimates: in brief, the more assumptions, 
the wider the uncertainty range, since each assumption introduces additional 
uncertainties. For example, the ranges around the estimates of adult HIV 
prevalence are smaller than those around the estimates of HIV incidence among 
children because the latter is based on prevalence among pregnant women and 
the probability of mother-to-child HIV transmission. 
UNAIDS is confident that the actual numbers of people living with HIV, people who 
are newly infected with HIV or people who have died from AIDS-related causes lie 
within the reported ranges. Over time, more and better data from countries will 
steadily reduce uncertainty. 
Improvements to the 2016 UNAIDS estimates model
Country teams create new Spectrum files every year. The files may differ from one 
year to the next for two reasons. First, new surveillance and programme data are 
entered into the model; this can change HIV prevalence and incidence trends over 
time, including for past years. Second, improvements are incorporated into the 
model based on the latest available science and understanding of the epidemic.  
Because of these improvements to the model and the addition of new data to 
create the estimates for each year, the results from previous years cannot be 
compared with the results from this year. A full historical set of estimates has also 
been created for this year, enabling a description of trends over time.
Between the previous and 2016 rounds of estimates, the following changes 
were applied to the model under the guidance of the UNAIDS Reference Group 
on Estimates, Modelling and Projections and based on the latest scientific 
evidence.
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 ■ Updated demographic data from the United Nations Population Division’s 
World Population Prospects, 2015 Revision were used as the basis for the 
demographic projections in the model.
 ■ For countries with high-burden epidemics that model separate HIV 
prevalence and incidence trends for rural and urban areas, the distribution of 
the urban population was updated using the World Urbanization Prospects 
2014 data set.
 ■ In the adult estimation model, the probability of dying for those on 
antiretroviral therapy was updated based on data provided to UNAIDS by the 
IeDEA Consortium.
 ■ The probabilities of HIV transmission during pregnancy, delivery and 
breastfeeding have been updated based on a comprehensive and recent 
review of published literature. Most importantly, the estimated transmission 
probability among women who seroconvert during pregnancy or 
breastfeeding was significantly lower than a previous review of the literature 
had found. As a result, the number of children estimated to have become 
infected was revised downward in the current model.
 ■ The estimation model for children was modified to apply a probability of 
initiating antiretroviral therapy by the child’s age, year and geographical 
region rather than assuming that antiretroviral therapy was initiated when the 
child became eligible for treatment. The new probabilities were based on 
special analyses done for UNAIDS by the IeDEA Consortium and provided 
region-specific probabilities. As a result of more accurately reflecting when 
children initiate antiretroviral therapy, the number of children estimated to 
have survived in previous years has been corrected downwards.
 ■ Wider use was made of the AIDS Epidemic Model developed by the East-
West Center and the case reporting and mortality fitting tools in Spectrum 
to construct national prevalence and incidence trends in countries with 
concentrated epidemics. This improved the overall accuracy of the estimates 
in these countries.
 ■ For countries using HIV case reporting and mortality data as model inputs, 
uncertainty around the incidence curve has been integrated into the 
incidence fitting process. As a result, the uncertainty bounds for countries 
using this approach were narrower than in the previous year.
More detailed information on these revisions to the 2016 model can be found at 
www.epidem.org and in a collection of topical articles by the UNAIDS Reference 
Group on Estimates, Modelling and Projections to be published in a journal 
supplement to be released in December 2016.
Measuring antiretroviral therapy coverage
Since 2013, UNAIDS has provided the number and estimates of the proportion of 
adults and children living with HIV who are on antiretroviral therapy (rather than 
estimates of the proportion of adults and children eligible according to national 
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or international guidelines who are on antiretroviral therapy). This coverage 
reflects the WHO recommendations of starting antiretroviral therapy among 
everyone diagnosed as HIV-positive.
Publication of country-specific estimates
UNAIDS aims to publish estimates for all countries with populations of 250 000 
or more. For the countries with populations of 250 000 or more that did not 
submit estimates, UNAIDS developed estimates using the Spectrum software 
that were based on published or otherwise available information. These 
estimates contributed to regional and global totals but were not included in our 
reports or website.
In countries with low-level epidemics, the number of pregnant women living 
with HIV is difficult to estimate. Many women living with HIV in these countries 
are sex workers, people who use drugs or sexual partners of people who use 
drugs or gay men or other men who have sex with men, and thus they are likely 
to have different fertility levels than the general population. UNAIDS does not 
present estimates of mother-to-child HIV transmission or estimates related 
to children infected with HIV through mother-to-child transmission in some 
countries with concentrated epidemics unless adequate data are available to 
validate these estimates.
With regard to reporting incidence trends, if there are not enough historical data 
to confidently state whether a decline in incidence has occurred, UNAIDS will not 
publish earlier data to avoid users making inaccurate inferences about trends. 
Specifically, incidence trends are not published if there are fewer than four data 
points for the key population or if there have been no data for the past four years.
Finally, in a few instances, UNAIDS will not publish country estimates when 
further data or analyses are needed to produce valid estimates. More information 
on the UNAIDS estimates and the individual Spectrum files for most countries can 
be found on the UNAIDS website (www.unaids.org) 
Methods for measuring progress against the  
90–90–90 target
To measure progress against the 90–90–90 target worldwide and by region in 
2015, UNAIDS analysed HIV surveillance, survey and programme data reported 
by 121 countries through the Global AIDS Response Progress Reporting (GARPR) 
tool and other published and unpublished data provided to UNAIDS especially 
for this purpose. A description of the GARPR system and indicators is available 
in the Global AIDS response progress reporting 2016 guidelines. Data reported 
by countries through GARPR are available at http://aidsinfo.unaids.org/. Not all 
countries were able to report on all three measures of the target.
All progress measures in this report, unless otherwise stated, are based on 
UNAIDS global, regional and country-specific modelled estimates of the 
numbers of people living with HIV in 2015. Upper and lower uncertainty bounds 
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around the measures were calculated from the range of estimated numbers of 
people living with HIV. More details about how UNAIDS derives estimates and 
uncertainty bounds can be found earlier in this section.
Knowledge of HIV status among people living with HIV
Global and regional measures of the number of people living with HIV 
who know their status were derived using the most recent HIV case-based 
surveillance and nationally-representative population-based survey data 
available for 87 countries. Where data were available separately for children 
(aged 0-14 years) and adults (aged 15 years and older), age-specific measures 
were calculated and then aggregated to produce a national measure.
For 66 countries, knowledge of status was taken as the cumulative number of 
people notified to the HIV surveillance system, minus deaths among people 
known to have been HIV-positive, divided by the estimate of people living 
with HIV. If the measure from the HIV surveillance system was lower than the 
UNAIDS estimate of antiretroviral therapy coverage in the country, the reported 
value from the surveillance system was excluded from the analysis.
A country’s measure was included only if the case-based surveillance system 
had been in place since 2011 and was able to report on notifications and 
deaths. Countries with more recent systems may not have yet captured all 
people living with HIV who were diagnosed prior to 2011. Even in countries 
with long-standing HIV surveillance systems where data were included, biases 
may still exist. For example, a country’s measure of the knowledge of status 
may be underestimated if not all people who are diagnosed are reported to 
the HIV surveillance system in a timely manner. On the other hand, the measure 
may be overestimated if people are notified to the system more than once, but 
these duplicate reports are not detected. Equally, if people die or emigrate 
but are not removed from the system, the percentage of people living with HIV 
who know their status will be overstated. 
Countries with 
available data
Percentage of people living with HIV 
represented in the reporting countries
Asia and Pacific 41% (16 of 39) 93%
Eastern and southern Africa 57% (12  of 21) 85%
Eastern Europe and central Asia 65% (11 of 17) 98%
Latin America and the Caribbean 45% (15 of 33) 76%
Middle East and North Africa 33% (7 of 21) 77%
West and Central Africa 48% (12 of 25) 73%
Western and central Europe and North America 83% (14 of 40) 83%
Global 44% (87 of 196) 84%
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For 19 countries in sub-Saharan Africa and two countries in Latin America, 
knowledge of status was based on nationally representative population-based 
surveys conducted since 2010 and other care and treatment data reported through 
GARPR. In these countries, a mid-point value was calculated from the percentage of 
people living with HIV reporting to have ever been tested and the UNAIDS estimate 
of the country’s antiretroviral therapy coverage or the percentage of people living 
with HIV reported to be in care, whichever was greater.
Knowledge of status based on survey data may tend to underestimate actual 
knowledge of status since the survey data provide a proxy of people who did not 
know their status at the time when the survey was conducted, while the estimate 
of the number of people living with HIV are from 2015. It may be the case that that 
people living with HIV who did not know their status in the earlier survey year have 
subsequently gone on to test and are now aware of their status in 2015.
Coverage of antiretroviral therapy among people living with HIV
Global and regional measures of antiretroviral therapy coverage are derived from 
country-reported programme data through GARPR and the UNAIDS-supported 
Spectrum software. For a small number of countries where reported numbers of 
people on treatment are not available— primarily in western and central Europe and 
North America—estimates of the number of people on treatment are developed 
either in consultation with the public health agency responsible for monitoring the 
national treatment programme or based on other published data sources.
UNAIDS— in partnership with the World Health Organization and the United 
Nations Children’s Fund and other partners that support treatment service delivery 
in countries—reviews and validates treatment numbers reported through GARPR 
and Spectrum on an annual basis. UNAIDS staff also provide technical assistance 
and training to country public health and clinical officers to ensure the quality of 
the treatment data that are reported. Nevertheless, this measure may overestimate 
coverage if people who transfer from one facility to another are reported by both 
facilities. Similarly, coverage may be overestimated if people who have died, who 
have disengaged from care, or who have emigrated are not identified.
Viral suppression among people living with HIV
Progress towards reaching regional and global viral suppression targets was 
determined using HIV case-based surveillance and nationally representative 
population-based survey data available from 86 countries between 2013 and 2015. 
The measure was defined as the number of people with viral suppression (<1000 
copies per ml) among people tested. This proportion was applied to the total 
number of people on antiretroviral therapy to obtain an estimate of the number 
and percentage of people on antiretroviral therapy who were virally suppressed.
Availability of data on viral load testing, global and by region
There are several limitations in the availability and quality of data on viral 
suppression that are important to note when using findings from this report. 
First, for many countries, viral load testing may not be universally available or 
may be episodic (i.e., to assess suspected treatment failure) rather than routine, 
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possibly leading to an underestimate of viral suppression. Second, viral load 
testing may be done only for people who have been on antiretroviral treatment 
for 12 months, which could lead to higher viral suppression levels in the testing 
population, especially if retention is low or the number newly initiating treatment 
is high. Finally, countries may be reporting according to different detection 
thresholds, ranging from an undetectable viral load (<50 copies) to the WHO-
defined standard (<1000 copies), although there is no evidence to suggest that 
these differences will result in a severe bias in comparability. 
While country reported data were reviewed to exclude small cohorts or episodic 
testing, the quality of this measure will vary within and across the regions.
Countries with 
available data
Percentage of people on antiretroviral 
therapy who received a viral load test 
in the reporting period
Asia and Pacific 38% (15 of 39) 29%
Eastern and southern Africa 38% (8 of 21) 14%
Eastern Europe and central Asia 77% (11 of 17) 77%
Latin America and the Caribbean 65% (21 of 33) 77%
Middle East and North Africa 64% (8 of 21) 41%
West and Central Africa 38% (7 of 25) 2%
Western and central Europe and North America 28% (16 of 40) 44%
Global 40% (86 of 196) 22%
Part 2. HIV incidence among young women ages  
15–19 and 20-24 years in eastern and southern Africa 
Subnational modelled estimates were used to calculate HIV incidence among 
young women aged 15–19 and 20–24 years for Ethiopia, Kenya, Malawi, 
Mozambique, Namibia, the United Republic of Tanzania, Uganda, Zambia and 
Zimbabwe. The values are based on Spectrum-derived estimates for provincial 
or district level areas. With the exception of Ethiopia and Uganda, sub-national 
estimates were produced in 2016 using data up until 2015. For Ethiopia and 
Uganda, files produced in 2015, with data updated up until 2014, were used as 
more recent subnational estimates files were not available. National modelled 
estimates were used to calculate HIV incidence for Lesotho and Swaziland.
Incidence was calculated for the respective age groups as the proportion of new 
HIV infections in 2015 (2014 for Ethiopia and Uganda) over the non-HIV-positive 
population in the previous year.
For Botswana and South Africa, the district level incidence calculations used 
alternative sources. The number of young women living with HIV for each age 
group was calculated based on the proportion of infections among young 
women, aged 15–19 years and 20–24 years respectively, to the total prevalence 
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among adults, aged 15–49 years. The relative proportion was then applied to the 
new adult infections in each district. The number of young women aged 15–19 
and 20–24 years living with HIV was calculated using the same method. The 
population aged 15–19 and 20–24 years by district was pulled from census data. 
Incidence was then calculated using the method described above. For Botswana, 
the HIV prevalence data came from the 2012 Botswana AIDS Indicator Survey and 
the 2011 census. For South Africa, the district prevalence was calculated based 
on surveillance estimates and Statistics South Africa 2014 population data.
Part 3. Distribution of new HIV infections by 
subpopulation
The distribution of new HIV infections by region was estimated based on data for 
163 countries using five data sources.
For countries that model their HIV epidemic based on data from subpopulations, 
including key populations, the numbers of new infections were extracted from 
Spectrum 2015 files. This source provided data from 63 countries for sex workers, 
36 countries for people who inject drugs, 57 countries for men who have sex with 
men and 11 countries–only in Latin America and Asia–for transgender people.
The second source was of mode of transmission studies conducted in countries 
between 2006 and 2012. The proportions of new infections estimated for each 
subpopulation, calculated by modes of transmission analyses, were multiplied by 
the number of total new adult (15–49) infections, by relevant gender, to derive an 
estimated number of new infections by subpopulation. This source provided data 
from 18 countries for sex workers, 23 countries for people who inject drugs and 22 
countries for men who have sex with men.
New HIV infections for European countries with neither of the aforementioned 
data were derived from the European Centre for Disease Prevention and Control 
(ECDC) HIV Surveillance Report 2014. The proportions of new diagnoses for each 
region in Europe (West, central and East) were applied to UNAIDS estimates of 
new infections in each country for people who inject drugs and men who have 
sex with men. Data for sex workers were not available from the ECDC report. New 
HIV infections in China, Russia and the United States of America were taken from 
available national reports of new diagnoses.
New HIV infections among countries without a direct data source were calculated 
from regional benchmarks. The benchmarks were set by the median proportion of 
new infections in the specific subpopulation in all available countries in the same 
region. The majority of these countries were located in sub-Saharan Africa. There 
were 93 countries which used benchmark values for the sex work estimate, 63 
countries for the people who inject drugs estimate, 66 countries for the men who 
have sex with men estimate and 44 countries for the transgender people estimate.
The calculated proportions of infections for each key population include the sex 
partners of members of key populations. New infections among sex partners of key 
populations were estimated using transmission probabilities from the literature.
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Part 4. Estimating the cost of homophobia
The two studies considered in this report are aiming to compare the level of 
homophobia among countries and regions and then to estimate the corresponding 
economic cost. To do so requires analysis of variables that are available for most 
countries. We collected data on 171 countries and reduced the final sampling 
to 162 countries, corresponding to those with sufficient data to complete the 
Homophobic Climate Index (HCI).
Data on gay men and other men who have sex with men were obtained from 
AIDSinfo (http://aidsinfo.unaids.org), peer-reviewed articles and grey literature. 
Available data include population size estimations for gay men and other men who 
have sex with men.
Data on the level of institutionalised homophobia were obtained from the 
International Lesbian, Gay, Bisexual, Trans and Intersex Association (ILGA) 2016 
report “State-sponsored homophobia: a world survey of laws—criminalisation, 
protection and recognition of same-sex love” (1). This report provides a global 
overview of lesbian, gay and bisexual legislations for all countries in the world.
Data on the human and economic development of United Nations countries were 
based on the United Nations Development Programme “Human development 
report 2015” (2).
For all calculations, we used the latest data available, including gross domestic 
product values from the International Monetary Fund (3). Population estimates 
come from the Department of Economic and Social Affairs of the United Nations 
Population Division (4). Country income categories refer to those published by 
the World Bank in July 2016. We used waves 4, 5 and 6 of the World Values Survey 
(http://www.worldvaluessurvey.org) as well as the European Values Survey (http://
www.europeanvaluesstudy.eu) for measuring social homophobia at the country 
level. Behavioural homophobia is measured with reported homophobic violence 
and internalised homophobia. The level of reported homophobic violence is 
measured by the share of the 93 000 individuals among 38 European countries 
in the framework of the EU LGBT survey conducted in 2012 (http://fra.europa.eu/
en/survey/2012/eu-lgbt-survey). We considered the data related to internalised 
homonegativity from the work of Ross and colleagues (5), who studied the data of 
more than 144 000 participants in the European MSM Internet Survey conducted 
in 2010 in 38 European countries (http://www.emis-project.eu/project.html). All 
statistical calculations were performed with Stata 14.
Homophobia, or homonegativity, includes negative responses to and prejudice 
against lesbian, gay, bisexual, transgender and intersex people. The study 
conducted by Lamontagne and colleagues (6) built an index of the level of 
homophobia based on three types of homophobic reactions, as developed by 
O’Donohue and Caselles (7); The index reflects i) institutional homophobia; ii) 
social homophobia; and iii) behavioural homophobia. The latter component 
has only been included in a subset of 38 European countries for which the 
corresponding variables are currently available. The set of variables describing 
each type of homophobia has been checked for internal consistency and 
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collinearity, as we verified the collinearity among the three components 
themselves. See the study for more details (6).
The economic cost of homophobia is assessed through two key components, the 
productivity cost (PC) and the health-related cost (HC) for each country (i).
CHi = PCi + HCi (1)
For the productivity cost, we estimate the wage differential for each country 
based on its level of homophobia (Homophobic Climate Index, HCI):
For each country (i) we use the level of homophobia given from the Homophobic 
Climate Index described above for 162 countries. We assume that for each 
country, the population of gay men and other men who have sex with men 
represents 1–3% of all 15- to 64-year-old males.
For health-related costs, let βi define the number of life-years lost due to 
homophobia for country i, adjusted for the country-specific level of homophobia   
and the life expectancy at age 15 years for the male population LEm15y              i . The health-
related economic cost can then be defined as follows, where  MSMei               represents 
the number of gay men and other men who have sex with men as a share of the 
male 15–64 years population, with lower (1%) and an upper (3%) bound:
PCt = MSMei              .  0.11δHCI  .  GDPрci
HCi = MSMei             .  βi  .  
GDPрci
LEm15y              i
HCi = MSMei             (3)
(2)
See the complete study for more details (8).
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1. Estimated number of people newly infected with HIV (all ages), 2000 and 2015
2010 2015
Estimate Lower estimate Upper estimate Estimate Lower estimate Upper estimate 
Asia and the Pacific 310 000 270 000 360 000 300 000 240 000 380 000
Afghanistan <1000 <500 1400 <1000 <500 2700
Australia 1100 1100 1200 1200 1200 1300
Bangladesh 1400 1200 1500 1100 <1000 1100
Bhutana ... ... ... ... ... ...
Brunei Darussalama ... ... ... ... ... ...
Cambodia 1700 1500 1800 <1000 <1000 <1000
Chinaa ... ... ... ... ... ...
Democratic People's 
Republic of Koreaa
... ... ... ... ... ...
Fijia ... ... ... ... ... ...
Indiab 100 000 82 000 130 000 86 000 67 000 110 000
Indonesia 69 000 62 000 75 000 73 000 66 000 80 000
Japana ... ... ... ... ... ...
Lao People's Democratic 
Republica
... ... ... ... ... ...
Malaysia 8500 7700 9300 5200 4700 5600
Maldivesa ... ... ... ... ... ...
Mongolia <100 <100 <100 <100 <100 <100
Myanmar 15 000 14 000 17 000 12 000 11 000 13 000
Nepal 2300 2100 2600 1300 1200 1500
New Zealanda ... ... ... ... ... ...
Pakistan 11 000 7900 17 000 17 000 12 000 30 000
Papua New Guinea 2400 2100 2600 2700 2300 3200
Philippines 4200 3100 6300 6400 3400 34 000
Republic of Koreaa ... ... ... ... ... ...
Singaporea ... ... ... ... ... ...
Sri Lanka <500 <500 <1000 <1000 <500 1100
Thailand 12 000 10 000 13 000 6900 6300 7600
Timor-Lestea ... ... ... ... ... ...
Viet Nam 19 000 17 000 20 000 14 000 13 000 15 000
Eastern and southern 
Africa
1 100 000 1 000 000 1 200 000 960 000 830 000 1 100 000
Angola 28 000 19 000 41 000 26 000 16 000 41 000
Botswana 12 000 11 000 13 000 9700 8200 11 000
Eritrea <500 <500 <1000 <1000 <500 <1000
Ethiopiaa ... ... ... ... ... ...
Kenya 83 000 67 000 100 000 78 000 57 000 110 000
Lesotho 19 000 17 000 21 000 18 000 16 000 20 000
Madagascar 3300 2700 4000 6300 4300 8700
Malawi 56 000 47 000 68 000 33 000 24 000 44 000
Mauritius <1000 <500 <1000 <500 <200 <500
Mozambique 130 000 97 000 160 000 81 000 56 000 120 000
Namibia 9200 7700 11 000 7800 6000 9500
Rwanda 9000 7300 11 000 7500 5300 9800
South Africa 350 000 310 000 400 000 380 000 330 000 430 000
South Sudan 15 000 9200 21 000 15 000 6400 23 000
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2010 2015
Estimate Lower estimate Upper estimate Estimate Lower estimate Upper estimate 
Swaziland 15 000 14 000 16 000 11 000 9700 14 000
Uganda 130 000 110 000 140 000 83 000 63 000 110 000
United Republic of 
Tanzania
82 000 72 000 92 000 54 000 45 000 64 000
Zambia 73 000 65 000 81 000 60 000 52 000 69 000
Zimbabwe 79 000 69 000 88 000 64 000 52 000 76 000
Eastern Europe and 
central Asia
120 000 110 000 130 000 190 000 170 000 200 000
Albaniaa ... ... ... ... ... ...
Armenia <500 <200 <500 <500 <500 <1000
Azerbaijan <1000 <1000 1400 1200 <1000 1800
Belarus 2600 2000 3300 5300 4100 6900
Bosnia and Herzegovinaa ... ... ... ... ... ...
Georgia <1000 <1000 1100 1100 <1000 1500
Kazakhstan 1900 1600 2100 3700 2700 5000
Kyrgyzstan <1000 <1000 1100 <1000 <1000 1500
Montenegroa ... ... ... ... ... ...
Republic of Moldova 1800 1500 2300 1400 1100 1700
Russian Federationa ... ... ... ... ... ...
Tajikistan 1600 1300 2000 1600 1100 2400
The former Yugoslav 
Republic of Macedoniaa
... ... ... ... ... ...
Ukraine 9500 7000 12 000 16 000 12 000 21 000
Uzbekistan <1000 <500 1100 <500 <500 <1000
Latin America and the 
Caribbean
100 000 86 000 120 000 100 000 86 000 120 000
Argentina 5300 4500 5700 5100 4400 5600
Bahamas <500 <500 <500 <500 <500 <1000
Barbados <200 <200 <200 <200 <200 <200
Belize <200 <200 <200 <200 <200 <200
Bolivia (Plurinational 
State of)
1500 <1000 2200 1300 <1000 2000
Brazil 43 000 31 000 58 000 44 000 32 000 59 000
Chile 1700 <1000 2600 1800 <1000 3600
Colombia 10 000 8800 11 000 11 000 9000 11 000
Costa Rica <1000 <1000 <1000 <1000 <1000 <1000
Cuba 1700 1400 1800 3100 2500 3400
Dominican Republic 2300 1500 3400 2000 1300 3300
Ecuador 1500 1100 1900 1300 <1000 1700
El Salvador 1100 <1000 1200 <1000 <500 <1000
Guatemala 3000 1700 5500 3700 1800 6400
Guyana <500 <500 <1000 <500 <500 <500
Haiti 3700 2700 5100 1500 1000 2300
Honduras <1000 <1000 <1000 <500 <500 <1000
Jamaica 1600 1300 2100 1700 1300 2100
Mexico 10 000 9300 11 000 11 000 9800 12 000
Nicaragua <1000 <500 <1000 <1000 <500 1200
Panama <1000 <1000 1000 <1000 <1000 1100
1. Estimated number of people newly infected with HIV (all ages), 2000 and 2015
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2010 2015
Estimate Lower estimate Upper estimate Estimate Lower estimate Upper estimate 
Paraguay 1200 <1000 2100 1100 <1000 1800
Peru 3100 2100 4400 2800 1800 4500
Suriname <200 <200 <500 <200 <200 <500
Trinidad and Tobago <1000 <500 <1000 <500 <500 <500
Uruguay <1000 <500 <1000 <500 <500 <1000
Venezuela (Bolivarian 
Republic of)
6000 5500 6500 5600 5000 6100
Middle East and North 
Africa
20 000 15 000 29 000 21 000 12 000 37 000
Algeria <1000 <1000 <1000 <500 <100 <1000
Djibouti <1000 <500 <1000 <1000 <500 1000
Egypt 1000 <1000 1700 1500 <1000 2800
Iran (Islamic Republic of) 6600 4500 11 000 7100 4400 16 000
Lebanon <200 <200 <200 <200 <200 <500
Morocco 1800 1400 2300 1200 <1000 1600
Omana ... ... ... ... ... ...
Somalia 2800 1900 3800 3000 1600 4400
Sudan 5400 3200 8100 5600 2000 11 000
Tunisia <500 <200 <500 <500 <200 <500
Yemen <1000 <500 1400 1000 <1000 2100
Western and central 
Africa
450 000 350 000 560 000 410 000 310 000 530 000
Benin 4400 3200 6000 4200 2900 6600
Burkina Faso 5000 3600 6700 4200 2300 6300
Burundi 3100 1600 4100 1200 <500 2200
Cameroon 45 000 40 000 49 000 44 000 35 000 51 000
Cape Verde <200 <200 <500 <200 <200 <500
Central African Republic 7700 6700 8700 7000 5700 8900
Chad 11 000 7900 15 000 8300 5400 12 000
Congoa ... ... ... ... ... ...
Côte d'Ivoire 26 000 19 000 32 000 25 000 18 000 33 000
Democratic Republic of 
the Congo
23 000 17 000 30 000 15 000 8800 21 000
Equatorial Guinea 2300 1900 2600 <500 <200 <1000
Gabon 2300 1700 2800 1500 <1000 2400
Gambia 1600 1200 2000 1400 1100 1900
Ghana 18 000 15 000 22 000 13 000 9800 16 000
Guinea 9400 7700 11 000 7600 5700 9800
Guinea-Bissaua ... ... ... ... ... ...
Liberia 1700 1300 2100 1600 1100 2200
Mali 9700 7900 12 000 10 000 7500 15 000
Mauritania <1000 <1000 1500 <1000 <500 1400
Niger 1900 1700 2200 2400 2100 2800
Nigeria 260 000 180 000 350 000 250 000 180 000 350 000
Senegal 1600 1100 2100 1600 <1000 2500
Sierra Leone 4000 3300 4700 2500 1700 3400
Togo 5100 4100 6300 4400 3200 6100
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2010 2015
Estimate Lower estimate Upper estimate Estimate Lower estimate Upper estimate 
Western and central 
Europe and North 
America
92 000 89 000 97 000 91 000 89 000 97 000
Austriaa ... ... ... ... ... ...
Belgiuma ... ... ... ... ... ...
Bulgariaa ... ... ... ... ... ...
Canadaa ... ... ... ... ... ...
Croatiaa ... ... ... ... ... ...
Cyprusa ... ... ... ... ... ...
Czech Republica ... ... ... ... ... ...
Denmarka ... ... ... ... ... ...
Estoniaa ... ... ... ... ... ...
Finlanda ... ... ... ... ... ...
Francea ... ... ... ... ... ...
Germanya ... ... ... ... ... ...
Greece <1000 <1000 1000 <1000 <1000 1000
Hungarya ... ... ... ... ... ...
Icelanda ... ... ... ... ... ...
Irelanda ... ... ... ... ... ...
Israela ... ... ... ... ... ...
Italy 4700 4600 5000 4500 4400 4800
Latvia <1000 <1000 <1000 <500 <500 <1000
Lithuaniaa ... ... ... ... ... ...
Luxembourga ... ... ... ... ... ...
Maltaa ... ... ... ... ... ...
Netherlandsa ... ... ... ... ... ...
Norwaya ... ... ... ... ... ...
Polanda ... ... ... ... ... ...
Portugala ... ... ... ... ... ...
Romaniaa ... ... ... ... ... ...
Serbiaa ... ... ... ... ... ...
Slovakiaa ... ... ... ... ... ...
Sloveniaa ... ... ... ... ... ...
Spain 3600 2500 4700 3000 2000 4000
Swedena ... ... ... ... ... ...
Switzerlanda ... ... ... ... ... ...
Turkeya ... ... ... ... ... ...
United Kingdoma ... ... ... ... ... ...
United States of 
Americaa
... ... ... ... ... ...
Global 2 200 000 2 000 000 2 500 000 2 100 000 1 800 000 2 400 000
a Estimates were unavailable at the time of publication.
b Some estimates were unavailable at the time of publication.
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2010 2015
Estimate Lower estimate Upper estimate Estimate Lower estimate Upper estimate 
Asia and the Pacific 26 000 21 000 29 000 19 000 16 000 21 000
Afghanistan <100 <100 <100 <100 <100 <200
Australia <100 <100 <100 <100 <100 <100
Bangladesh <100 <100 <100 <100 <100 <100
Bhutana ... ... ... ... ... ...
Brunei Darussalama ... ... ... ... ... ...
Cambodiad ... ... ... ... ... ...
Chinaa ... ... ... ... ... ...
Democratic People's 
Republic of Koreaa
... ... ... ... ... ...
Fijia ... ... ... ... ... ...
Indiab … … … ... ... ...
Indonesia 3000 2300 3800 5000 3900 6100
Japana ... ... ... ... ... ...
Lao People's Democratic 
Republica
... ... ... ... ... ...
Malaysia <100 <100 <100 <100 <100 <100
Maldivesa ... ... ... ... ... ...
Mongolia <100 <100 <100 <100 <100 <100
Myanmar 1800 1300 2300 <1000 <1000 <1000
Nepal <500 <500 <500 <200 <100 <200
New Zealanda ... ... ... ... ... ...
Pakistan <500 <500 <1000 <1000 <1000 1400
Papua New Guinea <1000 <1000 <1000 <500 <500 <1000
Philippines <100 <100 <100 <100 <100 <500
Republic of Koreaa ... ... ... ... ... ...
Singaporea ... ... ... ... ... ...
Sri Lanka <100 <100 <100 <100 <100 <100
Thailand <500 <200 <500 <100 <100 <200
Timor-Lestea ... ... ... ... ... ...
Viet Nam <1000 <500 <1000 <500 <500 <500
Eastern and southern 
Africa
170 000 140 000 190 000 56 000 40 000 76 000
Angola 5700 3900 8200 4300 2300 7100
Botswana <1000 <1000 <1000 <500 <200 <1000
Eritrea <500 <200 <500 <200 <100 <500
Ethiopiaa ... ... ... ... ... ...
Kenya 12 000 9500 16 000 6600 4100 9800
Lesotho 2000 1700 2300 1300 <1000 1600
Madagascar <1000 <1000 <1000 <1000 <1000 <1000
Malawi 16 000 14 000 18 000 4800 3400 6500
Mauritiusc ... ... ... ... ... ...
Mozambique 29 000 21 000 38 000 6600 2700 15 000
Namibia 1500 1200 1800 <500 <500 <1000
Rwanda 1700 1300 2100 <500 <200 <1000
South Africa 16 000 14 000 22 000 5100 4500 7900
South Sudan 2800 1800 3800 2000 <1000 3200
2. Estimated number of children (0–14 years old) newly infected with HIV, 2000 and 2015
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2010 2015
Estimate Lower estimate Upper estimate Estimate Lower estimate Upper estimate 
Swaziland 1600 1400 1900 <500 <500 <1000
Uganda 25 000 22 000 29 000 3500 1600 6500
United Republic of 
Tanzania
14 000 11 000 18 000 6500 3800 9500
Zambia 13 000 12 000 15 000 4700 3400 6100
Zimbabwe 12 000 11 000 14 000 4900 3700 6300
Eastern Europe and 
central Asiaa
... ... ... ... ... ...
Albaniaa ... ... ... ... ... ...
Armeniac ... ... ... ... ... ...
Azerbaijan <100 <100 <100 <100 <100 <100
Belarus <100 <100 <100 <100 <100 <200
Bosnia and Herzegovinaa ... ... ... ... ... ...
Georgia <100 <100 <100 <100 <100 <100
Kazakhstan <100 <100 <100 <100 <100 <200
Kyrgyzstand <100 <100 <100 <100 <100 <100
Montenegroa ... ... ... ... ... ...
Republic of Moldova <100 <100 <100 <100 <100 <100
Russian Federationa ... ... ... ... ... ...
Tajikistan <100 <100 <100 <100 <100 <100
The former Yugoslav 
Republic of Macedoniaa
... ... ... ... ... ...
Ukraine <500 <500 <1000 <500 <500 <1000
Uzbekistan <100 <100 <500 <100 <100 <100
Latin America and the 
Caribbean
4700 3500 6400 2100 1600 2900
Argentina <100 <100 <100 <100 <100 <100
Bahamas <100 <100 <100 <100 <100 <100
Barbadosc ... ... ... ... ... ...
Belize <100 <100 <100 <100 <100 <100
Bolivia (Plurinational 
State of)
<100 <100 <200 <100 <100 <100
Brazil <1000 <500 1900 <500 <500 <1000
Chilec ... ... ... ... ... ...
Colombia <200 <100 <500 <200 <200 <500
Costa Rica <100 <100 <100 <100 <100 <100
Cuba <100 <100 <100 <100 <100 <100
Dominican Republic <500 <200 <1000 <100 <100 <500
Ecuador <100 <100 <100 <100 <100 <100
El Salvador <100 <100 <100 <100 <100 <100
Guatemala <500 <200 <500 <500 <500 <1000
Guyana <100 <100 <100 <100 <100 <100
Haiti 1900 1400 2500 <500 <200 <500
Honduras <100 <100 <200 <100 <100 <100
Jamaica <100 <100 <100 <100 <100 <100
Mexico <500 <500 <500 <200 <100 <200
Nicaragua <100 <100 <100 <100 <100 <100
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2010 2015
Estimate Lower estimate Upper estimate Estimate Lower estimate Upper estimate 
Panama <100 <100 <100 <100 <100 <100
Paraguay <100 <100 <100 <100 <100 <100
Peru <200 <200 <500 <100 <100 <200
Suriname <100 <100 <100 <100 <100 <100
Trinidad and Tobago <100 <100 <100 <100 <100 <100
Uruguay <100 <100 <100 <100 <100 <100
Venezuela (Bolivarian 
Republic of)
<500 <500 <500 <500 <500 <500
Middle East and North 
Africa
2100 1700 2600 2100 1400 3200
Algeria <100 <100 <100 <100 <100 <100
Djibouti <200 <200 <500 <100 <100 <200
Egypt <100 <100 <100 <100 <100 <200
Iran (Islamic Republic of) <500 <500 <1000 <500 <200 <1000
Lebanonc ... ... ... ... ... ...
Morocco <100 <100 <100 <100 <100 <100
Omana ... ... ... ... ... ...
Somalia <1000 <500 <1000 <1000 <500 <1000
Sudan <1000 <1000 <1000 <1000 <500 1300
Tunisiac ... ... ... ... ... ...
Yemen <100 <100 <200 <200 <100 <200
Western and central 
Africa
96 000 75 000 120 000 66 000 47 000 87 000
Benin <1000 <1000 1100 <1000 <500 <1000
Burkina Faso 1300 1000 1700 <500 <100 <1000
Burundi 1500 1100 1900 <500 <100 <1000
Cameroon 6500 5300 7800 4100 2800 5600
Cape Verde <100 <100 <100 <100 <100 <100
Central African Republic 1700 1500 2000 <1000 <1000 1200
Chad 3800 3000 4800 2000 1300 3000
Congoa ... ... ... ... ... ...
Côte d'Ivoire 4800 3800 5900 3600 2600 4600
Democratic Republic of 
the Congo
8800 7100 11 000 3300 1900 4800
Equatorial Guinea <1000 <500 <1000 <200 <200 <500
Gabon <1000 <500 <1000 <200 <100 <500
Gambia <500 <500 <500 <500 <500 <500
Ghana 3700 2900 4500 2200 1600 2900
Guinea 1900 1600 2200 <500 <500 <500
Guinea-Bissaua ... ... ... ... ... ...
Liberia <1000 <1000 <1000 <500 <500 <1000
Mali 2300 1900 2700 2100 1600 2700
Mauritania <500 <200 <500 <200 <200 <500
Niger <1000 <1000 1000 <1000 <1000 1000
Nigeria 50 000 35 000 67 000 41 000 28 000 57 000
Senegal <1000 <1000 1000 <1000 <500 <1000
Sierra Leone 1200 1000 1400 <500 <200 <1000
Togo 1800 1500 2200 <500 <200 <1000
2. Estimated number of children (0–14 years old) newly infected with HIV, 2000 and 2015
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2010 2015
Estimate Lower estimate Upper estimate Estimate Lower estimate Upper estimate 
Western and central 
Europe and North 
Americaa
... ... ... ... ... ...
Austriaa ... ... ... ... ... ...
Belgiuma ... ... ... ... ... ...
Bulgariaa ... ... ... ... ... ...
Canadaa ... ... ... ... ... ...
Croatiaa ... ... ... ... ... ...
Cyprusa ... ... ... ... ... ...
Czech Republica ... ... ... ... ... ...
Denmarka ... ... ... ... ... ...
Estoniaa ... ... ... ... ... ...
Finlanda ... ... ... ... ... ...
Francea ... ... ... ... ... ...
Germanya ... ... ... ... ... ...
Greece <100 <100 <100 <100 <100 <100
Hungarya ... ... ... ... ... ...
Icelanda ... ... ... ... ... ...
Irelanda ... ... ... ... ... ...
Israela ... ... ... ... ... ...
Italy <200 <200 <200 <200 <200 <200
Latvia <100 <100 <100 <100 <100 <100
Lithuaniaa ... ... ... ... ... ...
Luxembourga ... ... ... ... ... ...
Maltaa ... ... ... ... ... ...
Netherlandsa ... ... ... ... ... ...
Norwaya ... ... ... ... ... ...
Polanda ... ... ... ... ... ...
Portugala ... ... ... ... ... ...
Romaniaa ... ... ... ... ... ...
Serbiaa ... ... ... ... ... ...
Slovakiaa ... ... ... ... ... ...
Sloveniaa ... ... ... ... ... ...
Spain <100 <100 <100 <100 <100 <100
Swedena ... ... ... ... ... ...
Switzerlanda ... ... ... ... ... ...
Turkeya ... ... ... ... ... ...
United Kingdoma ... ... ... ... ... ...
United States of 
Americaa
... ... ... ... ... ...
Global 290 000 250 000 350 000 150 000 110 000 190 000
a Estimates were unavailable at the time of publication.
b Some estimates were unavailable at the time of publication.
c The estimates for children are not published because of small numbers. 
d The estimates for children are not published.
2. Estimated number of children (0–14 years old) newly infected with HIV, 2000 and 2015
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2010 2015
Estimate Lower estimate Upper estimate Estimate Lower estimate Upper estimate 
Asia and the Pacific 4 700 000 4 100 000 5 500 000 5 100 000 4 400 000 5 900 000
Afghanistan 4500 2800 8500 6900 3800 16 000
Australia 21 000 19 000 25 000 27 000 24 000 30 000
Bangladesh 8100 7100 9000 9600 8400 11 000
Bhutana ... ... ... ... ... ...
Brunei Darussalama ... ... ... ... ... ...
Cambodia 84 000 74 000 98 000 74 000 67 000 82 000
Chinaa ... ... ... ... ... ...
Democratic People's 
Republic of Koreaa
... ... ... ... ... ...
Fijia ... ... ... ... ... ...
Indiab 2 200 000 1 800 000 2 700 000 2 100 000 1 700 000 2 600 000
Indonesia 500 000 440 000 560 000 690 000 600 000 790 000
Japana ... ... ... ... ... ...
Lao People's Democratic 
Republica
... ... ... ... ... ...
Malaysia 110 000 92 000 120 000 92 000 80 000 110 000
Maldivesa ... ... ... ... ... ...
Mongolia <200 <200 <500 <500 <500 <1000
Myanmar 230 000 200 000 280 000 220 000 200 000 260 000
Nepal 46 000 39 000 53 000 39 000 34 000 46 000
New Zealanda ... ... ... ... ... ...
Pakistan 48 000 36 000 74 000 100 000 77 000 160 000
Papua New Guinea 36 000 32 000 39 000 40 000 37 000 44 000
Philippines 16 000 13 000 21 000 42 000 30 000 120 000
Republic of Koreaa ... ... ... ... ... ...
Singaporea ... ... ... ... ... ...
Sri Lanka 2500 1700 3600 4200 2800 6500
Thailand 480 000 420 000 560 000 440 000 400 000 490 000
Timor-Lestea ... ... ... ... ... ...
Viet Nam 230 000 210 000 270 000 260 000 230 000 290 000
Eastern and southern 
Africa
17 200 000 16 100 000 18 500 000 19 000 000 17 700 000 20 500 000
Angola 260 000 190 000 350 000 320 000 220 000 440 000
Botswana 320 000 300 000 340 000 350 000 330 000 370 000
Eritrea 15 000 12 000 20 000 14 000 11 000 18 000
Ethiopiaa ... ... ... ... ... ...
Kenya 1 400 000 1 100 000 1 600 000 1 500 000 1 300 000 1 800 000
Lesotho 280 000 260 000 300 000 310 000 280 000 330 000
Madagascar 42 000 35 000 48 000 48 000 39 000 58 000
Malawi 960 000 880 000 1 000 000 980 000 900 000 1 100 000
Mauritius 9200 7700 10 000 8200 6800 9600
Mozambique 1 300 000 1 100 000 1 600 000 1 500 000 1 200 000 1 900 000
Namibia 190 000 180 000 210 000 210 000 200 000 230 000
Rwanda 190 000 170 000 210 000 200 000 180 000 220 000
South Africa 6 400 000 6 000 000 6 800 000 7 000 000 6 700 000 7 400 000
South Sudan 160 000 110 000 210 000 180 000 110 000 240 000
3. People living with HIV (all ages), 2000 and 2015
229 
3. People living with HIV (all ages), 2000 and 2015
2010 2015
Estimate Lower estimate Upper estimate Estimate Lower estimate Upper estimate 
Swaziland 180 000 170 000 190 000 220 000 200 000 240 000
Uganda 1 200 000 1 100 000 1 300 000 1 500 000 1 300 000 1 600 000
United Republic of 
Tanzania
1 400 000 1 200 000 1 500 000 1 400 000 1 200 000 1 600 000
Zambia 1 100 000 1 000 000 1 100 000 1 200 000 1 200 000 1 300 000
Zimbabwe 1 200 000 1 100 000 1 300 000 1 400 000 1 300 000 1 500 000
Eastern Europe and 
central Asia
1 000 000 950 000 1 100 000 1 500 000 1 400 000 1 700 000
Albaniaa ... ... ... ... ... ...
Armenia 3000 2200 3900 3600 2900 4900
Azerbaijan 6800 4900 9700 11 000 7400 15 000
Belarus 21 000 17 000 27 000 35 000 29 000 43 000
Bosnia and Herzegovinaa ... ... ... ... ... ...
Georgia 6200 5000 7700 9600 7700 12 000
Kazakhstan 13 000 12 000 14 000 23 000 20 000 27 000
Kyrgyzstan 5700 4600 7100 8100 6400 10 000
Montenegroa ... ... ... ... ... ...
Republic of Moldova 15 000 13 000 19 000 18 000 15 000 21 000
Russian Federationa ... ... ... ... ... ...
Tajikistan 12 000 10 000 15 000 16 000 13 000 20 000
The former Yugoslav 
Republic of Macedoniaa
... ... ... ... ... ...
Ukraine 230 000 200 000 260 000 220 000 190 000 250 000
Uzbekistan 49 000 35 000 72 000 33 000 24 000 47 000
Latin America and the 
Caribbean
1 800 000 1 500 000 2 100 000 2 000 000 1 700 000 2 300 000
Argentina 99 000 89 000 110 000 110 000 99 000 120 000
Bahamas 7400 6700 8300 8100 7500 9000
Barbados 2100 2000 2300 2600 2500 2900
Belize 3300 2900 3800 3600 3200 4000
Bolivia (Plurinational 
State of)
16 000 11 000 22 000 18 000 11 000 25 000
Brazil 700 000 520 000 940 000 830 000 610 000 1 100 000
Chile 26 000 20 000 33 000 32 000 22 000 45 000
Colombia 110 000 100 000 130 000 150 000 130 000 160 000
Costa Rica 8000 7200 8700 10 000 9000 11 000
Cuba 11 000 9200 12 000 22 000 19 000 24 000
Dominican Republic 80 000 59 000 120 000 68 000 53 000 92 000
Ecuador 28 000 23 000 33 000 29 000 23 000 35 000
El Salvador 20 000 18 000 22 000 20 000 18 000 22 000
Guatemala 44 000 32 000 65 000 55 000 38 000 80 000
Guyana 6800 6400 7600 7800 7200 8700
Haiti 180 000 150 000 230 000 130 000 110 000 160 000
Honduras 24 000 20 000 29 000 20 000 17 000 24 000
Jamaica 29 000 25 000 33 000 29 000 25 000 34 000
Mexico 170 000 150 000 190 000 200 000 180 000 220 000
Nicaragua 8900 6400 15 000 9900 7600 14 000
Panama 15 000 13 000 16 000 17 000 16 000 19 000
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2010 2015
Estimate Lower estimate Upper estimate Estimate Lower estimate Upper estimate 
Paraguay 16 000 11 000 26 000 17 000 12 000 27 000
Peru 61 000 51 000 73 000 66 000 56 000 79 000
Suriname 3800 3400 4200 3800 3300 4400
Trinidad and Tobago 10 000 9700 11 000 11 000 10 000 11 000
Uruguay 9800 8400 12 000 10 000 8700 12 000
Venezuela (Bolivarian 
Republic of)
94 000 85 000 100 000 110 000 99 000 120 000
Middle East and North 
Africa
190 000 150 000 240 000 230 000 160 000 330 000
Algeria 6900 6200 7500 8800 6800 11 000
Djibouti 10 000 7100 15 000 9400 6600 13 000
Egypt 6700 4600 10 000 11 000 7200 19 000
Iran (Islamic Republic of) 60 000 44 000 82 000 73 000 50 000 130 000
Lebanon 1700 1500 1900 2400 2100 2700
Morocco 23 000 19 000 27 000 24 000 21 000 28 000
Omana ... ... ... ... ... ...
Somalia 29 000 22 000 38 000 30 000 21 000 41 000
Sudan 44 000 37 000 53 000 56 000 33 000 90 000
Tunisia 1600 1100 2500 2600 1700 3800
Yemen 6400 4400 9800 9200 5700 16 000
Western and central 
Africa
6 300 000 5 200 000 7 700 000 6 500 000 5 300 000 7 800 000
Benin 64 000 50 000 82 000 69 000 54 000 92 000
Burkina Faso 98 000 81 000 120 000 95 000 79 000 120 000
Burundi 93 000 77 000 110 000 77 000 61 000 92 000
Cameroon 580 000 520 000 640 000 620 000 550 000 690 000
Cape Verde 3300 2700 4000 3200 2700 3900
Central African Republic 130 000 120 000 150 000 120 000 100 000 130 000
Chad 180 000 150 000 210 000 170 000 130 000 210 000
Congoa ... ... ... ... ... ...
Côte d'Ivoire 470 000 400 000 530 000 460 000 400 000 530 000
Democratic Republic of 
the Congo
450 000 360 000 550 000 370 000 290 000 460 000
Equatorial Guinea 29 000 28 000 31 000 27 000 25 000 30 000
Gabon 48 000 42 000 54 000 47 000 40 000 54 000
Gambia 19 000 16 000 23 000 21 000 17 000 25 000
Ghana 290 000 240 000 340 000 270 000 230 000 330 000
Guinea 100 000 89 000 120 000 120 000 100 000 140 000
Guinea-Bissaua ... ... ... ... ... ...
Liberia 34 000 29 000 39 000 30 000 25 000 35 000
Mali 110 000 96 000 130 000 120 000 100 000 150 000
Mauritania 15 000 12 000 20 000 14 000 8800 21 000
Niger 58 000 51 000 67 000 49 000 43 000 55 000
Nigeria 3 200 000 2 400 000 4 200 000 3 500 000 2 600 000 4 500 000
Senegal 50 000 43 000 59 000 46 000 38 000 56 000
Sierra Leone 53 000 47 000 58 000 51 000 44 000 58 000
Togo 120 000 99 000 140 000 110 000 92 000 120 000
3. People living with HIV (all ages), 2000 and 2015
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2010 2015
Estimate Lower estimate Upper estimate Estimate Lower estimate Upper estimate 
Western and central 
Europe and North 
America
2 100 000 1 900 000 2 300 000 2 400 000 2 200 000 2 700 000
Austriaa ... ... ... ... ... ...
Belgiuma ... ... ... ... ... ...
Bulgariaa ... ... ... ... ... ...
Canadaa ... ... ... ... ... ...
Croatiaa ... ... ... ... ... ...
Cyprusa ... ... ... ... ... ...
Czech Republica ... ... ... ... ... ...
Denmarka ... ... ... ... ... ...
Estoniaa ... ... ... ... ... ...
Finlanda ... ... ... ... ... ...
Francea ... ... ... ... ... ...
Germanya ... ... ... ... ... ...
Greece 14 000 13 000 15 000 16 000 15 000 18 000
Hungarya ... ... ... ... ... ...
Icelanda ... ... ... ... ... ...
Irelanda ... ... ... ... ... ...
Israela ... ... ... ... ... ...
Italy 120 000 110 000 130 000 140 000 120 000 150 000
Latvia 6800 6000 7700 6800 6100 7700
Lithuaniaa ... ... ... ... ... ...
Luxembourga ... ... ... ... ... ...
Maltaa ... ... ... ... ... ...
Netherlandsa ... ... ... ... ... ...
Norwaya ... ... ... ... ... ...
Polanda ... ... ... ... ... ...
Portugala ... ... ... ... ... ...
Romaniaa ... ... ... ... ... ...
Serbiaa ... ... ... ... ... ...
Slovakiaa ... ... ... ... ... ...
Sloveniaa ... ... ... ... ... ...
Spain 150 000 120 000 170 000 150 000 130 000 180 000
Swedena ... ... ... ... ... ...
Switzerlanda ... ... ... ... ... ...
Turkeya ... ... ... ... ... ...
United Kingdoma ... ... ... ... ... ...
United States of 
Americaa
... ... ... ... ... ...
Global 33 300 000 30 800 000 36 100 000 36 700 000 34 000 000 39 800 000
3. People living with HIV (all ages), 2000 and 2015
a Estimates were unavailable at the time of publication.
b Some estimates were unavailable at the time of publication.
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4. Estimated number of people dying from AIDS-related causes (all ages), 2000 and 2014
2010 2015
Estimate Lower estimate Upper estimate Estimate Lower estimate Upper estimate 
Asia and the Pacific 240 000 200 000 270 000 180 000 150 000 220 000
Afghanistan <500 <200 <500 <500 <200 <1000
Australia <500 <500 <500 <200 <200 <500
Bangladesh <1000 <500 <1000 <1000 <1000 <1000
Bhutana ... ... ... ... ... ...
Brunei Darussalama ... ... ... ... ... ...
Cambodia 3200 2100 4500 2000 1500 3300
Chinaa ... ... ... ... ... ...
Democratic People's 
Republic of Koreaa
... ... ... ... ... ...
Fijia ... ... ... ... ... ...
Indiab 120 000 86 000 200 000 68 000 47 000 99 000
Indonesia 18 000 14 000 21 000 35 000 31 000 40 000
Japana ... ... ... ... ... ...
Lao People's  
Democratic Republica
... ... ... ... ... ...
Malaysia 8000 7200 8900 7200 6400 8100
Maldivesa ... ... ... ... ... ...
Mongolia <100 <100 <100 <100 <100 <100
Myanmar 16 000 14 000 18 000 9700 7600 12 000
Nepal 2600 2200 2900 2300 1900 2700
New Zealanda ... ... ... ... ... ...
Pakistan 1500 <1000 2600 3600 2300 6100
Papua New Guinea 1500 1200 1700 <1000 <1000 1100
Philippines <500 <200 <500 <1000 <500 1200
Republic of Koreaa ... ... ... ... ... ...
Singaporea ... ... ... ... ... ...
Sri Lanka <100 <100 <200 <200 <100 <500
Thailand 19 000 12 000 29 000 14 000 11 000 21 000
Timor-Lestea ... ... ... ... ... ...
Viet Nam 7700 6400 9000 8900 7400 11 000
Eastern and southern 
Africa
760 000 670 000 860 000 470 000 390 000 560 000
Angola 12 000 8100 18 000 12 000 6900 19 000
Botswana 5300 4500 6000 3200 2800 3600
Eritrea <1000 <1000 1100 <500 <500 <1000
Ethiopiaa ... ... ... ... ... ...
Kenya 51 000 40 000 63 000 36 000 26 000 47 000
Lesotho 9100 7700 10 000 9900 8700 11 000
Madagascar 3600 3000 4300 3200 2800 3800
Malawi 47 000 41 000 52 000 27 000 22 000 31 000
Mauritius <1000 <1000 <1000 <500 <500 <500
Mozambique 54 000 39 000 73 000 39 000 26 000 56 000
Namibia 4900 4000 5800 3100 2500 3900
Rwanda 5000 3900 6200 2900 2300 3500
South Africa 320 000 280 000 370 000 180 000 150 000 220 000
South Sudan 11 000 7200 15 000 12 000 7300 16 000
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4. Estimated number of people dying from AIDS-related causes (all ages), 2000 and 2014
2010 2015
Estimate Lower estimate Upper estimate Estimate Lower estimate Upper estimate 
Swaziland 5400 4800 6000 3800 3300 4200
Uganda 50 000 43 000 59 000 28 000 22 000 35 000
United Republic of 
Tanzania
66 000 58 000 74 000 36 000 29 000 42 000
Zambia 29 000 24 000 34 000 20 000 16 000 24 000
Zimbabwe 52 000 46 000 56 000 29 000 25 000 34 000
Eastern Europe and 
central Asia
38 000 33 000 45 000 47 000 39 000 55 000
Albaniaa ... ... ... ... ... ...
Armenia <200 <100 <500 <200 <100 <200
Azerbaijan <500 <200 <500 <500 <200 <1000
Belarus <1000 <1000 1200 <1000 <1000 1400
Bosnia and Herzegovinaa ... ... ... ... ... ...
Georgia <200 <200 <500 <500 <200 <500
Kazakhstan <500 <500 <1000 <1000 <500 <1000
Kyrgyzstan <200 <200 <500 <500 <200 <500
Montenegroa ... ... ... ... ... ...
Republic of Moldova <1000 <1000 <1000 <1000 <1000 1100
Russian Federationa ... ... ... ... ... ...
Tajikistan <1000 <1000 <1000 <1000 <1000 <1000
The former Yugoslav 
Republic of Macedoniaa
... ... ... ... ... ...
Ukraine 14 000 12 000 17 000 7900 6000 10 000
Uzbekistan 3700 2700 5300 2600 1600 4200
Latin America and the 
Caribbean
60 000 51 000 70 000 50 000 41 000 59 000
Argentina 2200 1900 2500 2300 2000 2600
Bahamas <500 <500 <500 <500 <500 <500
Barbados <100 <100 <100 <100 <100 <100
Belize <200 <100 <200 <200 <100 <200
Bolivia (Plurinational 
State of)
<1000 <1000 1200 <1000 <500 1200
Brazil 15 000 11 000 21 000 15 000 11 000 21 000
Chile <1000 <500 <1000 <500 <500 <1000
Colombia 4600 4000 5300 2300 1800 2700
Costa Rica <200 <200 <500 <500 <200 <500
Cuba <200 <200 <500 <500 <200 <500
Dominican Republic 5000 3300 7700 3100 1800 5500
Ecuador 1000 <1000 1400 <1000 <1000 1300
El Salvador <500 <500 <500 <500 <500 <1000
Guatemala <1000 <500 1400 1700 <1000 2900
Guyana <200 <100 <200 <200 <100 <200
Haiti 14 000 11 000 18 000 8000 5500 11 000
Honduras 1500 1100 1900 1000 <1000 1400
Jamaica 1400 1100 1700 1200 <1000 1600
Mexico 5200 4400 5900 4000 3200 4500
Nicaragua <1000 <500 <1000 <500 <500 <1000
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2010 2015
Estimate Lower estimate Upper estimate Estimate Lower estimate Upper estimate 
Panama <500 <500 <500 <500 <500 <1000
Paraguay <1000 <500 1100 <1000 <500 1300
Peru 2000 1600 2600 1600 1100 2300
Suriname <200 <200 <200 <200 <200 <200
Trinidad and Tobago <500 <500 <500 <500 <200 <500
Uruguay <1000 <500 <1000 <500 <200 <500
Venezuela (Bolivarian 
Republic of)
1700 1500 2000 3300 2900 3700
Middle East and North 
Africa
9500 7400 12 000 12 000 8700 16 000
Algeria <200 <200 <200 <200 <100 <200
Djibouti <1000 <1000 1100 <1000 <500 <1000
Egypt <500 <200 <500 <500 <200 <1000
Iran (Islamic Republic of) 3200 2400 4300 4000 2700 6000
Lebanon <100 <100 <100 <100 <100 <100
Morocco <1000 <1000 1300 <1000 <1000 1300
Omana ... ... ... ... ... ...
Somalia 2100 1600 2800 2000 1500 2700
Sudan 1800 1200 2300 3000 2100 4300
Tunisia <100 <100 <100 <100 <100 <200
Yemen <500 <200 <500 <500 <200 <1000
Western and central 
Africa
370 000 290 000 470 000 330 000 250 000 430 000
Benin 2400 1700 3500 2800 1900 4100
Burkina Faso 5200 3600 6900 3600 2500 4900
Burundi 6100 5100 7100 3000 1800 4000
Cameroon 28 000 26 000 31 000 33 000 30 000 36 000
Cape Verde <200 <200 <500 <200 <100 <200
Central African Republic 9500 8700 10 000 7800 7000 8600
Chad 8400 6600 11 000 8500 6400 11 000
Congoa ... ... ... ... ... ...
Côte d'Ivoire 22 000 18 000 26 000 25 000 20 000 30 000
Democratic Republic of 
the Congo
33 000 27 000 41 000 22 000 16 000 28 000
Equatorial Guinea 1300 1100 1600 1100 <1000 1200
Gabon 2500 2000 3000 1300 <1000 1600
Gambia 1100 <1000 1400 1000 <1000 1300
Ghana 19 000 16 000 22 000 13 000 10 000 16 000
Guinea 4700 3800 5600 4600 3700 5600
Guinea-Bissaua ... ... ... ... ... ...
Liberia 2600 2300 2900 1900 1600 2300
Mali 5100 4300 6100 6500 5400 7800
Mauritania <1000 <1000 1100 <1000 <1000 1300
Niger 4200 3500 5000 3600 3100 4200
Nigeria 190 000 130 000 270 000 180 000 120 000 250 000
Senegal 1800 1300 2400 2200 1800 2800
Sierra Leone 2600 2100 3200 2500 2100 2900
Togo 7900 6600 9500 5100 4000 6500
4. Estimated number of people dying from AIDS-related causes (all ages), 2000 and 2014
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2010 2015
Estimate Lower estimate Upper estimate Estimate Lower estimate Upper estimate 
Western and central 
Europe and North 
America
29 000 27 000 31 000 22 000 20 000 24 000
Austriaa ... ... ... ... ... ...
Belgiuma ... ... ... ... ... ...
Bulgariaa ... ... ... ... ... ...
Canadaa ... ... ... ... ... ...
Croatiaa ... ... ... ... ... ...
Cyprusa ... ... ... ... ... ...
Czech Republica ... ... ... ... ... ...
Denmarka ... ... ... ... ... ...
Estoniaa ... ... ... ... ... ...
Finlanda ... ... ... ... ... ...
Francea ... ... ... ... ... ...
Germanya ... ... ... ... ... ...
Greece <1000 <500 <1000 <500 <500 <500
Hungarya ... ... ... ... ... ...
Icelanda ... ... ... ... ... ...
Irelanda ... ... ... ... ... ...
Israela ... ... ... ... ... ...
Italy <1000 <1000 <1000 <1000 <1000 <1000
Latvia <500 <500 <500 <500 <500 <500
Lithuaniaa ... ... ... ... ... ...
Luxembourga ... ... ... ... ... ...
Maltaa ... ... ... ... ... ...
Netherlandsa ... ... ... ... ... ...
Norwaya ... ... ... ... ... ...
Polanda ... ... ... ... ... ...
Portugala ... ... ... ... ... ...
Romaniaa ... ... ... ... ... ...
Serbiaa ... ... ... ... ... ...
Slovakiaa ... ... ... ... ... ...
Sloveniaa ... ... ... ... ... ...
Spain 1300 1100 1500 1200 1000 1400
Swedena ... ... ... ... ... ...
Switzerlanda ... ... ... ... ... ...
Turkeya ... ... ... ... ... ...
United Kingdoma ... ... ... ... ... ...
United States of 
Americaa
... ... ... ... ... ...
Global 1 500 000 1 300 000 1 700 000 1 100 000 940 000 1 300 000
4. Estimated number of people dying from AIDS-related causes (all ages), 2000 and 2014
a Estimates were unavailable at the time of publication.
b Some estimates were unavailable at the time of publication.
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Number of pregnant 
women receiving 
antiretroviral 
medicines
Estimated number of pregnant women living with HIV Estimated coverage (%)
Estimate Lower estimate Upper estimate Estimate Lower estimate Upper estimate 
Asia and the Pacific 29 600 77 000 67 000 87 000 39 34 44
Afghanistan 7 <200 <200 <500 4 2 8
Australia 119 <200 <200 <200 >95 95 >95
Bangladesh 20 <200 <200 <200 14 11 16
Bhutana ... ... ... ... ... ... ...
Brunei Darussalama ... ... ... ... ... ... ...
Cambodiad ... ... ... ... ... ... ...
Chinaa ... ... ... ... ... ... ...
Democratic People's 
Republic of Koreaa
... ... ... ... ... ... ...
Fijia ... ... ... ... ... ... ...
Indiab 13 511 35 000 29 000 44 000 38 31 47
Indonesia 1466 16 000 13 000 18 000 9 8 11
Japana ... ... ... ... ... ... ...
Lao People's 
Democratic Republica
... ... ... ... ... ... ...
Malaysia 320 <500 <500 <500 80 75 87
Maldivesa ... ... ... ... ... ... ...
Mongolia 2 <100 <100 <100 >95 50 >95
Myanmar 3923 5100 4500 5700 77 68 88
Nepal 145 <500 <500 <500 35 30 41
New Zealanda ... ... ... ... ... ... ...
Pakistan 103 2400 1800 3700 4 3 7
Papua New Guinea 497 1500 1400 1700 33 29 36
Philippines 32 <500 <500 <1000 10 7 22
Republic of Koreaa ... ... ... ... ... ... ...
Singaporea ... ... ... ... ... ... ...
Sri Lanka 16 <100 <100 <200 24 17 36
Thailand 4280 4500 3800 5200 >95 81 >95
Timor-Lestea ... ... ... ... ... ... ...
Viet Nam 1692 2900 2500 3300 58 49 65
Eastern and southern 
Africa
861 600 960 000 880 000 1 000 000 90 82 >95
Angola 8398 21 000 15 000 29 000 40 29 57
Botswana 11 899 13 000 12 000 14 000 92 86 >95
Eritrea 300 <1000 <1000 <1000 45 35 59
Ethiopiaa ... ... ... ... ... ... ...
Kenya 59 024 79 000 67 000 92 000 74 63 86
Lesotho 8061 12 000 10 000 13 000 70 64 77
Madagascar 54 1800 1500 2200 3 2 4
Malawi 44 023 55 000 50 000 61 000 80 73 89
Mauritiusc 90 ... ... ... ... ... ...
Mozambique 99 823 110 000 82 000 130 000 95 74 >95
Namibia 8641 9100 8300 10 000 >95 87 >95
Rwanda 9604 10 000 9200 11 000 93 82 >95
South Africa 257 456 250 000 230 000 270 000 >95 94 >95
5. Estimated percentage of pregnant women living with HIV who received effective 
antiretroviral medicines to prevent the mother-to-child transmission of HIV, 2015
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Number of pregnant 
women receiving 
antiretroviral 
medicines
Estimated number of pregnant women living with HIV Estimated coverage (%)
Estimate Lower estimate Upper estimate Estimate Lower estimate Upper estimate 
South Sudan 3879 9500 6100 13 000 41 26 57
Swaziland 10 830 11 000 11 000 12 000 95 87 >95
Uganda 117 887 120 000 110 000 130 000 >95 88 >95
United Republic of 
Tanzania
74 190 86 000 77 000 96 000 86 77 >95
Zambia 70 991 81 000 75 000 88 000 87 81 94
Zimbabwe 57 378 68 000 62 000 75 000 84 77 92
Eastern Europe and 
Central Asiaa
... ... ... ... ... ... ...
Albaniaa ... ... ... ... ... ... ...
Armeniac 29 ... ... ... ... ... ...
Azerbaijan 56 <200 <100 <200 49 32 71
Belarus 270 <1000 <500 <1000 48 37 62
Bosnia and 
Herzegovinaa
... ... ... ... ... ... ...
Georgia 57 <100 <100 <100 >95 81 >95
Kazakhstan 354 <500 <500 <1000 89 67 >95
Kyrgyzstand 87 <100 <100 <200 89 74 >95
Montenegroa ... ... ... ... ... ... ...
Republic of Moldova 175 <500 <200 <500 76 62 94
Russian Federationa ... ... ... ... ... ... ...
Tajikistan 168 <500 <500 <500 58 48 71
The former Yugoslav 
Republic of Macedoniaa
... ... ... ... ... ... ...
Ukraine 2698 2800 2200 3400 >95 78 >95
Uzbekistan 543 <500 <500 <500 >95 >95 >95
Latin America and the 
Caribbean
24 300 28 000 24 000 32 000 88 77 >95
Argentina 1481 1600 1500 1800 93 85 >95
Bahamas 52 <200 <100 <200 50 46 54
Barbadosc 15 ... ... ... ... ... ...
Belize 54 <100 <100 <100 63 54 72
Bolivia (Plurinational 
State of)
284 <500 <500 <1000 76 47 >95
Brazil 10 541 8500 6300 11 000 >95 91 >95
Chilec 232 ... ... ... ... ... ...
Colombia 805 1600 1500 1800 49 45 54
Costa Rica 41 <200 <100 <200 41 36 46
Cuba 157 <200 <200 <200 >95 >95 >95
Dominican Republic 894 1200 <1000 1700 72 57 >95
Ecuador 285 <500 <500 <1000 60 48 71
El Salvador 158 <500 <500 <500 55 51 60
Guatemala 214 1600 1100 2400 13 9 21
Guyana 167 <500 <200 <500 76 67 86
Haiti 4568 4800 3900 5700 >95 79 >95
Honduras 175 <500 <500 <500 53 45 63
Jamaica 414 <500 <500 <1000 >95 82 >95
5. Estimated percentage of pregnant women living with HIV who received effective 
antiretroviral medicines to prevent the mother-to-child transmission of HIV, 2015
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Number of pregnant 
women receiving 
antiretroviral 
medicines
Estimated number of pregnant women living with HIV Estimated coverage (%)
Estimate Lower estimate Upper estimate Estimate Lower estimate Upper estimate 
Mexico 1395 1800 1700 2000 76 70 82
Nicaragua 117 <200 <100 <200 >95 89 >95
Panama 180 <500 <500 <500 78 71 85
Paraguay 175 <500 <500 <500 56 41 87
Peru 790 1000 <1000 1200 79 66 >95
Suriname 122 <100 <100 <200 >95 >95 >95
Trinidad and Tobago 113 <200 <200 <200 63 57 68
Uruguay 155 <200 <100 <200 >95 >95 >95
Venezuela (Bolivarian 
Republic of)
761 1800 1600 2000 43 39 47
Middle East and North 
Africa
900 7000 4900 10 000 12 9 18
Algeria 112 <500 <500 <500 34 28 38
Djibouti 114 <500 <500 <500 37 26 53
Egypt 27 <500 <200 <500 10 6 16
Iran (Islamic Republic of) 186 <1000 <1000 1600 20 14 34
Lebanonc 3 ... ... ... ... ... ...
Morocco 171 <500 <500 <500 46 39 53
Omana ... ... ... ... ... ... ...
Somalia 74 1800 1200 2400 4 3 6
Sudan 114 2600 1400 4000 4 2 7
Tunisiac 18 ... ... ... ... ... ...
Yemen 31 <500 <500 <1000 9 5 15
Western and central 
Africa
162 900 340 000 280 000 410 000 48 40 58
Benin 2031 3600 2800 4700 57 45 75
Burkina Faso 4731 5300 4500 6300 89 75 >95
Burundi 3885 4400 3300 5300 89 67 >95
Cameroon 26 678 33 000 29 000 36 000 82 73 91
Cape Verde 73 <100 <100 <100 >95 79 >95
Central African Republic 2721 4800 4200 5500 56 49 64
Chad 4671 10 000 8000 13 000 46 36 60
Congoa ... ... ... ... ... ... ...
Côte d'Ivoire 17 711 22 000 19 000 26 000 79 67 91
Democratic Republic of 
the Congo
14 476 22 000 17 000 27 000 67 53 82
Equatorial Guinea 1010 1300 1200 1500 75 68 84
Gabon 1665 2100 1800 2500 78 66 91
Gambia 874 1400 1100 1600 64 52 76
Ghana 7813 12 000 10 000 15 000 63 53 74
Guinea 5437 6400 5400 7500 85 72 >95
Guinea-Bissaua ... ... ... ... ... ... ...
Liberia 1358 2000 1600 2300 70 57 84
Mali 2628 7900 6700 9500 33 28 40
Mauritania 80 <1000 <500 1000 12 7 18
Niger 981 3500 3200 4000 28 25 31
Nigeria 52 711 180 000 140 000 230 000 30 23 39
5. Estimated percentage of pregnant women living with HIV who received effective 
antiretroviral medicines to prevent the mother-to-child transmission of HIV, 2015
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Number of pregnant 
women receiving 
antiretroviral 
medicines
Estimated number of pregnant women living with HIV Estimated coverage (%)
Estimate Lower estimate Upper estimate Estimate Lower estimate Upper estimate 
Senegal 1143 3200 2700 3800 36 31 43
Sierra Leone 3212 3900 3300 4500 83 70 >95
Togo 4642 4900 4200 5600 >95 82 >95
Western and central 
Europe and North 
Americaa
... ... ... ... ... ... ...
Austriaa ... ... ... ... ... ... ...
Belgiuma ... ... ... ... ... ... ...
Bulgariaa ... ... ... ... ... ... ...
Canadaa ... ... ... ... ... ... ...
Croatiaa ... ... ... ... ... ... ...
Cyprusa ... ... ... ... ... ... ...
Czech Republica ... ... ... ... ... ... ...
Denmarka ... ... ... ... ... ... ...
Estoniaa ... ... ... ... ... ... ...
Finlanda ... ... ... ... ... ... ...
Francea ... ... ... ... ... ... ...
Germanya ... ... ... ... ... ... ...
Greece 72 <100 <100 <100 >95 92 >95
Hungarya ... ... ... ... ... ... ...
Icelanda ... ... ... ... ... ... ...
Irelanda ... ... ... ... ... ... ...
Israela ... ... ... ... ... ... ...
Italy 382 1200 1100 1300 31 29 34
Latvia 64 <100 <100 <100 >95 86 >95
Lithuaniaa ... ... ... ... ... ... ...
Luxembourga ... ... ... ... ... ... ...
Maltaa ... ... ... ... ... ... ...
Netherlandsa ... ... ... ... ... ... ...
Norwaya ... ... ... ... ... ... ...
Polanda ... ... ... ... ... ... ...
Portugala ... ... ... ... ... ... ...
Romaniaa ... ... ... ... ... ... ...
Serbiaa ... ... ... ... ... ... ...
Slovakiaa ... ... ... ... ... ... ...
Sloveniaa ... ... ... ... ... ... ...
Spain 544 <1000 <500 <1000 >95 77 >95
Swedena ... ... ... ... ... ... ...
Switzerlanda ... ... ... ... ... ... ...
Turkeya ... ... ... ... ... ... ...
United Kingdoma ... ... ... ... ... ... ...
United States of 
Americaa
... ... ... ... ... ... ...
Global 1 110 000 1 400 000 1 300 000 1 600 000 77 69 86
5. Estimated percentage of pregnant women living with HIV who received effective 
antiretroviral medicines to prevent the mother-to-child transmission of HIV, 2015
a Estimates were unavailable at the time of publication.
b Some estimates were unavailable at the time of publication.
c The estimates for children are not published because of small numbers. 
d The estimates for children are not published.
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6. Estimated percentage of adults (age 15+ years) living with HIV receiving antiretroviral 
therapy, 2015
Number of adults 
(age 15+ years) living 
with HIV receiving 
antiretroviral therapy
Adults (age 15+ years) living with HIV, 2015 Estimated coverage (%)
Estimate Lower estimate Upper estimate Estimate Lower estimate Upper estimate 
Asia and the Pacific 1 991 000 4 900 000 4 200 000 5 700 000 41 35 47
Afghanistan 338 6700 3600 15 000 5 3 11
Australia 24 150 27 000 24 000 30 000 90 82 >95
Bangladesh 1393 9300 8100 11 000 15 13 17
Bhutana ... ... ... ... ... ... ...
Brunei Darussalama ... ... ... ... ... ... ...
Cambodia 51 088 70 000 64 000 78 000 73 66 81
Chinaa ... ... ... ... ... ... ...
Democratic People's 
Republic of Koreaa
... ... ... ... ... ... ...
Fijia 255 ... ... ... ... ... ...
Indiab 868 165 2 000 000 1 600 000 2 500 000 44 36 55
Indonesia 60 358 680 000 590 000 780 000 9 8 10
Japana ... ... ... ... ... ... ...
Lao People's 
Democratic Republica
3657 ... ... ... ... ... ...
Malaysia 25 213 91 000 80 000 110 000 28 25 32
Maldivesa 9 ... ... ... ... ... ...
Mongolia 147 <500 <500 <1000 36 28 45
Myanmar 99 404 220 000 190 000 250 000 46 40 54
Nepal 11 029 38 000 33 000 44 000 29 25 35
New Zealanda ... ... ... ... ... ... ...
Pakistan 6433 100 000 75 000 160 000 6 5 10
Papua New Guinea 20 028 37 000 33 000 41 000 54 49 60
Philippines 12 492 42 000 30 000 120 000 30 19 81
Republic of Koreaa ... ... ... ... ... ... ...
Singaporea 1533 ... ... ... ... ... ...
Sri Lanka 768 4100 2800 6400 19 13 29
Thailand 278 322 430 000 400 000 480 000 64 59 72
Timor-Lestea ... ... ... ... ... ... ...
Viet Nam 101 508 250 000 220 000 280 000 41 36 46
Eastern and southern 
Africa
9 594 000 18 000 000 16 700 000 19 400 000 53 50 57
Angola 84 172 290 000 200 000 410 000 29 20 41
Botswana 264 482 340 000 320 000 360 000 78 73 83
Eritrea 7961 13 000 10 000 16 000 62 49 80
Ethiopiaa 364 114 ... ... ... ... ... ...
Kenya 826 097 1 400 000 1 200 000 1 700 000 58 49 68
Lesotho 121 661 290 000 270 000 320 000 41 37 45
Madagascar 1218 44 000 36 000 54 000 3 2 3
Malawi 543 699 890 000 820 000 970 000 61 56 66
Mauritius 2514 8100 6700 9600 31 26 36
Mozambique 738 386 1 400 000 1 100 000 1 700 000 53 43 65
Namibia 134 486 200 000 190 000 220 000 67 62 73
Rwanda 150 462 190 000 170 000 210 000 79 70 87
South Africa 3 209 270 6 700 000 6 400 000 7 200 000 48 45 51
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6. Estimated percentage of adults (age 15+ years) living with HIV receiving antiretroviral 
therapy, 2015
Number of adults 
(age 15+ years) living 
with HIV receiving 
antiretroviral therapy
Adults (age 15+ years) living with HIV, 2015 Estimated coverage (%)
Estimate Lower estimate Upper estimate Estimate Lower estimate Upper estimate 
South Sudan 18 825 170 000 110 000 220 000 11 7 15
Swaziland 139 211 210 000 190 000 230 000 67 62 72
Uganda 774 902 1 400 000 1 300 000 1 500 000 57 52 62
United Republic of 
Tanzania
688 604 1 300 000 1 200 000 1 500 000 53 47 60
Zambia 706 743 1 100 000 1 100 000 1 200 000 63 59 67
Zimbabwe 817 397 1 300 000 1 200 000 1 500 000 61 55 66
Eastern Europe and 
central Asia
312 700 1 500 000 1 400 000 1 600 000 21 19 22
Albaniaa 407 ... ... ... ... ... ...
Armenia 917 3600 2800 4900 26 20 35
Azerbaijan 2960 11 000 7300 15 000 28 19 38
Belarus 7174 35 000 29 000 43 000 21 16 24
Bosnia and 
Herzegovinaa
125 ... ... ... ... ... ...
Georgia 2991 9600 7700 12 000 31 25 39
Kazakhstan 5906 23 000 20 000 27 000 26 22 30
Kyrgyzstan 1722 8000 6300 10 000 22 17 28
Montenegroa 90 ... ... ... ... ... ...
Republic of Moldova 3744 18 000 15 000 21 000 21 18 25
Russian Federationa ... ... ... ... ... ... ...
Tajikistan 2638 16 000 13 000 20 000 17 13 20
The former Yugoslav 
Republic of Macedoniaa
... ... ... ... ... ... ...
Ukraine 58 338 220 000 190 000 250 000 27 23 31
Uzbekistan 8611 32 000 24 000 46 000 27 20 39
Latin America and the 
Caribbean
1 072 000 2 000 000 1 700 000 2 300 000 55 47 64
Argentina 68 933 110 000 98 000 120 000 63 57 69
Bahamas 2943 8100 7400 8900 37 34 40
Barbados 1131 2600 2400 2900 43 40 47
Belize 1549 3400 3100 3900 45 40 51
Bolivia (Plurinational 
State of)
5101 18 000 11 000 24 000 29 18 39
Brazil 452 229 820 000 600 000 1 100 000 55 41 74
Chile 27 938 32 000 22 000 45 000 87 59 >95
Colombiac ... 140 000 130 000 160 000 ... ... ...
Costa Rica 5558 9900 8900 11 000 56 50 62
Cuba 15 054 22 000 19 000 24 000 69 59 75
Dominican Republic 30 512 66 000 52 000 90 000 46 36 63
Ecuador 14 972 29 000 23 000 34 000 52 41 63
El Salvador 10 530 19 000 18 000 21 000 54 49 59
Guatemala 15 459 53 000 37 000 77 000 29 21 43
Guyana 4394 7600 7100 8500 58 53 64
Haiti 65 984 120 000 100 000 150 000 53 44 64
Honduras 9884 19 000 16 000 23 000 51 44 61
Jamaica 9098 29 000 25 000 33 000 32 27 37
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Number of adults 
(age 15+ years) living 
with HIV receiving 
antiretroviral therapy
Adults (age 15+ years) living with HIV, 2015 Estimated coverage (%)
Estimate Lower estimate Upper estimate Estimate Lower estimate Upper estimate 
Mexico 115 671 200 000 180 000 210 000 59 54 64
Nicaragua 3228 9700 7400 14 000 33 25 47
Panama 10 065 17 000 15 000 18 000 59 54 65
Paraguay 5324 17 000 12 000 27 000 31 22 48
Peru 36 313 65 000 55 000 78 000 56 47 67
Suriname 2002 3700 3300 4300 54 47 62
Trinidad and Tobago 6589 11 000 10 000 11 000 61 58 65
Uruguay 6000 10 000 8600 12 000 59 51 69
Venezuela (Bolivarian 
Republic of)
62 183 110 000 97 000 110 000 59 54 64
Middle East and North 
Africa
36 000 220 000 150 000 320 000 16 12 24
Algeria 7333 8600 6600 10 000 86 66 >95
Djibouti 1871 8500 5900 12 000 22 15 31
Egypt 2074 11 000 7000 19 000 18 11 31
Iran (Islamic Republic of) 6251 71 000 49 000 120 000 9 6 15
Lebanon 885 2400 2100 2700 37 32 42
Morocco 8437 24 000 20 000 28 000 35 30 41
Omana 1067 ... ... ... ... ... ...
Somalia 2198 27 000 18 000 37 000 8 5 11
Sudan 3994 52 000 30 000 85 000 8 4 12
Tunisia 714 2600 1700 3700 28 19 40
Yemen 1215 8800 5400 15 000 14 9 24
Western and central 
Africa
1 731 000 6 000 000 4 900 000 7 300 000 29 24 35
Benin 31 757 64 000 51 000 85 000 49 39 65
Burkina Faso 49 955 88 000 72 000 110 000 57 47 69
Burundi 39 515 68 000 53 000 82 000 58 45 70
Cameroon 161 153 580 000 520 000 650 000 28 25 31
Cape Verde 1290 3100 2600 3800 42 35 51
 Central African 
Republic
25 900 110 000 95 000 120 000 24 21 27
Chad 55 784 150 000 120 000 190 000 38 30 48
Congoa ... ... ... ... ... ... ...
Côte d'Ivoire 154 228 440 000 370 000 500 000 35 30 41
Democratic Republic of 
the Congo
113 083 330 000 260 000 410 000 34 27 42
Equatorial Guinea 8264 25 000 23 000 27 000 33 30 36
Gabon 25 662 44 000 37 000 51 000 58 49 68
Gambia 4584 19 000 15 000 22 000 25 20 29
Ghana 89 113 260 000 210 000 300 000 35 29 41
Guinea 31 993 110 000 93 000 130 000 29 25 34
Guinea-Bissaua ... ... ... ... ... ... ...
Liberia 7002 26 000 22 000 31 000 27 22 32
Mali 32 309 110 000 94 000 140 000 29 24 35
Mauritania 2301 12 000 7600 19 000 19 11 28
Niger 11 965 43 000 38 000 49 000 28 24 32
6. Estimated percentage of adults (age 15+ years) living with HIV receiving antiretroviral 
therapy, 2015
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Number of adults 
(age 15+ years) living 
with HIV receiving 
antiretroviral therapy
Adults (age 15+ years) living with HIV, 2015 Estimated coverage (%)
Estimate Lower estimate Upper estimate Estimate Lower estimate Upper estimate 
Nigeria 785 212 3 200 000 2 400 000 4 200 000 25 19 32
Senegal 17 192 41 000 34 000 50 000 42 35 52
Sierra Leone 13 466 47 000 40 000 54 000 29 24 33
Togo 40 545 97 000 84 000 110 000 42 36 49
Western and central 
Europe and North 
America
1 414 000 2 400 000 2 200 000 2 700 000 59 54 66
Austriaa ... ... ... ... ... ... ...
Belgiuma ... ... ... ... ... ... ...
Bulgariaa 819 ... ... ... ... ... ...
Canadaa ... ... ... ... ... ... ...
Croatiaa 921 ... ... ... ... ... ...
Cyprusa ... ... ... ... ... ... ...
Czech Republica ... ... ... ... ... ... ...
Denmarka ... ... ... ... ... ... ...
Estoniaa ... ... ... ... ... ... ...
Finlanda ... ... ... ... ... ... ...
Francea ... ... ... ... ... ... ...
Germanya ... ... ... ... ... ... ...
Greecec ... 16 000 15 000 18 000 ... ... ...
Hungarya ... ... ... ... ... ... ...
Icelanda ... ... ... ... ... ... ...
Irelanda ... ... ... ... ... ... ...
Israela ... ... ... ... ... ... ...
Italyc ... 140 000 120 000 150 000 ... ... ...
Latvia 1352 6800 6100 7700 20 18 22
Lithuaniaa 561 ... ... ... ... ... ...
Luxembourga 698 ... ... ... ... ... ...
Maltaa ... ... ... ... ... ... ...
Netherlandsa ... ... ... ... ... ... ...
Norwaya ... ... ... ... ... ... ...
Polanda ... ... ... ... ... ... ...
Portugala ... ... ... ... ... ... ...
Romaniaa 10 308 ... ... ... ... ... ...
Serbiaa 1389 ... ... ... ... ... ...
Slovakiaa ... ... ... ... ... ... ...
Sloveniaa ... ... ... ... ... ... ...
Spain 109 600 150 000 130 000 180 000 74 62 87
Swedena ... ... ... ... ... ... ...
Switzerlanda ... ... ... ... ... ... ...
Turkeya ... ... ... ... ... ... ...
United Kingdoma ... ... ... ... ... ... ...
United States of 
Americaa
... ... ... ... ... ... ...
Global 16 200 000 34 900 000 32 400 000 37 900 000 46 43 50
a Estimates were unavailable at the time of publication.
b Some estimates were unavailable at the time of publication.
c The estimates for children are not published because of small numbers. 
6. Estimated percentage of adults (age 15+ years) living with HIV receiving antiretroviral 
therapy, 2015
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7. Estimated percentage of children (age 0–14 years) living with HIV receiving antiretroviral 
therapy, 2015
Number of  children 
(age 0–14 years) living 
with HIV receiving 
antiretroviral therapy
 Children (age 0–14 years) living with HIV, 2015 Estimated coverage (%)
Estimate Lower estimate Upper estimate Estimate Lower estimate Upper estimate 
Asia and the Pacific 78 700 190 000 140 000 250 000 41 30 52
Afghanistan 26 <500 <200 <500 11 6 21
Australia 19 <100 <100 <100 90 73 >95
Bangladesh 90 <500 <500 <500 31 26 35
Bhutana ... ... ... ... ... ... ...
Brunei Darussalama ... ... ... ... ... ... ...
Cambodiad ... ... ... ... ... ... ...
Chinaa ... ... ... ... ... ... ...
Democratic People's 
Republic of Koreaa
... ... ... ... ... ... ...
Fijia 4 ... ... ... ... ... ...
Indiab 50 976 … … … … … …
Indonesia 2708 17 000 14 000 20 000 16 13 18
Japana ... ... ... ... ... ... ...
Lao People's 
Democratic Republica
222 ... ... ... ... ... ...
Malaysia 487 <500 <500 <1000 >95 91 >95
Maldivesa 0 ... ... ... ... ... ...
Mongolia 0 <100 <100 <100 0 0 0
Myanmar 7086 9500 8000 11 000 75 63 86
Nepal 893 1600 1300 1800 58 49 67
New Zealanda ... ... ... ... ... ... ...
Pakistan 131 2500 1900 3900 5 4 8
Papua New Guinea 1170 3300 3000 3600 36 33 39
Philippines 41 <500 <500 <1000 10 8 16
Republic of Koreaa ... ... ... ... ... ... ...
Singaporea 0 ... ... ... ... ... ...
Sri Lanka 36 <100 <100 <200 46 32 66
Thailand 3813 4100 3500 4800 >95 89 >95
Timor-Lestea ... ... ... ... ... ... ...
 Viet Nam 4865 4900 3900 6100 >95 80 >95
Eastern and southern 
Africa
658 200 1 000 000 930 000 1 200 000 63 56 71
Angola 6032 25 000 17 000 37 000 24 16 34
Botswana 8490 8500 7300 10 000 >95 85 >95
Eritrea 470 1400 <1000 1800 35 25 47
Ethiopiaa 22 009 ... ... ... ... ... ...
Kenya 71 547 98 000 81 000 120 000 73 60 88
Lesotho 7466 13 000 12 000 14 000 56 51 61
Madagascar 16 3800 3300 4400 0 0 0
Malawi 51 487 84 000 75 000 92 000 61 55 68
Mauritiusc 23 ... ... ... ... ... ...
Mozambique 64 273 110 000 81 000 160 000 57 41 80
Namibia 10 010 10 000 9400 11 000 >95 86 >95
Rwanda 8266 11 000 9200 13 000 74 61 86
South Africa 174 891 240 000 210 000 260 000 74 68 82
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7. Estimated percentage of children (age 0–14 years) living with HIV receiving antiretroviral 
therapy, 2015
Number of  children 
(age 0–14 years) living 
with HIV receiving 
antiretroviral therapy
 Children (age 0–14 years) living with HIV, 2015 Estimated coverage (%)
Estimate Lower estimate Upper estimate Estimate Lower estimate Upper estimate 
South Sudan 728 14 000 9200 19 000 5 3 7
Swaziland 8063 10 000 9700 11 000 78 74 84
Uganda 60 029 96 000 84 000 110 000 63 55 71
United Republic of 
Tanzania
51 474 91 000 77 000 110 000 56 47 65
Zambia 51 903 85 000 77 000 94 000 61 55 67
Zimbabwe 61 064 77 000 68 000 86 000 80 70 89
Eastern Europe and 
central Asiaa
... ... ... ... ... ... ...
Albaniaa 16 ... ... ... ... ... ...
Armeniac 24 ... ... ... ... ... ...
Azerbaijan 73 <100 <100 <200 83 52 >95
Belarus 218 <500 <100 <500 94 34 >95
Bosnia and 
Herzegovinaa
1 ... ... ... ... ... ...
Georgia 53 <100 <100 <100 >95 >95 >95
Kazakhstan 379 <500 <200 <500 >95 >95 >95
Kyrgyzstand 387 <200 <200 <200 >95 >95 >95
Montenegroa 2 ... ... ... ... ... ...
Republic of Moldova 106 <200 <100 <500 75 52 >95
Russian Federationa ... ... ... ... ... ... ...
Tajikistan 501 <500 <500 <500 >95 >95 >95
The former Yugoslav 
Republic of Macedoniaa
... ... ... ... ... ... ...
Ukraine 2415 3200 2600 4000 75 61 93
Uzbekistan 4575 <1000 <500 1000 >95 >95 >95
Latin America and the 
Caribbean
20 400 32 000 27 000 38 000 64 54 76
Argentina 1597 <1000 <1000 <1000 >95 >95 >95
Bahamas 49 <100 <100 <100 89 78 >95
Barbadosc 8 ... ... ... ... ... ...
Belize 90 <200 <100 <200 80 62 >95
Bolivia (Plurinational 
State of)
173 <500 <500 <1000 48 29 72
Brazil 5657 7500 6000 11 000 76 61 >95
Chilec 144 ... ... ... ... ... ...
Colombiae ... 1400 1300 1600 ... ... ...
Costa Rica 65 <200 <200 <200 53 48 59
Cuba 29 <100 <100 <100 >95 83 >95
Dominican Republic 809 2100 1400 3300 39 27 61
Ecuador 670 <500 <500 <1000 >95 >95 >95
El Salvador 273 <500 <500 <500 78 70 84
Guatemala 856 2000 1400 2900 44 32 64
Guyana 157 <200 <200 <500 >95 85 >95
Haiti 2865 9500 7600 12 000 30 24 37
Honduras 573 <1000 <1000 <1000 74 59 91
Jamaica 666 <500 <500 <500 >95 >95 >95
Mexico 1960 1800 1600 2100 >95 95 >95
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Number of  children 
(age 0–14 years) living 
with HIV receiving 
antiretroviral therapy
 Children (age 0–14 years) living with HIV, 2015 Estimated coverage (%)
Estimate Lower estimate Upper estimate Estimate Lower estimate Upper estimate 
Nicaragua 122 <200 <200 <500 69 47 >95
Panama 162 <200 <200 <500 92 75 >95
Paraguay 175 <500 <200 <1000 58 35 >95
Peru 888 1100 <1000 1400 84 62 >95
Suriname 74 <100 <100 <100 >95 89 >95
Trinidad and Tobago 131 <100 <100 <100 >95 >95 >95
Uruguay 113 <100 <100 <100 >95 >95 >95
Venezuela (Bolivarian 
Republic of)
1145 2100 1900 2300 55 50 61
Middle East and North 
Africa
2200 11 000 8600 14 000 20 16 25
Algeria 582 <500 <200 <500 >95 >95 >95
Djibouti 74 <1000 <1000 1300 8 6 12
Egypt 73 <500 <200 <500 27 18 43
Iran (Islamic Republic of) 233 1900 1400 2800 12 9 18
Lebanonc 5 ... ... ... ... ... ...
Morocco 489 <500 <500 <1000 >95 82 >95
Omana 31 ... ... ... ... ... ...
Somalia 112 3100 2400 4000 4 3 5
Sudan 394 3500 2800 4500 11 9 15
Tunisiac 20 ... ... ... ... ... ...
Yemen 140 <500 <500 <1000 32 21 50
Western and central 
Africa
99 300 500 000 400 000 630 000 20 16 25
Benin 1845 4800 3500 6400 39 29 52
Burkina Faso 2349 7700 6000 9600 31 24 38
Burundi 2654 9100 7400 11 000 29 24 34
Cameroon 7096 39 000 34 000 44 000 18 16 21
Cape Verde 65 <200 <200 <200 47 38 62
Central African Republic 2403 9400 8500 10 000 25 23 28
Chad 3838 18 000 14 000 22 000 22 17 27
Congoa ... ... ... ... ... ... ...
Côte d'Ivoire 6945 29 000 24 000 34 000 24 20 28
Democratic Republic of 
the Congo
9185 42 000 34 000 51 000 22 18 27
Equatorial Guinea 245 2400 2200 2600 10 9 11
Gabon 1375 2600 2200 3100 52 44 60
Gambia 438 1800 1500 2300 24 19 30
Ghana 4934 19 000 15 000 22 000 27 22 32
Guinea 1532 7000 6000 8000 22 19 25
Guinea-Bissaua ... ... ... ... ... ... ...
Liberia 389 3900 3400 4400 10 9 11
Mali 2665 12 000 9900 14 000 23 19 27
Mauritania 157 1300 <1000 1600 13 10 16
Niger 922 5900 5100 6800 16 13 18
Nigeria 43 655 260 000 190 000 360 000 17 12 23
Senegal 1183 4800 4000 5700 25 21 30
7. Estimated percentage of children (age 0–14 years) living with HIV receiving antiretroviral 
therapy, 2015
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Number of  children 
(age 0–14 years) living 
with HIV receiving 
antiretroviral therapy
 Children (age 0–14 years) living with HIV, 2015 Estimated coverage (%)
Estimate Lower estimate Upper estimate Estimate Lower estimate Upper estimate 
Sierra Leone 575 4400 3800 5000 13 11 15
Togo 3058 9000 7600 11 000 34 29 41
Western and central 
Europe and North 
Americaa
... ... ... ... ... ... ...
Austriaa ... ... ... ... ... ... ...
Belgiuma ... ... ... ... ... ... ...
Bulgariaa 5 ... ... ... ... ... ...
Canadaa ... ... ... ... ... ... ...
Croatiaa 3 ... ... ... ... ... ...
Cyprusa ... ... ... ... ... ... ...
Czech Republica ... ... ... ... ... ... ...
Denmarka ... ... ... ... ... ... ...
Estoniaa ... ... ... ... ... ... ...
Finlanda ... ... ... ... ... ... ...
Francea ... ... ... ... ... ... ...
Germanya ... ... ... ... ... ... ...
Greecee ... <100 <100 <100 ... ... ...
Hungarya ... ... ... ... ... ... ...
Icelanda ... ... ... ... ... ... ...
Irelanda ... ... ... ... ... ... ...
Israela ... ... ... ... ... ... ...
Italye ... 1400 1100 1600 ... ... ...
Latvia 36 <100 <100 <100 >95 >95 >95
Lithuaniaa 5 ... ... ... ... ... ...
Luxembourga 2 ... ... ... ... ... ...
Maltaa ... ... ... ... ... ... ...
Netherlandsa ... ... ... ... ... ... ...
Norwaya ... ... ... ... ... ... ...
Polanda ... ... ... ... ... ... ...
Portugala ... ... ... ... ... ... ...
Romaniaa 243 ... ... ... ... ... ...
Serbiaa 11 ... ... ... ... ... ...
Slovakiaa ... ... ... ... ... ... ...
Sloveniaa ... ... ... ... ... ... ...
Spain 400 <100 <100 <100 >95 >95 >95
Swedena ... ... ... ... ... ... ...
Switzerlanda ... ... ... ... ... ... ...
Turkeya ... ... ... ... ... ... ...
United Kingdoma ... ... ... ... ... ... ...
United States of 
Americaa
... ... ... ... ... ... ...
Global 872 500 1 800 000 1 500 000 2 000 000 49 42 55
7. Estimated percentage of children (age 0–14 years) living with HIV receiving antiretroviral 
therapy, 2015
a Estimates were unavailable at the time of publication.
b Some estimates were unavailable at the time of publication.
c The estimates for children are not published because of small numbers. 
d The estimates for children are not published.
e Antiretroviral therapy data were not available at the time of publication.
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8. Estimated percentage of women and men (15+ years) living with HIV receiving antiretroviral 
therapy
2010 2015
Estimate Lower estimate Upper estimate Estimate Lower estimate Upper estimate 
Asia and the Pacific 47 41 54 37 32 44
Afghanistan 5 3 13 5 3 11
Australia 90 81 >95 90 82 >95
Bangladesh 18 15 20 14 12 16
Bhutana ... ... ... ... ... ...
Brunei Darussalama ... ... ... ... ... ...
Cambodia 75 69 83 70 64 78
Chinaa ... ... ... ... ... ...
Democratic People's 
Republic of Koreaa
... ... ... ... ... ...
Fijia ... ... ... ... ... ...
Indiab 51 42 62 39 32 49
Indonesia 9 8 10 9 8 10
Japana ... ... ... ... ... ...
Lao People's Democratic 
Republica
... ... ... ... ... ...
Malaysia 56 51 62 23 20 27
Maldivesa ... ... ... ... ... ...
Mongolia 39 30 48 35 27 44
Myanmar 59 52 68 39 34 45
Nepal 41 36 47 22 19 26
New Zealanda ... ... ... ... ... ...
Pakistan 6 5 10 6 5 10
Papua New Guinea 57 51 63 51 46 56
Philippines 9 7 23 32 23 94
Republic of Koreaa ... ... ... ... ... ...
Singaporea ... ... ... ... ... ...
Sri Lanka 21 15 33 18 12 28
Thailand 74 68 81 57 53 63
Timor-Lestea ... ... ... ... ... ...
 Viet Nam 45 41 51 38 34 43
Eastern and southern 
Africa
59 55 64 44 41 48
Angola 33 23 45 24 17 33
Botswana 85 80 91 67 63 72
Eritrea 55 44 72 75 60 >95
Ethiopiaa ... ... ... ... ... ...
Kenya 68 57 79 44 37 52
Lesotho 45 41 49 36 33 39
Madagascar 4 3 4 2 2 3
Malawi 67 62 72 52 48 57
Mauritius 26 22 31 32 27 38
Mozambique 63 51 76 39 31 47
Namibia 71 66 78 61 56 66
Rwanda 84 74 93 71 63 79
South Africa 53 50 57 40 38 42
South Sudan 14 9 19 7 5 10
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8. Estimated percentage of women and men (15+ years) living with HIV receiving antiretroviral 
therapy
2010 2015
Estimate Lower estimate Upper estimate Estimate Lower estimate Upper estimate 
Swaziland 74 69 80 56 52 61
Uganda 65 60 71 45 42 49
United Republic of 
Tanzania
62 55 69 40 36 45
Zambia 67 63 72 56 54 60
Zimbabwe 65 59 70 54 49 59
Eastern Europe and 
central Asia
26 24 28 18 17 19
Albaniaa ... ... ... ... ... ...
Armenia 47 38 63 20 16 27
Azerbaijan 27 19 37 28 20 39
Belarus 21 17 26 19 16 23
Bosnia and Herzegovinaa ... ... ... ... ... ...
Georgia 46 37 57 27 22 34
Kazakhstan 35 30 42 21 18 25
Kyrgyzstan 30 24 39 17 14 22
Montenegroa ... ... ... ... ... ...
Republic of Moldova 33 28 39 15 13 18
Russian Federationa ... ... ... ... ... ...
Tajikistan 23 19 29 13 10 16
The former Yugoslav 
Republic of Macedoniaa
... ... ... ... ... ...
Ukraine 29 25 34 25 22 29
Uzbekistan 51 38 70 17 12 24
Latin America and the 
Caribbean
58 49 68 54 46 62
Argentina 76 71 83 57 52 63
Bahamas 42 39 45 34 31 37
Barbados 60 55 65 36 33 39
Belize 47 42 53 43 38 48
Bolivia (Plurinational 
State of)
33 21 45 26 16 36
Brazil 58 43 77 54 40 72
Chile >95 >95 >95 75 51 >95
Colombiac ... ... ... ... ... ...
Costa Rica 36 33 39 64 57 71
Cuba 56 50 62 73 62 80
Dominican Republic 53 43 71 40 31 54
Ecuador 66 53 80 46 36 55
El Salvador 60 55 65 51 46 56
Guatemala 32 22 47 28 20 41
Guyana 63 58 71 52 48 58
Haiti 57 48 69 47 40 57
Honduras 59 51 68 45 38 53
Jamaica 43 37 49 24 21 28
Mexico 58 54 63 59 54 64
Nicaragua 47 36 68 28 22 41
Panama 59 55 63 60 55 65
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2010 2015
Estimate Lower estimate Upper estimate Estimate Lower estimate Upper estimate 
Paraguay 37 27 57 29 20 44
Peru 69 58 83 50 43 60
Suriname 52 46 61 55 48 64
Trinidad and Tobago 66 62 70 57 54 60
Uruguay 78 67 92 53 45 62
Venezuela (Bolivarian 
Republic of)
40 37 43 69 64 75
Middle East and North 
Africa
18 13 26 15 11 23
Algeria >95 75 >95 77 59 93
Djibouti 21 15 30 23 16 33
Egypt 16 10 26 20 12 33
Iran (Islamic Republic of) 7 5 12 10 7 17
Lebanon 32 29 36 38 33 43
Morocco 52 45 60 26 22 30
Omana ... ... ... ... ... ...
Somalia 9 6 13 7 4 9
Sudan 7 4 12 8 4 13
Tunisia 38 26 55 23 16 34
Yemen 13 8 23 14 9 25
Western and central 
Africa
34 28 42 22 18 26
Benin 49 39 65 50 39 66
Burkina Faso 66 55 81 42 35 51
Burundi 65 51 78 48 37 58
Cameroon 33 30 37 20 18 22
Cape Verde 43 36 52 40 34 49
Central African Republic 23 20 26 25 22 28
Chad 40 33 51 34 27 44
Congoa ... ... ... ... ... ...
Côte d'Ivoire 44 38 50 23 20 27
Democratic Republic of 
the Congo
40 31 49 25 20 31
Equatorial Guinea 45 41 49 17 16 19
Gabon 57 48 68 60 51 70
Gambia 30 25 36 16 13 20
Ghana 39 33 46 29 24 34
Guinea 32 27 38 24 20 28
Guinea-Bissaua ... ... ... ... ... ...
Liberia 30 25 36 21 17 25
Mali 34 29 41 21 18 26
Mauritania 19 12 29 18 11 28
Niger 35 31 39 20 18 23
Nigeria 30 22 39 17 13 23
Senegal 45 38 55 36 30 45
Sierra Leone 34 29 39 20 17 23
Togo 49 42 57 31 27 36
8. Estimated percentage of women and men (15+ years) living with HIV receiving antiretroviral 
therapy
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2010 2015
Estimate Lower estimate Upper estimate Estimate Lower estimate Upper estimate 
Western and central 
Europe and North 
America
61 55 69 59 53 65
Austriaa ... ... ... ... ... ...
Belgiuma ... ... ... ... ... ...
Bulgariaa ... ... ... ... ... ...
Canadaa ... ... ... ... ... ...
Croatiaa ... ... ... ... ... ...
Cyprusa ... ... ... ... ... ...
Czech Republica ... ... ... ... ... ...
Denmarka ... ... ... ... ... ...
Estoniaa ... ... ... ... ... ...
Finlanda ... ... ... ... ... ...
Francea ... ... ... ... ... ...
Germanya ... ... ... ... ... ...
Greecec ... ... ... ... ... ...
Hungarya ... ... ... ... ... ...
Icelanda ... ... ... ... ... ...
Irelanda ... ... ... ... ... ...
Israela ... ... ... ... ... ...
Italyc ... ... ... ... ... ...
Latvia 20 17 22 20 18 22
Lithuaniaa ... ... ... ... ... ...
Luxembourga ... ... ... ... ... ...
Maltaa ... ... ... ... ... ...
Netherlandsa ... ... ... ... ... ...
Norwaya ... ... ... ... ... ...
Polanda ... ... ... ... ... ...
Portugala ... ... ... ... ... ...
Romaniaa ... ... ... ... ... ...
Serbiaa ... ... ... ... ... ...
Slovakiaa ... ... ... ... ... ...
Sloveniaa ... ... ... ... ... ...
Spain 74 61 89 74 62 87
Swedena ... ... ... ... ... ...
Switzerlanda ... ... ... ... ... ...
Turkeya ... ... ... ... ... ...
United Kingdoma ... ... ... ... ... ...
United States of 
Americaa
... ... ... ... ... ...
Global 52 48 57 40 37 44
8. Estimated percentage of women and men (15+ years) living with HIV receiving antiretroviral 
therapy
a Estimates were unavailable at the time of publication.
b Some estimates were unavailable at the time of publication.
c The estimates for children are not published because of small numbers. 
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Donor 2010 2011 2012 2013 2014 2015
Asia and the Pacific
Afghanistan
Global Fund  2 148 734  1 462 669  2 185 368  2 055 495  1 988 748  120 285 
PEPFAR  a  a  a  a  b  b 
Total bilateral and 
multilateral disbursements
 6 791 728  4 454 982  4 550 199  2 380 094  2 183 508  b 
Bangladesh
Global Fund  10 828 843  13 454 642  6 278 255  15 533 268  12 617 234  9 281 275 
PEPFAR  a  a  a  a  b  b 
Total bilateral and 
multilateral disbursements
 16 486 926  20 461 079  12 097 445  20 656 403  16 813 541  b 
Cambodia
Global Fund  15 188 097  38 011 480  7 168 485  19 896 780  24 399 178  14 472 482 
PEPFAR  a  a  a  a  11 376 758  13 715 250 
Total bilateral and 
multilateral disbursements
 41 618 606  66 703 078  30 317 409  35 583 522  40 941 761  b 
China
Global Fund  5 226 659  27 494 678  65 850 097  b  b  b 
PEPFAR  a  a  a  a  1 343 978  2 326 965 
Total bilateral and 
multilateral disbursements
 58 038 337  83 949 932  84 298 511  19 102 425  4 998 066  b 
Fiji
Global Fund  b  b  b  b  b  b 
PEPFAR  a  a  a  a  b  b 
Total bilateral and 
multilateral disbursements
 583 941  727 836  1 524 504  1 051 897  485 790  b 
India
Global Fund  114 688 269  126 025 279  144 437 206  168 643 823  54 063 937  139 034 722 
PEPFAR  a  a  a  a  24 545 854  21 047 803 
Total bilateral and 
multilateral disbursements
 225 831 542  312 572 610  202 335 515  249 245 652  100 941 701  b 
Indonesia
Global Fund  25 881 085  32 066 012  19 726 545  38 594 494  18 369 789  18 070 601 
PEPFAR  a  a  a  a  8 638 353  7 568 393 
Total bilateral and 
multilateral disbursements
 43 635 341  58 454 293  59 749 467  66 228 653  46 858 908  b 
Kiribati
Global Fund  b  b  b  b  b  b 
PEPFAR  a  a  a  a  b  b 
Total bilateral and 
multilateral disbursements
 b  b  b 6476  b  b 
Lao People's 
Democratic Republic
Global Fund  3 149 970  7 712 314  3 576 231  6 422 269  4 652 176  2 416 390 
PEPFAR  a  a  a  a  b  b 
Total bilateral and 
multilateral disbursements
 6 395 375  10 954 882  5 965 593  9 193 335  7 534 799  b 
Malaysia
Global Fund     1 333 367  1 421 411  2 049 553  2 739 557  1 110 397 
PEPFAR  a  a  a  a  b  b 
Total bilateral and 
multilateral disbursements
 64 201  1 374 442  1 544 143  5 447 609  2 776 044  b 
Marshall Islands
Global Fund  b  b  b  b  b  b 
PEPFAR  a  a  a  a  b  b 
Total bilateral and 
multilateral disbursements
 b  b  b  b  984 000  b 
International assistance for the AIDS response in low- and middle-income countries as reported 
by donors, 2010–2015 
The table contains the international financial assistance for the AIDS response in US dollars provided annually to low- and middle-income countries as reported by 
bilateral and multilateral entities. International assistance reported by the Global Fund to Fight AIDS, Tuberculosis and Malaria and the United States President’s 
Emergency Plan for AIDS Relief (PEPFAR) are presented separately. Total disbursements by bilateral and multilateral entities are the amounts they reported to the 
Organisation for Economic Co-operation and Development (OECD) under two AIDS categories. These totals may omit disbursements for HIV-related services within 
grants that cover broader health and development work. Discrepancies between the disbursements reported by different sources may be due to variation in financial 
years and the underlying reporting methods and standards. 
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Donor 2010 2011 2012 2013 2014 2015
Micronesia  
(Federated States of)
Global Fund  b  b  b  b  b  b 
PEPFAR  a  a  a  a  b  b 
Total bilateral and 
multilateral disbursements
 b  b  b  b  17 680  b 
Mongolia
Global Fund  1 867 235  661 581  1 323 685  826 295  845 708  2 081 375 
PEPFAR  a  a  a  a  b  b 
Total bilateral and 
multilateral disbursements
 4 239 746  873 274  1 346 514  860 820  906 945  b 
Myanmar
Global Fund  15 281 620  6 642 873  21 951 886  46 483 647  35 120 662  21 122 035 
PEPFAR  a  a  a  a  3 571 642  4 833 024 
Total bilateral and 
multilateral disbursements
 25 985 231  23 287 006  30 278 059  56 846 793  40 613 012  b 
Nauru
Global Fund  b  b  b  b  b  b 
PEPFAR  a  a  a  a  b  b 
Total bilateral and 
multilateral disbursements
 b  b  b  b  b  b 
Nepal
Global Fund  3 436 598  5 900 232  10 872 417  10 588 046  6 400 232  9 672 103 
PEPFAR  a  a  a  a  b  b 
Total bilateral and 
multilateral disbursements
 17 300 476  22 880 248  21 729 231  26 658 307  20 923 940  b 
Pakistan
Global Fund  b  2 820 559  3 470 399  6 131 242  3 080 328  8 982 268 
PEPFAR  a  a  a  a  b  b 
Total bilateral and 
multilateral disbursements
 4 657 788  15 633 815  5 845 002  4 768 943  8 132 736  b 
Palau
Global Fund  b  b  b  b  b  b 
PEPFAR  a  a  a  a  b  b 
Total bilateral and 
multilateral disbursements
 b  b  b  b  b  b 
Papua New Guinea
Global Fund  b  b  6 357 282  6 854 227  2 513 803  1 781 634 
PEPFAR  a  a  a  a  5 069 390  4 134 699 
Total bilateral and 
multilateral disbursements
 39 282 829  47 205 714  71 625 772  75 385 653  81 944 956  b 
Philippines
Global Fund  3 987 421  1 100 816  5 713 849  1 174 069  1 783 496  2 408 266 
PEPFAR  a  a  a  a  b  b 
Total bilateral and 
multilateral disbursements
 5 559 520  2 980 175  7 822 513  2 108 555  3 183 817  b 
Samoa
Global Fund  b  b  b  b  b  b 
PEPFAR  a  a  a  a  b  b 
Total bilateral and 
multilateral disbursements
2095  75 521  b  b  44 790  b 
Solomon Islands
Global Fund  b  b  b  b  b  b 
PEPFAR  a  a  a  a  b  b 
Total bilateral and 
multilateral disbursements
 54 936  b  45 592  b  200 000  b 
International assistance for the AIDS response in low- and middle-income countries as reported 
by donors, 2010–2015 
The table contains the international financial assistance for the AIDS response in US dollars provided annually to low- and middle-income countries as reported by 
bilateral and multilateral entities. International assistance reported by the Global Fund to Fight AIDS, Tuberculosis and Malaria and the United States President’s 
Emergency Plan for AIDS Relief (PEPFAR) are presented separately. Total disbursements by bilateral and multilateral entities are the amounts they reported to the 
Organisation for Economic Co-operation and Development (OECD) under two AIDS categories. These totals may omit disbursements for HIV-related services within 
grants that cover broader health and development work. Discrepancies between the disbursements reported by different sources may be due to variation in financial 
years and the underlying reporting methods and standards. 
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Donor 2010 2011 2012 2013 2014 2015
Sri Lanka
Global Fund  355 522  1 087 445  1 462 623  2 016 229  1 063 445  1 021 467 
PEPFAR  a  a  a  a  b  b 
Total bilateral and 
multilateral disbursements
 1 178 416  4 134 917  2 333 556  4 600 454  1 229 795  b 
Thailand
Global Fund  30 784 549  35 727 916  16 813 436  31 309 001  23 318 693  17 911 402 
PEPFAR  a  a  a  a  9 566 163  12 810 056 
Total bilateral and 
multilateral disbursements
 41 723 751  48 809 500  24 142 415  38 105 395  25 700 573  b 
Timor-Leste
Global Fund  1 403 905  1 587 672  2 914 706  1 450 924  3 136 373  620 909 
PEPFAR  a  a  a  a  b  b 
Total bilateral and 
multilateral disbursements
 1 571 565  1 592 562  3 230 105  1 740 822  3 561 806  b 
Tonga
Global Fund  b  b  b  b  b  b 
PEPFAR  a  a  a  a  b  b 
Total bilateral and 
multilateral disbursements
 b  b  b  b  b  b 
Tuvalu
Global Fund  b  b  b  b  b  b 
PEPFAR  a  a  a  a  b  b 
Total bilateral and 
multilateral disbursements
 b  b  b  b  b  b 
Vanuatu
Global Fund  b  b  b  b  b  b 
PEPFAR  a  a  a  a  b  b 
Total bilateral and 
multilateral disbursements
 461 207  2 519 003  2 717 418  3 416 005  673 952  b 
Viet Nam
Global Fund  3 767 635  21 003 681  17 825 251  27 477 324  10 697 000  16 886 080 
PEPFAR  a  a  a  a  55 184 197  54 439 507 
Total bilateral and 
multilateral disbursements
 90 094 243  124 252 938  88 843 058  90 791 042  63 147 051  b 
Eastern and southern 
Africa
Angola
Global Fund  12 562 039  3 787 437  3 272 516  11 408 657     2 547 131 
PEPFAR  a  a  a  a  b  b 
Total bilateral and 
multilateral disbursements
 24 882 818  21 823 335  21 082 779  33 379 283  15 705 810  b 
Botswana
Global Fund  b  b  b  b  b  b 
PEPFAR  a  a  a  a  53 580 483  52 284 175 
Total bilateral and 
multilateral disbursements
 73 920 684  71 936 054  60 403 897  72 552 802  52 615 657  b 
Comoros
Global Fund  416 854  904 555  716 258  339 961  505 131  300 098 
PEPFAR  a  a  a  a  b  b 
Total bilateral and 
multilateral disbursements
 466 649  969 687  705 625  510 453  624 540  b 
Eritrea
Global Fund  16 581 281  6 862 092  17 629 496  11 148 902  18 876 114  3 190 836 
PEPFAR  a  a  a  a  b  b 
Total bilateral and 
multilateral disbursements
 19 492 980  8 298 453  18 106 707  11 749 080  19 200 793  b 
International assistance for the AIDS response in low- and middle-income countries as reported 
by donors, 2010–2015 
The table contains the international financial assistance for the AIDS response in US dollars provided annually to low- and middle-income countries as reported by 
bilateral and multilateral entities. International assistance reported by the Global Fund to Fight AIDS, Tuberculosis and Malaria and the United States President’s 
Emergency Plan for AIDS Relief (PEPFAR) are presented separately. Total disbursements by bilateral and multilateral entities are the amounts they reported to the 
Organisation for Economic Co-operation and Development (OECD) under two AIDS categories. These totals may omit disbursements for HIV-related services within 
grants that cover broader health and development work. Discrepancies between the disbursements reported by different sources may be due to variation in financial 
years and the underlying reporting methods and standards. 
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Donor 2010 2011 2012 2013 2014 2015
Ethiopia
Global Fund  215 714 813  132 686 767  48 194 656  128 167 098  83 080 302  89 667 925 
PEPFAR  a  a  a  a  176 534 730  172 380 546 
Total bilateral and 
multilateral disbursements
 467 600 139  389 278 246  305 394 339  370 239 973  284 659 309  b 
Kenya
Global Fund  24 888 872  5 924 903  58 860 080  72 296 655  61 114 348  96 966 592 
PEPFAR  a  a  a  a  440 328 935  452 443 970 
Total bilateral and 
multilateral disbursements
 404 062 935  458 674 403  572 802 760  626 132 472  510 108 030  b 
Lesotho
Global Fund  21 183 169  19 318 443  20 481 647  22 194 600  11 724 007  17 240 397 
PEPFAR  a  a  a  a  31 143 203  30 024 410 
Total bilateral and 
multilateral disbursements
 56 101 111  61 821 432  68 454 862  58 153 452  46 691 978  b 
Madagascar
Global Fund  4 101 619  860 398  2 236 364  2 701 830  2 657 223  2 401 661 
PEPFAR  a  a  a  a  b  b 
Total bilateral and 
multilateral disbursements
 11 141 296  8 680 674  7 933 867  7 150 274  3 849 822  b 
Malawi
Global Fund  44 326 129  55 055 304  67 566 143  58 452 885  72 347 383  94 860 201 
PEPFAR  a  a  a  a  72 668 869  76 418 564 
Total bilateral and 
multilateral disbursements
 125 948 922  140 113 794  163 048 374  149 833 676  156 758 733  b 
Mauritius
Global Fund  2 157 350  1 305 621  1 809 891  1 692 696  1 741 557  336 738 
PEPFAR  a  a  a  a  b  b 
Total bilateral and 
multilateral disbursements
 2 133 202  1 520 317  1 771 809  1 738 892  1 848 567  b 
Mozambique
Global Fund  53 247 835  3 726 604  42 099 041  9 489 862  56 321 398  73 839 562 
PEPFAR  a  a  a  a  297 968 209  265 707 269 
Total bilateral and 
multilateral disbursements
 251 163 910  247 333 703  259 673 425  259 070 540  312 735 693  b 
Namibia
Global Fund  28 283 249  6 659 406  30 448 548  13 847 781  12 241 871  7 785 182 
PEPFAR  a  a  a  a  58 168 020  49 788 008 
Total bilateral and 
multilateral disbursements
 123 307 253  89 836 254  118 117 013  92 003 459  78 772 186  b 
Rwanda
Global Fund  105 057 292  99 578 064  110 640 732  77 211 192  109 916 064  83 081 276 
PEPFAR  a  a  a  a  106 705 116  89 468 785 
Total bilateral and 
multilateral disbursements
 202 815 055  208 874 084  198 935 526  147 456 704  190 398 891  b 
Seychelles
Global Fund  b  b  b  b  b  b 
PEPFAR  a  a  a  a  b  b 
Total bilateral and 
multilateral disbursements
 31 340    243        b 
South Africa
Global Fund  43 645 114  19 014 188  101 829 264  88 530 866  91 156 196  99 374 402 
PEPFAR  a  a  a  a  420 974 849  390 487 953 
Total bilateral and 
multilateral disbursements
 572 817 195  591 367 076  602 325 601  559 771 968  590 150 248  b 
International assistance for the AIDS response in low- and middle-income countries as reported 
by donors, 2010–2015 
The table contains the international financial assistance for the AIDS response in US dollars provided annually to low- and middle-income countries as reported by 
bilateral and multilateral entities. International assistance reported by the Global Fund to Fight AIDS, Tuberculosis and Malaria and the United States President’s 
Emergency Plan for AIDS Relief (PEPFAR) are presented separately. Total disbursements by bilateral and multilateral entities are the amounts they reported to the 
Organisation for Economic Co-operation and Development (OECD) under two AIDS categories. These totals may omit disbursements for HIV-related services within 
grants that cover broader health and development work. Discrepancies between the disbursements reported by different sources may be due to variation in financial 
years and the underlying reporting methods and standards. 
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Donor 2010 2011 2012 2013 2014 2015
South Sudan
Global Fund  3 341 546  3 854 008  4 896 512  5 612 274  7 042 265  16 531 406 
PEPFAR  a  a  a  a  8 299 805  9 827 135 
Total bilateral and 
multilateral disbursements
 b  11 146 615  20 281 975  29 468 933  16 071 039  b 
Swaziland
Global Fund  34 301 715  12 289 970  3 135 203  18 463 565  1 210 157  7 176 776 
PEPFAR  a  a  a  a  39 572 162  39 795 064 
Total bilateral and 
multilateral disbursements
 57 983 371  60 780 625  46 707 641  57 679 553  45 471 929  b 
Uganda
Global Fund  24 294 101  16 550 863  55 083 867  30 347 253  34 532 073  79 830 305 
PEPFAR  a  a  a  a  281 812 819  262 609 562 
Total bilateral and 
multilateral disbursements
 261 252 845  282 933 013  322 399 137  348 214 053  324 739 271  b 
United Republic of 
Tanzania
Global Fund  90 956 378  48 001 671  63 101 776  158 644 650  134 537 812  89 311 491 
PEPFAR  a  a  a  a  314 822 878  276 527 338 
Total bilateral and 
multilateral disbursements
 365 161 467  366 800 254  384 756 518  479 223 984  444 195 347  b 
Zambia
Global Fund  37 366 179  88 285 317  63 359 492  153 110 575  68 808 573  25 854 905 
PEPFAR  a  a  a  a  246 173 444  233 395 902 
Total bilateral and 
multilateral disbursements
 220 144 112  299 819 914  288 448 574  277 060 632  309 290 099  b 
Zimbabwe
Global Fund  47 216 789  26 820 573  130 481 599  97 238 291  100 570 822  183 534 746 
PEPFAR  a  a  a  a  90 377 038  101 837 712 
Total bilateral and 
multilateral disbursements
 109 433 259  93 623 661  211 346 999  163 531 078  182 143 055  b 
Eastern Europe and 
central Asia
Albania
Global Fund  678 581  492 117  216 371  180 595  192 107  b 
PEPFAR  a  a  a  a  b  b 
Total bilateral and 
multilateral disbursements
 799 841  533 864  283 338  243 451  255 664  b 
Armenia
Global Fund  1 221 346  3 416 111  4 468 956  3 251 611  3 411 031  1 039 721 
PEPFAR  a  a  a  a  b  b 
Total bilateral and 
multilateral disbursements
 2 364 375  4 571 804  4 567 778  3 899 989  3 503 587  b 
Azerbaijan
Global Fund  4 764 455  8 060 295  1 814 375  5 007 607  6 830 019  2 389 838 
PEPFAR  a  a  a  a  b  b 
Total bilateral and 
multilateral disbursements
 4 841 565  8 379 378  2 099 516  5 298 481  6 875 131  b 
Belarus
Global Fund  5 861 402  8 040 884  6 646 196  6 982 976  4 738 897  4 769 193 
PEPFAR  a  a  a  a  b  b 
Total bilateral and 
multilateral disbursements
 6 413 576  8 525 019  6 925 481  7 571 547  5 044 354  b 
Bosnia and Herzegovina
Global Fund  6 311 692  5 742 682  3 153 132  7 834 022  4 580 935  3 105 366 
PEPFAR  a  a  a  a  b  b 
Total bilateral and 
multilateral disbursements
 6 587 904  5 981 250  2 922 774  7 978 904  4 593 745  b 
International assistance for the AIDS response in low- and middle-income countries as reported 
by donors, 2010–2015 
The table contains the international financial assistance for the AIDS response in US dollars provided annually to low- and middle-income countries as reported by 
bilateral and multilateral entities. International assistance reported by the Global Fund to Fight AIDS, Tuberculosis and Malaria and the United States President’s 
Emergency Plan for AIDS Relief (PEPFAR) are presented separately. Total disbursements by bilateral and multilateral entities are the amounts they reported to the 
Organisation for Economic Co-operation and Development (OECD) under two AIDS categories. These totals may omit disbursements for HIV-related services within 
grants that cover broader health and development work. Discrepancies between the disbursements reported by different sources may be due to variation in financial 
years and the underlying reporting methods and standards. 
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Bulgaria
Global Fund  7 068 997  7 128 610  3 480 858  1 588 912  4 345 631  2 526 171 
PEPFAR  a  a  a  a  b  b 
Total bilateral and 
multilateral disbursements
 b  b  b  b  b  b 
Estonia
Global Fund  b  b  b  b  b  b 
PEPFAR  a  a  a  a  b  b 
Total bilateral and 
multilateral disbursements
 b  b  b  b  b  b 
Georgia
Global Fund  6 128 146  6 521 849  8 440 540  10 332 111  5 470 762  7 476 707 
PEPFAR  a  a  a  a  b  b 
Total bilateral and 
multilateral disbursements
 7 268 734  9 229 376  8 702 631  11 389 784  6 861 238  b 
Kazakhstan
Global Fund  2 992 093  5 692 218  7 411 779  5 105 512  299 652  3 594 040 
PEPFAR  a  a  a  a  2 660 159  4 149 083 
Total bilateral and 
multilateral disbursements
 4 111 187  7 356 548  8 733 448  6 164 557  693 727  b 
Kyrgyzstan
Global Fund  5 449 518  7 370 614  5 559 589  7 157 157  5 359 960  5 667 648 
PEPFAR  a  a  a  a  4 818 270  2 801 132 
Total bilateral and 
multilateral disbursements
 7 752 375  9 009 428  6 645 416  8 054 923  6 356 566  b 
Montenegro
Global Fund  1 371 826  1 517 821  861 849  857 485  818 732  b 
PEPFAR  a  a  a  a  b  b 
Total bilateral and 
multilateral disbursements
 1 314 188  1 555 812  821 000  857 485  818 732  b 
Republic of Moldova
Global Fund  10 072 219  4 724 277  5 349 508  6 378 626  8 393 141  686 624 
PEPFAR  a  a  a  a  b  b 
Total bilateral and 
multilateral disbursements
 10 263 923  5 250 920  5 778 957  6 615 829  8 464 787  b 
Romania
Global Fund  910 457  b  b  b  b  b 
PEPFAR  a  a  a  a  b  b 
Total bilateral and 
multilateral disbursements
 b  b  b  b  b  b 
Russian Federationd
Global Fund  29 990 820  10 827 432  2 244 665  8 065 329  3 288 070  3 629 518 
PEPFAR  b  b  b  b  b  b 
Total bilateral and 
multilateral disbursements
 b  b  b  b  b  b 
Serbia
Global Fund  3 926 085  3 856 674  3 640 999  3 890 594  1 217 362  b 
PEPFAR  a  a  a  a  b  b 
Total bilateral and 
multilateral disbursements
 3 952 775  3 981 848  3 681 935  4 162 546  1 322 808  b 
Tajikistan
Global Fund  9 291 100  4 429 234  11 923 348  8 047 459  4 687 168  4 414 531 
PEPFAR  a  a  a  a  4 361 656  2 977 627 
Total bilateral and 
multilateral disbursements
 11 566 476  5 987 078  13 062 648  9 249 778  6 183 748  b 
International assistance for the AIDS response in low- and middle-income countries as reported 
by donors, 2010–2015 
The table contains the international financial assistance for the AIDS response in US dollars provided annually to low- and middle-income countries as reported by 
bilateral and multilateral entities. International assistance reported by the Global Fund to Fight AIDS, Tuberculosis and Malaria and the United States President’s 
Emergency Plan for AIDS Relief (PEPFAR) are presented separately. Total disbursements by bilateral and multilateral entities are the amounts they reported to the 
Organisation for Economic Co-operation and Development (OECD) under two AIDS categories. These totals may omit disbursements for HIV-related services within 
grants that cover broader health and development work. Discrepancies between the disbursements reported by different sources may be due to variation in financial 
years and the underlying reporting methods and standards. 
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The former Yugoslav 
Republic of Macedonia
Global Fund  1 514 506  3 966 878  1 564 231  2 474 129  1 207 267  2 998 601 
PEPFAR  a  a  a  a  b  b 
Total bilateral and 
multilateral disbursements
 1 489 009  3 915 082  1 592 006  2 474 129  1 207 295  b 
Turkey
Global Fund  b  b  b  b  b  b 
PEPFAR  a  a  a  a  b  b 
Total bilateral and 
multilateral disbursements
 153 907  31 827  b  b  12 048  b 
Turkmenistan
Global Fund  b  b  b  b  b  b 
PEPFAR  a  a  a  a  30 662  b 
Total bilateral and 
multilateral disbursements
 b  b  b  b  b  b 
Ukraine
Global Fund  32 047 425  37 207 617  54 985 981  44 710 266  32 352 908  47 972 450 
PEPFAR  a  a  a  a  11 735 752  17 193 846 
Total bilateral and 
multilateral disbursements
 44 185 758  50 246 169  67 878 644  63 216 025  52 567 007  b 
Uzbekistan
Global Fund  1 868 251  6 983 392  18 117 218  2 144 023  7 381 095  3 663 479 
PEPFAR  a  a  a  a  310 320  140 925 
Total bilateral and 
multilateral disbursements
 4 552 320  9 099 057  19 276 467  3 402 582  7 814 539  b 
Latin America and the 
Caribbean
Argentinae
Global Fund  b 1 524 599 503 631 1 488 035  b  b 
PEPFAR
Total bilateral and 
multilateral disbursements
 645 290  2 362 323  1 734 711  2 345 447  208 494  b 
Belize
Global Fund  944 471  356 980  1 543 941  1 450 840  100 000  2 839 718 
PEPFAR  a  a  a  a  1 059 922  1 035 022 
Total bilateral and 
multilateral disbursements
 1 151 562  811 832  1 642 965  1 610 373  184 342  b 
Bolivia  
(Plurinational State of)
Global Fund  b  b  b  b  b  b 
PEPFAR  a  a  a  a  b  b 
Total bilateral and 
multilateral disbursements
 5 522 699  7 091 420  2 154 876  9 542 872  3 252 256  b 
Brazil
Global Fund  b  b  b  b  b  b 
PEPFAR  a  a  a  a  b  b 
Total bilateral and 
multilateral disbursements
 7 565 073  5 112 205  5 057 630  3 754 811  2 484 837  b 
Chiled
Global Fund  b  b  b  b  b  b 
PEPFAR  b  b  b  b  b  b 
Total bilateral and 
multilateral disbursements
359 964 260 145 124 180 126 583  b  b 
Colombia
Global Fund  b  11 055 251  1 884 395  13 942 010  3 403 505  6 070 693 
PEPFAR  a  a  a  a  b  b 
Total bilateral and 
multilateral disbursements
 752 498  11 397 656  2 536 680  14 950 854  3 967 819  b 
International assistance for the AIDS response in low- and middle-income countries as reported 
by donors, 2010–2015 
The table contains the international financial assistance for the AIDS response in US dollars provided annually to low- and middle-income countries as reported by 
bilateral and multilateral entities. International assistance reported by the Global Fund to Fight AIDS, Tuberculosis and Malaria and the United States President’s 
Emergency Plan for AIDS Relief (PEPFAR) are presented separately. Total disbursements by bilateral and multilateral entities are the amounts they reported to the 
Organisation for Economic Co-operation and Development (OECD) under two AIDS categories. These totals may omit disbursements for HIV-related services within 
grants that cover broader health and development work. Discrepancies between the disbursements reported by different sources may be due to variation in financial 
years and the underlying reporting methods and standards. 
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Costa Rica
Global Fund  b  b  b  b  b  933 088 
PEPFAR  a  a  a  a  960 167  989 597 
Total bilateral and 
multilateral disbursements
 179 338  196 134  91 075  79 571  36 827  b 
Cuba
Global Fund  9 425 384  8 133 543  8 147 427  8 720 617  1 987 824  6 827 772 
PEPFAR  a  a  a  a  b  b 
Total bilateral and 
multilateral disbursements
 9 707 699  8 583 640  8 270 000  9 422 039  2 162 660  b 
Dominica
Global Fund  b  b  b  b  b  b 
PEPFAR  a  a  a  a  852 382  369 002 
Total bilateral and 
multilateral disbursements
 b  b  b  b  b  b 
Dominican Republic
Global Fund  14 201 973  12 521 662  8 855 439  15 089 509  11 008 145  4 566 014 
PEPFAR  a  a  a  a  15 195 075  12 245 528 
Total bilateral and 
multilateral disbursements
 24 831 117  26 068 604  29 308 525  33 495 106  25 725 514  b 
Ecuador
Global Fund  1 398 364  3 114 302  1 223 859  4 960 881  4 783 821  2 611 274 
PEPFAR  a  a  a  a  b  b 
Total bilateral and 
multilateral disbursements
 5 384 684  4 316 276  1 974 522  5 984 961  5 315 663  b 
El Salvador
Global Fund  7 758 232  5 185 392  5 143 657  13 460 707  1 050 360  7 028 602 
PEPFAR  a  a  a  a  2 119 072  2 470 504 
Total bilateral and 
multilateral disbursements
 9 736 353  6 694 285  6 528 376  10 180 865  1 242 908  b 
Grenada
Global Fund  b  b  b  b  b  b 
PEPFAR  a  a  a  a  469 605  216 448 
Total bilateral and 
multilateral disbursements
3931 5904 7206     b  b 
Guatemala
Global Fund  6 520 131  15 199 667  10 265 179  11 388 651  9 725 198  10 517 286 
PEPFAR  a  a  a  a  4 279 183  3 749 015 
Total bilateral and 
multilateral disbursements
 11 201 262  20 405 683  13 766 005  14 680 735  11 169 281  b 
Guyana
Global Fund  2 553 738  4 707 845  763 594  2 198 871  1 977 247  1 971 299 
PEPFAR  a  a  a  a  7 522 489  6 759 435 
Total bilateral and 
multilateral disbursements
 19 952 103  18 019 123  12 748 680  10 239 428  8 852 650  b 
Haiti
Global Fund  12 118 386  15 911 930  14 711 119  14 607 121  16 924 653  11 255 989 
PEPFAR  a  a  a  a  117 771 589  110 549 082 
Total bilateral and 
multilateral disbursements
 118 094 007  119 174 870  107 863 493  114 349 096  127 346 608  b 
Honduras
Global Fund  7 277 702  9 765 403  8 430 701  8 425 195  2 281 131  1 077 634 
PEPFAR  a  a  a  a  3 932 495  4 172 935 
Total bilateral and 
multilateral disbursements
 13 668 005  18 584 627  16 486 045  16 313 148  7 115 065  b 
International assistance for the AIDS response in low- and middle-income countries as reported 
by donors, 2010–2015 
The table contains the international financial assistance for the AIDS response in US dollars provided annually to low- and middle-income countries as reported by 
bilateral and multilateral entities. International assistance reported by the Global Fund to Fight AIDS, Tuberculosis and Malaria and the United States President’s 
Emergency Plan for AIDS Relief (PEPFAR) are presented separately. Total disbursements by bilateral and multilateral entities are the amounts they reported to the 
Organisation for Economic Co-operation and Development (OECD) under two AIDS categories. These totals may omit disbursements for HIV-related services within 
grants that cover broader health and development work. Discrepancies between the disbursements reported by different sources may be due to variation in financial 
years and the underlying reporting methods and standards. 
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Jamaica
Global Fund  11 686 451  8 870 742  3 211 112  8 409 518  b  3 246 622 
PEPFAR  a  a  a  a  7 544 813  6 029 087 
Total bilateral and 
multilateral disbursements
 14 509 613  16 439 946  8 399 136  13 871 482  5 249 379  b 
Mexico
Global Fund  3 387 683  9 964 718  11 311 799  11 448 986  b  b 
PEPFAR  a  a  a  a  b  b 
Total bilateral and 
multilateral disbursements
 6 300 832  12 319 608  14 239 043  12 496 260  654 037  b 
Nicaragua
Global Fund  7 526 489  2 764 944  8 815 274  4 203 718  3 637 567  3 957 020 
PEPFAR  a  a  a  a  2 230 403  2 403 508 
Total bilateral and 
multilateral disbursements
 11 990 514  6 228 332  11 407 586  6 399 117  5 725 131  b 
Panama
Global Fund  b  b  1 503 322  1 857 295  937 207  1 927 284 
PEPFAR  a  a  a  a  1 932 814  1 850 767 
Total bilateral and 
multilateral disbursements
 643 046  435 722  1 902 795  2 131 562  968 107  b 
Paraguay
Global Fund  4 098 277  2 634 380  2 608 915  2 753 991  3 072 621  2 708 913 
PEPFAR  a  a  a  a  b  b 
Total bilateral and 
multilateral disbursements
 6 163 168  3 924 322  4 443 447  4 884 556  4 070 305  b 
Peru
Global Fund  8 356 240  2 904 093  3 903 342  496 689  2 834 260  b 
PEPFAR  a  a  a  a  b  b 
Total bilateral and 
multilateral disbursements
 12 380 832  5 763 999  6 191 797  2 470 605  3 708 815  b 
Saint Lucia
Global Fund  b  b  b  b  b  b 
PEPFAR  a  a  a  a  777 176  218 282 
Total bilateral and 
multilateral disbursements
 b  b  b  b  b  b 
Saint Vincent and the 
Grenadines
Global Fund  b  b  b  b  b  b 
PEPFAR  a  a  a  a  458 576  368 661 
Total bilateral and 
multilateral disbursements
 16 317  b  b 714     b 
Suriname
Global Fund  839 112  870 357  143 036  243 551  b  1 176 504 
PEPFAR  a  a  a  a  713 638  565 608 
Total bilateral and 
multilateral disbursements
 997 226  1 105 246  164 031  405 444 9084  b 
Trinidad and Tobagoc
Global Fund  b  b  b  b  b  b 
PEPFAR  b  b  b  b 1 311 510 1 141 316
Total bilateral and 
multilateral disbursements
 420 082  b  b  b b  b 
Uruguayd
Global Fund  b  b  2 151 170  1 048 753 369 689  b 
PEPFAR  b  b  b  b b  b 
Total bilateral and 
multilateral disbursements
 228 647  94 313  2 192 697  1 099 181 429 276  b 
International assistance for the AIDS response in low- and middle-income countries as reported 
by donors, 2010–2015 
The table contains the international financial assistance for the AIDS response in US dollars provided annually to low- and middle-income countries as reported by 
bilateral and multilateral entities. International assistance reported by the Global Fund to Fight AIDS, Tuberculosis and Malaria and the United States President’s 
Emergency Plan for AIDS Relief (PEPFAR) are presented separately. Total disbursements by bilateral and multilateral entities are the amounts they reported to the 
Organisation for Economic Co-operation and Development (OECD) under two AIDS categories. These totals may omit disbursements for HIV-related services within 
grants that cover broader health and development work. Discrepancies between the disbursements reported by different sources may be due to variation in financial 
years and the underlying reporting methods and standards. 
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Venezuela (Bolivarian 
Republic of)e
Global Fund  b  b  b  b  b  b 
PEPFAR  b  b  b  b  b  b 
Total bilateral and 
multilateral disbursements
 408 811  502 461  638 735  430 159 214 313  b 
Middle East and North 
Africa
Algeria
Global Fund  b  b  b  b  b  b 
PEPFAR  a  a  a  a  b  b 
Total bilateral and 
multilateral disbursements
 1 146 469  1 002 875  309 680  310 436  123 384  b 
Djibouti
Global Fund  987 472  2 387 338  877 968  3 208 807  416 791  b 
PEPFAR  a  a  a  a  b  b 
Total bilateral and 
multilateral disbursements
 1 953 809  2 927 393  1 549 567  5 196 206  2 666 820  b 
Egypt
Global Fund  1 413 280     1 833 391  771 460     211 476 
PEPFAR  a  a  a  a  b  b 
Total bilateral and 
multilateral disbursements
 3 819 928  1 372 925  2 591 588  1 760 203  471 504  b 
Iran (Islamic Republic of)
Global Fund  3 078 579  6 323 375  5 602 799  3 988 763  6 646 279  5 743 976 
PEPFAR  a  a  a  a  b  b 
Total bilateral and 
multilateral disbursements
 3 716 918  7 238 290  6 487 266  4 841 928  7 090 241  b 
Jordan
Global Fund  544 583  769 573  629 607  b 8450  32 950 
PEPFAR  a  a  a  a  b  b 
Total bilateral and 
multilateral disbursements
 634 674  780 362  630 000  70 229  72 450  b 
Lebanon
Global Fund  b  b  b  b  b  b 
PEPFAR  a  a  a  a  b  b 
Total bilateral and 
multilateral disbursements
 311 349  307 180  222 412 1690  168 167  b 
Morocco
Global Fund  5 862 988  7 062 370  6 163 402  3 487 662  8 022 786  1 176 342 
PEPFAR  a  a  a  a  b  b 
Total bilateral and 
multilateral disbursements
 7 241 217  8 403 619  7 085 706  4 301 183  8 536 829  b 
Somalia
Global Fund  11 764 000  11 719 451  6 218 112  9 284 707  5 643 730  5 776 906 
PEPFAR  a  a  a  a  b  b 
Total bilateral and 
multilateral disbursements
 12 486 246  12 579 160  6 840 058  10 274 725  6 185 732  b 
Sudan
Global Fund  20 804 263  19 875 794  9 656 856  14 808 996  10 040 575  4 759 590 
PEPFAR  a  a  a  a  b  b 
Total bilateral and 
multilateral disbursements
 45 000 365  29 685 185  20 346 838  18 446 566  12 022 483  b 
Syrian Arab Republic
Global Fund  b  b  457 301  297 472  1 246 730  b 
PEPFAR  a  a  a  a  b  b 
Total bilateral and 
multilateral disbursements
 210 724  291 718  467 910  830 187  1 322 174  b 
International assistance for the AIDS response in low- and middle-income countries as reported 
by donors, 2010–2015 
The table contains the international financial assistance for the AIDS response in US dollars provided annually to low- and middle-income countries as reported by 
bilateral and multilateral entities. International assistance reported by the Global Fund to Fight AIDS, Tuberculosis and Malaria and the United States President’s 
Emergency Plan for AIDS Relief (PEPFAR) are presented separately. Total disbursements by bilateral and multilateral entities are the amounts they reported to the 
Organisation for Economic Co-operation and Development (OECD) under two AIDS categories. These totals may omit disbursements for HIV-related services within 
grants that cover broader health and development work. Discrepancies between the disbursements reported by different sources may be due to variation in financial 
years and the underlying reporting methods and standards. 
262 
Donor 2010 2011 2012 2013 2014 2015
Tunisia
Global Fund  4 037 197  1 160 011  1 382 024  1 846 015  1 135 547  474 350 
PEPFAR  a  a  a  a  b  b 
Total bilateral and 
multilateral disbursements
 4 058 801  1 486 144  1 454 317  1 960 409  1 276 474  b 
Yemen
Global Fund  4 554 899  b  321 546  495 529  217 725  390 249 
PEPFAR  a  a  a  a  b  b 
Total bilateral and 
multilateral disbursements
 5 390 953  282 107  601 182  933 950  685 051  b 
Western and Central 
Africa
Benin
Global Fund  21 333 967  16 364 873  2 293 658  8 046 445  13 763 590  10 638 542 
PEPFAR  a  a  a  a  b  b 
Total bilateral and 
multilateral disbursements
 30 365 666  26 618 560  9 833 507  10 240 707  15 884 009  b 
Burkina Faso
Global Fund  14 318 645  7 196 930  13 191 511  26 275 144  5 620 443  14 548 838 
PEPFAR  a  a  a  a  b  b 
Total bilateral and 
multilateral disbursements
 41 531 910  18 245 695  25 732 578  40 982 393  13 331 787  b 
Burundi
Global Fund  6 002 968  13 309 111  13 177 356  12 164 557  10 845 679  6 303 255 
PEPFAR  a  a  a  a  11 788 765  15 661 306 
Total bilateral and 
multilateral disbursements
 19 354 300  25 046 775  21 157 979  19 717 618  18 900 450  b 
Cameroon
Global Fund  8 893 822  7 081 726  15 863 396  26 913 809  9 128 195  16 347 617 
PEPFAR  a  a  a  a  18 510 202  24 571 641 
Total bilateral and 
multilateral disbursements
 18 174 862  15 846 038  29 853 265  45 606 785  35 505 709  b 
Cabo Verde
Global Fund  1 973 998  2 283 820  271 956  2 965 528  1 282 849  1 613 688 
PEPFAR  a  a  a  a  b  b 
Total bilateral and 
multilateral disbursements
 1 976 373  2 358 820  272 000  2 966 277  1 304 972  b 
Central African  
Republic
Global Fund  6 112 689  5 575 151  604 960  4 992 177  4 692 168  3 317 505 
PEPFAR  a  a  a  a  b  b 
Total bilateral and 
multilateral disbursements
 10 897 251  8 565 293  5 059 702  7 425 558  6 050 391  b 
Chad
Global Fund  9 607 716  10 744 715  2 223 686  9 979 297  9 025 689  5 677 982 
PEPFAR  a  a  a  a  b  b 
Total bilateral and 
multilateral disbursements
 14 216 563  20 357 482  8 791 606  16 160 359  10 995 099  b 
Congo
Global Fund  8 573 601  8 769 052  3 140 658  6 623 467  2 849 951  1 190 244 
PEPFAR  a  a  a  a  b  b 
Total bilateral and 
multilateral disbursements
 12 700 803  11 210 190  4 754 622  8 009 654  3 533 060  b 
Côte d'Ivoire
Global Fund  3 869 762  6 089 125  4 425 420  13 824 869  19 961 796  13 477 500 
PEPFAR  a  a  a  a  108 348 645  100 684 466 
Total bilateral and 
multilateral disbursements
 91 521 424  75 900 354  81 487 250  87 404 428  111 916 912  b 
International assistance for the AIDS response in low- and middle-income countries as reported 
by donors, 2010–2015 
The table contains the international financial assistance for the AIDS response in US dollars provided annually to low- and middle-income countries as reported by 
bilateral and multilateral entities. International assistance reported by the Global Fund to Fight AIDS, Tuberculosis and Malaria and the United States President’s 
Emergency Plan for AIDS Relief (PEPFAR) are presented separately. Total disbursements by bilateral and multilateral entities are the amounts they reported to the 
Organisation for Economic Co-operation and Development (OECD) under two AIDS categories. These totals may omit disbursements for HIV-related services within 
grants that cover broader health and development work. Discrepancies between the disbursements reported by different sources may be due to variation in financial 
years and the underlying reporting methods and standards. 
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Donor 2010 2011 2012 2013 2014 2015
Democratic Republic of 
the Congo
Global Fund  35 866 198  25 559 566  73 612 559  45 805 912  14 728 985  37 547 490 
PEPFAR  a  a  a  a  39 456 622  40 699 672 
Total bilateral and 
multilateral disbursements
 72 049 235  64 824 273  117 393 018  97 636 366  58 283 727  b 
Equatorial Guinea
Global Fund  1 420 187  607 483  b  b  b  b 
PEPFAR  a  a  a  a  b  b 
Total bilateral and 
multilateral disbursements
 1 552 638  614 633  56 151 9221  25 174  b 
Gabon
Global Fund  1 338 199  907 263  b  748 873  b  b 
PEPFAR  a  a  a  a  b  b 
Total bilateral and 
multilateral disbursements
 2 222 431  2 237 491  1 578 502  1 992 292  984 234  b 
Gambia
Global Fund  6 238 502  6 785 081  5 329 616  9 479 594  3 710 404  1 891 695 
PEPFAR  a  a  a  a  b  b 
Total bilateral and 
multilateral disbursements
 6 473 200  6 680 815  5 174 251  10 836 258  6 929 353  b 
Ghana
Global Fund  20 629 791  34 425 214  21 889 738  38 380 447  8 357 408  27 724 999 
PEPFAR  a  a  a  a  9 634 465  6 214 229 
Total bilateral and 
multilateral disbursements
 33 712 568  56 839 348  46 336 646  57 964 684  24 154 220  b 
Guinea
Global Fund  1 509 558  5 903 927  1 151 871  7 847 766  8 043 852  11 374 331 
PEPFAR  a  a  a  a  b  b 
Total bilateral and 
multilateral disbursements
 7 272 932  10 578 592  7 051 515  14 256 747  11 386 846  b 
Guinea-Bissau
Global Fund  5 930 028  3 807 332  1 443 139  12 991 148  1 867 462  4 134 432 
PEPFAR  a  a  a  a  b  b 
Total bilateral and 
multilateral disbursements
 6 848 591  5 089 296  1 705 825  372 649  2 277 836  b 
Liberia
Global Fund  9 963 258  11 577 441  8 118 208  12 069 290  3 636 418  4 984 087 
PEPFAR  a  a  a  a  b  b 
Total bilateral and 
multilateral disbursements
 15 275 187  16 709 545  14 819 936  19 057 597  7 286 414  b 
Mali
Global Fund  6 217 393  10 130 370  24 583 100  2 929 594  23 998 363  11 193 131 
PEPFAR  a  a  a  a  b  b 
Total bilateral and 
multilateral disbursements
 19 235 548  18 879 198  33 998 506  12 708 876  32 264 388  b 
Mauritania
Global Fund  b  b  1 039 512  2 718 517  944 771  1 269 045 
PEPFAR  a  a  a  a  b  b 
Total bilateral and 
multilateral disbursements
 244 685  727 141  2 643 262  3 229 197  1 314 156  b 
Niger
Global Fund  1 376 802  5 157 922  3 520 769  4 726 398  2 564 775  4 879 866 
PEPFAR  a  a  a  a  b  b 
Total bilateral and 
multilateral disbursements
 6 452 977  13 837 217  8 338 522  11 757 972  5 930 662  b 
International assistance for the AIDS response in low- and middle-income countries as reported 
by donors, 2010–2015 
The table contains the international financial assistance for the AIDS response in US dollars provided annually to low- and middle-income countries as reported by 
bilateral and multilateral entities. International assistance reported by the Global Fund to Fight AIDS, Tuberculosis and Malaria and the United States President’s 
Emergency Plan for AIDS Relief (PEPFAR) are presented separately. Total disbursements by bilateral and multilateral entities are the amounts they reported to the 
Organisation for Economic Co-operation and Development (OECD) under two AIDS categories. These totals may omit disbursements for HIV-related services within 
grants that cover broader health and development work. Discrepancies between the disbursements reported by different sources may be due to variation in financial 
years and the underlying reporting methods and standards. 
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Donor 2010 2011 2012 2013 2014 2015
Nigeria
Global Fund  24 430 509  56 318 978  73 771 207  137 864 355  71 677 320  61 621 279 
PEPFAR  a  a  a  a  402 033 019  380 420 716 
Total bilateral and 
multilateral disbursements
 416 803 014  384 253 533  441 549 677  580 314 429  442 063 154  b 
Sao Tome and Principe
Global Fund  b  421 721  164 617  571 733  426 709  313 634 
PEPFAR  a  a  a  a  b  b 
Total bilateral and 
multilateral disbursements
 b  b  b  b  b  b 
  Senegal
Global Fund  16 843 641  21 467 639  12 527 816  15 007 238  9 530 458  10 818 583 
PEPFAR  a  a  a  a  b  b 
Total bilateral and 
multilateral disbursements
 24 954 904  29 527 409  17 833 499  22 070 480  15 311 616  b 
  Sierra Leone
Global Fund  15 295 127  9 569 576  11 478 396  8 045 006  16 361 920  5 124 179 
PEPFAR  a  a  a  a  b  b 
Total bilateral and 
multilateral disbursements
 21 659 750  16 117 239  16 531 816  11 010 148  17 743 364  b 
  Togo
Global Fund  9 608 627  8 718 163  4 745 285  10 567 421  10 364 619  7 971 533 
PEPFAR  a  a  a  a  b  b 
Total bilateral and 
multilateral disbursements
 11 342 210  12 090 257  7 342 613  13 271 163  12 462 101  b 
International assistance for the AIDS response in low- and middle-income countries as reported 
by donors, 2010–2015 
The table contains the international financial assistance for the AIDS response in US dollars provided annually to low- and middle-income countries as reported by 
bilateral and multilateral entities. International assistance reported by the Global Fund to Fight AIDS, Tuberculosis and Malaria and the United States President’s 
Emergency Plan for AIDS Relief (PEPFAR) are presented separately. Total disbursements by bilateral and multilateral entities are the amounts they reported to the 
Organisation for Economic Co-operation and Development (OECD) under two AIDS categories. These totals may omit disbursements for HIV-related services within 
grants that cover broader health and development work. Discrepancies between the disbursements reported by different sources may be due to variation in financial 
years and the underlying reporting methods and standards. 
Sources: OECD creditor reporting system online reports (accessed May 2016); PEPFAR expenditure analysis; Global Fund disbursement reports
(https://stats.oecd.org/Index.aspx?DataSetCode=CRS1, accessed May 2016).
a The time series for expenditure from PEPFAR expenditure analysis reports starts from 2014.
b Data not available.
c Classified by the World Bank as a high-income country before 2013.
d Classified by the World Bank as a high-income country since July 2013.
e Classified by the World Bank as a high-income country since July 2015.
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Source of 
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resource tracking 
method
2010 2011 2012 2013 2014 2015
Asia and the Pacific
Afghanistan
  
International 4 237 825 8 002 074 9 028 297 5 067 479 4 077 138 b
Domestic public 200 000 a 24 250 245 000 104 000 b
Resource tracking 
method
Other Other NASA Other NASA b
Australia
International a a a a a a
Domestic public a a a a a a
Resource tracking 
method
a a a a a a
Bangladesh
International 13 912 481 17 900 906 11 499 100 17 673 105 16 533 877 b
Domestic public 1 202 508 746 225 984 252 3 470 437 2 871 845 b
Resource tracking 
method
Other Other Other NASA Other b
Bhutan
International a a a a a a
Domestic public a a a a a a
Resource tracking 
method
a a a a a a
Brunei Darussalam
International a a a a a a
Domestic public a a a a a a
Resource tracking 
method
a a a a a a
Cambodia
International 55 571 098 46 569 946 44 713 950 a a a
Domestic public 2 436 832 5 300 117 5 212 931 a a a
Resource tracking 
method
NASA NASA NASA a a a
China
International 86 317 453 59 997 523 76 621 435 36 775 945 8 866 450 b
Domestic public 497 309 402 529 376 006 554 007 385 714 079 592 977 788 274 b
Resource tracking 
method
WHO Health 
Accounts
WHO Health 
Accounts
Other Other Other b
Democratic People's 
Republic of Korea
  
International 5000 75 000 a a a a
Domestic public 1 009 600 1 070 420 a a a a
Resource tracking 
method
NASA NASA a a a a
Fiji
International a a a a 62 554 b
Domestic public a a a a 150 833 b
Resource tracking 
method
Other Other NASA
UNAIDS/
UNFPA/NIDI
WHO Health 
Accounts
b
India
International a a a a a b
Domestic public 225 715 496 275 000 076 205 808 366 144 554 317 164 330 065 b
Resource tracking 
method
Other Other Other Other Other a
Indonesia
International 41 224 115 42 815 648 50 150 781 b b a
Domestic public 27 577 082 29 727 973 36 851 913 b b a
Resource tracking 
method
NASA NASA NASA a b a
Japan
International a a a a a a
Domestic public 73 455 936 67 907 854 a a a a
Resource tracking 
method
Other Other a a a a
Domestic public and international expenditure reported by countries to UNAIDS (2010–2015) 
The table contains the annual AIDS response expenditure (in US dollars) of domestic public resources and total international resources provided by bilateral and 
multilateral donors, private foundations and other international partners, as reported by countries through the Global AIDS Response Progress Reporting system.
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2010 2011 2012 2013 2014 2015
Kiribati
International 429 800 258 888 339 277 a 377 217 b
Domestic public a a a a 292 161 b
Resource tracking 
method
Other Other Other a Other a
Lao People's 
Democratic Republic
International 7 752 050 10 916 446 a a a a
Domestic public 827 689 827 689 a a a a
Resource tracking 
method
NASA NASA a a a a
Malaysia
International 561 880 2 396 941 1 665 338 2 105 998 2 538 989 b
Domestic public 31 383 249 36 168 067 54 088 511 55 220 508 49 775 178 b
Resource tracking 
method
NASA
WHO Health 
Accounts
WHO Health 
Accounts
WHO Health 
Accounts
a a
Marshall Islands
International 190 906 134 208 371 142 431 765 594 774 b
Domestic public 200 027 40 000 75 000 85 000 85 000 b
Resource tracking 
method
WHO Health 
Accounts
NASA NASA NASA Other a
Maldives
International a a a a a a
Domestic public a a a a a a
Resource tracking 
method
a a a a a a
Micronesia  
(Federated States of)
International 521 806 473 469 446 688 519 360 344 004 a
Domestic public a a a a a a
Resource tracking 
method
WHO Health 
Accounts
WHO Health 
Accounts
WHO Health 
Accounts
WHO Health 
Accounts
a a
Mongolia
International 2 550 191 2 562 338 a 2 165 745 1 166 608 a
Domestic public 950 996 1 169 128 a 1 329 438 1 619 212 a
Resource tracking 
method
NASA NASA a Other Other a
Myanmar
International 37 904 167 42 349 184 37 310 502 47 950 309 b b
Domestic public 2 596 875 3 944 294 726 157 4 131 753 b b
Resource tracking 
method
Other Other NASA NASA a a
Nauru
International a a a a a a
Domestic public a a a a a a
Resource tracking 
method
a a a a a a
Nepal
International a a a a a a
Domestic public a a a a a a
Resource tracking 
method
a a a a a a
New Zealand
International a a a a a a
Domestic public a a a a a a
Resource tracking 
method
a a a a a a
Pakistan
International 8 163 974 2 181 908 6 992 470 6 361 662 a b
Domestic public 4 768 321 3 027 839 3 457 681 3 631 968 a b
Resource tracking 
method
NASA Other Other Other a a
Domestic public and international expenditure reported by countries to UNAIDS (2010–2015) 
The table contains the annual AIDS response expenditure (in US dollars) of domestic public resources and total international resources provided by bilateral and 
multilateral donors, private foundations and other international partners, as reported by countries through the Global AIDS Response Progress Reporting system.
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Source of 
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resource tracking 
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2010 2011 2012 2013 2014 2015
Palau
International 588 166 650 636 a 373 641 30 032 b
Domestic public 394 323 394 323 a 35 400 a b
Resource tracking 
method
Other Other a Other Other a
Papua New Guinea
International 38 821 670 34 509 487 29 533 509 a a a
Domestic public 12 077 392 11 835 240 6 385 677 a a a
Resource tracking 
method
NASA Other Other a a a
Philippines
International 5 002 720 3 872 142 4 964 855 5 778 805 b b
Domestic public 3 372 467 4 181 055 4 654 505 4 522 803 b b
Resource tracking 
method
NASA NASA NASA NASA a a
Republic of Korea
International a a a a a a
Domestic public 11 161 000 11 171 000 a a a a
Resource tracking 
method
NASA NASA a a a a
Samoa
International 183 334 134 637 a 843 852 a a
Domestic public 161 694 172 845 a 60 000 a a
Resource tracking 
method
Other Other a
WHO Health 
Accounts
a a
Singapore
International a a a a a a
Domestic public 16 486 429 23 091 270 23 746 298 23 739 323 23 202 747 a
Resource tracking 
method
WHO Health 
Accounts
WHO Health 
Accounts
WHO Health 
Accounts
WHO Health 
Accounts
WHO Health 
Accounts
a
Solomon Islands
International 654 294 756 680 a a a a
Domestic public 150 032 151 749 a a a a
Resource tracking 
method
Other Other a a a a
Sri Lanka
International 2 034 477 a a 555 795 a a
Domestic public 2 277 906 a a 671 143 a a
Resource tracking 
method
NASA a a a a a
Thailand
International 35 926 668 46 643 421 28 969 017 30 516 721 a a
Domestic public 200 251 009 269 161 586 253 666 819 256 685 666 a a
Resource tracking 
method
NASA NASA NASA NASA a a
Timor-Leste
International a a a a a a
Domestic public a a a a a a
Resource tracking 
method
a a a a a a
Tonga
International a a a a 79 715 b
Domestic public a a a a 55 676 b
Resource tracking 
method
Other Other a a Other a
Tuvalu
International 47 641 156 916 a 24 455 a a
Domestic public 12 000 20 180 a 10 000 a a
Resource tracking 
method
Other Other a NASA a a
Domestic public and international expenditure reported by countries to UNAIDS (2010–2015) 
The table contains the annual AIDS response expenditure (in US dollars) of domestic public resources and total international resources provided by bilateral and 
multilateral donors, private foundations and other international partners, as reported by countries through the Global AIDS Response Progress Reporting system.
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Source of 
expenditure and 
resource tracking 
method
2010 2011 2012 2013 2014 2015
Vanuatu
International 1 625 013 1 847 008 328 089 805 583 a a
Domestic public 36 510 36 482 a 61 703 a a
Resource tracking 
method
Other Other Other NASA a a
Viet Nam
International 102 221 779 73 756 583 65 119 393 a a a
Domestic public 21 431 087 26 088 343 30 327 094 a a a
Resource tracking 
method
NASA NASA NASA a a a
Eastern and southern 
Africa
Angola
International 18 187 724 12 014 753 a a a b
Domestic public 15 877 187 21 462 786 a a a b
Resource tracking 
method
NASA NASA a a a b
Botswana
International 100 669 402 91 393 937 a a a a
Domestic public 262 400 227 299 022 611 a a a a
Resource tracking 
method
NASA NASA a a a a
Comoros
International a a 1 353 302 462 275 780 581 b
Domestic public 169 643 936 323 174 303 230 686 271 568 b
Resource tracking 
method
NASA NASA NASA NASA NASA b
Eritrea
International a a a a a a
Domestic public a a a a a a
Resource tracking 
method
a a a a a a
Ethiopia
International a 348 861 208 a a a b
Domestic public a 54 448 264 a a a b
Resource tracking 
method
a NASA a a a b
Kenya
International 591 376 323 601 390 268 551 245 316 583 989 611 a a
Domestic public 134 682 271 133 150 448 141 044 502 153 454 537 a a
Resource tracking 
method
NASA NASA NASA NASA a a
Lesotho
International a a a 68 266 451 b a
Domestic public a a a 25 900 622 b a
Resource tracking 
method
a a a NASA a a
Madagascar
International 4 938 015 7 849 887 5 565 185 2 592 546 3 066 078 b
Domestic public 4 473 518 6 005 101 4 250 295 4 051 608 2 636 728 b
Resource tracking 
method
NASA NASA NASA NASA a a
Malawi
International 65 560 000 148 891 014 133 575 811 a a b
Domestic public a 2 666 009 11 827 301 a a b
Resource tracking 
method
Other NASA NASA a a a
Domestic public and international expenditure reported by countries to UNAIDS (2010–2015) 
The table contains the annual AIDS response expenditure (in US dollars) of domestic public resources and total international resources provided by bilateral and 
multilateral donors, private foundations and other international partners, as reported by countries through the Global AIDS Response Progress Reporting system.
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Source of 
expenditure and 
resource tracking 
method
2010 2011 2012 2013 2014 2015
Mauritius
International 2 363 920 a a a a a
Domestic public 4 894 627 a a a a a
Resource tracking 
method
NASA a a a a a
Mozambique
International 203 113 942 246 656 413 246 658 915 332 640 878 339 379 364 b
Domestic public 10 136 250 13 393 157 8 635 144 16 870 748 12 217 622 b
Resource tracking 
method
NASA NASA Other Other Other a
Namibia
International 110 213 091 a 87 408 615 74 283 368 a a
Domestic public 168 791 097 a 111 050 386 136 620 606 a a
Resource tracking 
method
NASA a NASA NASA a a
Rwanda
International a 216 864 731 223 721 213 a a a
Domestic public a 17 748 631 19 946 470 a a a
Resource tracking 
method
a Other Other a a a
Seychelles
International 57 495 66 215 408 110 53 378 36 177 b
Domestic public 2 297 113 2 104 150 4 278 262 2 847 408 3 497 367 b
Resource tracking 
method
NASA NASA NASA NASA NASA a
South Africa
International a a a a 388 000 000 b
Domestic public a a a a 1492 672 908 b
Resource tracking 
method
a a a a NASA a
South Sudan
International a 29 353 055 21 852 538 a a b
Domestic public a 1 885 823 2 302 076 a a b
Resource tracking 
method
a NASA NASA a a a
Swaziland
International a 55 863 617 56 115 914 63 776 395 a a
Domestic public a 30 877 575 26 452 555 33 155 127 a a
Resource tracking 
method
a Other Other Other a a
Uganda
International a a a a a a
Domestic public a a a a a a
Resource tracking 
method
a a a a a a
United Republic of 
Tanzania
International a a a a a a
Domestic public a a a a a a
Resource tracking 
method
a a a a a a
Zambia
International a b 263 305 968 a a a
Domestic public a b 15 829 478 a a a
Resource tracking 
method
a a NASA a a a
Zimbabwe
International 164 119 186 171 866 911 220 722 218 219 131 824 a a
Domestic public 20 833 554 28 642 838 34 570 495 34 347 820 a a
Resource tracking 
method
NASA NASA NASA Other a a
Domestic public and international expenditure reported by countries to UNAIDS (2010–2015) 
The table contains the annual AIDS response expenditure (in US dollars) of domestic public resources and total international resources provided by bilateral and 
multilateral donors, private foundations and other international partners, as reported by countries through the Global AIDS Response Progress Reporting system.
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method
2010 2011 2012 2013 2014 2015
Eastern Europe and 
central Asia
Albania
International a a a a a a
Domestic public a a a a a a
Resource tracking 
method
a a a a a a
Armenia
International 3 084 750 3 501 166 4 238 978 3 927 672 4 985 553 b
Domestic public 1 961 038 2 079 270 1 090 732 1 072 918 1 823 256 b
Resource tracking 
method
Other Other Other Other Other b
Azerbaijan
International 1 378 711 5 992 295 a 5 221 578 6 411 468 b
Domestic public 6 857 540 8 563 409 a 13 390 123 14 215 892 b
Resource tracking 
method
UNAIDS/
UNFPA/NIDI
UNAIDS/
UNFPA/NIDI
a
UNAIDS/
UNFPA/NIDI
Other b
Belarus
International 6 476 941 10 195 678 7 314 821 6 869 816 6 470 149 a
Domestic public 13 246 041 9 668 805 12 471 166 11 712 470 15 975 774 a
Resource tracking 
method
NASA NASA NASA NASA NASA a
Bosnia and Herzegovina
International a a b a a a
Domestic public a a b a a a
Resource tracking 
method
a a b a a a
Bulgaria
International 5 640 456 6 754 982 3 921 623 3 072 407 b a
Domestic public 4 252 150 6 961 911 6 759 210 8 734 044 b a
Resource tracking 
method
NASA NASA NASA NASA b a
Croatia
International a a 29 802 1 763 a a
Domestic public a a 11 248 515 14 362 023 a a
Resource tracking 
method
a a Other Other a a
Cyprus
International a a a a a a
Domestic public a a a a a a
Resource tracking 
method
a a a a a a
Czech Republic
International a a a a a a
Domestic public a a a a a a
Resource tracking 
method
a a a a a a
Estonia
International a a a a a a
Domestic public 16 353 142 a a a a a
Resource tracking 
method
Other a a a a a
Georgia
International 6 832 963 8 521 914 11 064 342 9 137 970 7 021 656 b
Domestic public 4 260 499 4 478 054 4 716 172 5 361 536 8 166 782 b
Resource tracking 
method
WHO Health 
Accounts
WHO Health 
Accounts
WHO Health 
Accounts
WHO Health 
Accounts
WHO Health 
Accounts
b
Domestic public and international expenditure reported by countries to UNAIDS (2010–2015) 
The table contains the annual AIDS response expenditure (in US dollars) of domestic public resources and total international resources provided by bilateral and 
multilateral donors, private foundations and other international partners, as reported by countries through the Global AIDS Response Progress Reporting system.
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 Hungary
International a a a a a a
Domestic public a a a a a a
Resource tracking 
method
a a a a a a
Kazakhstan
International a 6 540 161 7 457 644 6 926 144 2 373 667 b
Domestic public a 30 346 857 30 352 251 30 876 471 40 667 500 b
Resource tracking 
method
a Other Other
UNAIDS/
UNFPA/NIDI
Other a
Kyrgyzstan
International 9 827 360 4 279 280 9 512 763 13 417 113 9 037 888 b
Domestic public 1 407 901 1 441 565 3 886 526 4 192 877 a b
Resource tracking 
method
UNAIDS/
UNFPA/NIDI
UNAIDS/
UNFPA/NIDI
WHO Health 
Accounts
Other Other a
Latvia
International 172 558 a a a 77 372 b
Domestic public 5 996 109 267 460 619 656 9 452 207 8 686 036 b
Resource tracking 
method
NASA NASA NASA NASA NASA a
Lithuania
International a 68 390 a a a a
Domestic public a 3 601 011 2 496 551 a a a
Resource tracking 
method
a NASA Other a a a
Malta
International a a a a a a
Domestic public a a a a a a
Resource tracking 
method
a a a a a a
Montenegro
International a a a a a a
Domestic public a a a a a a
Resource tracking 
method
a a a a a a
Poland
International 14 862 12 661 15 588 a a a
Domestic public 66 971 268 74 411 053 83 243 881 90 199 774 83 684 559 a
Resource tracking 
method
WHO Health 
Accounts
WHO Health 
Accounts
WHO Health 
Accounts
WHO Health 
Accounts
Other a
Republic of Moldova
International 6 103 215 8 516 841 6 709 992 5 503 307 6 817 600 b
Domestic public 4 617 721 5 124 220 2 381 695 2 459 879 2 332 684 b
Resource tracking 
method
Other Other Other Other Other a
Romania
International 3 995 755 5 677 124 199 177 a 0 b
Domestic public 91 512 275 102 458 472 34 383 944 a 98 535 201 b
Resource tracking 
method
Other Other Other a Other a
Russian Federation
International a a a a a a
Domestic public a a a 546 296 296 512 676 056 a
Resource tracking 
method
a a a Other Other a
Serbia
International a a 4 288 028 4 864 726 a a
Domestic public a a 9 071 059 11 468 548 a a
Resource tracking 
method
a a Other Other a a
Domestic public and international expenditure reported by countries to UNAIDS (2010–2015) 
The table contains the annual AIDS response expenditure (in US dollars) of domestic public resources and total international resources provided by bilateral and 
multilateral donors, private foundations and other international partners, as reported by countries through the Global AIDS Response Progress Reporting system.
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Slovakia
International a a a a a a
Domestic public a a a a a a
Resource tracking 
method
a a a a a a
Slovenia
International a a a a a a
Domestic public a a a a a a
Resource tracking 
method
a a a a a a
Tajikistan
International 13 514 154 13 032 202 9 803 764 10 364 317 a a
Domestic public 1 718 968 2 269 834 2 569 872 3 363 876 a a
Resource tracking 
method
NASA NASA NASA NASA a a
The former Yugoslav 
Republic of Macedonia
International 2 356 682 a a a a a
Domestic public 2 366 290 a a a a a
Resource tracking 
method
NASA a a a a a
Turkey
International a a 0 a a a
Domestic public a a 12 291 905 a a a
Resource tracking 
method
a a Other a a a
Turkmenistan
International a a a a a a
Domestic public a a a a a a
Resource tracking 
method
a a a a a a
Ukraine
International 33 877 730 36 438 190 41 506 392 b b a
Domestic public 38 054 198 60 423 675 71 777 758 b b a
Resource tracking 
method
Other Other Other a a a
Uzbekistan
International 6 678 413 6 513 177 10 771 819 9 396 131 7 481 521 b
Domestic public 16 985 205 12 636 531 13 334 449 11 919 410 11 631 595 b
Resource tracking 
method
WHO Health 
Accounts
WHO Health 
Accounts
WHO Health 
Accounts
NASA NASA a
Latin America and the 
Caribbean
Antigua and Barbuda
International 1 061 081 290 466 689 549 1 064 377 a b
Domestic public 300 777 326 796 297 612 355 037 a b
Resource tracking 
method
Other Other Other
WHO Health 
Accounts
a b
Argentina
International 377 261 4 793 171 137 252 a a a
Domestic public 105 790 678 168 869 560 178 870 021 a a a
Resource tracking 
method
NASA NASA NASA a a a
Aruba
International a a a a a a
Domestic public a a a a a a
Resource tracking 
method
a a a a a a
Domestic public and international expenditure reported by countries to UNAIDS (2010–2015) 
The table contains the annual AIDS response expenditure (in US dollars) of domestic public resources and total international resources provided by bilateral and 
multilateral donors, private foundations and other international partners, as reported by countries through the Global AIDS Response Progress Reporting system.
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2010 2011 2012 2013 2014 2015
Bahamas
International a a a a a a
Domestic public a a a a a a
Resource tracking 
method
a a a a a a
Barbados
International a 3 246 554 2 164 578 10 492 579 a a
Domestic public 7 390 301 4 831 821 6 207 005 5 478 563 a a
Resource tracking 
method
Other
WHO Health 
Accounts
WHO Health 
Accounts
WHO Health 
Accounts
a a
Belize
International 1 412 896 a 1 886 377 a a a
Domestic public 1 134 649 a 832 345 a a a
Resource tracking 
method
NASA a NASA a a a
Bolivia  
(Plurinational State of)
International a 6 975 047 4 869 735 a a a
Domestic public a 2 276 663 4 786 726 a a a
Resource tracking 
method
a NASA NASA a a a
Brazil
International 9 171 381 9 743 606 9 258 557 a 0 a
Domestic public 725 071 213 802 860 939 685 482 920 a 804 365 939 a
Resource tracking 
method
Other Other Other a Other a
Chile
International 468 527 438 142 227 585 a a a
Domestic public 119 224 642 123 180 023 136 781 489 a a a
Resource tracking 
method
NASA NASA NASA a a a
Colombia
International 275 591 a 176 131 306 020 a b
Domestic public 86 962 224 62 819 944 99 335 154 84 674 170 a b
Resource tracking 
method
Other Other Other Other a b
Costa Rica
International 2 178 897 a 1 701 913 a a b
Domestic public 24 765 744 a 18 402 940 a a b
Resource tracking 
method
NASA a NASA a a b
Cuba
International 8 261 407 9 321 423 9 053 819 5 927 082 a a
Domestic public 58 593 535 61 245 963 62 992 629 63 807 290 a a
Resource tracking 
method
WHO Health 
Accounts
WHO Health 
Accounts
WHO Health 
Accounts
WHO Health 
Accounts
a a
Dominica
International a a 160 000 a a a
Domestic public 223 664 223 664 176 411 a a a
Resource tracking 
method
Other Other Other a a a
Dominican Republic
International a b 20 711 558 b b b
Domestic public a b 9 262 504 b b b
Resource tracking 
method
a b NASA b b b
Ecuador
International 2 975 540 a a a 6 584 696 a
Domestic public 24 270 868 a a a 6 645 825 a
Resource tracking 
method
NASA a a a NASA a
Domestic public and international expenditure reported by countries to UNAIDS (2010–2015) 
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Source of 
expenditure and 
resource tracking 
method
2010 2011 2012 2013 2014 2015
El Salvador
International 11 455 432 a 13 976 689 13 764 792 14 771 149 b
Domestic public 37 297 450 a 41 243 741 46 595 135 45 120 439 b
Resource tracking 
method
NASA a NASA NASA NASA b
Grenada
International 87 980 7 435 120 141 39 398 a a
Domestic public 5 521 a a 155 431 a a
Resource tracking 
method
Other
WHO Health 
Accounts
WHO Health 
Accounts
WHO Health 
Accounts
a a
Guatemala
International 12 885 696 14 967 041 20 625 980 14 788 915 b a
Domestic public 28 765 245 26 885 645 27 225 413 32 791 651 b a
Resource tracking 
method
NASA NASA NASA NASA b a
Guyana
International a 18 053 225 17 431 482 a a a
Domestic public a a a a a a
Resource tracking 
method
a Other Other a a a
Haiti
International 164 523 917 207 401 048 114 921 741 127 522 213 a a
Domestic public 1 608 233 1 608 233 884 655 352 174 a a
Resource tracking 
method
UNAIDS/
UNFPA/NIDI
UNAIDS/
UNFPA/NIDI
Other Other a a
Honduras
International 15 716 346 15 691 183 17 981 687 17 236 972 a a
Domestic public 16 025 455 15 999 798 16 466 390 15 784 431 a a
Resource tracking 
method
NASA NASA NASA NASA a a
Jamaica
International 10 771 906 a a a a a
Domestic public 3 848 958 a a a a a
Resource tracking 
method
NASA a a a a a
Mexico
International a 12 168 390 a a a a
Domestic public a 483 415 094 a a a a
Resource tracking 
method
a NASA a a a a
Nicaragua
International 14 061 971 a a a a a
Domestic public 9 682 304 a a a a a
Resource tracking 
method
NASA a a a a a
Panama
International 1 527 635 a 3 411 932 a a a
Domestic public 15 702 066 a 19 286 886 a a a
Resource tracking 
method
NASA a NASA a a a
Paraguay
International 6 767 336 5 094 780 2 515 630 2 966 599 a a
Domestic public 2 677 348 2 507 935 9 521 067 10 841 743 a a
Resource tracking 
method
NASA NASA Other Other a a
Peru
International 12 474 168 a a 4 505 007 a b
Domestic public 15 445 506 a a 70 356 265 78 148 248 b
Resource tracking 
method
WHO Health 
Accounts
a a Other Other a
Domestic public and international expenditure reported by countries to UNAIDS (2010–2015) 
The table contains the annual AIDS response expenditure (in US dollars) of domestic public resources and total international resources provided by bilateral and 
multilateral donors, private foundations and other international partners, as reported by countries through the Global AIDS Response Progress Reporting system.
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Source of 
expenditure and 
resource tracking 
method
2010 2011 2012 2013 2014 2015
Saint Kitts and Nevis
International 83 625 16 000 a a a a
Domestic public 67 548 77 349 82 440 85 110 a a
Resource tracking 
method
WHO Health 
Accounts
WHO Health 
Accounts
WHO Health 
Accounts
WHO Health 
Accounts
a a
Saint Lucia
International a a a a a a
Domestic public a a a a a a
Resource tracking 
method
a a a a a a
Saint Vincent and the 
Grenadines
International 1 482 535 1 568 710 821 178 a a a
Domestic public 2 508 745 1 267 636 615 427 a a a
Resource tracking 
method
WHO Health 
Accounts
WHO Health 
Accounts
WHO Health 
Accounts
a a a
Suriname
International 4 105 985 2 343 104 a a a a
Domestic public 1 939 620 2 249 605 a a a a
Resource tracking 
method
NASA NASA a a a a
Trinidad and Tobago
International a a a a a a
Domestic public a a a a a a
Resource tracking 
method
a a a a a a
Turks and Caicos Islands
International a a a a a a
Domestic public a a a a a a
Resource tracking 
method
a a a a a a
Uruguay
International a a a a a a
Domestic public a a a a a a
Resource tracking 
method
a a a a a a
Venezuela  
(Bolivarian Republic of)
International 626 411 133 327 702 563 817 796 b b
Domestic public 109 037 329 80 352 294 65 915 889 71 785 912 b b
Resource tracking 
method
NASA NASA NASA NASA a a
North Africa and the 
Middle East
Algeria
International 438 044 805 358 799 949 433 411 389 311 b
Domestic public 5 320 965 5 508 774 5 973 758 12 022 798 16 879 342 b
Resource tracking 
method
NASA NASA NASA NASA
WHO Health 
Accounts
b
Bahrain
International a a a a a a
Domestic public a a a a a a
Resource tracking 
method
a a a a a a
Djibouti
International 4 418 725 3 696 788 2 961 380 a 2 609 339 a
Domestic public 627 309 596 705 867 075 a 274 426 a
Resource tracking 
method
Other Other NASA a NASA a
Egypt
International a a a b b b
Domestic public a a a b b b
Resource tracking 
method
a a a b b b
Domestic public and international expenditure reported by countries to UNAIDS (2010–2015) 
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Source of 
expenditure and 
resource tracking 
method
2010 2011 2012 2013 2014 2015
Iran (Islamic Republic of)
International a a 2 972 133 a b a
Domestic public a a 69 420 049 a a a
Resource tracking 
method
a a Other a a a
Iraq
International a a a a a a
Domestic public a a a a a a
Resource tracking 
method
a a a a a a
Jordan
International 723 768 433 831 968 903 79 616 a a
Domestic public 1 000 000 1 000 000 1 000 000 1 000 000 a a
Resource tracking 
method
Other Other NASA NASA a a
Kuwait
International 0 a 0 0 0 a
Domestic public 56 791 069 a 59 515 455 5 952 004 22 365 503 a
Resource tracking 
method
Other a Other Other Other a
Lebanon
International 850 000 850 000 a 2 036 622 a a
Domestic public 1 570 000 1 570 000 a 3 154 875 a a
Resource tracking 
method
Other Other a Other a a
Libya
International a a a a a a
Domestic public a a a a a a
Resource tracking 
method
a a a a a a
Morocco
International 7 099 104 6 389 275 10 290 706 10 355 925 a b
Domestic public 6 357 832 6 728 697 8 021 984 9 943 419 a b
Resource tracking 
method
Other Other Other Other a a
Oman
International a 175 040 103 261 57 000 11 390 b
Domestic public a 4 528 882 5 318 814 3 833 134 4 313 471 b
Resource tracking 
method
a Other Other Other Other a
Qatar
International a a a a a a
Domestic public a a a a a a
Resource tracking 
method
a a a a a a
Saudi Arabia
International a a a a a a
Domestic public a a a a a a
Resource tracking 
method
a a a a a a
Somalia
International a a a a a a
Domestic public a a a a a a
Resource tracking 
method
a a a a a a
Sudan
International a 14 477 993 12 345 112 9 052 243 a a
Domestic public a 6 558 053 4 698 522 3 717 832 a a
Resource tracking 
method
a NASA NASA NASA a a
Domestic public and international expenditure reported by countries to UNAIDS (2010–2015) 
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Source of 
expenditure and 
resource tracking 
method
2010 2011 2012 2013 2014 2015
Syrian Arab Republic 
International a 189 850 a a a a
Domestic public a 620 000 a a a a
Resource tracking 
method
a Other a a a a
Tunisia
International 2 928 100 2 625 149 a a a b
Domestic public 110 040 117 400 a a a b
Resource tracking 
method
Other Other a a a a
United Arab Emirates
International a a a a a a
Domestic public 25 480 829 30 630 854 32 476 417 a a a
Resource tracking 
method
Other Other Other a a a
Yemen
International 1 768 765 1 146 525 a a a a
Domestic public 442 233 467 395 a a a a
Resource tracking 
method
WHO Health 
Accounts
WHO Health 
Accounts
a a a a
Western and central 
Africa
Benin
International 11 259 886 19 280 694 18 740 206 18 819 303 16 408 412 b
Domestic public 6 937 649 7 796 210 11 709 193 3 173 027 3 936 233 b
Resource tracking 
method
Other NASA NASA NASA NASA b
Burkina Faso
International 38 914 497 28 775 307 20 793 731 41 177 658 b a
Domestic public 11 118 728 7 214 347 28 122 266 7 780 061 b a
Resource tracking 
method
NASA NASA NASA NASA b a
Burundi
International 39 908 205 23 408 823 36 476 780 39 481 263 16 026 325 b
Domestic public 1 774 303 2 034 615 2 132 874 1 841 735 289 800 b
Resource tracking 
method
NASA Other NASA Other Other b
Cameroon
International 40 916 286 34 159 215 30 513 008 43 997 798 a a
Domestic public 14 395 254 9 170 306 15 726 635 14 805 716 a a
Resource tracking 
method
NASA NASA NASA NASA a a
Cabo Verde
International 2 045 844 3 073 161 16 761 3 095 629 1 375 173 a
Domestic public 499 368 522 275 17 194 1 814 407 2 343 480 a
Resource tracking 
method
Other Other Other
WHO Health 
Accounts
NASA a
Central African Republic
International 13 024 181 13 892 462 a a a a
Domestic public 1 873 217 1 892 102 a a a a
Resource tracking 
method
Other NASA a a a a
Chad
International 7 929 254 15 164 149 9 884 338 12 886 293 a a
Domestic public 3 862 235 2 610 372 6 343 779 4 622 591 a a
Resource tracking 
method
NASA NASA NASA NASA a a
Congo
International 8 368 357 a a a a a
Domestic public 8 104 228 a a a a a
Resource tracking 
method
NASA a a a a a
Domestic public and international expenditure reported by countries to UNAIDS (2010–2015) 
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Source of 
expenditure and 
resource tracking 
method
2010 2011 2012 2013 2014 2015
Côte d'Ivoire
International 106 998 408 87 632 863 111 893 979 91 192 629 a b
Domestic public 4 654 699 11 721 794 14 095 682 14 025 624 a b
Resource tracking 
method
NASA NASA NASA NASA a b
Democratic Republic of 
the Congo
International 102 437 817 101 268 276 139 843 066 b b b
Domestic public 2 759 539 1 765 235 2 710 269 b b b
Resource tracking 
method
NASA NASA NASA b b b
Equatorial Guinea
International a a 459 534 611 672 a a
Domestic public a a 1 686 984 7 844 051 a a
Resource tracking 
method
a a
UNAIDS/
UNFPA/NIDI
Other a a
Gabon
International 2 356 058 3 510 777 2 009 292 750 861 454 441 a
Domestic public 5 679 337 6 423 890 12 280 214 10 121 784 4 808 085 a
Resource tracking 
method
NASA
UNAIDS/
UNFPA/NIDI
UNAIDS/
UNFPA/NIDI
UNAIDS/
UNFPA/NIDI
Other a
Gambia
International a a a a 0 a
Domestic public a a a a 3 850 001 a
Resource tracking 
method
a a a a Other a
Ghana
International 48 015 481 60 807 945 87 433 712 40 457 844 a b
Domestic public 8 087 144 14 854 634 4 524 557 6 830 808 a b
Resource tracking 
method
NASA NASA NASA NASA a b
Guinea
International 11 106 795 14 139 106 9 486 461 11 834 280 10 753 092 b
Domestic public 317 576 638 185 2 302 175 2 579 555 3 339 108 b
Resource tracking 
method
NASA Other
UNAIDS/
UNFPA/NIDI
NASA NASA b
Guinea-Bissau
International 4 647 063 a a a a a
Domestic public 611 774 2 401 970 3 347 064 a a a
Resource tracking 
method
Other Other Other a a a
Liberia
International 28 274 595 30 933 572 a a a a
Domestic public 83 100 190 000 a a a a
Resource tracking 
method
Other Other a a a a
Mali
International 30 015 865 17 896 310 15 450 592 b a a
Domestic public 6 502 189 5 988 081 6 136 480 b a a
Resource tracking 
method
NASA NASA NASA a a a
Mauritania
International 247 500 361 557 3 317 575 2 731 148 b b
Domestic public 698 854 3 720 945 616 666 a b b
Resource tracking 
method
Other Other Other
WHO Health 
Accounts
a a
Niger
International 14 111 145 13 635 812 10 760 854 a a a
Domestic public 69 420 424 986 4 786 972 a a a
Resource tracking 
method
Other NASA NASA a a a
Domestic public and international expenditure reported by countries to UNAIDS (2010–2015) 
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Source of 
expenditure and 
resource tracking 
method
2010 2011 2012 2013 2014 2015
Nigeria
International 370 927 337 409 348 953 442 069 265 b b a
Domestic public 125 139 587 88 875 936 122 964 880 b b a
Resource tracking 
method
NASA NASA NASA a a a
Sao Tome and Principe
International 597 949 768 219 422 726 761 127 695 603 a
Domestic public 7803 112 650 15 664 60 573 30 800 a
Resource tracking 
method
WHO Health 
Accounts
WHO Health 
Accounts
WHO Health 
Accounts
NASA NASA a
Senegal
International a 19 809 176 b b a a
Domestic public a 2 709 561 b b a a
Resource tracking 
method
a NASA a a a a
Sierra Leone
International a 20 696 274 a a a a
Domestic public a 168 584 a a a a
Resource tracking 
method
a NASA a a a a
Togo
International 13 512 726 16 113 033 12 328 341 15 845 876 15 356 578 a
Domestic public 8 878 290 4 225 730 6 300 102 3 757 204 2 197 218 a
Resource tracking 
method
NASA NASA NASA NASA NASA a
Western and central 
Europe and North 
America
Andorra
International a a a a a a
Domestic public a a a a a a
Resource tracking 
method
a a a a a a
Austria
International a a a a a a
Domestic public a a a a a a
Resource tracking 
method
a a a a a a
Belgium
International a a a a a a
Domestic public 159 087 442 a a a a a
Resource tracking 
method
NASA a a a a a
Canada
International a a a a a a
Domestic public a a a a a a
Resource tracking 
method
a a a a a a
Denmark
International a a a a a a
Domestic public a a a a a a
Resource tracking 
method
a a a a a a
Finland
International a a a a a a
Domestic public a a a a a a
Resource tracking 
method
a a a a a a
France
International a a a a a a
Domestic public a a a a a a
Resource tracking 
method
a a a a a a
Domestic public and international expenditure reported by countries to UNAIDS (2010–2015) 
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Source of 
expenditure and 
resource tracking 
method
2010 2011 2012 2013 2014 2015
Germany
International a a a a a a
Domestic public a a a a a a
Resource tracking 
method
a a a a a a
Greece
International a a a a a a
Domestic public a a a a a a
Resource tracking 
method
a a a a a a
Iceland
International a a a a a a
Domestic public a a a a a a
Resource tracking 
method
a a a a a a
Ireland
International a a a a a a
Domestic public a a a a a a
Resource tracking 
method
a a a a a a
Israel
International a a a a a a
Domestic public a a a a a a
Resource tracking 
method
a a a a a a
Italy
International a 0 a a a a
Domestic public a 508 145 475 a a a a
Resource tracking 
method
a Other a a a a
Liechtenstein
International a a a a a a
Domestic public a a a a a a
Resource tracking 
method
a a a a a a
Luxembourg
International a a a a a a
Domestic public a a a a a a
Resource tracking 
method
a a a a a a
Monaco
International a a a a a a
Domestic public a a a a a a
Resource tracking 
method
a a a a a a
Netherlands
International a a a a a a
Domestic public a a a a a a
Resource tracking 
method
a a a a a a
Norway
International a a a a a a
Domestic public a a a a a a
Resource tracking 
method
a a a a a a
Portugal
International a a a a a a
Domestic public 175 446 308 201 374 452 10 356 197 274 577 668 a a
Resource tracking 
method
NASA NASA NASA NASA a a
Domestic public and international expenditure reported by countries to UNAIDS (2010–2015) 
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Source of 
expenditure and 
resource tracking 
method
2010 2011 2012 2013 2014 2015
San Marino
International a a a a a a
Domestic public a a a a a a
Resource tracking 
method
a a a a a a
Spain
International a 14 410 597 969 363 395 623 286 a b
Domestic public 980 914 000 1065 927 534 8 339 679 918 865 056 a b
Resource tracking 
method
Other Other Other Other a a
Sweden
International a a a a a a
Domestic public a a a a a a
Resource tracking 
method
a a a a a a
Switzerland
International a a a a a a
Domestic public 3 067 779 3 608 480 3 411 878 a a a
Resource tracking 
method
Other Other Other a a a
United Kingdom
International a a a a a a
Domestic public a a a a a a
Resource tracking 
method
a a a a a a
United States of 
America
International a a a a a a
Domestic public a a a a a a
Resource tracking 
method
a a a a a a
Domestic public and international expenditure reported by countries to UNAIDS (2010–2015) 
The table contains the annual AIDS response expenditure (in US dollars) of domestic public resources and total international resources provided by bilateral and 
multilateral donors, private foundations and other international partners, as reported by countries through the Global AIDS Response Progress Reporting system.
a Country either did not report expenditure or reported that the data were not availabile.
b Expenditure reported in 2016 but not yet validated. These data are expected to be available on AIDSinfo by September 2016. 
NASA: national AIDS spending assessment. NIDI: Netherlands Interdisciplinary Demographic Institute.


PREVE 
NTION 
GAP  
RE 
PORT
Joint United Nations 
Programme on HIV/AIDS 
20 Avenue Appia
1211 Geneva 27
Switzerland
+41 22 791 3666
unaids.org
